,ID,Sentence,disease
0,0,Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements,{''}
1,1,Non-small cell lunch cancer (NSLC) with untreated asymptomatic brain metastases,"{'Non - small cell lunch cancer, N ##SL ##C'}"
2,2,Age≥18y,{''}
3,3,Clinical diagnosis of mild to severe OSA in the past year,{'OS ##A'}
4,4,Has localized high-risk or very high-risk prostate cancer based on the NCCN v4.2023 classification.,"{'pro, ##state cancer'}"
5,5,Being a nursing student,{''}
6,6,Have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) according to the American Joint Committee on Cancer Staging Handbook.,"{'non - small cell lung cancer, N ##SC ##LC Cancer'}"
7,7,At least the 3rd day of hospitalization,{''}
8,8,"Male or female, aged 18 or older.",{''}
9,9,- COPD Cases,{'CO ##PD'}
10,10,Women of childbearing potential must not be known to be pregnant or lactating,{''}
11,11,years or older,{''}
12,12,Subject has moderate to severe plaque psoriasis for 6 months or longer with at least 10% Body Surface Area (BSA) affected,{'plaque ps ##oria ##sis'}
13,13,Healthy and free of any significant medical problems,{''}
14,14,"Have a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer who have received systemic chemotherapy including platinum-based chemotherapy","{'o ##var ##ian , fall ##op ##ian tube , or primary per ##ito ##nea ##l cancer'}"
15,15,(non-burned individuals),{''}
16,16,"A documented diagnosis of Hailey-Hailey disease confirmed with clinical, and histopathologic findings",{'Hailey - Hailey disease'}
17,17,"Adult patients (above 18 and older),",{''}
18,18,Signed written informed consent before inclusion in the investigation.,{''}
19,19,Be between 8 and 12 years of age inclusive at the time of enrollment.,{''}
20,20,Medical condition or disease to be investigated,{''}
21,21,Person over 60 years of age.,{''}
22,22,"Diagnosed with osteoarthritis of the knee,","{'o, ##ste ##oar ##th ##rit ##is of the knee'}"
23,23,Adult participants ≥18 years of age on the day of signing the informed consent form.,{''}
24,24,Subjects must be 22 years of age or older on the date the Informed Consent Form (ICF) is signed.,{''}
25,25,Age 18 years or older,{''}
26,26,Age between 18-60 years,{''}
27,27,"Age 18-85 years, BMI ≥ 18.5, have had clinical type 1 diabetes for at least one year, and have taken insulin for at least 1 year",{'type 1 diabetes'}
28,28,"moderate to severe allergic rhinitis due to grass pollen, with Rhinitis Total Symptom Score \>/= 8.","{'all ##ergic r ##hin ##itis pollen, R, ##hin ##itis'}"
29,29,Subject can provide written informed consent.,{''}
30,30,Male,{''}
31,31,"Pregnant female subjects at the study institution, admitted for labor (spontaneous, augmented, or induced) or cesarean delivery",{''}
32,32,Adults aged 19 years and older experiencing chronic neuropathic pain that is refractory to medical treatment and eligible for SCS based on FDA-approved indications.,"{'chronic ne ##uro ##pathic pain, SC ##S'}"
33,33,General Anaesthesia delivered with Propofol and Remifentanil with Targeted Controlled Infusion,{''}
34,34,Subject gives voluntary informed consent to participate in the study.,{''}
35,35,Prescribed micafungin for prophylaxis or treatment of fungal infections.,{'fun ##gal infections'}
36,36,Diagnosed with spinocerebellar ataxia,{'spin ##oc ##ere ##bella ##r at ##ax ##ia'}
37,37,Age 20-75 years,{''}
38,38,Male and female (if postmenopausal or hysterectomized) aged 18 years or older,{'h'}
39,39,Healthy Adults,{''}
40,40,The patients who were started Pirfenidone or Nintedanib treatment with the diagnosis of Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis according to An Official ATS/ERS/JRS/ALAT Clinical Practice guideline and treated for at least one year in our department between January 1 2010 and December 31 2022 The included patients had not previously used steroids or similar drugs for lung disease.,"{'I, ##dio ##pathic P ##ul ##mona ##ry Fi ##bro ##sis, Progressive P ##ul ##mona ##ry Fi ##bro ##sis, lung disease'}"
41,41,Novice pediatric nurses,{''}
42,43,Eligibility criteria for receiving the intervention in the feasibility study,{''}
43,44,Cases,{''}
44,45,Adult patients underwent surgical intervention for arthromyolysis according to Judet with modified surgical technique for knee stiffness from January 2008 to December 2019.,"{'art ##hr ##omy ##oly, knee stiff ##ness'}"
45,46,Subject eligible for enrolment in the study and treatment for benralizumab according to the specific Russian label and in line with reimbursement condition must meet all the following criteria,{''}
46,47,"Provide written informed consent, signed, and dated by the participant and study partner, or by the participant's legally authorized representative if applicable, according to local regulations for the ICF and, if applicable, country specific ICFs.",{''}
47,48,years of age or older,{''}
48,49,"Patients must be enrolled or agree to consent to the companion genomic profiling study MSKCC IRB# 12-245 Part A. Results are not required prior to initiating treatment on protocol, unless patients do not have other test results by IHC or FISH confirming HER2 overexpression.",{''}
49,50,"Complained of neck pain during work for at least 3 months,",{'neck pain'}
50,51,Patient aged ≥ 18 years,{''}
51,52,age 65 or older,{''}
52,54,Aged 18 years or older,{''}
53,55,"Being a 2nd year student at the Faculty of Nursing,",{''}
54,56,"Veterans are currently enrolled in or within 6 weeks of discharge from (as relevant) a VA San Diego Healthcare System (VASDHS) psychosocial rehabilitation and recovery center (PRRC), VASDHS mental health residential rehabilitation treatment program (RRTP), VASDHS acute inpatient hospitalization or VASDHS outpatient mental health treatment",{'mental'}
55,57,Subjects who are ≥18 years of age or legal age in host country and have been identified as a candidate for a Portico™ valve implant,{''}
56,58,"All patients must have a pathologically documented, definite diagnosis of epithelial cancer of the ovary, the fallopian tube or the peritoneum","{'e ##pit ##hel ##ial cancer of the o ##vary , fall ##op ##ian tube'}"
57,59,for Both Stages,{''}
58,60,Subject volunteered to participate in the study and signed an informed consent;,{''}
59,61,all adult patients,{''}
60,62,Patients aged 19 years to 89 years with diabetes mellitus,{'diabetes me ##lli ##tus'}
61,63,"Histologically confirmed, non-muscle invasive urothelial carcinoma with carcinoma in situ (CIS) (with or without papillary disease)","{'non - muscle invasive u ##roth ##eli ##al car ##cin ##oma, car, ##cin ##oma in sit ##u, C, p, ##ap ##illa ##ry disease'}"
62,64,Mental Health Programs,{''}
63,65,Are at least 18 years old,{''}
64,66,"Body weight at screening ≥ 50.0 kg and \< 80.0 kg for male, ≥ 40.0 kg and \< 70.0 kg for female.",{''}
65,67,ECOG Performance Status ≤ 1,{''}
66,68,for Adolescent,{''}
67,69,Patients aged 0 to 6 years who have visited the institution for symptoms caused by a traffic accident and have received at least one session of integrative Korean medicine treatment as inpatient or outpatient care.,{''}
68,71,Anyone working at GHSIF,{''}
69,72,Have Type 2 Diabetes,{'Type 2 Di ##abe ##tes'}
70,73,mCRPC with pathological confirmation of adenocarcinoma without small-cell or neuroendocrine features.,"{'m ##CR ##PC, ad, ##eno ##car ##cin ##oma'}"
71,74,All B-ALL patients must be enrolled on APEC14B1 and consented to Eligibility Screening (Part A) prior to treatment and enrollment on AALL1731. APEC 14B1 is not a requirement for B-LLy patients. B-LLy patients may directly enroll on AALL1731.,"{'B - AL ##L, B - LL ##y, B - LL ##y'}"
72,75,"Men or women aged 30 to 85 years (inclusive), at the time of informed consent.",{''}
73,76,"Patients with a confirmed diagnosis of classical familial adenomatous polyposis (FAP) based on colonoscopy, histopathology, and genetic testing.","{'f, ##ami ##lial ad ##eno ##mat ##ous p ##oly ##po ##sis, FA ##P'}"
74,77,"Moderate or severe heart failure, defined as NYHA Class III-IV despite optimal pharmacological heart failure therapy","{'heart failure, heart failure'}"
75,78,Over 18 years,{''}
76,79,Children in Kindergarten (approximate ages 4-9 years),{''}
77,80,\<28 weeks gestation at birth,{''}
78,81,Adult from both sex,{''}
79,82,"Children of either gender aged between 6 months and 5 years, at Baseline/Randomisation (Visit 2) inclusive.",{''}
80,84,Patients with basic type intermittent exotropia,{''}
81,85,Skeletal Class II pattern with ANB angle exceeding 6° and Wits appraisal of 2 mm or more.,{''}
82,86,")Age 18-70 years old (both ends included), both male and female;",{''}
83,87,"Patients undergone nonphysiological reconstruction of the gastrointestinal tract (such as Billroth-II, Roux-en-Y, Child, Whipple reconstruction)","{'Bill ##roth - II - en - Y , Child , W ##hip ##ple'}"
84,88,"Study participant must be ≥18 years of age, at the time of signing the informed consent",{''}
85,90,Aortic Valve Area (AVA) ≥1.0 cm2 ≤ 1.5 cm2 and either mean aortic Pressure Gradient (mPG) of \>25 - \< 40 mmHg or maximum velocity (Vmax) ≥3 ≤4 m/sec in normal flow conditions; or,{''}
86,91,Genetically-defined HeFH,{'He'}
87,92,At least 18 years old,{''}
88,93,HIV positive,{''}
89,94,For human treatment/safety cohort,{''}
90,95,Providing care to a pediatric patient,{''}
91,96,"Has American Joint Committee on Cancer (AJCC) Stage IV, M1D melanoma","{'me, ##lan'}"
92,97,Histologically proven cancer of the head and neck cancer,{'cancer of the head and neck cancer'}
93,98,Patients must be newly diagnosed with histologically-proven hepatoblastoma,"{'he, ##pa ##to ##blast ##oma'}"
94,99,Patients who start NEXAVAR treatment for radioactive iodine-refractory unresectable Differentiated Thyroid Carcinoma (DTC),"{'Different ##iated T ##hy ##roid Car ##cin ##oma, D ##TC'}"
95,100,Diagnosis of AD (as defined by Hanifin and Rajka criteria for AD).,"{'AD, AD'}"
96,101,Total body weight \>= 50 kg and body mass index (BMI) \>=18 kg/m2 and \<=35 kg/m2,{''}
97,102,"Participant must have documented multiple myeloma satisfying the CRAB (calcium elevation, renal insufficiency, anemia and bone abnormalities) criteria, monoclonal plasma cells in the bone marrow greater than or equal to (\>=) 10 percent (%) or presence of a biopsy proven plasmacytoma and measurable disease as defined by any of the following (a) immunoglobulin (Ig) G myeloma (serum monoclonal paraprotein \[M-protein\] level \>=1.0 gram/deciliter \[g/dL\] or urine M-protein level \>=200 milligram\[mg\]/24 hours\[hrs\]; or (b) IgA, IgM, IgD, or IgE multiple myeloma (serum M-protein level \>=0.5 g/dL or urine M-protein level \>=200 mg/24 hrs); or (c) light chain multiple myeloma without measurable disease in serum or urine (serum immunoglobulin free light chain \>=10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio)","{'multiple my ##elo ##ma, calcium elevation, re, ##nal ins ##uff ##iciency, an ##emia, bone abnormal ##ities, plasma ##cy ##tom ##a G my ##elo, multiple my ##elo ##ma, light chain multiple my ##elo ##ma'}"
98,104,"Signed informed consent, inclusive of release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documentation.",{''}
99,105,Participants with histologically or cytologically confirmed R/M HNSCC that is considered incurable by local therapies,"{'R / M, H ##NS ##CC'}"
100,106,Treatment naïve patients,{''}
101,107,Participant in SJLIFE and \> 5 years from diagnosis.,{''}
102,108,Presenting (with or without glasses) distance visual acuity of 6/12 or worse in the better-seeing eye;,{''}
103,109,Subject must meet all of the following applicable inclusion criteria to participate in this study,{''}
104,110,"Suitable candidate for intra-cardiac mapping and ablation of atrial arrhythmias including atrial fibrillation, atrial flutter and/or atrial tachycardia","{'at ##rial a ##rr ##hy ##th ##mia, at ##rial fi ##bri ##lla ##tion, at ##rial flutter, at ##rial ta ##chy ##card ##ia'}"
105,111,"Biopsy proven Merkel cell carcinoma which is unresectable or metastatic, stage III or IV",{'Me ##rk ##el cell car ##cin ##oma'}
106,112,Referred to elective (non-emergency) cesarean section,{''}
107,113,Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Waivers of informed consent for deceased patients will be pursued if permitted by local regulation,{''}
108,114,Participants between ages 12-80,{''}
109,116,to have at least 14 years old,{''}
110,117,Willing and able to provide informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.,{''}
111,118,"Participants must have histologically- or cytologically-confirmed follicular-derived nonanaplastic thyroid cancer that is metastatic and/or unresectable AND harbors a known oncogenic RET gene fusion, performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory.","{'f, ##oll ##icular - derived non ##ana ##p ##lastic thy ##roid cancer'}"
112,119,"Any participant presenting for an IUD placement, either for contraception or treatment of abnormal uterine bleeding or to regulate menstrual periods",{'abnormal u ##ter ##ine bleeding'}
113,120,"consecutive patients treated at a single center between April 2018 and July 2023 for malignant brain tumors, including glioma, metastasis, and lymphoma.","{'ma, ##li ##gnant brain tumors, g, ##lio ##ma, meta, l, ##ymph ##oma'}"
114,121,Adult female patients having bilateral mastectomy surgery at University of New Mexico Outpatient Surgical and Imaging Services (OSIS) facility,{''}
115,122,"Participant has a body mass index range of 18.5 to 40.0 kg/m\^2, inclusive and weighs at least 50 kg at screening.",{''}
116,123,African Americans with a confirmed diagnosis of Inflammatory Bowel Disease (IBD),"{'In, ##f ##lam ##mat ##ory Bow ##el Disease, I ##B ##D'}"
117,125,Provision of signed and dated informed consent form,{''}
118,126,Adults aged 18 to 70 years.,{''}
119,127,A woman aged 18 through 45 (inclusive) who is planning a pregnancy or with an already confirmed pregnancy with pregnancy term up to 12 weeks (pregnancy was confirmed by laboratory and/or ultrasound method).,{''}
120,128,Children aged 3 years or older and 7 years and 7 months or younger,{''}
121,129,Infants less than or equal to 37 weeks gestation at birth,{''}
122,130,"Provide informed consent or assent as appropriate and, if \< 18 years of age have a parent or legal guardian provide informed consent",{''}
123,131,Refugees older than 18 years old.,{''}
124,132,perimenopausal or early postmenopausal women aged 45-60 years old,{''}
125,133,students whose caregivers signed informed consents;,{''}
126,135,Meets 2016 revised diagnostic criteria for fibromyalgia (FM),"{'fi ##bro ##my ##al ##gia, FM'}"
127,136,"Female patients,",{''}
128,137,Age range 5-30 years old.,{''}
129,138,Patients,{''}
130,139,Male and female of non-childbearing potential participants with suitable veins for cannulation or repeated venipuncture.,{''}
131,140,"The subject has undergone an abdominal or chest non-contrast CT scan, categorized as follows",{''}
132,142,Adults with bilateral pseudophakia who have been implanted with the LAL in at least one eye and who have completed LDD light treatments,{'bilateral pseudo ##pha ##ki ##a'}
133,143,"According to the Goligher classification in the Chinese guidelines for the diagnosis and treatment of hemorrhoids (2020) , patients who are diagnosed with grade II-III internal hemorrhoids .","{'hem ##or ##r ##ho ##ids, internal hem ##or ##r ##ho ##ids'}"
134,144,Male or Female,{''}
135,145,Adults with bilateral pseudophakia who have been implanted with the LAL+ in at least one eye and who have completed LDD light treatments,{'bilateral pseudo ##pha ##ki ##a'}
136,146,Subject has rheumatoid arthritis (RA) diagnosed according to the 1987 revised ACR criteria for at least 6 months prior to Screening,"{'r, ##he ##uma ##to ##id art ##hr ##itis, RA'}"
137,147,Hemophilia patients with liver cirrhosis caused by HIV/HCV co-infection that fall under the following 1) and 2).,"{'He, ##mo ##phi ##lia, liver c ##ir ##r ##hos ##is, HC'}"
138,148,Histologically/cytologically confirmed adenocarcinoma of the prostate,{'ad ##eno ##car ##cin ##oma of the pro ##state'}
139,149,Age 20-75 years,{''}
140,150,Age ≥18 years old;,{''}
141,151,The subjects who meet all inclusion criteria can be enrolled into the trial,{''}
142,152,Pregnant who is between 28-32 weeks of gestation.,{''}
143,154,Pregnant women in the 3rd trimester of pregnancy (3T) with a normal course of pregnancy up to 39 weeks consulting for the monitoring visit at the Robert-Debré hospital.,{''}
144,155,Agree to comply with study procedures and visit plan. Subject is capable of giving informed consent;,{''}
145,156,The patient met the diagnostic criteria of asthma remission in the Guidelines for prevention and treatment of bronchial asthma；,"{'as ##th ##ma, br ##on ##chia ##l as ##th ##ma'}"
146,157,Selection criteria for in-depth interview subjects,{''}
147,159,Patients must have histologically or cytologically confirmed epithelial endometrial carcinoma; all histologies are accepted; patients with diagnosis of endometrial carcinosarcoma will be enrolled in the exploratory cohort (arm C) and will receive combination of cabozantinib and nivolumab,"{'e ##pit ##hel ##ial end ##ome ##tri ##al car ##cin ##oma, end ##ome ##tri ##al car ##cin ##osa ##rc ##oma'}"
148,160,"severe seizures in neonates or generalized epilepsy or intractable epilepsy in infancy with generalized tonic-clonic seizures,","{'generalized e ##pile ##psy, in ##able e ##pile ##psy, ton ##ic - c ##lon ##ic seizure'}"
149,161,Willing and able to give written informed consent or sign consent forms with a fingerprint.,{''}
150,162,"Patients must have histologically or cytologically confirmed invasive breast carcinoma. We limit the molecular subtype to triple negative (TNBC) and hormone receptor-low and Her2 negative (hormone receptor \[HR\]-low/Her2\[-\]) breast cancer. TNBC is defined as HER2 expression 0 or 1+ on immunohistochemistry (IHC) or non-amplified (defined as HER2/CEP17 ratio \< 2 or copy number \< 6) on fluorescence in situ hybridization (FISH). If HER2 expression is 2+ on IHC, negative HER2 expression must be confirmed by FISH. Pathologic diagnosis of TNBC (negative HER2 status by cytogenetics, \< 1% of cells stained positive for estrogen receptor \[ER\] by IHC, and \< 1% of cells stained positive for progesterone receptor \[PR\] by IHC) (Allison et al., 2020, Wolff et al., 2013). HR-low/Her2(-) is defined as HER2 expression 0 or 1+ on IHC or non-amplified (defined as HER2/CEP17 ratio \< 2 or copy number \< 6) on fluorescence in situ hybridization (FISH). If HER2 expression is 2+ on IHC, negative HER2 expression must be confirmed by FISH. 1-10% of cells stained positive for ER by IHC, and/or 1-10% of cells stained positive for PR by IHC) (Allison et al., 2020, Wolff et al., 2013).","{'invasive breast car ##cin ##oma, triple negative, T negative, breast cancer, T, T'}"
151,163,"Male or female subjects between 28 days and less than 18 years of age, with clinical features that are consistent with a diagnosis of ARPKD.",{'AR ##P ##K ##D'}
152,164,Participants must meet each of the following criteria for enrolment into the study,{''}
153,165,"Having had a stroke for the first time,",{'stroke'}
154,166,female,{''}
155,167,Subjects will include those men and women,{''}
156,168,Male and females aged 18-65 years old,{''}
157,169,subjects \> 6 months and \< 12 years of age；,{''}
158,170,Middle school students studying in school and their parents,{''}
159,171,meet DSM-5 criteria for an SU disorder at the time of assessment at APT or VACHS;,{'S ##U disorder'}
160,172,All participants,{''}
161,174,Age 21-75,{''}
162,175,Adult aged 18-60,{''}
163,176,Patients undergoing primary total knee arthroplasty for osteoarthritis of the knee.,"{'total knee art ##hr ##op, o ##ste ##oar ##th ##rit ##is of the knee'}"
164,177,Age ≥45 years;,{''}
165,178,Participant has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene based on genetic test reports.,{'X ##LM ##TM'}
166,179,Has histologically or cytologically confirmed melanoma,"{'me, ##lan'}"
167,180,-75 years of age,{''}
168,181,"Metastatic castration-resistant prostate cancer (mCRPC) as defined by Prostate Cancer Working Group 3 (PCWG3) Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with small cell or neuroendocrine (NE) features is permitted. However, small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma is disallowed","{'Met cast ##ration - resistant pro ##state cancer, m ##CR ##PC, Pro, ##state Cancer, ad ##eno ##car ##cin ##oma of the pro ##state, Aden ##oc ##ar ##cin ##oma, ne ##uro ##end ##oc ##rine, small cell car ##cin ##oma, car, ##cin ##oid tumor, mixed NE car ##cin ##oma, large cell NE car ##cin ##oma'}"
169,182,Hereditary Pancreatitis or,{''}
170,183,Newly diagnosed or relapsed cancer diagnosis.,{'cancer'}
171,184,years of age and older (some regional variations to inclusion age exist),{''}
172,185,Participant is ≥ 8 kg and ≤ 21 years of age at the time of informed consent and assent.,{''}
173,186,Voluntary participation in clinical studies.,{''}
174,187,months - 18 years of age at the time of the initial diagnosis.,{''}
175,188,Male Chinese subjects aged ≤ 70 years,{''}
176,189,"Upper age limit of =\< 18 years of age for medullary thyroid carcinoma (MTC), renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) =\< 30 years for all other diagnoses","{'me ##du ##llar ##y thy ##roid car ##cin ##oma, M ##TC, re, ##nal cell car ##cin ##oma, RC ##C, he, ##pa ##to ##cellular car ##cin ##oma, HC ##C'}"
177,190,Provision of informed consent prior,{''}
178,191,"In order to participate in this study, all subjects must meet ALL of the inclusion criteria described.",{'AL ##L'}
179,192,Meet the ALGS diagnostic criteria;,{'AL ##GS'}
180,194,"Patients \> age 18, seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with RSV infection","{'respiratory, RS ##V infection'}"
181,195,Males and females adults aged \> 18 years,{''}
182,196,"Subject is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the grafted ligament",{''}
183,197,Depression Trial,{''}
184,198,≥ 6 tender/painful joints; ≥ 6 swollen joints,{''}
185,199,Age 16 years or older (18 years or older \[France and Germany\]); participants age 16 or 17 years must physically have completed puberty;,{''}
186,200,Patients scheduled for corneal endothelial transplantation in one or both eyes,{''}
187,201,Patients with missing at least one maxillary posterior tooth,{''}
188,202,Current DSM-5 PTSD diagnosis,{'PT ##SD'}
189,203,Histologically or cytologically confirmed diagnosis of metastatic Stage IV NSCLC,{'meta Stage IV N ##SC ##LC'}
190,204,Acute Pain Trial,{''}
191,205,All participants,{''}
192,206,"Participant agrees and is able to adhere to the study requirements for the length of the study, including undergoing both aCPET and SHAPE Test.",{''}
193,207,Between the ages of 10 and 18,{''}
194,208,"age ≥18 years,",{''}
195,210,Patient diagnosed with osteoarthritis of the knee.,"{'o, ##ste ##oar ##th ##rit ##is of the knee'}"
196,211,"Inpatients with Diagnostic and Statistical Manual of Mental Disorders 4th Edition Text Revision (DSM-IV TR) diagnosis of schizophrenia, schizophreniform or schizoaffective disorder","{'s ##chi ##zophrenia, s ##chi ##zo ##ph ##ren ##iform, s ##chi ##zo ##af ##fect ##ive disorder'}"
197,212,"Inclusion criteria Healthy non-treatment seeking adults (age 18 to 60, N = 40) who report",{''}
198,213,Infertile patients aged 20-42 years,{'##fer'}
199,215,Adolescents with a clinical diagnosis of T1D,{'T ##1 ##D'}
200,216,"All men (age 45.0 - 75.0 years), regardless of race, presenting to a practicing urologist with symptoms that would lead to an evaluation for prostate cancer and who are scheduled to receive a needle biopsy of the prostate","{'pro, ##state cancer'}"
201,217,Confirmed diagnosis of 5q-autosomal recessive SMA,{''}
202,218,Born between 28 - 36+6 weeks of gestation,{''}
203,219,"History of ongoing spinal cord compression,",{'spinal cord compression'}
204,220,"Male and females, age 18 to 70.",{''}
205,221,Written informed consent and HIPAA authorization for release of personal health information prior to registration. Note HIPAA authorization may be included in the informed consent or obtained separately.,{''}
206,222,Northgate Gonzalez Market customer who currently receives SNAP benefits and has a valid EBT card,{''}
207,223,"i. Outpatient, male or female subjects of any race, and at least 12 years of age or older.",{''}
208,224,Participants in all parts of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.,{'Solid Tu ##mor'}
209,225,"Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features with high risk for development of metastases, defined as prostate-specific antigen doubling time (PSADT) less than or equal to (\<=) 10 months. PSADT is calculated using at least 3 prostate-specific antigen (PSA) values obtained during continuous ADT (androgen deprivation therapy)",{'ad ##eno ##car ##cin ##oma of the pro ##state'}
210,226,Participant has a body mass index range of 18.5 to 32.0 kg/m\^2 inclusive and weighs at least 50 kg at screening.,{''}
211,228,Healthy participants (ASA I) age six to nine years with diagnosis of TMD in the mixed dentition phase and with jaw deviation and/or deflection. Deviation is defined as the jaw following a deviated path to one side during opening. Deflection is defined as the jaw following a deviated path without returning to the midline when the mouth is fully opened.,{'T ##MD'}
212,229,"Subjects must have histologically confirmed non-Hodgkin lymphoma relapsed after 2 or more lines of therapy or disease refractory to chemotherapy (defined as progressive disease or stable disease lasting ≤6 months, as best response to most recent chemotherapy regimen; or disease progression or recurrence ≤12 months after prior autologous stem cell transplantation (ASCT).",{'non - Ho ##d ##g ##kin l ##ymph ##oma'}
213,230,"Participants, male or female, must be 18 to 65 years of age, inclusive, at the time of signing the ICD.",{''}
214,231,Age \>= 18 years of age,{''}
215,232,"Have a diagnosis, per the world health organization (WHO) 2022 criteria, of (a) Acute myeloid leukemia (AML) or (b) Moderate high, high, or very high-risk myelodysplastic neoplasms (MDS) per Molecular International Prognostic Scoring System (IPSS-M)","{'A, ##cute my ##elo ##id le ##uke ##mia, AM ##L, my, ##elo ##dy ##sp ##lastic neo ##p ##las ##ms, MD ##S'}"
216,233,All subjects,{''}
217,234,All subjects voluntarily participated in the study and signed informed consent.,{''}
218,235,"Either gender,",{''}
219,237,Diagnosed with MG at least 3 months (90 days) prior to the date of the Screening Visit. Confirmation of MG must be made via the following,"{'MG, MG'}"
220,239,years of age or older,{''}
221,241,"Must be healthy as confirmed by medical history, physical examination, vital signs, and clinical laboratory tests performed at screening",{''}
222,242,"years or older,",{''}
223,243,Body Mass Index (BMI) is ≥ 18.0 to ≤ 29.9 kg/m\^2 after rounding to the tenth decimal at screening.,{''}
224,245,Participant having freely given his oral agreement.,{''}
225,246,"Persons with a progranulin gene mutation and at risk of developing FTD symptoms as evidenced by a biomarker, or persons with a progranulin gene mutation and diagnosed with FTD.","{'F ##T ##D, F ##T ##D'}"
226,247,Patients enrolled in the VIOLET parent study,{''}
227,248,Age 16-22 inclusive recruited from outpatient pediatric clinic visit.,{''}
228,249,Adult (ages ≥18) subjects with NETs by local pathology.,{'NE ##T'}
229,250,"Preschool children aged 3-6 years,",{''}
230,251,Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.,"{'C, ##ID ##P'}"
231,252,Provision of written informed consent,{''}
232,253,Is HIV-1 positive with plasma HIV-1 RNA ≥500 copies/mL at screening,{''}
233,254,Adults 18\~65 years of age,{''}
234,255,Express consent to participate in the study,{''}
235,256,Adenocarcinoma of the prostate,{'Aden ##oc ##ar ##cin ##oma of the pro ##state'}
236,257,"Children aged 2-2.5 years, who live in Tower Hamlets and whose caregiver(s) are willing to provide written informed consent",{''}
237,258,Written informed consent and HIPAA authorization for release of personal health information. NOTE HIPAA authorization may be included in the informed consent or obtained separately.,{''}
238,259,days- \< 22 years (at time of study enrollment),{''}
239,260,"Body weight at screening ≥ 50.0 kg and \< 80.0 kg for male, ≥ 40.0 kg and \< 70.0 kg for female.",{''}
240,261,Women aged 40-75 (inclusive).,{''}
241,263,Newborns admitted to 17 units in 8 provinces from February 2021 to November 2023;,{''}
242,264,"HCT recipients over 12 years of age within the first 7 days of initial treatment of high-risk aGVHD, defined as",{'a ##G ##V ##HD'}
243,265,"Participants must have histologically or cytologically confirmed HER2-positive disease by local pathology, defined as immunohistochemistry (IHC) 3+ or amplification by FISH (HER2/CEP17 ratio ≥2 or an average of ≥6 HER2 gene copies per nucleus) AND confirmed by Central Pathology Review (Dr. Deborah Dillon at Brigham and Women's Hospital, Boston, MA) prior to patient being registered to begin protocol therapy. See section 3.4. http//ascopubs.org/doi/full/10.1200/jco.2013.50.9984",{''}
244,266,Informed consent obtained before any trial-related activity.,{''}
245,267,Self-identify as Latino,{''}
246,268,Single-segment thoracic or lumbar hemivertebrae scoliosis diagnosed by X-ray and CT.,{'Single - segment th ##ora ##ci ##c or l ##umba ##r hem ##iver ##te ##brae s ##co ##lio ##sis'}
247,269,to have at least 14 years old,{''}
248,270,"Patients and their relatives have provided informed consent,",{''}
249,271,"The subject must be able to fully understood the purpose, nature, method, and possible adverse effects of the study, must be able to voluntarily participate in the study and voluntarily able to provide the written informed consent form (ICF).",{''}
250,272,Histological confirmation of hematological malignancies,{'hem ##ato ##logical ma ##li'}
251,275,"Patients over 18 years of age,",{''}
252,276,aged ≥18 years,{''}
253,277,"Metastasized or locally advanced incurable triple negative breast cancer; patients with stage IV at diagnosis are eligible as well. If the primary lesion is the only measurable lesion according to RECIST criteria, every locoregional treatment must be mentioned to the investigators.",{'Met triple negative breast cancer'}
254,278,Patients;,{''}
255,279,Patients aged between 18 and 50 who have previously been diagnosed with traumatic meniscal tear through magnetic resonance imaging will be included in the study,{'traumatic men ##is ##cal tear'}
256,280,Their chronological age will be 5-7yeasr. 2. All children will receive prophylaxis therapy. 3. They will able to stand and walk independently. 4. They will be able to follow instructions during evaluation and treatment.,{''}
257,281,Patient has signed the Informed Consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements,{''}
258,282,The study will be conducted in patients under 18 years of age with American Society of Anesthesiologists (ASA) I-II.,{''}
259,283,Pediatric patients (age ≤18 years) with the diagnosis of hypoplastic left heart syndrome who underwent the Norwood palliation at the IRCCS Policlinico San Donato.,"{'h, ##y ##pop ##lastic left heart syndrome'}"
260,284,Healthy participants (men and women) between 35 and 65 years of age with knee discomfort.,{'knee discomfort'}
261,285,Age \>18 years;,{''}
262,286,Men with mCRPC who have been prescribed enzalutamide as part of standard clinical practice,{'m ##CR ##PC'}
263,288,"(1) Subjects must be between 18 and 75 years old when signing the informed consent form, and must have the ability to sign the consent form independently; (2) NASH patients who meet one of the following conditions",{'NAS ##H'}
264,289,years or older and overtly healthy,{''}
265,290,males and females age 18-65,{''}
266,291,-Age ≥ 18 years,{''}
267,292,Adult patient.,{''}
268,293,"Subject is a man or woman and considered to be an adult, according to the local legal definition, at the time of informed consent.",{''}
269,295,Subject with hemiparesis following stroke,"{'hem ##ip ##ares ##is, stroke'}"
270,296,Male or female aged 18-60 years.,{''}
271,297,Spinal cord injury (SCI) due to trauma,"{'Spin ##al cord injury, SC ##I'}"
272,298,Patient has thrombocytopenia associated with chronic liver disease and is planned for or underwent treatment with avatrombopag prior to a procedure,"{'th ##rom ##bo ##cy ##top ##enia, chronic liver disease'}"
273,299,years or older,{''}
274,300,Males and females aged ≥ 12 years,{''}
275,301,(Stroke Participants),{'St ##roke'}
276,302,Women aged 18 or older,{''}
277,303,N/A,{''}
278,304,"Subject has received a full explanation of the study drug and this study in advance, and written informed consent to participate in the study has been obtained from the subject himself/herself",{''}
279,306,diabetes,{''}
280,307,"Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.",{''}
281,308,MAIN PART,{''}
282,309,"In order to be eligible to participate in this study, an individual must meet all of the following criteria",{''}
283,310,age \> 18 years old.,{''}
284,311,Fasting Glucose \< 100 mg/dl,{''}
285,312,Patients treated with Koselugo (Selumetinib) under the approved label in South Korea,{''}
286,313,Patient aged 18 years or more,{''}
287,314,"Must be a healthcare worker (doctor, nurse, therapist, etc.) employed at Hospital León Becerra in Milagro, Ecuador.",{''}
288,315,Patients diagnosed with new or recurrent myeloid leukemia,{'my ##elo ##id le ##uke ##mia'}
289,316,age ≥ 18 years with stable refraction for at least two years;,{''}
290,317,Female patients with diarrhea-predominant irritable bowel syndrome,"{'di, ##ar ##r ##hea, i ##rri ##table bow ##el syndrome'}"
291,318,Child has one of the following presenting diagnoses,{''}
292,319,Male or Female 18 years or older,{''}
293,320,Age between 18-40 years old,{''}
294,321,-45 years of age at time of enrollment with an uncomplicated singleton pregnancy who are at no known increased risk for complications per clinical judgement of the investigator,{'single pregnancy'}
295,322,Age \> 65 years old,{''}
296,323,Willing and able to provide written informed consent;,{''}
297,324,Adult Asian women with locoregionally recurrent or metastatic disease not amenable to curative therapy,{''}
298,325,Individuals aged 65-84 years,{''}
299,326,"Histologic diagnosis of AL amyloidosis and typed with immunohistochemistry/ immunofluorescence, immunoelectron microscopy, or mass spectrometry. In patients with biopsy-confirmed amyloidosis, ambiguous amyloid typing results, and cardiac involvement alone, a negative pyrophosphate (PYP) or technetium-99m (99mTc) and 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD-Tc99m) bone scan is required to distinguish cardiac involvement due to AL amyloidosis from amyloid transthyretin (ATTR) amyloidosis. Data from the initial diagnosis are accepted.","{'AL am ##yl ##oid ##osis, am ##yl ##oid ##osis, cardiac involvement, cardiac involvement, AL am ##yl ##oid ##osis, am ##yl ##oid trans ##thy ##ret ##in ( AT ##TR ) am ##yl ##oid ##osis'}"
300,327,Be willing and able to provide written informed consent for the study.,{''}
301,328,• Suffered a mild or moderate traumatic brain injury within 3 months to 15 years prior to recruitment.,{'traumatic brain injury'}
302,329,diagnosed with esophagogastric junction outflow obstruction by high resolution manometry,{'es ##op ##ha ##go ##gas ##tric junction out ##flow o ##bs ##truction'}
303,330,Cases patients with AHI \> 30/h,{''}
304,331,Multiple myeloma meeting the following criteria,{'Multiple my ##elo ##ma'}
305,332,Subjects must voluntarily agree to participate by providing written informed consent and agreeing to comply with protocol and scheduled visit;,{''}
306,333,be willing and able to provide written informed consent/consent for the trial.,{''}
307,334,patients of upper gastrointestinal perforation,{'upper gas ##tro ##int ##est ##inal per ##fo ##ration'}
308,335,+ years of age,{''}
309,336,Previously participated in the SICCA study at Penn,{''}
310,337,"Age 50 to 80 years old (including 50 and 80 years old), male or female;",{''}
311,338,Rectus diastasis ≥3 cm,{''}
312,339,- Moderate or major depressive episode as primary diagnosis,{'de'}
313,340,Patient must be ≥ 18 years of age,{''}
314,342,"The patient's clinical manifestations, physical examination, and imaging data all support the diagnosis of degenerative lumbar spondylosis.",{'de ##gene ##rative l ##umba ##r s ##po ##ndy ##los ##is'}
315,343,"In order to be eligible to participate in this study, an individual must meet all of the following criteria",{''}
316,344,"Patient with advanced metastatic solid tumors with documented tumor progression after at least one line of systemic therapy and for which no further standard therapies are available, feasible or accepted by the patient. Prior exposure to an immune checkpoint inhibitor (ICPI) is allowed. Patient with a localized disease for which no curative therapy is available and a measurable lesion is still amenable for RECIST assessment after biopsy (to manufacture the vaccine) are allowed (example GBM or sarcoma with local relapse after surgery, chemo-radiation)","{'meta ##static solid tumors, tumor, GB ##M, sa, ##rc ##oma'}"
317,345,"Meets classification criteria for primary Sjogren's syndrome (pSS) by the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) at the time of screening, and was diagnosed with pSS no less than 26 weeks prior to screening","{""S ##jo ##gren ' s syndrome, p ##SS R ##he ##uma ##tism, p ##SS""}"
318,346,"All patients must be diagnosed with neuroblastoma, and categorized as high risk at the time of diagnosis; exception patients who are initially diagnosed as non-high-risk neuroblastoma, but later converted (and/or relapsed) to high risk neuroblastoma are also eligible","{'ne ##uro ##blast ##oma, ne ##uro ##blast ##oma, ne ##uro ##blast ##oma'}"
319,347,"Arm A dose escalation patients with histologically or cytologically proven advanced solid tumors for which standard treatments are not available, or for whom the current dose level of cisplatin in combination with pemetrexed is appropriate; =\< 2 prior cytotoxic chemotherapy regimen",{''}
320,348,ATG-F administration to prophylaxis rejection in kidney transplantation recipient.,{'rejection'}
321,349,Willing and able to provide informed consent;,{''}
322,350,Participant must be 40 to 70 years of age inclusive,{''}
323,351,Type 1 diabetes mellitus children with genetic immunodeficiency,"{'Type 1 diabetes me ##lli ##tus, genetic im ##mu ##no ##de ##ficiency'}"
324,352,Patients will be eligible for inclusion into the study if they meet all of the following criteria,{''}
325,353,"Female,",{''}
326,354,Age 18-69 years,{''}
327,355,women and men 40-70 years old;,{''}
328,356,Histologically or cytologically confirmed diagnosis of stage IV NSCLC (or recurrent NSCLC not a candidate for definitive multimodality therapy),"{'stage IV N ##SC ##LC, re N ##SC ##LC'}"
329,357,Patients aged ≥ 18 years,{''}
330,358,Provision of signed and dated informed consent form.,{''}
331,359,Able to understand the purpose and the procedures involved in this study and sign the informed consent form.,{''}
332,360,STEMI patient; Symptom onset in 12 hours; Intended to perform PPCI,{'ST ##EM ##I'}
333,361,INTERVENTION (SURVIVORS) INCLUSION,{''}
334,362,"In the dose escalation, patients must have a histologically documented locally advanced, unresectable, or metastatic solid tumor that has progressed following at least one prior line of treatment in the metastatic setting or has no satisfactory alternative treatment option and all of the following",{'meta ##static solid tumor'}
335,363,have had at least one vertebral fracture in the past two years confirmed by a radiology report,{'ve ##rte ##bra ##l fracture'}
336,364,Histologic diagnosis/confirmation of prostate adenocarcinoma and no evidence of small cell cancer.,"{'pro, ##state ad ##eno ##car ##cin ##oma, small cell cancer'}"
337,365,"Subject completed the week 12 visit in one of the Phase 2, ASP015K Rheumatoid Arthritis studies within the previous 14 days.","{'R, ##he ##uma ##to ##id Art ##hr ##itis'}"
338,366,"Subject is age 18 to 55 years, inclusive.",{''}
339,367,"Nonpregnant adults between 18 years and 50 years of age, inclusive.",{''}
340,369,Diagnosed heart failure with preserved ejection fraction,{'heart failure'}
341,370,Patients with good mental status,{''}
342,371,PRE-REGISTRATION INCLUSION CRITERIA,{''}
343,373,Older than 18 years old,{''}
344,374,"Unmarried woman and couple of women with societal infertility,",{'societal in ##fer ##tility'}
345,375,Have metastatic castration-resistant prostate cancer,{'cast ##ration - resistant pro ##state cancer'}
346,376,Provide written informed consent.,{''}
347,377,At least 18 years of age; Patients with chronic widespread pain; Able to complete the questionnaire.,{'chronic widespread pain'}
348,378,Subject who is aged 18 years or older who signed informed consent,{''}
349,379,MCADD patients,{'MCA ##D ##D'}
350,380,Patients 18 years of age or older;,{''}
351,381,"The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;",{''}
352,382,Age 40 or greater,{''}
353,383,"All adult patients presenting to the Emergency Department, with a blood culture order in the Emergency Department, who are classified as Group D, in whom a clinician initiates a normal saline order",{''}
354,384,Patients aged 18 years or older.,{''}
355,385,-,{''}
356,386,"willing to sign consent and have samples collected,",{''}
357,387,toddlers who were ≤ 36 weeks gestational age (GA) at birth who attend the University of Minnesota Masonic Children's Hospital NICU Follow Up Clinic,{''}
358,388,The patient must have given their free and informed consent and signed the consent form,{''}
359,389,Parent's infant agreeing to participate in the study,{''}
360,390,"Age related cataracts over 50 years old, nuclear grades II-III",{'cat ##ara ##cts'}
361,391,Chronic Pain Trial,"{'Ch, ##ronic Pain'}"
362,392,continuous coverage of at least 365 days (\>= 1 year) pre-index date for the cohort,{''}
363,394,Age 20-75 years,{''}
364,395,Age ≥18,{''}
365,396,Age 18 or older,{''}
366,397,"- Ethnically-diverse Black prostate cancer (CaP) survivors who are either native-born, Caribbean-born, or African-born, within the early phase of their CaP survivorship journey (defined as within the first five years after diagnosis).","{'pro ##state cancer, C ##a ##P, C, ##a ##P'}"
367,398,capable of giving written informed consent,{''}
368,399,"Ages 18-65,",{''}
369,400,Both parents are of Chinese origin;,{''}
370,402,Ability of participant to understand and the willingness to sign a written informed consent document.,{''}
371,403,Have measurable disease per Response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) as assessed by the local site investigator.,{'solid tumors'}
372,404,"Male or female, between 20-80 years of age, who request dental implant treatment options to replace missing teeth as part of comprehensive dental care",{''}
373,405,Participant with a clinical diagnosis of chronic kidney disease (CKD) and the following,"{'chronic kidney disease, C ##K ##D'}"
374,406,"Aged 18 to 80 years old (including boundary value), gender is not limited;",{''}
375,407,"Documented heavy prenatal alcohol exposure (self-report, social service records, or adoption records) and meeting criteria for an associated FASD diagnosis (FAS, partial FAS, or ARND).","{'FA ##SD, FA ##S, FA ##S, AR ##ND'}"
376,408,Man or woman at least 18 years old.,{''}
377,409,The target group are all adult (age \>=18 years) physically ill patients capable of giving consent on the pilot ward.,{''}
378,410,Age,{''}
379,411,Cohort A,{''}
380,412,"Subjects who have decided to voluntarily participate in the study and provided a written consent regarding observance of precautions after having been informed of and having fully understood the objectives, methods, and effects of the study in detail;",{''}
381,413,Age \> 50 years,{''}
382,414,"Participant has a BMI range of 18.5 to 36.0 kg/m\^2, inclusive and weighs at least 50 kg at screening.",{''}
383,415,Listed for liver transplantation,{''}
384,416,EfFORT Trial Probands,{''}
385,417,Meet the 1990 American College of Rheumatology (ACR) Research Classification Criteria for fibromyalgia;,"{'fi, ##bro ##my ##al ##gia'}"
386,418,Age ranging from 18-85 years old;,{''}
387,419,For patients with aniridia,{'an ##iri'}
388,420,"Relapsed or progressive medulloblastoma, ependymoma or ATRT (at least one site of untreated recurrent disease)","{'me ##du ##llo ##blast ##oma, e ##pen ##dy ##mo ##ma, AT ##RT'}"
389,421,An individual who has previously consented to the Biospecimen Resource for Pancreas Research (Substudy #2 Family Studies) - IRB 355-06,{''}
390,422,years or older,{''}
391,423,Ages 18 or older,{''}
392,424,Age ≥ 18 years,{''}
393,425,"i. Outpatient, male or female subjects of any race, and at least 12 years of age or older.",{''}
394,426,Males and females 12+ years of age.,{''}
395,427,"Adult, non-pregnant patients with biopsy-proven or clinically obvious primary, recurrent or metastatic breast cancer",{'breast cancer'}
396,428,patients with the ten warning signs are four or more new ear,{''}
397,429,Adult (≥ 18 years),{''}
398,431,Patients with signed informed consent.,{''}
399,432,"Pathologically (histologically) proven diagnosis of HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx prior to registration;",{'H ##NS ##CC'}
400,433,Patient with a liver transplant performed in the previous year and for whom the conversion from Prograf® to Advagraf® was decided by the physician.,{''}
401,434,Age Patients must be ≥12 months and ≤30 years of age at the time of enrollment onto this screening protocol.,{''}
402,435,Patients over 18 years of age,{''}
403,436,"- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.",{'H ##F ##p ##EF'}
404,437,"HCWs from selected participating health facilities in DRC, junior doctors during their first year resident and permanent health care staff from participating secondary hospitals in Iraq",{''}
405,438,"Males and females, Age ≥18 years at the time of signing informed consent.",{''}
406,439,Patient is between 21 and ≤70 years of age,{''}
407,440,"Patients must have a diagnosis endometrial carcinoma on a tissue sample obtained at MSK (biopsy). Patients with the following histologic epithelial cell types are eligible endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma, carcinosarcoma.","{'end, ##ome ##tri ##al car ##cin ##oma, end, ##ome ##tri ##oid ad ##eno ##car ##cin ##oma, se ##rous ad ##eno ##car ##cin ##oma, und ##iff ##ere ##nti ##ated car ##cin ##oma, clear cell ad ##eno ##car ##cin ##oma, mixed e ##pit ##hel ##ial car ##cin ##oma, ad ##eno ##car ##cin ##oma, m ##uc ##ino ##us ad ##eno ##car ##cin ##oma, sq ##ua ##mous cell car ##cin ##oma, transitional cell car ##cin ##oma, car, ##cin ##osa ##rc ##oma'}"
408,441,Test participants; Male and female 3 to 11-year-old children diagnosed by ACPOS clinicians as likely having amblyopia (strabismic or anisometropic). They will be tested following 6 weeks (or more) of refractive adaption.,"{'am, ##bly ##op ##ia ##tra ##bis ##mic, an, ##is ##ome ##tro ##pic'}"
409,442,"One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors",{''}
410,443,Age \>6 months and ≤80 years at the beginning of the index MAS episode.,{'MA ##S'}
411,444,Children and young people (male and female) aged 1-18 yr receiving height measurements as part of their routine / prearranged attendance to a paediatric endocrinology or other paediatric out-patient appointment at Barts Health Trust.,{''}
412,445,Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis,{'tumor'}
413,446,Male or female \>18 years of age,{''}
414,448,• Men or women aged 18-30,{''}
415,449,Be ≥ 18 years of age,{''}
416,450,Female aged 10-13 years for HPV vaccination and SRH education,{''}
417,451,Age from 18 years old or more,{''}
418,452,"Male of female, aged 55 or older",{''}
419,453,Age Adults aged 18 years and above.,{''}
420,454,hospitalized and treated with parenteral antifungal medication,{''}
421,456,"Multiple polyps resection, ESD(Endoscopic Submucosal Dissection) , EMR(Endoscopic Mucosal Resection), enteroscopy and other gastrointestinal endoscopic diagnosis and treatment were performed",{'Multiple p ##oly ##ps'}
422,457,Male or female subject aged 18 to 60 years.,{''}
423,458,"Male or female participants age ≥18 years at the time of informed consent. 2. Capable of giving signed informed consent/assent. 3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.",{''}
424,459,To be between 7-12 years old,{''}
425,460,Patients undergoing anterior resection (resection of the rectum and colorectal or coloanal anastomosis) due to a rectal tumour and a protective stoma is planned.,{'re ##ct ##al t ##umour'}
426,461,Adult patient with haemopathy or paediatric patients with haemopathy or solid tumor.,"{'ha, ##em ##op ##athy, ha ##em ##op ##athy, solid tumor'}"
427,464,"Must have participated in one of the following protocols 2015-0399, 2012-0642, or 2010-0675",{''}
428,465,Undergoing a scheduled laparoscopic bariatric surgery under general anesthesia.,{''}
429,466,"Male or female Grade 1-2 hypertensive patients with mean sitting SBP ≥140 mmHg and ≤179 mmHg and/or mean sitting DBP ≥ 90 mmHg and ≤109 mmHg at Screening, with ≥18 and ≤65 years of age, on monotherapy either with ZOF 30 mg or AML 5mg or any other ACE-I or CCBs (Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nisoldipine) for at least 1 month before Visit 1 (Screening).",{'Grade 1 - 2 h ##yper ##tensive'}
430,467,Healthy young volunteers that participated regularly in strength training,{''}
431,468,Patients must have histologically or cytologically confirmed recurrent primary mucinous ovarian cancer,{'m ##uc ##ino ##us o ##var ##ian cancer'}
432,470,"Histologic, cytologic, or radiologically evidence of locally advanced, residual or recurrent solid malignancy of the abdomen or pelvis requiring surgical resection",{'solid ma ##li ##gna ##ncy of the abdomen or p ##el ##vis'}
433,471,Subjects with severe visual disturbance (count-fingers or worse vision for severe eyes) at the time of obtaining the consent and at screening,"{'visual disturbance, count - fingers or, worse vision eyes'}"
434,472,Patients at least 18 years of age.,{''}
435,473,years of age or older,{''}
436,474,Adult male or female patients from ≥ 18 years of age.,{''}
437,475,Patients whose age of operation is 14-90 d. Sex and race are not restricted;,{''}
438,476,Histologic or cytologic proof of pancreatic adenocarcinoma,{'pan ##cre ##atic ad ##eno ##car ##cin ##oma'}
439,477,Children with CHD who needed gastric tube in CCU were admitted,{'CH ##D'}
440,478,Adult participants aged 18-65 (inclusive),{''}
441,479,Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.,{''}
442,480,These criteria are similarly applicable to patients enrolled to the phase I dose escalation and to the phase IB dose expansion portions of the trial.,{''}
443,481,Age ≥ 18,{''}
444,482,Ability to understand and willingness to sign an informed consent form (ICF) prior to initiation of the study and any study procedures.,{''}
445,483,Myelopathy secondary to Progressive MS,{'My ##elo ##pathy MS'}
446,484,Female Subjects ≥18 years of age,{''}
447,485,"Families (one or two parents) with a newborn or infant under 2 months with confirmed or suspected Hirschsprung disease, for whom nursings are effective and performed 1 to 2 times a day while waiting for surgery.",{'Hi ##rsch ##sp ##rung disease'}
448,486,Being a Physiotherapy and Rehabilitation student,{''}
449,487,Adult patients of at least 18 years of age,{''}
450,489,Provision of signed and dated informed assent form;,{''}
451,490,Adult patients who do not object to the use of their medical data and samples for this research,{''}
452,491,Both genders,{''}
453,492,"patients should be males or females (age≥18 years) with diagnosed OSA and candidates for CPAP therapy (with any type of pressure delivery mode), and are cohabiting with their partner for at least one year",{'OS ##A'}
454,493,Males and females with Fontan physiology who are 12 to less than 19 years of age at enrollment.,{'F ##ont ##an physiology'}
455,494,Patients undergoing elective pancreatoduodenectomy with a high risk for contaminated bile defined as patients with preoperative biliary drainage or an ampullary malignancy.,"{'pan ##cre ##ato ##du ##ode, am ##pu ##llar ##y ma ##li ##gna ##ncy'}"
456,495,Enrolled in the preschool classroom,{''}
457,497,Both male and female patients ≥16 years of age will be included,{''}
458,498,participating in prison-based SUD treatment program,{'S ##U ##D'}
459,499,Age18-75 years old,{''}
460,500,Participants must be ≥18 years of age at the time of signing the informed consent.,{''}
461,501,genetic pathology of ocular surface,{''}
462,502,"Patients taking one of the following target drugs at the time of enrollment isavuconazonium sulfate (ISAV), voriconazole (VORI), posaconazole (POSA).",{''}
463,503,Not meeting Physical Activity Guidelines,{''}
464,504,Adult age 18 or older,{''}
465,505,Voluntary written informed consent of the participant has been obtained prior to any screening procedures,{''}
466,506,Age between 18 and 65 years,{''}
467,507,Patient referred for diagnostic colonoscopy,{''}
468,508,"Confirmed VTE (acute deep-vein thrombosis, pulmonary embolism and/or superficial venous thrombosis) by objective tests.","{'V ##TE, acute deep - vein th ##rom ##bos ##is, pulmonary em ##bol ##ism, superficial ve ##nous th ##rom ##bos ##is'}"
469,510,Age \> 18,{''}
470,511,Non-pregnant females who are,{''}
471,512,Age 60 years and over,{''}
472,513,Informed Consent and Assent have been completed,{''}
473,514,"Presence of four (medial and lateral, left and right) prominent platysmal bands",{''}
474,515,Must be ≥18 years of age;,{''}
475,516,"Outpatients and inpatients aged 19 years or older showing hypotension, normal blood pressure, prehypertension, and hypertension","{'h ##y ##pot ##ens ##ion, pre, ##hy ##pert ##ens ##ion, h ##yper ##tens ##ion'}"
476,517,meet the 1990 American College of Rheumatology (ACR) Research Classification Criteria for fibromyalgia and 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria;,"{'fi, ##bro ##my ##al ##gia, fi, ##bro ##my ##al ##gia'}"
477,518,Diagnosed as BP by specialist.,{'BP'}
478,519,"Diagnosis of sickle cell hemoglobinopathy (Homozygous sickle cell disease, Hemoglobin SC disease, or Sickle/beta-thalassemia);","{'sick ##le cell hem ##og ##lo ##bino ##pathy, Ho, sick ##le cell disease, He ##mo ##g ##lo ##bin SC disease, Sick ##le / beta - th ##ala ##sse ##mia'}"
479,520,"requesting termination of pregnancy by means of mifepristone followed by home administration of misoprostol at \< /=63 days of gestation, no contraindication to medical abortion and self administration of misoprostol at home, and who have given their informed consent",{''}
480,523,Willing and able to provide signed informed consent,{''}
481,524,Patients over 18 years old.,{''}
482,525,Patients who are converted to Graceptor® from cyclosporine in the maintenance phase after kidney transplantation.,{''}
483,526,Fluent in English,{''}
484,527,"recent initiation of methadone or buprenorphine at APT Foundation within the past 6 months (i.e., period of time during which treatment drop-out and risk for relapse is highest);",{''}
485,528,"Pathologically confirmed AML or CLL, otherwise eligible for VEN-containing therapy at Screening","{'AM ##L, C ##LL'}"
486,529,American Indians,{''}
487,530,T-ALL patients must be enrolled on AALL08B1 prior to treatment and enrollment on AALL0434,{'T - AL ##L'}
488,531,for patients with retinitis pigmentosa,{'re ##tin ##itis pig ##mento ##sa'}
489,532,Age ≥ 18 years,{''}
490,533,"Patients must have metastatic melanoma, uveal melanoma or stage III in-transit or regional nodal disease. (Turnstile I)","{'meta ##static me ##lan ##oma, u ##ve ##al me ##lan ##oma'}"
491,535,The key inclusion criteria include but are not limited to the following,{''}
492,536,Mother was enrolled in the GN ASPIRIN trial,{''}
493,537,Feminine gender,{''}
494,538,"If female, subject must be at least 2 years post menopausal or is surgically sterile per documentation provided by a medical professional and the subject is not pregnant as documented by a negative serum pregnancy test at Screening and negative urine pregnancy test at check-in",{''}
495,539,"In order to be eligible to participate in this study, an individual must meet all of the following criteria",{''}
496,540,"• Primiparous mothers who are over 18 years of age and have given birth vaginally,",{''}
497,541,French-speaking and non-demented patient  able to speak and understand French and without dementia,{'dem ##ent'}
498,542,Participants must meet all the following inclusion criteria at the Screening Visit in order to be eligible to enroll into the genetic screening phase.,{''}
499,543,"Patients with infection due to a difficult-to-treat Gram-negative bacteria treated with CAZ/AVI alone, CEF alone, CAZ/AVI plus FOS, or CEF plus FOS (any age)",{''}
500,544,-,{''}
501,545,Adults ≥ 18 years of age.,{''}
502,546,"Proposed to perform painless GI endoscopy, and simple endoscopic maneuvers such as single small polyp clamping, performing HP examination, etc;",{'p'}
503,547,"Provide written informed consent, signed, and dated by the participant and study partner, or by the participant's legally authorized representative if applicable, according to local regulations for the ICF and, if applicable, country specific ICFs.",{''}
504,548,to 80 years of age.,{''}
505,549,Signed the informed consent；,{''}
506,550,written informed consent,{''}
507,551,Fluent English speakers,{''}
508,553,Patients who admitted to trauma intensive care unit.,{'trauma'}
509,554,"Participant has a history of RRMM, and must",{'R ##R ##MM'}
510,555,Parkinson's disease patients over 20 years old (the Unified Parkinson's Disease Rating Scale and Hoehn-Yahr Grading Scale are required to provide clinical staging).,"{""Parkinson ' s disease, Parkinson ' s Disease - Ya""}"
511,556,Patients must be aged less than 76 years at the time of diagnosis,{''}
512,557,Written informed consent has been obtained prior to initiating any study-specific procedures.,{''}
513,558,Age ≥ 18 years,{''}
514,559,Age Patients must be ≥ 12 months and ≤ 25 years of age at the time of study enrollment.,{''}
515,561,Able to provide written informed consent.,{''}
516,562,Age 18 and above,{''}
517,563,Self-reported difficulty or inability to walk ¼ mile,{''}
518,564,"Normal Body Mass index (BMI) and weight BMI\[= weight kg/(height m)\^2\] \> 19 kg/m\^2 and ≤ 24 kg/m\^2, the weight is no less than 50 kg for male and 45 kg for female at screening.",{''}
519,565,Planned Photorefractive Keratectomy in both eyes,{''}
520,566,Patients must have a diagnosis of neuroblastoma (International Classification of Disease for Oncology \[ICD-O\] morphology 9500/3) confirmed by MSKCC pathologic review,{'ne ##uro ##blast ##oma'}
521,567,patients with planned extubation assigned to the study,{''}
522,568,home resident older,{''}
523,569,Written informed consent and HIPAA authorization for release of personal health information. NOTE HIPAA authorization may be included in the informed consent or obtained separately.,{''}
524,570,A patient age of 14-70 years,{''}
525,571,Patients with head and neck cancer scheduled for combined head and neck surgery - plastic surgery free flap,"{'head and neck cancer, head and neck'}"
526,0,Patient has or is intended to receive or be treated with an eligible Medtronic product,{''}
527,1,NSLC lacks oncogenic driver mutations,{'N ##SL ##C'}
528,2,Histologically or cytologically confirmed metastatic clear cell renal cell carcinoma,{''}
529,3,Age between 20-65 years old.,{''}
530,4,Has ≥3 prostate biopsy cores with ≥50% tumor involvement.,{'tumor'}
531,5,volunteer,{''}
532,6,Determined to have detectable mutations in codons 12 or 13 of the kirsten rat sarcoma (KRAS) oncogene by an investigational assay at the study central laboratory. A KRAS positive mutation result in codons 12 or 13 of the KRAS oncogene from tumor tissue per local laboratory will be permitted in no more than 10% of randomized participants.,"{'k ##irs ##ten rat sa ##rc ##oma, tumor'}"
533,7,Their child has an acute or chronic disease,{''}
534,8,"Diagnosis of CDI defined as a new or recent history of 3 or more bowel movements per day with a loose or watery consistency (Bristol Stool Scale 5, 6, or 7); a positive stool C. difficile toxin B immunoassay (stool collected no more than 7 days before first dose of LMN-201/placebo), and no other likely explanation for diarrhea. NOTE Diarrhea is not required to be present on the day of enrollment.","{'CD ##I, di, ##ar ##r ##hea, Di, ##ar ##r ##hea'}"
535,9,"COPD (FEV1/FVC \< 0.7, FVC \>= LLN), GOLD Stage I/II/III (FEV1 \>= 40%)","{'CO ##PD, GO'}"
536,10,"Patients must be scheduled for, or have intent to schedule, a screening mammogram",{''}
537,11,Resident of one of the 9 housing authority agencies,{''}
538,12,Subject must be a candidate for phototherapy and/or systemic therapy,{''}
539,13,Normal resting electrocardiogram,{''}
540,14,Have a cancer antigen (CA)-125 that normalized after first-line therapy,{'cancer'}
541,15,Healthy male and female subjects,{''}
542,16,Disease affecting more than one body site with at least moderate severity,{''}
543,17,Patients undergoing operative hysteroscopy under anesthesia in our OR due to uterine findings previously diagnosed during diagnostic hysteroscopy.,{''}
544,18,"Any gender, any ethnic origin, 19-69 years old inclusive.",{''}
545,19,Manifest Refraction - Spherical Equivalent Refractive Error (SERE) at baseline between -0.50 D and -7.00 D inclusive (at the corneal plane).,{''}
546,20,- Pathologically prevascularized cornea with need for corneal transplantation,{''}
547,21,Intern in residence for the elderly.,{''}
548,22,"-70 years old,",{''}
549,23,Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.,{''}
550,24,Subjects must have the capability to understand and provide informed consent on the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved Informed Consent Form (ICF) and authorization as appropriate for local privacy regulations.,{''}
551,25,A planned flexible bronchoscopy,{''}
552,26,Written informed consent of the patient,{''}
553,27,"Prescription diabetes medication regimen stable for \> 1 month, including any adjunctive anti-diabetic medications (except for medications that will not affect the safety of the study and are not expected to affect any outcome of the study, in the judgment of the site principal investigator)",{''}
554,28,informed consent,{''}
555,29,"Chronic non-cancer pain diagnosis such as low back pain, chronic neck pain, osteoarthritis, and prolonged post-surgical pain with daily pain for a minimum of 6 months.","{'##ronic non - cancer pain, low back pain, chronic neck pain, o, ##ste ##oar ##th ##rit ##is, prolonged post - surgical pain'}"
556,30,Age 18-45 years (both inclusive) at the time of signing informed consent,{''}
557,32,Individuals who can legally provide informed consent.,{''}
558,33,Use of Laryngeal Mask airway,{''}
559,34,"Subject is ≥40 years of age, inclusive, at the time of signing informed consent.",{''}
560,35,"According to treatment guidelines, micafungin may not be a suitable treatment for the following patients",{''}
561,36,Cerebellar atrophy on MRI,{'Ce ##re ##bella ##r at ##rop ##hy'}
562,37,Type 2 diabetes controlled with diet or diet and metformin (Glucophage),{'Type 2 diabetes'}
563,38,Acute symptomatic proximal deep vein thrombosis (DVT) documented by compression ultrasound (CUS) and all of the following,"{'pro ##ximal deep vein th ##rom ##bos ##is, D ##V ##T'}"
564,39,Not exercising regularly for the last 6 months,{''}
565,40,Patients aged 18 years who have not used steroids or similar medication after diagnosis,{''}
566,41,Continued engagement in full-time nursing studies;,{''}
567,43,Patients with a diagnosis of asthma indicated in online clinical records.,"{'as, ##th ##ma'}"
568,44,"Acute lymphoblastic leukemia survivor, OR living with chronic lung disease of prematurity, OR living with heart transplant","{'##cute l ##ymph ##ob ##lastic le ##uke ##mia, chronic lung disease of pre ##mat ##urity'}"
569,45,Patients with post-traumatic injuries (fractures treated surgically).,"{'post - traumatic injuries, fracture'}"
570,46,"Male or female patients older than 18 years with physician's confirmed diagnosis of severe, uncontrolled asthma.",{'as ##th ##ma'}
571,47,Participant is at least 18 years old.,{''}
572,48,-\>4 weeks after the participant had lung transplant surgery,{'lung'}
573,49,Patients must have recurrent or persistent HER2 overexpressing endometrial cancer or endometrial carcinosarcoma. HER2 overexpression is defined as 3+ by IHC or 2+ with gene amplification by FISH (HER2/CEP17 ratio ≥ 2) or HER2 amplified (fold change ≥ 2) on MSK IMPACT.,"{'end ##ome ##tri ##al cancer, end ##ome ##tri ##al car ##cin ##osa ##rc ##oma'}"
574,50,"Neck pain severity of 3 and above according to the Numerical Pain Rating Scale,",{'Neck pain'}
575,51,Fibrosing PID with fibrosis score \> 10% of lung volume on chest CT scan,"{'Fi, ##bro ##sing P ##ID, fi'}"
576,52,English-speaking,{''}
577,54,Reside in the United States,{''}
578,55,Agreeing to participate in the research,{''}
579,56,"have a DSM-5 mental illness, including",{'mental illness'}
580,57,"Subjects who have been informed of the nature of the study, agree to its provisions and have provided written informed consent as approved by the Ethics Committee (EC) of the respective clinical center",{''}
581,58,Relapsed disease with a platinum-free interval \>3 months,{''}
582,59,Measurable disease per RECIST v1.1,{''}
583,60,Male or female aged ≥18 years and ≤75 years;,{''}
584,62,Signs or symptoms of neuropathy and maximum baseline visual-analog pain scale ≥ 5 cm and peripheral arterial disease (diagnosed by ankle-brachial index \&amp;lt; 0.90 or vascular imaging studies) with claudication and exertion-induced visual-analog pain scale ≥ 6 cm for a minimum of 3 months.,"{'ne ##uro ##pathy, peripheral art ##erial disease, c ##lau ##dication ex ##ert ##ion pain'}"
585,63,Predominant histologic component (\>50 percent) must be urothelial (transitional cell) carcinoma,{'u ##roth ##eli ##al ( transitional cell ) car ##cin ##oma'}
586,64,Publicly-funded,{''}
587,65,Unilateral transfemoral prosthesis user (limb absence between the knee and hip),{''}
588,66,Body Mass Index (BMI) at screening ≥ 17.6 kg/m\^2 and \< 26.4 kg/m\^2 \[BMI = Body weight (kg) ÷ {Body height (m)\^2}\].,{''}
589,67,"Presence of at least one measurable lesion according to RECIST v1.1. c-i) FGF401 single agent-Phase I and Phase II, Group 3 Patients with HCC or advanced solid tumors, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists. c-ii) FGF401 single agent-Phase II, Groups 1 and 2 HCC patients previously treated with sorafenib for advanced HCC with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment c-iii) FGF401 in combination with PDR001Advanced HCC patients who have received up to 2 previous lines of systemic treatment and one treatment must have included sorafenib with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment","{'HC ##C, advanced solid tumors, HC ##C, advanced, HC ##C, HC ##C'}"
590,68,Ages 12 to \< 18 years,{''}
591,69,"Among the patients described in 1, those whose guardians understand the purpose and content of the research and consent to participate in the study.",{''}
592,72,Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol) despite diet and exercise treatment,{''}
593,73,"Documented progressive mCRPC per PCWG3, defined when at least one of the following criteria is met",{'m ##CR ##PC'}
594,74,Age at diagnosis,{''}
595,75,Body weight range of ≥40 kg (88 lbs) to ≤110 kg (242 lb) and a BMI of 18 to 34 kg/m2.,{''}
596,76,"Aged between 18 and 80 years, with no restriction on gender.",{''}
597,77,On heart failure medical regimen (beta blockers and ACE-I or ARB's) for at least one month before randomization,{'heart failure'}
598,78,Diagnosis of cancer cachexia,{'cancer cache ##xia'}
599,79,Native English speakers,{''}
600,80,Post-Menstrual Age (PMA) of 29-32 weeks gestation,{''}
601,81,Neurosurgery requiring a functional diagnosis by cortical electrical stimulation OR a histological diagnosis with or without fluorescent agent (5-ALA) for a tumor pathology or epilepsy or an arteriovenous malformation.,"{'tumor, e, ##pile ##psy, art ##eri ##ove ##nous ma ##lf ##orm ##ation'}"
602,82,"For children ≥1 year of age, ≥4 RTIs (as reported by parents or LAR of subject), including ≥2 episodes of wLRIs (including ≥1 triggering hospitalisation or medical visit) within 12 months prior to enrolment.","{'R, w ##LR ##I'}"
603,84,Measurable angle 25-40 prism diopters,{''}
604,85,Mandibular deficiency (SNB angle less than 77°).,"{'Man ##di ##bula ##r deficiency, S ##N ##B'}"
605,86,")At least one evaluable lesion with previous biopsy or pathohistologic confirmation of high-grade glioma (WHO grade IV), with imaging suggestive of continued progression or recurrence after comprehensive treatment;","{'high grade, g, ##lio ##ma'}"
606,87,Aged over 18 years old;,{''}
607,88,"Study participant has documented diagnosis of generalized myasthenia gravis (gMG) at Visit 1, based on study participant's history and supported by previous evaluations","{'generalized my ##ast ##hen ##ia g ##ra ##vis, g ##MG'}"
608,90,"Normal-flow, low-gradient aortic stenosis (AS) with preserved ejection fraction (mean aortic Pressure Gradient (mPG) \<40 mmHg, Aortic Valve Area (AVA) ≥0.8 ≤1.0 cm2, Left Ventricular Ejection Fraction (LVEF) ≥50%, Stroke Volume Index (SVi) \>35 mL/m2);","{'a ##ort ##ic s ##ten ##osis, AS'}"
609,91,Premenopausal women with a regular menstrual cycle for \>3 months,{''}
610,92,Stable medical condition.,{''}
611,93,years of age and older,{''}
612,94,Residents of the study area,{''}
613,95,Agreeing to participate in the study,{''}
614,96,Is neurologically asymptomatic from brain metastases and has not received systemic corticosteroid therapy in the 10 days prior to beginning study intervention,{''}
615,97,"Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)",{''}
616,98,"In emergency situations when a patient meets all other eligibility criteria and has had baseline required observations, but is too ill to undergo a biopsy safely, the patient may be enrolled on AHEP0731 without a biopsy",{''}
617,100,Age 6 to \<12 years at time of the baseline visit.,{''}
618,101,"in good health with no history, or current evidence of clinically significant medical condition of laboratory, ECG or vital sign abnormality",{''}
619,102,"Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2",{''}
620,104,Age 21 years or older.,{''}
621,105,"The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx",{'tumor'}
622,106,Bilateral PRP for proliferative diabetic retinopathy required,"{'pro, ##life ##rative di ##abe ##tic re ##tino ##pathy'}"
623,107,\>18 years of age at time of enrollment.,{''}
624,108,"Refractive error of at least 0.75 diopters (D) of myopia, 2.00 D of hyperopia or 1.00 D of astigmatism;","{'my, h ##yper, as'}"
625,109,Written informed consent with HIPAA authorization for release of personal health information.,{''}
626,110,Above eighteen (18) years of age or of legal age to give informed consent specific to state and national law,{''}
627,111,"Prior first-line treatment with aPD1 monotherapy (defined as at least one dose of pembrolizumab, avelumab, nivolumab, etc.) with evidence of progression of disease ≥10 weeks after starting therapy, in the absence of significant clinical deterioration",{''}
628,112,Undergoing spinal anesthesia) with American Society of Anesthesiologists (ASA) classification I and II,{''}
629,113,Patients aged ≥18 years at first ATTR-CM diagnosis,{''}
630,114,"Diabetic patients with gastroparesis, diabetic patients without gastroparesis and who are willing to have a gastric emptying test if they have not had one in the last 6 months and an IV inserted.","{'gas ##tro ##par ##esis, di, ##abe, gas ##tro ##par ##esis'}"
631,116,to have at least 2 years of experience in the sport,{''}
632,117,Adult participants ≥ 18 years of age.,{''}
633,118,"Tumor tissue or liquid biopsy-based next-generation sequencing (NGS), quantitative polymerase chain reaction (qPCR), and fluorescence in situ hybridization (FISH) for RET gene fusion detection will be permitted.",{''}
634,119,"All IUDs (copper, hormonal) eligible",{''}
635,121,Age \>18 years,{''}
636,122,Female participant is not pregnant and at least 1 of the following conditions apply,{''}
637,123,African Americans without a diagnosis of IBD and without a family history of IBD for comparison purposes,"{'I ##B ##D, I ##B ##D'}"
638,125,Stated willingness to comply with all study procedures and availability for the duration of the study,{''}
639,126,Currently on sick leave due to mental health issues.,{'mental health'}
640,127,"Decision to use Elevit® MMN or monocomponent supplementation of folic acid was made independent of study participation, and made prior to inclusion into this study.",{''}
641,128,"Those diagnosed with autism spectrum disorder through a standardized diagnostic tool according to the diagnostic criteria for autism spectrum disorder in the DSM-5 (Diagnostic and Statistical Manual of Mental disorder-5) at the time of screening \[Diagnostic tool Korean version of Autism Diagnostic Observation Schedule version 2 (K-ADOS-2), Korean version of Autism Diagnostic Interview-Revised (K-ADI-R)\] (However, if diagnosed with autism spectrum disorder through a diagnostic evaluation within 6 months of screening, only the K-ADOS-2 test will be re-evaluated.)","{'autism spectrum disorder, autism spectrum disorder Mental disorder, autism spectrum disorder'}"
642,129,Current care provided by the UAMS NICU,{''}
643,130,Age 12-35 years (both inclusive) at the time of signing informed consent and assent,{''}
644,131,From Arabic speaking countries.,{''}
645,132,not on HRT for at least one year before the initiation of the study,{''}
646,133,students with serum 25(OH)D concentrations below 20 ng/mL;,{''}
647,135,Has access to video conferencing (including web cameras and audio) and a private space for the remote study visits.,{''}
648,136,"aged 18 and older,",{''}
649,137,Patients with spinal muscular atrophy (SMA).,"{'spinal muscular at ##rop ##hy, SM ##A'}"
650,138,Aged 12-25 years,{''}
651,139,All females must have a negative pregnancy test.,{''}
652,140,Physical exam population,{''}
653,143,Patients who voluntarily participate and sign the informed consent form.,{''}
654,144,Age ≥50 years,{''}
655,145,Sign a written Informed Consent Form,{''}
656,146,Subject has been treated with oral methotrexate (MTX) for a minimum of 90 days and at a stable dose for 28 days prior to the first dose of study drug,{''}
657,147,"HIV-RNA positive in serum or HIV antibody positive patients (the amount of HIV-RNA in the blood at the time of screening is less than 200 copies/mL, and the number of CD4 positive T lymphocytes can be maintained at 200/micro L or more).",{''}
658,148,Metastatic disease by conventional imaging,{''}
659,149,Type 2 diabetes controlled with diet or diet and metformin (Glucophage),{'Type 2 diabetes'}
660,150,Admission to a critical care unit/intensive care unit (ICU) for \> 24 hours;,{''}
661,151,"Sign the Informed Consent Form (ICF) voluntarily, understand the study and be willing and able to comply with all study procedures;",{''}
662,152,Normal development of pregnancy.,{''}
663,154,Patients who did not receive antibiotic treatment or probiotics in 3T.,{''}
664,155,"Male between the ages of 18 and 49 years, inclusive;",{''}
665,156,"\~18 years old, course of disease \> 1 year;",{''}
666,157,One male or female aged 30 or over but below 40 years old.,{''}
667,159,"Patients must have advance, recurrent or metastatic endometrial cancer",{'end ##ome ##tri ##al cancer'}
668,160,"seizures onset before 1 year of age,",{''}
669,161,"Male or female, age ≥ 18 years.",{''}
670,162,Patients must have confirmed locally advanced and unresectable or metastatic disease by either imaging or tissue diagnosis,{''}
671,163,"Ability for parent/legal guardian to provide written, informed consent prior to initiation of any trial-related procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the trial. Ability to provide written informed assent from all subjects old enough per local laws to provide assent.",{''}
672,164,"Male or nonpregnant, nonlactating females, age 18-75. Males and females of childbearing potential must agree to use adequate birth control measures during the study. Females of childbearing potential must have a negative serum pregnancy test prior to Visit 2 and either be sexually abstinent or must use a hormonal (oral, implantable, or injectable) or double barrier method of birth control throughout the study, and until 60 days after the last dose of study drug. Females unable to bear children must have documentation of such in the source records (i.e., tubal ligation, hysterectomy, or postmenopausal \[defined as a minimum of 1 year since the last menstrual period\]).",{''}
673,165,"Being 18 years or older,",{''}
674,166,- 50 years of age,{''}
675,167,"aged 65-80 years,",{''}
676,168,Generally healthy,{''}
677,169,subjects been intubated and mechanically ventilated for \< 24 hours at the time of screening;,{''}
678,170,"Capable of hearing, speaking, reading, and writing",{''}
679,171,"report FV within the last 12 months prior to screening (based on self, court, police or child protection reports);",{'F'}
680,172,"Male or nonpregnant, nonbreastfeeding female participants.",{''}
681,174,Body mass index (BMI) 30-50 kg/m2,{''}
682,175,Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for PTSD according to the Clinician-Administered PTSD Scale for DSM-5,"{'PT ##SD, PT ##SD'}"
683,176,Patients of the ages of 18 and 95 years.,{''}
684,177,Type 2 diabetes diagnosed according to the American Diabetes Association criteria;,"{'Type 2 diabetes, Di ##abe ##tes'}"
685,178,"Participant requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full-time mechanical ventilation, to non-invasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours)",{''}
686,179,Has clinically detectable and resectable Stage IIIB or IIIC or IIID melanoma amenable to surgery,{'me ##lan ##oma'}
687,180,BMI of 27 kg/m2 or greater,{''}
688,181,Measurable or evaluable disease per PCWG3 criteria; all participants must have a serum PSA value greater than or equal to (\>=2) nanograms per milliliter (ng/mL) at time of screening,{''}
689,182,Peutz-Jeghers Syndrome or,{'P ##eu ##tz - Je ##gh ##ers S ##yn ##drome'}
690,183,years or older,{''}
691,184,Life expectancy of ≥ 3 months,{''}
692,185,"Histologically or cytologically confirmed recurrent or refractory solid tumor (Rhabdomyosarcoma, Ewing sarcoma, primary CNS malignancies, melanoma) after standard therapy which has failed all available curative therapy.","{'solid tumor, R ##hab ##dom ##yo ##sar ##com ##a, Ewing sa ##rc ##oma, C ##NS ma ##li ##gna ##ncies, me, ##lan ##oma'}"
693,186,Male or female aged ≥ 18 years at the time of signing the ICF.,{''}
694,187,≥ 3 years at the moment of inclusion in the trial.,{''}
695,188,Subjects with documented severe or moderately severe hemophilia B (FIX activity of ≤ 2%),{'hem ##op ##hil ##ia B'}
696,189,Patients must have a body surface area \>= 0.35 m\^2,{''}
697,190,Patients aged 18 years or older,{''}
698,191,Adults of ≥65 years of age on the day of vaccination.,{''}
699,192,Xanthoma of skin;,{'X ##ant ##hom ##a of skin'}
700,195,With a constitutional von Willebrand Disease (according to the phenotypic criteria of the French Reference Center of von Willebrand Disease),"{'von Will ##eb ##rand Disease, von Will ##eb ##rand Disease'}"
701,196,Subject provides written informed consent approved by the Ethics Committee prior to any clinical investigation related procedure,{''}
702,197,Age ≥ 8 years,{''}
703,198,C-Reactive Protein (CRP) of ≥ 0.8 mg/dL or Erythrocyte Sedimentation Rate (ESR) of ≥ 28 mm/hr,{''}
704,199,"Documented diagnosis of sickle cell disease (SCD) (HbSS, HbSC \[combined heterozygosity for hemoglobins S and C\], HbS/beta 0- thalassemia, HbS/ beta plus thalassemia, or other sickle cell syndrome variants);","{'sick ##le cell disease, SC ##D 0 plus th, sick ##le cell syndrome'}"
705,200,"History of vitrectomy, trabeculectomy, large iris defects, anterior synechiae on the eye to be operated on","{'v, i ##ris defects, anterior s ##yne ##chia ##e eye'}"
706,201,Patients free from any systemic disease,{''}
707,202,Minimum score of 31 on the PCL-5,{''}
708,203,Have at least 1 measurable lesion whose presence is assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1),{'Solid Tu ##mor'}
709,204,Age ≥ 8 years,{''}
710,205,Signed informed consent was obtained prior to participation in the study.,{''}
711,206,"Participant has a body mass index (BMI) range of 17.0 to 36 kg/m\^2, inclusive and weighs at least 50 kg (male participant) or 40 kg (female participant) at screening.",{''}
712,207,American Society of Anesthesiologists (ASA) physical statusclassification of I-II,{''}
713,208,"systemically healthy,",{''}
714,210,Age \>45 years.,{''}
715,211,"PANSS total score at baseline \> 75, at least two PANSS psychosis items ≥ 4, Clinical Global Impression of severity score moderately ill or more (≥4)",{'ps ##ych ##osis'}
716,212,"(a) infrequent cannabis use defined as at least one reported use in the past year with a negative THC urine toxicology at baseline, or",{''}
717,213,"Hysteroscopy and endometrial biopsy were performed, and the",{''}
718,215,-16 years of age,{''}
719,216,No prior diagnosis of prostate cancer,{'pro ##state cancer'}
720,217,"Prescribed or continued risdiplam based on clinical judgment of prescriber, as per the Evrysdi® USPI, after U.S. FDA approval (07 August 2020)",{''}
721,218,"Absence of active infection including blood, urine, cerebrospinal fluid",{''}
722,219,"clinical evidence of CSM as determined by signs and symptoms including, but not limited to loss of manual dexterity, extremity weakness, sensory abnormalities, quadriparesis, loss of proprioception, and positive Babinski's or Hoffman's sign.","{""CS ##M, loss of manual de ##x ##ter ##ity, ex ##tre ##mity weakness, sensory abnormal ##ities, q ##uad ##rip ##ares ##is, loss of prop ##rio ##ception, Ba ##ski ' s ' s""}"
723,220,Confirmed HIV-1 infection.,{'HIV'}
724,221,Age ≥ 18 years at the time of consent.,{''}
725,222,years of age or older,{''}
726,223,Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline (test must have a sensitivity of at least 25mIU/ml for human chorionic gonadotropin) and practice a reliable method of contraception throughout the study,{''}
727,224,Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.,{''}
728,225,"Castration-resistant prostate cancer demonstrated during continuous ADT, defined as 3 PSA rises, at least 1 week apart, with the last PSA greater than (\>) 2 nanogram per milliliter (ng/mL)",{'Cast ##ration - resistant pro ##state cancer'}
729,226,Male participant with female partner(s) of childbearing potential (including breastfeeding partner\[s\]) must agree to use contraception throughout the treatment period and for 90 days after investigational product (IP) administration.,{''}
730,229,No evidence of central nervous system (CNS) lymphoma.,{'central nervous system ( C ##NS ) l ##ymph ##oma'}
731,230,BMI of 16 to 32 kg/m2; and a total body weight\>50 kg (110 lb).,{''}
732,231,Have been diagnosed with a cancer and have finished treatment,{'cancer'}
733,232,Body weight that is greater than or equals to (\>=) 40 kg,{''}
734,233,Subjects 18 to 40 years of age.,{''}
735,234,Male or female aged ≥18 years and ≤75 years.,{''}
736,235,Aged between 18 and 60 years,{''}
737,237,"Positive serologic test for anti AChR antibodies at the Screening Visit, and",{''}
738,239,Reading level of 6th grade or higher determined by the Wide Range Achievement Test,{''}
739,241,"Contraceptive (birth control) use by female participants should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies. Before randomization, participants who were born female must be either a) not of childbearing potential; b) of childbearing potential and practicing a highly effective method of contraception and agreeing to remain on such a method of contraception from signing the informed consent until 3 months after the last dose of study vaccine. Use of hormonal contraception should start at least 28 days before the first administration of study vaccine. Highly effective methods for this study include hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion/ligation procedures, vasectomized partner (the vasectomized partner should be the sole partner for that participant), and sexual abstinence",{''}
740,242,"clinical diagnosis of first-ever ischemic stroke (onset \<72h at time of inclusion),","{'is, ##che ##mic stroke'}"
741,243,"A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.",{''}
742,245,"Participant with a major sickle cell syndrome, regardless of genotype (e.g. SS, SC, Sbeta).",{'sick ##le cell syndrome'}
743,246,"If symptomatic, one or more of the criteria for the diagnosis of possible behavioral variant FTD, or a diagnosis of Primary Progressive Aphasia.","{'F ##T ##D, Primary Progressive A ##pha ##sia'}"
744,248,Meeting positive screen criteria depression by PHQ-9 criteria (score greater than or equal to10).,{''}
745,249,Locally advanced/unresectable or metastatic NETs.,{'NE ##T'}
746,250,"Habit of lower lip sucking,",{''}
747,252,Male and female patients,{''}
748,253,Is naïve to antiretroviral therapy (ART) defined as having received no prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection,{'HIV - 1'}
749,254,Fluent in either Taiwanese/Chinese/English.,{''}
750,255,Only for case group primary open angle glaucoma (defined as the presence of visual field damage attributed to glaucomatous optic neuropathy) in both eyes,"{'open angle g ##lau ##com ##a damage, g, ##lau ##com ##ato ##us op ##tic ne ##uro ##pathy'}"
751,256,"Metastatic disease as documented by technetium-99m (99mTc) bone scan or metastatic lesions by computed tomography (CT) or magnetic resonance imaging (MRI) scans (visceral or lymph node disease). If lymph node metastasis is the only evidence of metastasis, it must be greater than or equal to (\>=) 2 centimeter (cm) in the longest diameter","{'Met, ##ast disease, meta, v ##cer ##al or l ##ymph node disease'}"
752,258,Age ≥ 18 years at the time of consent.,{''}
753,259,Patient must have a body surface area of ≥ 0.3 m\^2,{''}
754,260,Body-mass index (BMI) at screening ≥ 17.6 kg/m2 and \< 26.4 kg/m2 \[BMI = Body weight (kg) ÷ {Body height (m)2}\].,{''}
755,261,"Postmenopausal women with a body mass index between 18 and 34 kg/m2, inclusive.",{''}
756,263,"Birth weight \< 1500 g, gestational age \< 32 weeks;",{''}
757,264,Newly diagnosed Minnesota high-risk aGVHD -OR-,{'a ##G ##V ##HD'}
758,265,NOTE DCIS components should not be counted in the determination of HER2 status.,{''}
759,266,Diagnosis of SBS defined as remaining small bowel in continuity of estimated less than 200 cm and considered stable with regard to PS need. No restorative surgery planned in the trial period.,{'SBS'}
760,267,Age between 18 and 90 years,{''}
761,269,to have at least 2 years of experience as rugby player,{''}
762,270,"Patients aged 18 years or older undergoing femoral fracture surgery,","{'f, ##em ##oral fracture'}"
763,271,Subjects with confirmed Wilson Disease Leipzig scoring system assessment ≥ 4 points.,{'Wilson Disease'}
764,272,Acute leukemias,"{'A, ##cute le ##uke ##mia'}"
765,275,"Clinical suspicion or microbiological confirmation of bacterial infection, with initiation of antibiotic therapy in the last 72 hours.",{'bacterial'}
766,276,diagnosis of TMO was confirmed by X-ray,{'T ##MO'}
767,277,Histologically confirmed triple negative breast cancer (ER \< 10% nuclear staining of tumor cells on IHC; HER2 either score 0 or 1 at immunohistochemistry or negative at in situ hybridization \[CISH or FISH\] in case of score 2 or 3 on IHC),{'triple negative breast cancer'}
768,278,"must be over 18 years old,",{''}
769,281,Age ≥ 18 years at the time of informed consent,{''}
770,284,Mild knee joint pain (visual analog scale between 3 and 6 cm).,{'knee joint pain'}
771,285,"LVEF ≤40% quantified by either echocardiography, SPECT ventriculography, or magnetic resonance within 2 months of randomization;",{''}
772,286,Germany only Enzalutamide will be prescribed according to the current SmPC (Summary of Product Characteristics),{''}
773,288,"Liver biopsy was performed within 24 months before enrollment, and the pathological diagnosis was NASH and the fibrosis stage was F2 or above;","{'NAS ##H, fi ##sis'}"
774,289,Body mass Index (BMI) between 16-32 kg/m2; and a total body weight \>50 kg (110 lb),{''}
775,290,/6 or 6/6 classic HLA allele-matched donor,{''}
776,291,"Histological confirmation of adenocarcinoma of the pancreas (head, body, or tail of pancreas)",{'ad ##eno ##car ##cin ##oma of the pan ##cre ##as'}
777,292,"Sickle cell patient benefiting from a consultation or a session in a day hospital in one of the three reference centers (Necker Hospital, Mondor Hospital, Georges Pompidou European Hospital).",{'Sick ##le cell'}
778,293,Subject has RA diagnosed according to the 1987 American College of Rheumatology (ACR) criteria or the 2010 American College of Rheumatology/European League against Rheumatism (ACR/EULAR) criteria.,{'RA against R ##he ##uma ##tism'}
779,295,Subject participating in ecological activities during occupational therapy sessions,{''}
780,296,Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2.,{''}
781,297,"American Spinal Injury Association impairment scale A, B, C, or D",{'imp ##ment'}
782,298,Patient provides written informed consent,{''}
783,299,weeks pregnant or less,{''}
784,300,Diagnosed with clinically confirmed C1-INH HAE,{''}
785,301,Stroke diagnosed more than 6 months ago,"{'St, ##roke'}"
786,302,Dense breast identified on mammogram,{''}
787,304,Outpatient has RA that was diagnosed according to the 1987 revised criteria of the ACR at least 6 months prior to screening,{'RA'}
788,306,uses social media,{''}
789,307,Patients must be ≥ 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place.,{''}
790,308,Healthy Japanese male and female adult participants aged \>= 20 years of age at the time of signing of informed consent.,{''}
791,309,years of age or older,{''}
792,310,Diagnosed with Metastatic Breast Cancer.,{'Met ##ast ##atic B ##rea ##st Cancer'}
793,311,HbA1C \< 5.7%,{''}
794,312,Provision of signed and dated written informed consent by the patient or legally acceptable representative,{''}
795,313,"Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.",{'end ##ome ##tri ##al cancer'}
796,314,Must have been working at the hospital for at least 12 months. Aged 18 years or older. Willing to participate in the study and able to provide informed consent.,{''}
797,315,Aged \>= 18 years old,{''}
798,316,spherical equivalent (SE) \< -6.00 D;,{''}
799,318,gastroenteritis,{'gas ##tro ##enter ##itis'}
800,319,Moderate to severe GL at maximum frown as assessed by the Investigator,{'G'}
801,320,Clinical history and symptoms consistent with MRI-confirmed meniscus tear,{'men ##is ##cus tear'}
802,321,Understands and agrees to comply with all study procedures,{''}
803,322,Patient has meets eligibility criteria for (mild),{''}
804,323,years of age and above;,{''}
805,324,Confirmed diagnosis of ER positive breast cancer,{''}
806,325,Men and women,{''}
807,326,"Genetic testing must be negative for transthyretin mutations associated with hereditary amyloidosis, or immunohistochemistry/ immunofluorescence/ immunoelectron microscopy/ mass spectrometry of amyloid deposits must provide clear evidence of κ or λ light chains in patients who present with peripheral neuropathy or heart as the dominant organ involvement. Data from the initial diagnosis are accepted.","{'hereditary am ##yl ##oid ##osis, peripheral ne ##uro ##pathy'}"
808,327,Be ≥ 18 years of age on day of signing informed consent.,{''}
809,328,"\* TBI history will be assessed using the validated OSU TBI history questionnaire (Attachment 1). TBI severity will be defined as loss of consciousness of 0-30 minutes (mild) or \&gt;30 minutes and \&lt;24 hours (moderate). If no loss of consciousness was reported but post-traumatic amnesia was reported, then this is considered a mild TBI.","{'T ##BI, OS, T ##BI, T ##BI, post - traumatic am ##nesia, T ##BI'}"
810,330,Controls subjects with AHI \< 5/h and Epworth \<10,{''}
811,331,Pathologically-documented diagnosis of multiple myeloma that is relapsed or is refractory as defined by the following,{'multiple my ##elo ##ma'}
812,332,"Male or female subject aged 18-75 years, inclusive;",{''}
813,333,Be 18 years of age or older on the date of signing the informed consent form.,{''}
814,335,Currently resides in WA State,{''}
815,336,Be 18 years or older,{''}
816,337,"Meet the diagnostic criteria of ""likely ad dementia"" of the National Institute on aging Alzheimer's disease association (NIA-AA) (2011);","{""Alzheimer ' s disease""}"
817,338,BMI =\<28 kg/m2,{''}
818,340,Patient must have histologically or cytologically confirmed aggressive B-cell lymphoma as follows,{'B - cell l ##ymph ##oma'}
819,342,Those who have undergone strict and formal conservative treatment for at least 3 months before surgery and have no significant improvement in symptoms.,{''}
820,343,Patients with radiographically proven (by gadolinium-enhanced \[Gd-\] MRI) parenchymal brain metastases from histologically confirmed non-central nervous system (CNS) cancer.,{'non - central nervous system ( C ##NS ) cancer'}
821,344,Must be 18 years of age or older at the time of signing the informed consent.,{''}
822,345,At screening is seropositive for antibodies to pSS-associated antigen A (Ro/Sjogren's syndrome-related antigen A \[SSA\]),"{""p, ##SS, S ##jo ##gren ' s syndrome""}"
823,346,"All patients must have completed therapy including intensive induction followed by ASCT and radiotherapy to be eligible for ANBL0032; radiotherapy may be waived for patients who either have small adrenal masses which are completely resected up front, or who never have an identifiable primary tumor; examples of such therapies include",{'ad ##l'}
824,347,Arm A dose level 4 (75 mg/m\^2 cisplatin) patients with histologically proven chemotherapy-naive advanced unresectable solid tumors for which pemetrexed combined with cisplatin is an indicated regimen,{''}
825,348,"Patients capable to understand the purposes and risks of the study, who are willing and able to participate in the study and from whom written and dated informed consent to participate in the study is obtained.",{''}
826,349,Postmenopausal;,{''}
827,350,Physician diagnosis of COPD for at least 1 year (based on the Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] definition).,{'CO ##PD Ch ##ronic O ##bs ##truct ##ive Lu ##ng Disease'}
828,351,"Meet the diagnostic criteria of type 1 diabetes mellitus clinical manifestations of typical diabetes mellitus include polyphagia, polyuria, weight loss, or diabetic ketoacidosis, confirmed by blood sugar level, islet function and autoimmune antibody.","{'type 1 diabetes me ##lli ##tus, diabetes me ##lli ##tus, p ##oly ##pha ##gia, p, ##oly ##uria, weight loss, di, ##abe ##tic k ##eto ##ac ##ido ##sis'}"
829,352,Male or female \>18 years of age with documented or verbal informed consent. Emergency consent may be obtained where permitted by local regulations and institutional approval.,{''}
830,353,"Early HR+/HER-2- BC,",{''}
831,354,Confirmed Systemic Lupus Erythematosus (SLE) as per Systemic Lupus International Collaborating Clinics (SLICC) 2012 Criteria with one or more of the following,"{'System ##ic Lu ##pus E ##ry ##them ##ato ##sus, SL ##E, System ##ic Lu ##pus'}"
832,355,"chronic pain in the lumbar spine (at least 50 percent of the days of the last 3 months,",{''}
833,356,"Documented ALK re-arrangement as detected by (1) FISH, (2) IHC, (3) tissue NGS, or (4) cfDNA NGS",{''}
834,357,Confirmed Diagnosis of Rheumatoid Arthritis by rheumatologist,"{'R, ##he ##uma ##to ##id Art ##hr ##itis'}"
835,358,Age ≥12 years at time of informed consent.,{''}
836,359,"Male or non-pregnant female adults, 18-45 years of age inclusive.",{''}
837,361,Histologically confirmed prostate cancer or breast cancer without evidence of metastatic disease,"{'pro, ##state cancer, breast cancer'}"
838,362,"HER2 expression by immunohistochemistry (IHC) (1+, 2+, or 3+) or HER2 amplification by in situ hybridization (ISH) or next generation sequencing (NGS) (on any Clinical Laboratory Improvements Amendments \[CLIA\] platform), AND",{''}
839,363,willing to participate in once weekly virtual rehabilitation sessions for 8 weeks,{''}
840,364,"Stage IV at presentation or relapse after curative intent therapy, classification per AJCC 8th edition M1 disease with ≤ 5 metastases",{''}
841,365,Male and Female subjects must be willing to comply with contraception requirements as well as restrictions regarding egg and sperm donation,{''}
842,366,"Subject has a BMI of 18.0 to 30.0 kg/m2, inclusive.",{''}
843,367,"General good health, without significant medical illness, physical examination findings, or significant laboratory abnormalities as determined by the investigator.",{'medical illness abnormal'}
844,369,Symptomatic short-persistent atrial fibrillation (diagnosis within 1 year of study inclusion),{'short - persistent at ##rial fi ##bri ##lla ##tion'}
845,370,Pregnant patients aged ≥18 years,{''}
846,371,"Presence of active, chronic HCV infection confirmed by positive HCV RNA",{'HC ##V infection'}
847,373,Willing to comply with all study-related procedures,{''}
848,374,"couple with medical infertility defined as absence of pregnancy after 12 months without contraception,",{'medical in ##fer ##tility'}
849,375,Must have had prior abiraterone treatment,{''}
850,376,Subjects age \>18 and \<75 years at the time of signing the Informed Consent Form.,{''}
851,378,Subject is undergoing in-center hemodialysis,{''}
852,379,Male or female,{''}
853,380,"Patient with ARD defined by respiratory rate (RR) strictly superior to 25 and/or signs of struggle which are thoraco-abdominal rocking, active abdominal breathing, recruitment of extra-diaphragmatic respiratory muscles AND",{'AR ##D'}
854,381,years old ≤ 75 years old (calculated from the date of signing the informed consent form);,{''}
855,382,Clinical diagnosis of COPD,{'CO ##PD'}
856,384,Patient with clinical judgment of acute decompensated heart failure in the first 96 hours from the start of parenteral diuretic treatment.,{'de ##com ##pen ##sat ##ed heart failure'}
857,385,Sign the informed consent form. 2. ≥18 years and ≤75 years . 3.Histologically confirmed unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (tumor center located within 5 cm proximally or distally from the esophagogastric junction according to the Siewert classification system).,"{'gas ##tric or gas ##tro ##es ##op ##hage ##al junction ad ##eno ##car ##cin ##oma, tumor ##ha ##go ##gas ##tric'}"
858,386,"able to read and speak English,",{''}
859,387,written consent obtained from a parent before or at time of visit,{''}
860,388,The patient must be a member or beneficiary of a health insurance plan,{''}
861,389,The baby is being treated and monitored in the Neonatal Intensive Care Unit,{''}
862,391,Age ≥ 18 years,{''}
863,392,age \>= 18 years,{''}
864,394,Type 2 diabetes controlled with diet or diet and metformin (Glucophage),{'Type 2 diabetes'}
865,395,Diagnosed as having CRS,{'CR'}
866,396,Smokes at least one cigarette a day for the past 12 months,{''}
867,398,age ≥ 18 years,{''}
868,399,"Meet criteria for stimulant use disorder, based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)",{'s ##ti ##mu ##lant use disorder Mental Di ##sor'}
869,400,Postnatal age less than 28 days;,{''}
870,402,English speaking.,{''}
871,403,Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.,{''}
872,404,"Subjects are willing to sign an informed consent, participate, and return for follow-up visits.",{''}
873,405,In Part A eGFR 40-90 ml/min/1.73m\^2 (with no more than 20% having an eGFR \>75 ml/min/1.73m\^2) using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula at screening visit and at least one historical value of eGFR \<60 mL/min/1.73 m\^2 within 3 months or have a registered diagnosis of CKD.,"{'Ch, ##ronic Kid ##ney Disease, C, ##K ##D, C, ##K ##D'}"
874,406,The target lesion of the patient is a symptomatic intracranial atherosclerotic stenosis lesion (for part A only) or restenosis lesions after interventional therapy (for part B only);,"{'in ##tra ##c ##rani ##al at ##her ##os ##cle ##rot ##ic s ##ten ##osis les, rest ##eno ##sis lesions'}"
875,407,An available parent or legal guardian capable of giving informed consent,{''}
876,408,"Capable of understand, sign and date an informed consent approved by an IEC.",{''}
877,410,Participant aged 18 to 50 years.,{''}
878,411,"(1) Age between 20-100 years old. (2) VAS\>=30 or VAS\>=30 at 4 kg pressure (3) Diagnosed as myofascial pain syndrome patients and willing to receive treatment (including LLLT, therapeutic ultrasound, and local dextrose injection therapy) 2. Cohort B",{'my ##of ##as ##cial pain syndrome'}
879,412,Healthy male and female aged 18 years or above ;,{''}
880,413,PLCOm2012 risk prediction \> 4%,{''}
881,414,Female participant is not pregnant and at least 1 of the following conditions apply,{''}
882,415,Non-pediatric patients with a planned LDLT,{''}
883,416,Current MSK patient,{'MS'}
884,417,Be over 18 years of age;,{''}
885,418,Pathological confirmation of primary lung adenocarcinoma after surgery;,{'lung ad ##eno ##car ##cin ##oma'}
886,419,With aniridia,{'an'}
887,420,"Histological confirmation of medulloblastoma, ependymoma or ATRT at diagnosis or relapse","{'me ##du ##llo ##blast ##oma, e ##pen ##dy ##mo ##ma'}"
888,421,Individual who does not have a personal history of pancreatic cancer and meets one of the following,{'pan ##cre ##atic cancer'}
889,422,Self-identify as Black or African American,{''}
890,423,"Male, female, transgender, or non-binary",{''}
891,424,Intraocular tumor not previously treated with proton therapy,{'In ##tra ##oc ##ular tumor'}
892,425,Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline (test must have a sensitivity of at least 25mIU/ml for human chorionic gonadotropin) and practice a reliable method of contraception throughout the study,{''}
893,426,Subjects with mild to moderate acne.,"{'a, ##c ##ne'}"
894,427,Breast cancer from ER+ primary that is seen on other imaging tests. Tumor ER expression must have been confirmed by immunohistocytochemistry of primary tumor or recurrent disease.,"{'B, ##rea ##st cancer'}"
895,428,"infections within 1 year,two or more serious sinus infections within 1 year,two or more months on antibiotics with little effect,two or more pneumonias within 1 year,failure of an infant to gain weight or grow normally,recurrent, deep skin or organ abscesses, persistent thrush in mouth or fungal infection on skin, need for intravenous antibiotics to clear infections,Two or more deep-seated infections including septicemia and family history of IEIs -","{'sin ##us infections, pneumonia, skin or organ a ##bs ##cess ##es, th ##rush in mouth, fun ##gal infection, deep - seated infections, se ##ptic ##emia, I ##EI'}"
896,429,Patients with a probable (50-90% likelihood) or highly probable (\>90% likelihood) diagnosis of cardiac sarcoidosis (CS) by a multidisciplinary team meeting in a CS-specialist centre as per the WASOG criteria,"{'cardiac sa ##rc ##oid ##osis, CS, CS'}"
897,431,"Female and male patients, age at diagnosis 18 years and older.",{''}
898,432,"Patients with oropharynx cancer need p16 determination by immunohistochemistry (where positive is defined as greater than 70% strong nuclear or nuclear and cytoplasmic staining of tumor cells), Note Institutions must screen patients using a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. A rigorous laboratory accreditation process similar to the United States (U.S.) CLIA certification, such as the provincial accreditation status offered by the Ontario Laboratory Accreditation (OLA) Program in Canada, the College of American Pathologists (CAP), or an equivalent accreditation in other countries, is acceptable. The p16 results must be reported on the pathology report being submitted;",{'or ##op ##har ##ynx cancer'}
899,434,"Diagnosis Patients with newly diagnosed HGG, including DIPG are eligible. The diagnosis of HGG must have been confirmed by local pathology review. for the diagnosis of DIPG, patients must have a tumor with pontine epicenter and diffuse involvement of at least 2/3 of the pons, with histopathology consistent with diffuse WHO grade 2-4 glioma (eg, diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, H3K27-altered diffuse midline glioma). For all other tumors, histologic grade must be WHO grade 3-4.","{'H ##G ##G, D ##IP ##G, H, ##G ##G, D, ##IP ##G, g ##lio ##ma, di, ##ff ##use as ##tro ##cy ##tom ##a, an, ##ap ##lastic as ##tro ##cy ##tom ##a, g, ##lio ##blast ##oma, di ##ff ##use mid ##line g ##lio ##ma, tumors'}"
900,435,"Patients with diabetic kidney with eGFR \<60 ml / min / 1.73m2 and ≥15 ml / min / 1.73m2, (stage G3a, G3b and G4 respectively)","{'di, ##abe ##tic kidney'}"
901,436,Exclusion Criteria,{''}
902,437,HCWs and junior medical doctors and permanent health care staff must have been employed/ or worked as HCW/ medical doctors or as permanent health care staff for at least 6 months,{''}
903,438,Diagnosed with type 2 diabetes mellitus (T2DM) for at least 90 days prior to day of screening.,"{'type 2 diabetes me ##lli ##tus, T ##2 ##DM'}"
904,439,Subject has moderate to severe obstructive sleep apnea (defined as apnea-hypopnea index of 15-50 events/hour on baseline/screening polysomnogram),"{'o, ##bs ##truct ##ive sleep a ##p ##nea, a, ##p, ##nea - h ##y ##pop ##nea'}"
905,440,Age ≥ 18 years,{''}
906,441,"Control Participants; Male and female 3 to 11-year-old children who have been falsely referred into the Hospital Eye Service (ACPOS) by the visual screening service, but have satisfactory visual functions, as per the national screening guidelines.",{''}
907,442,"Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix","{'S ##qua ##mous cell car ##cin ##oma, ad ##eno ##s ##qua ##mous car ##cin ##oma, ad ##eno ##car ##cin ##oma of the c ##er ##vi ##x'}"
908,443,Diagnosis of Still's disease (sJIA (systemic Juvenile Idiopathic Arthritis) or AOSD (Adult Onset Stills Disease) diagnosis).,"{""Still ' s disease, s, ##J ##IA, systemic Ju ##ven ##ile I ##dio ##pathic Art ##hr ##itis, A, ##OS ##D, Adult On ##set Still ##s Disease""}"
909,444,Participants require a smartphone to take part in the study.,{''}
910,445,"Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.",{'Solid Tu ##mor'}
911,446,"Participant must have a diagnosis of an infection (HAP/VAP, cUTI, cIAI, BSI) due to confirmed carbapenem-resistant aerobic Gram-negative pathogens, requiring administration of IV antibacterial therapy","{'H ##AP, VA ##P, ##UT ##I, ##IA ##I, BS ##I'}"
912,449,Have been admitted to hospital,{''}
913,450,Male aged 10-13 years for SRH education,{''}
914,451,Open-angle glaucoma or ocular hypertension,"{'Open - angle g ##lau ##com ##a, o, ##cular h ##yper ##tens ##ion'}"
915,452,Scheduled to undergo phacoemulsification with the intraocular lens (IOL) implantation for the treatment of cataract,{'cat ##ara ##ct'}
916,453,"Gender Identity Individuals identifying as cisgender, transgender, or females.",{''}
917,454,first time treatment of the patient with parenteral antifungal in the medical center was anytime from 2005 through 2012,{''}
918,456,"The duration of anesthesia is more than 30 minutes, that is, from induction to withdrawal of anesthesia",{''}
919,457,"The subject has given written informed consent after being provided orally with information about the study objective and design, including the administration regimen of the studied probiotic and the study procedures, the available safety data, as well as the rights and obligations of a participant.",{''}
920,458,Participants with histologically or cytologically confirmed colorectal adenocarcinoma.,{'color ##ec ##tal ad ##eno ##car ##cin ##oma'}
921,459,Blood glucose monitoring of the child,{''}
922,460,"The exclusion criteria are (1) patient already having a stoma (or another stoma made during surgery), (2) technical inability to create ileo- or colostomy (e.g. previous bowel resection, anatomical factors), (3) age \<18 years, (4) inadequate ability to co-operate.",{''}
923,461,"Patient hospitalized in haematology, onco-haematology or onco-paediatrics unit.",{''}
924,464,Has an active email address or can be contacted by MyChart or personal email,{''}
925,465,Age group 18-65 years old.,{''}
926,466,Patients who are able to understand and give written informed consent at Screening,{''}
927,468,Age ≥18 years,{''}
928,470,"Maximum projected treatment length 15cm and width 5cm, which are the dimensions of the largest available CivaSheet",{''}
929,472,Non-English speakers may be enrolled.,{''}
930,473,Scheduled to undergo spinal cord stimulation,{''}
931,474,Signed informed consent must be obtained prior to participation in the study.,{''}
932,475,Patients who are born with gestational age older than 36 weeks;,{''}
933,476,"Locally advanced, stage III (T4NxM0) and unresectable by National Comprehensive Cancer Network (NCCN) Guidelines prior to perioperative chemotherapy",{''}
934,477,children aged 0-6 years,{''}
935,478,Capacity to sign informed consent.,{''}
936,479,"Provision of informed consent form prior to any study specific procedures, sampling and analysis.",{''}
937,480,Advanced/metastatic histologically confirmed solid tumor. All types of solid tumors are allowed in the study,"{'solid tumor, solid tumors'}"
938,481,AHI±15,{''}
939,482,Age 18 years.,{''}
940,483,No clinical or radiologic MS relapses for \> 5 years,{'MS'}
941,484,"OAB, UUI or Mixed Urinary Incontinence with urgency predominant symptoms and more bother from UUI than stress urinary incontinence","{'O ##AB, U ##UI, Mixed U ##rina ##ry Inc ##ont ##inen ##ce, U ##UI, stress u ##rina ##ry in ##con ##tine ##nce'}"
942,485,With a possible return home before surgery,{''}
943,486,"Not having taken a course/training on pelvic floor rehabilitation,",{'p'}
944,487,Undergoing unilateral or bilateral total or modified radical mastectomy,{''}
945,489,Provision of signed and dated informed parental consent form from at least 1 legal parent/guardian;,{''}
946,490,"With a biopsy of the care on native kidney and subject to a biological collection, finding tubulointerstitial nephritis in the foreground and retained as the main cause of renal dysfunction after etiological investigation.","{'tub ##ulo ##int ##ers ##ti ##tial ne ##ph ##rit ##is, re, ##nal d ##ys ##function'}"
947,491,Admitted between 3-28 days of age.,{''}
948,492,The partners of eligible patients will be recruited if they are not diagnosed with OSA and not using CPAP,{'OS ##A'}
949,493,Participant consent or parental/guardian consent and participant assent.,{''}
950,494,Age \>18 years,{''}
951,495,Express at least one word,{''}
952,497,All patients will have a diagnosis MINOCA. Any patient who does not have a clear cause of troponin rise,{''}
953,498,have a release date within 3 months,{''}
954,499,Advanced endometrial cancer and platinum-resistant ovarian cancer,"{'Advanced end ##ome ##tri ##al cancer, platinum - resistant o ##var ##ian cancer'}"
955,500,Evidence of biomarker enrichment at time of screening.,{''}
956,503,age range 21 to 65 years,{''}
957,504,Score in the moderate or higher range on the BDI-FastScreen,{''}
958,505,"Patients with primary open angle glaucoma (POAG), high tension glaucoma (HTG) and normal tension glaucoma (NTG), aged 40 - 75 years","{'primary, open angle g ##lau ##com ##a, P, ##OA ##G, high tension g ##lau ##com ##a, H ##T ##G, normal tension g ##lau ##com ##a, N, ##T ##G'}"
959,506,Good general health,{''}
960,507,Age between 40 and 85 years old,{''}
961,508,"Informed consent to the participation in the study, according to the requirements of the ethics committee within each hospital.",{''}
962,510,ECOG performance status 0-2,{''}
963,511,Currently trying to become pregnant;,{''}
964,512,"Willingness to give informed consent, to be randomized to one of the study groups, and comply with all study requirements",{''}
965,513,Be between 8 and 12 years of age inclusive at the time of enrollment.,{''}
966,514,Moderate to severe platysmal bands as assessed by the investigator and subject on the MAPS-D at maximum contraction,"{'p, ##lat ##ys ##mal bands'}"
967,515,Must have moderate to severe OUD;,"{'O, ##U ##D'}"
968,516,"Individuals who meet the criteria for wrist circumference, age, gender, and upper arm circumference as specified in the target number of participants.",{''}
969,517,be between the ages of 18 to 70 years;,{''}
970,518,The score of FNGS 2.0 ≥ 15 at the day 21 since the onset of BP.,{'BP'}
971,519,Adequate facility with English;,{''}
972,523,"Female, post-menopausal, ≥18 years of age inclusive, at the time of signing the consent form",{''}
973,524,Diagnosis of pancreatic and periampullary tumor pathology that requires pancreatoduodenectomy,{'pan ##cre ##atic and per ##iam ##pu ##llar ##y tumor ##du'}
974,525,Patients who meet one or more of following criteria,{''}
975,526,Undergoing breast surgery,{''}
976,527,eligibility for MRI scanning;,{''}
977,528,Newly diagnosed patients with AML deemed ineligible for intensive induction chemotherapy (age 75 and older or \< 75 years of age with comorbidities that preclude the use of intensive induction therapy) eligible to receive VEN at Screening. VEN may be combined with azacitidine or decitabine at the discretion of the treating Investigator.,{'AM ##L'}
978,529,-39 years old,{''}
979,530,"Patients must have newly diagnosed T-ALL or T-lineage lymphoblastic lymphoma (T-NHL) stage II-IV; B-lineage lymphoblastic lymphoma will not be eligible for this study; a diagnosis of T-ALL is established when leukemic blasts lack myeloperoxidase or evidence of B-lineage derivation (cluster of differentiation \[CD\]19/CD22/CD20), and express either surface or cytoplasmic CD3 or two or more of the antigens CD8, CD7, CD5, CD4, CD2 or CD1a; if surface CD3 is expressed on all leukemic cells, additional markers of immaturity, including transmission disequilibrium test (TdT), CD34 or CD99 will be assessed for expression; cases with uncertain expression will receive additional review within the appropriate Children's Oncology Group (COG) reference laboratory","{'T - AL ##L, T - lineage l ##ymph ##ob ##lastic l ##ymph ##oma, T - NHL, B - lineage l ##ymph ##ob ##lastic l ##ymph ##oma, T - AL ##L'}"
980,531,Age ≥ 20 years,{''}
981,532,"Diagnosis of glioma requiring adjuvant chemotherapy. Patients with glioblastoma (GBM); astrocytoma, IDH-mutant; oligodendroglioma IDH-mutant, 1p/19q codeleted are eligible","{'g, ##lio ##ma, g, ##lio ##blast ##oma, GB ##M, as, ##tro ##cy ##tom ##a, o, ##li ##go ##den ##dr ##og ##lio ##ma'}"
982,533,"Patients must receive an MRI/CT of the brain or PET/CT within 6 months of consenting. If new lesions are present, PI or his designee should make final determination regarding enrollment. (Turnstile I)",{''}
983,535,Is in good health,{''}
984,536,Mother consented to be recontacted,{''}
985,537,Age between 35 to 50 years,{''}
986,538,"If male, subject must agree to sexual abstinence and/or to use a highly effective method of birth control during the study period and for 60 days after the last dose of study drug",{''}
987,539,Provision of signed and dated informed consent form in English.,{''}
988,540,"Having a nuclear family structure,",{''}
989,541,Adult patient (Age ≥ 18 years),{''}
990,542,Willing to participate in the study and able to communicate consent during the consent process,{''}
991,543,Signature of the informed consent (for pediatric patients parents or guardians able to provide consent),{''}
992,545,Diagnosed with T2DM for at least 6 months.,{'T ##2 ##DM'}
993,546,Gender is not limited;,{''}
994,547,Participant is at least 18 years old.,{''}
995,548,"Diagnosis of Crohn's disease established with verifiable clinical, imaging, endoscopic and/or histopathologic evidence.","{""C ##ro ##hn ' s disease""}"
996,549,Male or female patients ≥18 and ≤ 75 years old;,{''}
997,550,Men and women over 18 years of age.,{''}
998,551,Right-handed,{''}
999,553,Age ≥18.,{''}
1000,554,Part A Have previously received ≥ 3 prior lines of anti-myeloma therapy.,{''}
1001,555,non-Parkinson's disease patients over 20 years old (control group).,"{""Parkinson ' s disease""}"
1002,556,Patients must have had a baseline serum PSA level measured before starting any treatment and within six months of diagnosis,{''}
1003,557,"Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions, including eDiary questionnaire completion requirements.",{''}
1004,558,Post- craniotomy,{''}
1005,559,"Diagnosis Patients with histologically-confirmed adamantinomatous craniopharyngioma (ACP) Histologic confirmation of ACP may be made on solid tumor or, if no solid tumor can be safely obtained, cyst fluid with classic ACP characteristics of thick, cholesterol-rich, greenish-brown liquid in the context of imaging features consistent with craniopharyngioma, including lobulated, cystic/solid mass with calcifications that originates in the sellar/suprasellar region.","{'ad ##aman ##tino ##mat ##ous c ##rani ##op ##har ##yn ##gio ##ma, AC ##P, AC ##P, solid tumor, solid tumor, AC, c, ##rani ##op ##har ##yn ##gio ##ma'}"
1006,561,Able to communicate well with the investigator and understands and agrees to comply with all protocol requirements.,{''}
1007,562,Diagnosis of Pilonidal Disease,{'Pi ##lon ##idal Disease'}
1008,564,"Female subject must either Be of non-childbearing potential, postmenopausal (defined as at least 1 year without any menses) prior to screening, or documented surgically sterile. Or, if of childbearing potential agree not to try to become pregnant during the study and for 60 days after the final study drug administration, must have a negative pregnancy at Screening and Day -1, and if heterosexually active, agree to consistently use 1 form of highly effective birth control starting at Screening and throughout the study period, and for 60 days after the final study drug administration.",{''}
1009,565,"Simple myopia or myopic astigmatism, refractive spherical equivalent between -0.50 and -9.0 diopters in both eyes with regular corneal topography","{'Simple my ##op ##ia, my ##op ##ic as ##ti ##gma ##tism'}"
1010,566,Patients must have high-risk neuroblastoma as defined by the COG Risk Stratification Schema,{'ne ##uro ##blast ##oma'}
1011,567,able to swallow the fluid,{''}
1012,568,healthy individuals,{''}
1013,569,Age ≥ 18 years at the time of consent.,{''}
1014,570,Patients diagnosed with Severe Aplastic Anemia (SAA) or Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) according to the Chinese Guidelines for the Diagnosis and Treatment of Aplastic Anemia (2022 Edition) and suitable for allo-HSCT,"{'Se, ##vere A ##p ##lastic An ##emia, SA ##A, Trans - De ##pen ##dent Non - Se ##vere A ##p ##lastic An ##emia, TD - NSA ##A, A ##p ##lastic An ##emia'}"
1015,571,Competent to give informed consent,{''}
1016,0,Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment,{''}
1017,1,Absence of new onset neurological symptoms,{'ne ##uro ##logical symptoms'}
1018,2,Progression after or cannot undergo standard therapy with tyrosine kinase inhibitor (TKI) treatment or TKI combined with immune checkpoint inhibitor treatment.,{''}
1019,4,Has PSA \>4 ng/mL ≤28 days prior to enrollment.,{''}
1020,6,Have progressed after platinum-based chemotherapy (with or without maintenance therapy) AND have received one additional therapy which may include an immune checkpoint inhibitor or other anti-cancer therapy for advanced and/or metastatic disease OR is judged by the physician as ineligible for further standard second-line chemotherapy. Participants who have progressed after platinum-based chemotherapy and an immune checkpoint inhibitor (immunotherapy) e.g. pembrolizumab or nivolumab alone or in combination with other agents are eligible.,{''}
1021,7,Able to speak and write Turkish and have no communication problems,{''}
1022,8,Provision of signed and dated informed consent form.,{''}
1023,9,Current or former smoker of at least 10 pack years,{''}
1024,10,Patients must be able to tolerate digital breast tomosynthesis and full-field digital mammographic imaging required by protocol.,{''}
1025,11,"Willing to participate in Zoom meetings and complete online assessments at baseline, 3-month, and 6-month timepoints",{''}
1026,13,+ years of age,{''}
1027,14,CA-125 increased to more than twice the upper limit of normal or two times the nadir value after most recent second or later line of treatment,{''}
1028,15,-65 years of age.,{''}
1029,16,"If patients are taking other systemic therapies for their HHD (antibiotics, prednisone), they must be taking a stable dose of the other medication(s) for at least 3 months with no plans to change the regimen in the next 6 months. With the exception of antibiotics, methotrexate or low dose prednisone (less than 5 mg daily), use of concomitant immunosuppressants, e.g. azathioprine, etc. and biologics other than TNF-α inhibitors will not be permitted.",{'H ##HD'}
1030,18,Body Mass Index 18.5-40 kg/m2 inclusive.,{''}
1031,19,Best-corrected visual acuity by manifest refraction of at least 20/25 bilaterally,{''}
1032,20,Further inclusion criteria,{''}
1033,21,Sign informed consent.,{''}
1034,22,"BMI \<40 kg/m2,",{''}
1035,23,"Histologically confirmed PTCL-NOS, FHTCLs or sALCL per The International Consensus Classification of Mature Lymphoid Neoplasms.","{'PT ##CL, F ##ure L ##ymph ##oid Neo ##p ##las ##ms'}"
1036,24,"Subjects must have a Best-corrected Distance Visual Acuity (BCDVA) worse than 20/40 in each eye, with or without a glare source, due to a clinically significant cataract (cortical, nuclear, subcapsular, or combination) that is considered amenable to treatment with standard phacoemulsification cataract extraction and capsular IOL implantation.","{'cat, ##ara ##ct'}"
1037,25,Being able to communicate with Mandarin Chinese or Taiwanese Hokkien,{''}
1038,26,Spontaneous arterial and/or venous thrombosis,{'art ##erial and / or ve ##nous th ##rom ##bos ##is'}
1039,27,"This does not include changes to any insulin doses, including basal rates/long-acting insulin doses, carbohydrate to insulin ratios and correction factors",{''}
1040,29,"Self-reported use of prescribed oral opioid medication(s) (tablets, pills or capsules) of at least 50 morphine mg equivalent (MME) but no higher than 240 mg MME daily or near daily (≥5 days per week) for at least 12 weeks and seeking to discontinue their opioid medication.",{''}
1041,30,Body mass index between 18.5 and 29.9 Kilogram Per Square Meter (kg/m\^2) (both inclusive),{''}
1042,34,"The subject has a diagnosis of IPF based on the 2018 ATS/ERS/JRS/ALAT Clinical Practice Guideline (Raghu 2018) and confirmed by central review of high-resolution computed tomography (HRCT) (performed within the previous 12 months), and if available, surgical lung biopsy.",{'IP ##F'}
1043,35,"The patient has evidence of impaired liver function alanine aminotransferase (AST), aspartate aminotransferase (ALT) \>5 times the upper limit of normal (ULN) or total bilirubin \>2 times ULN.",{'impaired'}
1044,36,Prevalence of ataxia on clinical exam (SARA \>2)\*,{'at ##ax ##ia'}
1045,37,Hemoglobin A1C less than 9.0%,{''}
1046,38,duration of symptoms 14 days or less,{''}
1047,39,To have participated in the study voluntarily,{''}
1048,41,Successful completion of pre-employment training evaluation at the hospital.,{''}
1049,43,Aged 16 years and above.,{''}
1050,44,-25 years old,{''}
1051,45,Patients with a minimum of 4 years of follow-up.,{''}
1052,46,Asthma requiring high-dose ICS plus LABA as maintenance treatment.,"{'As, ##th ##ma'}"
1053,47,People of childbearing potential,{''}
1054,48,Discharged from the hospital after your lung transplant surgery,{''}
1055,49,Histologic documentation of diagnosis of endometrial carcinoma or carcinosarcoma is required.,"{'end ##ome ##tri ##al car ##cin ##oma, car ##cin ##osa ##rc ##oma'}"
1056,50,"Office worker between the ages of 25-55,",{''}
1057,51,Be able to attend physical reconditioning 3 times a week,{''}
1058,52,reside in Kentucky,{''}
1059,54,Can read and speak English,{''}
1060,56,schizophrenia,{'s ##chi ##zophrenia'}
1061,58,"All histologic subtypes of ovarian carcinoma including carcinosarcoma (malignant mixed Mullerian tumors, MMMT)","{'o ##var ##ian car ##cin ##oma, car, ##cin ##osa ##rc ##oma, ma mixed Muller ##ian tumors, M, ##MM ##T'}"
1062,59,Adequate hematologic and end organ function,{''}
1063,60,Expected survival time ≥3 months;,{''}
1064,62,Otherwise appropriate candidates for spinal cord stimulator implantation.,{''}
1065,63,"Participants must have high-risk Bacillus Calmette-Guerin (BCG) - unresponsive disease, defined as (where adequate BCG therapy is defined as one of the following 5 of 6 doses of an initial induction course + at least 2 of 3 doses maintenance therapy or 5 of 6 doses of an initial induction course + at least 2 of 6 doses of a second induction course)",{'Ba ##ci ##llus Cal ##mett ##e - G ##uer ##in ( BC ##G ) - un ##res ##po ##ns ##ive disease'}
1066,64,Providing outpatient or school-based psychotherapy services to children,{''}
1067,65,Current user of a microprocessor-controlled knee (MPK),{''}
1068,66,Female subjects must agree to consistently use 2 forms of highly effective birth control starting at screening and throughout the study period and for 28 days after the final study drug administration.,{''}
1069,68,Body mass index (BMI) \>/= 95th percentile,{''}
1070,69,"Among the patients described in 1, those whose guardians have the communicative ability, as well as the mental and physical capacity to respond appropriately to surveys.",{''}
1071,72,Are of stable weight 5%) during the 90 days preceding screening and agree not to initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment,{'diabetes'}
1072,73,"PSA progression (defined as 2 consecutive increases over a previous reference value obtained at a minimum of 1-week intervals, with a minimum starting value of 1.0 ng/mL)",{''}
1073,74,Patients must be \>= 365 days and \< 10 years of age (B-ALL patients without DS).,"{'B - AL ##L, DS'}"
1074,75,"Has symptomatic frontotemporal dementia (FTD), including mild behavioral, cognitive, motor or language impairment per Investigator's assessment (behavioral-variant FTD, primary progressive aphasia-FTD, FTD with corticobasal syndrome, or a combination of syndromes are allowed for enrollment).","{'front ##ote ##mpo ##ral dem ##ent ##ia, F ##T ##D, behavioral , cognitive , motor or language imp ##air ##ment, F ##T ##D, primary progressive a ##pha ##sia F ##T ##D, F ##T ##D, co ##rt ##ico ##bas ##al syndrome'}"
1075,76,"No history of total colectomy, with remaining bowel segments available for evaluation.",{''}
1076,77,A 12-lead electrocardiogram (ECG) obtained no more than 90 days prior to enrollment documenting a QRS duration \> 120 ms,{''}
1077,78,Able to participate in exercise program,{''}
1078,80,"Requiring invasive positive pressure respiratory support and FiO2 ≥ 25% or requiring non-invasive positive pressure respiratory support (NCPAP≥ 5 cm H20, NIPPV/BiPhasic CPAP) and FiO2 ≥ 30%.",{''}
1079,81,Patient able to sign a non-opposition,{''}
1080,82,OR,{''}
1081,85,Growing patients.,{''}
1082,86,) Surgically resected pathological tissue capable of being used for immunohistochemical detection of target proteins and positive for B7H3 expression;,{''}
1083,87,Malnutrition is assessed by Nutritional Risk Screening 2002 score≥3 and Patient Generated Subjective Global Assessment (PG-SGA) score≥4;,{'Mal ##nut ##rit ##ion'}
1084,88,Study participant has a confirmed positive record of autoantibodies against acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) at Screening (Visit 1).The presence of autoantibodies may be confirmed with repeat testing at Visit 1,{''}
1085,90,Age ≥18 years;,{''}
1086,91,Postmenopausal women (without hormone replacement),{''}
1087,92,"Has a spinal cord injury caused by trauma (fall, car accident, etc.) for at least one year that is not getting worse over time",{'spinal cord injury'}
1088,93,Self identifies as Latino/Hispanic,{''}
1089,94,Male or female weighing more than 15kg,{''}
1090,96,"If capable of producing sperm, male participants agree to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention. The length of time required to continue contraception for each study intervention is",{''}
1091,97,Planned primary or adjuvant radiation or chemoradiation therapy,{''}
1092,98,"Clinical situations in which such emergent treatment may be indicated include, but are not limited to, the following circumstances",{''}
1093,100,Body weight at baseline of ≥17 kg.,{''}
1094,101,Sero suitable for challenge virus,{''}
1095,102,Participants who are newly diagnosed and not considered for high-dose chemotherapy due to being age \>=65 years; or participants less than (\<) 65 years with presence of important comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation. Sponsor review and approval of participants below 65 years of age is required before randomization,{''}
1096,104,"Planned and scheduled on-pump, arrested heart CABG.",{''}
1097,105,Participants should not have had prior systemic therapy administered in the R/M setting; systemic therapy which was completed prior to randomization/enrollment if given as part of multimodal treatment for locally or locoregionally advanced disease is allowed,{''}
1098,106,\>500 applications to each eye,{''}
1099,107,Diagnosed with ALL (treated with CRT or chemotherapy only) or CNS tumors (posterior fossa tumors or supratentorial tumors) or non-CNS solid tumors (with abdominal or chest radiation or bilateral retinoblastoma survivors).,"{'AL ##L, C ##NS tumors, posterior f ##ossa tumors, su ##ten ##l tumors, non - C ##NS solid tumors, re ##tino ##blast ##oma'}"
1100,108,Visual acuity is correctable to 6/7.5 or better with eyeglasses.,{''}
1101,109,"Age ≥18 years at the time of consent. Because no dosing or adverse event data are currently available on the use of fiducials in combination with SBRT in subjects \<18 years of age, children are excluded from this study.",{''}
1102,110,"Left atrial (LA) diameter ≤ 5.5 cm or LA volume index ≤ 50 mL/m2 (use whichever measure is available or if both available, use the lesser of the two to qualify)",{''}
1103,111,Patients with clinical deterioration during aPD1 monotherapy are eligible ≥6 weeks after starting aPD1 therapy,{''}
1104,112,Term gestational age,{''}
1105,113,Patients with confirmed diagnosis of ATTR-CM after 01 June 2019,{'AT ##TR - C ##M'}
1106,114,Patients with idiopathic gastroparesis,"{'id, ##io ##pathic gas ##tro ##par ##esis'}"
1107,117,"Participants with a documented history of histopathological confirmed metastatic NSCLC that is unresectable, progressive and for which standard treatment measures are no longer effective.",{'meta ##static N ##SC ##LC'}
1108,118,"Participants ≥ 18 years of age must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.",{'Solid Tu ##mor'}
1109,119,All parities of patients are eligible,{''}
1110,121,Consenting to regional anesthesia for postoperative pain control,{''}
1111,122,Not a woman of child-bearing potential (WOCBP),{''}
1112,125,Has histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate,{'ad ##eno ##car ##cin ##oma of the pro ##state'}
1113,126,"Has access to and is capable of using a digital device (smartphone, tablet, or computer) to interact with the Metrikamind platform.",{''}
1114,127,Provided signed Informed Consent to participate in the study,{''}
1115,128,"Those judged by the investigator on the day of screening to be able to consume the food for this human test (control food) without chewing it, with water or the provided puree",{''}
1116,130,Diagnosis of T1D within 100 days of the baseline visit (V0).,{'T ##1 ##D'}
1117,131,"Has been resident in Alexandria, Egypt for at least 6 months.",{''}
1118,132,maintaining normal exercise level (\<7 h/wk) and willing to avoid exercise 24-h prior to blood and stool sampling and 12-h prior to bone measurements,{''}
1119,133,students with self-reported depressive symptoms (BDI-II score of 14 or higher),{'de'}
1120,136,"with a complaint of hair in the axillary region,",{''}
1121,137,The subject or guardian is willing and able to sign an informed consent form.,{''}
1122,138,Recent diagnosis (\< 3 months) of a poor prognosis cancer with an estimated survival of 50% or less by the primary oncologist (cohort 1) OR recent history of disease relapse/progression within the past 3 months (cohort 2) OR active enrollment on a phase I/II trial (cohort 3).,{'cancer'}
1123,139,Participants with elevated lipids.,{''}
1124,140,Outpatient population,{''}
1125,144,Post-menopausal if Female,{''}
1126,146,≥6 tender/painful joints; ≥6 swollen joints,{''}
1127,147,HCV-RNA positive in serum or HCV antibody positive patients (regardless of the amount of viral and treatment).,{''}
1128,148,PSA of ≥5.0 ng/ml (5.0 ug/L) prior to commencement of ADT,{''}
1129,149,Hemoglobin A1C less than 9.0%,{''}
1130,150,Receiving vasoactive therapy AND/OR undergoing mechanical ventilation (including non-invasive mechanical ventilation (NIMV));,{''}
1131,151,Male or female ≥ 18 years at signing the ICF;,{''}
1132,152,Singleton pregnancy.,{''}
1133,154,Patient with a negative PV for Strepto B,{''}
1134,155,Clinically diagnosed as androgenetic alopecia;,{'and ##rogen ##etic al ##ope ##cia'}
1135,156,Patients with complete clinical data and able to cooperate with treatment.,{''}
1136,157,One male or female aged 60 or over but below 70 years old.,{''}
1137,159,Patients must have radiological evidence of disease progression following the most recent treatment,{''}
1138,160,epileptic syndromes/epileptic-encephalopathies with unknown etiology.,"{'e, ##pile ##ptic syndrome, e, ##pile ##ptic - en ##ce ##pha ##lop ##ath ##ies'}"
1139,161,Willing to comply with study procedures,{''}
1140,162,Patients must have received at least 2 lines of systemic treatment for metastatic disease,{''}
1141,164,"Diagnosis of CD based on clinical, endoscopic, and histologic evidence established at least 3 months prior to Screening.",{'CD'}
1142,165,"Having an ischemic type stroke,",{'is ##che ##mic type stroke'}
1143,166,at least 50 kg,{''}
1144,167,"with amnestic Mild Cognitive Impairment (Montreal Cognitive Assessment Battery score \[MoCA\] total score 19-25; and score of \> 1.0 on the Mail-in Cognitive Function Screening Instrument),",{'am Mi ##ld Co ##gni ##tive I ##mp ##air ##ment'}
1145,168,Able to provide informed consent,{''}
1146,169,the Glasgow Coma Scale (GCS) on admission of Pediatric Intensive Care Unit (PICU) is greater than 3,{''}
1147,171,have at least one biological child aged 1 to 12 years with whom they live or have at least twice per month in person visits;,{''}
1148,172,For PsO Participants,{'P ##O'}
1149,175,No metal implants,{''}
1150,177,Willingness and ability to complete systematic neuropsychological tests;,{''}
1151,178,Participant (as applicable) and/or parent(s) or legally authorized representative (LAR(s)) is willing to comply with the recommended schedule of assessments.,{''}
1152,179,"Has been untreated for Stage IIIB, IIIC or IIID melanoma",{'me ##lan ##oma'}
1153,180,at risk for developing type 2 diabetes (prediabetes),"{'type 2 diabetes, pre ##dia ##bet ##es'}"
1154,181,"Prior orchiectomy or medical castration; participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analog (agonist or antagonist), prior to the first dose of study drug and must continue this therapy throughout the treatment phase","{'or, or'}"
1155,182,Strong family history of pancreas cancer on one side of the family tree or,{'pan ##cre ##as cancer'}
1156,183,Diagnosis of relapse or progressive disease (any cancer diagnosis) as identified by imaging or biopsy and confirmed by physician.,{'cancer'}
1157,184,"Histological diagnosis of squamous or non-squamous, inoperable, metastatic NSCLC",{'N ##SC ##LC'}
1158,185,Acceptable performance status and an estimated life expectancy of \> 6 months.,{''}
1159,186,Histologically or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system).,{'E ##S - SC ##LC'}
1160,187,"Diagnosis relapsed/refractory solid tumours with positive uptake on SSTR-PET (PET-CT or PET-MRI), performed in the previous three months before entering the study. The positiveness of the study in patients with localized CNS tumours that do not spread through the spine, will be assessed according to",{'C ##NS t ##umour'}
1161,188,Subjects have received FIX products for ≥ 150 exposure days (EDs) (subjects aged ≥ 6 years) or ≥ 50 EDs (subjects aged \< 6 years),{''}
1162,189,"Patients must have recurrent or refractory disease, or newly diagnosed disease with no known curative therapy or therapy proven to prolong survival with an acceptable quality of life; patients must have had histologic verification of one of the malignancies listed below at original diagnosis or at relapse","{'ma, ##li'}"
1163,190,Patients with histological confirmation of locally advanced or metastatic NSCLC,{''}
1164,191,"Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.",{''}
1165,192,"Before treatment with atorvastatin,non-HDL-C≥5.76mmol/L（223 mg/dL）;",{''}
1166,195,"With a GI bleeding \[either overt (any hematemesis, any melena or hematochezia with at least a 2g/dL drop in hemoglobin) or occult (iron deficiency anemia with at least 2g/dL drop in hemoglobin)\] with the presence of angiodysplasia or a negative finding on digestive conventional endoscopy OR with a severe epistaxis (requiring red blood cells transfusion or treatment with VWF concentrates)","{'G ##I bleeding, hem ##ate ##mes ##is, me, ##lena, hem ##ato ##che ##zia, iron deficiency an ##emia, an, ##gio ##dy ##sp ##lasia, e, ##pis ##ta ##xi ##s'}"
1167,196,Subject must agree to undergo all clinical investigation plan - required clinical follow-up visits,{''}
1168,197,English speaking or Spanish speaking,{''}
1169,198,"Subject meets the ACR 1991 Revised Criteria for Global Functional Status in RA Class I, II or III at Screening and Baseline",{''}
1170,199,At least 2 SCPCs and no more than 10 SCPCs in the past 12 months;,"{'SC, SC'}"
1171,200,Pseudophakia or aphakia in the eye to be operated on,"{'P, ##se, ##udo ##pha ##ki ##a, a ##pha ##ki ##a in the eye'}"
1172,201,Patients who approve to be included in the trial and sign the informed consent,{''}
1173,202,Clinically significant difficulties in interpersonal relationships,{''}
1174,203,"Have molecular evidence of an epidermal growth factor receptor mutation (EGFRmt) known to be associated with EGFR tyrosine kinase inhibitor (TKI) drug sensitivity (G719X, exon 19 deletion, L858R, L861Q)",{''}
1175,204,English speaking or Spanish speaking,{''}
1176,205,"Male and non-childbearing potential female\* participants 18 to 70 years of age, inclusive, at Screening.",{''}
1177,206,"Participants with reduced maximum oxygen uptake due to poor SOE, defined as peak exercise (\[Ca-VO2\])/\[Hb\]) ≤ 0.85 and VO2max \< 85% predicted in the absence of a cardiac or pulmonary mechanical limit, determined by aCPET within 6 months prior to day 1 or participants with reduced maximum oxygen uptake due to poor SOE, defined as peak exercise (\[Ca-VO2\])/\[Hb\]) ≤ 0.85 and VO2max \< 85% predicted in the absence of a cardiac or pulmonary mechanical limit, determined by historical aCPET within 45 months of screening and confirmed reduction in skeletal muscle citrate synthase activity.",{''}
1178,207,Lenke 5 type adolescent idiopathic scoliosis,{'Len ##ke 5 type adolescent id ##io ##pathic s ##co ##lio ##sis'}
1179,208,"presenting adjacent RT1/RT2 recessions, on both sides of the anterior maxilla, with an apico-coronal extension (i.e. recession depth) \> 2mm combined with thick phenotype and deep root concavity.",{''}
1180,210,The patient presents with knee pain during physical activity.,{'knee pain'}
1181,211,Increase in the level of care (outpatient care to day clinic or inpatient care),{''}
1182,212,(b) report frequent cannabis use defined as \> 5 days per week for \> 1 year with a positive THC urine toxicology at baseline.,{''}
1183,213,Pathological diagnosis was chronic endometritis,{'chronic end ##ome ##tri ##tis'}
1184,215,"Receiving diabetes care at one of 4 university teaching hospital-based pediatric diabetes clinics in Quebec Montreal Children's Hospital-McGill University Health Centre, Centre hospitalier universitaire de Sherbrooke, Le Copain-Hôpital de Gatineau, Centre Hospitalier Universitaire de Québec",{''}
1185,218,Absence of congenital and genetic disorders and chromosomal abnormalities,"{'con ##gen ##ital and genetic disorders, ch, ##rom ##oso ##mal abnormal ##ities'}"
1186,220,"On antiretroviral therapy with plasma HIV-1 RNA levels of \< 50 copies/ml and no reported interruption of ART for 7 consecutive days or longer for at least 48 weeks, and \< 20 copies/ml at screening.",{''}
1187,221,ECOG Performance Status of 0-2.,{''}
1188,222,Speaks and reads in English or Spanish,{''}
1189,223,A female is considered of childbearing potential unless she is,{''}
1190,224,Participants must have a life expectancy of at least 3 months at the time of first dose.,{''}
1191,225,Maintain castrate levels of testosterone within 4 weeks prior to randomization and throughout the study,{''}
1192,226,Male participant must not donate sperm during the treatment period and for 90 days after IP administration.,{''}
1193,229,Male or female \> 18 years of age.,{''}
1194,230,"Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs assessments, oral temperature, 12-lead ECGs, and laboratory tests.",{''}
1195,231,Have been cleared for physical activity by a physician or nurse practitioner (physician or nurse practitioner name and date clearance received),{''}
1196,232,Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2,{''}
1197,233,Subjects are capable of giving informed consent,{''}
1198,234,Expected survival time ≥3 months.,{''}
1199,235,Presenting with de quervain's tenosynovitis,"{""de que ##rva ##in ' s ten ##osy ##nov ##itis""}"
1200,237,"Abnormal neuromuscular transmission demonstrated by single fiber electromyography or repetitive nerve stimulation, or",{''}
1201,239,Moderate or severe anxiety and/or depression determined by the Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI),{'anxiety depression'}
1202,241,All female participants of childbearing potential must a) have a negative highly sensitive serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening; b) have a negative urine beta-hCG pregnancy test immediately prior to each study vaccine administration,{''}
1203,242,"admitted at stroke unit of UZ Brussel,",{'stroke'}
1204,245,"Participant with a sufficient command of spoken and written French to take the assessments, complete the questionnaires, follow the program sessions and carry out the home exercises.",{''}
1205,246,Study partner who consents to study participation and who cares for/visits the participant daily for at least 5 hours per week.,{''}
1206,248,English-speaking (participant),{''}
1207,249,Radiological evidence of measurable disease by RECIST v1.1 criteria on CT with contrast or MRI of the areas of tumor involvement within 60 days of enrollment.,{'tumor'}
1208,250,"No anterior crossbite or open bite,",{'anterior cross ##bit ##e bite'}
1209,252,Weight \> 50 kg,{''}
1210,253,"If female, is not a participant of childbearing potential (POCBP); or if a POCBP, is not pregnant or breastfeeding, and is willing to use an acceptable contraceptive method or abstain from heterosexual intercourse for study duration","{'child, P, P, ##OC'}"
1211,255,Only for control group Absence optic nerve pathology (including primary open angle glaucoma),"{'op nerve path, primary open angle g ##lau ##com ##a'}"
1212,256,"Castration-resistant prostate cancer demonstrated during continuous androgen deprivation therapy (ADT), defined as 3 rises of PSA, at least 1 week apart with the last androgen deprivation therapy (PSA) \>= 2 nanogram per milliliters (ng/mL)",{'Cast ##ration - resistant pro ##state cancer'}
1213,258,ECOG Performance Status of 0-2 within 10 days prior to registration.,{''}
1214,259,"Patients with progressive, relapsed, or recurrent LCH with measurable disease at study entry",{'L ##CH'}
1215,261,"Postmenopausal, defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels \> 40 mIU/mL or 6 weeks post-surgical bilateral oophorectomy.","{'am, ##eno ##rr ##hea, am, ##eno ##rr ##hea'}"
1216,263,admitted in NICU within 24 hours after birth;,{''}
1217,264,"Newly diagnosed Minnesota standard risk aGVHD with plasma amphiregulin ≥ 33 pg/ml tested at the UMN Cytokine Reference Lab. For amphiregulin lab ordering information, see Fairview Lab Guide http//labguide.fairview.org/showtest.asp?testid=6766\&format=long -OR-",{'a ##G ##V ##HD'}
1218,265,Age ≥60 years at the time of study registration (men and women eligible),{''}
1219,266,Requiring PS at least 3 days per week and maintains a stable PS volume for at least 2 weeks.,{'PS'}
1220,267,Diagnosed with end-stage kidney disease,{'end - stage kidney disease'}
1221,270,"ASA score of I-III,",{''}
1222,271,Subjects with confirmed WD bichromosomal ATP7B gene mutation or missing by laboratory testing.,{'W ##D'}
1223,272,Acute Myeloid Leukemia (AML) and related precursor neoplasms,"{'A, ##cute My ##elo ##id Le ##uke ##mia, AM ##L, neo ##p'}"
1224,275,Signing of the free and informed consent term by the patient or companion if the patient is unable to sign it (Annex 1).,{''}
1225,276,suffering from pain at the base of the thumb,{''}
1226,277,Histological confirmation of triple negative breast cancer of a metastatic lesion is recommended,{'triple negative breast cancer'}
1227,278,"have no visual or hearing impairment,",{'visual or hearing imp ##air ##ment'}
1228,281,Metastatic or advanced-stage malignant tumors confirmed histologically for whom no standard therapy is considered to be appropriate by the investigator,{''}
1229,285,"Prognostically important multivessel CAD (triple vessel CAD or double vessel disease including the left anterior descending (LAD) or LM). Significant coronary stenosis is defined as ≥ 70% based on coronary angiography, and/or fractional flow reserve (FFR) ≤0.80 or instantaneous wave-free ratio (iFR) ≤0.89. For LM disease, significant coronary stenosis is defined as \>50% based on coronary angiography, intravascular ultrasound (IVUS) minimal luminal area (MLA) ≤6.0 mm2 (\<4.5 mm2 Asian descent), or equivalent optical coherence tomography (OCT) measurements;","{'multi ##ves ##sel CA ##D, triple vessel CA ##D, double vessel disease the left anterior descending LA ##D, L ##M s, L ##M disease s'}"
1230,288,FibroScan-AST (FAST) score ≥ 0.30 within 24 months before enrollment;,{''}
1231,290,planned GCSF-mobilized peripheral blood stem cell transplant,{''}
1232,291,"Imaging consistent with T1-4, N0-2, M0 pancreas cancer, including potentially resectable, boarderline resectable, or unresectable disease as per NCCN classification. When CT of the chest, abdomen, and pelvis are performed, this must be with contras per pancreas protocol. Imagining with a PET/MRI alone is acceptable on study. If a PET/CT is performed, a separate pancreas protocol CT is required for inclusion.",{'pan ##cre ##as cancer'}
1233,292,Patient informed of the study and not opposed to participating in the research.,{''}
1234,293,"Subject did not receive the following drugs, or received the drugs with stable dosage for at least 28 days prior to the baseline (start of treatment) for RA treatment Non-steroidal anti-inflammatory drugs (NSAIDs; excluding topical formulations), oral morphine or equivalent opioid analgesics (≤ 30 mg/day), acetaminophen, or oral corticosteroids (≤ 10 mg/day in prednisolone equivalent).",{''}
1235,295,Adult subject aged 18 or over,{''}
1236,296,Chronic HBV infection for ≥ 6 months.,{''}
1237,298,Minimum Data for Retrospective Enrollment,{''}
1238,299,carrying only one baby (not twins or triplets),{''}
1239,300,Experienced ≥ 3 HAE attacks during the 3 months before Screening,{'H ##A ##E'}
1240,301,Are 18 years of age or older,{''}
1241,304,At screening subject has active RA as evidenced by all of the following,{'RA'}
1242,307,Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.,{''}
1243,308,Participant who completed 2 doses primary vaccinations with another specified mRNA vaccine which is available in Japan 6 to 12 months prior to the trial vaccination.,{''}
1244,309,Histologically- or cytologically-confirmed solid tumors (excluding lymphomas) that are metastatic or unresectable and that meet the following criteria,"{'solid tumors, l, ##ymph ##oma'}"
1245,310,Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).,{''}
1246,311,-h OGTT value \< 140 mg/dl,{''}
1247,313,"Patient with localized endometrial cancer, presenting",{'localized end ##ome ##tri ##al cancer'}
1248,315,Eastern Cooperative Oncology Group (ECOG) performance status \< 4,{''}
1249,316,corrected distance visual acuity of 20/20 or better;,{''}
1250,318,dehydration,{''}
1251,319,Moderate to severe GL at maximum frown as assessed by the subject,{'G ##L'}
1252,321,Willing and able to provide consent for study participation for themselves and their infant prior to initiation of any study procedures,{''}
1253,322,Patient has signed study-specific informed consent form,{''}
1254,323,"Documented histopathology or cytopathology of PCa, adenocarcinoma;","{'PC ##a, ad, ##eno ##car ##cin ##oma'}"
1255,324,No prior systemic anti-cancer therapy for advanced ER+ disease,{''}
1256,325,Involuntary total body weight variation in the last 6 months \< 10%,{''}
1257,326,"Eastern Cooperative Oncology Group (ECOG) performance status 0,1 or 2",{''}
1258,327,Willingness to undergo \[18F\]F-AraG PET imaging at pre- and week 3 timepoints.,{''}
1259,328,"If clinical reports from the time of injury are available and Glasgow Coma Scale scores are available, then 13-15 is considered mild and 9-12 moderate. A clinical neurologist will review the de-identified OSU TBI forms for accuracy and confirm TBI severity.","{'OS ##U, T ##BI, T ##BI'}"
1260,331,"Relapsed after \> or = 3 lines of prior therapy that must include all approved and available therapies deemed eligible by the investigator, inclusing at a minimum of a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and, where approved and available, a CD38-directed cytolytic antibody in combination in the same line or separate lines of treatment OR refractory to PI, IMiD, and CD38- directed cytolytic antibody,",{''}
1261,332,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;,{''}
1262,333,"patients with histologically or cytologically documented locally advanced, advanced, or first recurrent cervical cancer. For treatment-naive patients, 4) no previous cancer treatment including chemotherapy or radiotherapy; Patients with an initial recurrence had not received any other cancer treatment, including chemotherapy or radiotherapy, after the diagnosis of an initial recurrence before enrollment.","{'cancer, cancer'}"
1263,335,Fluent in English,{''}
1264,336,Have signed an IRB consent form agreeing to the terms of the study,{''}
1265,337,"The subjects are primary school graduates / graduates and above, and have the ability to complete the cognitive ability test and other tests specified in the program;",{''}
1266,338,non smoker,{''}
1267,340,"CD10-negative DLBCL, which includes",{'DL ##BC ##L'}
1268,342,Preoperative imaging examination showed L4-5 and L5-S1 responsible segment protrusion or protrusion leading to segment stenosis.,{'segment s ##ten ##osis'}
1269,343,"Patients with a ""targetable"", bidimensionally-measurable, intracranial lesion that is radiographically recurrent after previous treatment with SRS +/- surgery (craniotomy or LITT). To classify a lesion as radiographically progressive, the lesion must demonstrate a ≥ 25% increase in size following treatment based on the Neuro-Oncology Criteria of Tumor Response for CNS Tumors. To be ""targetable"" for this study, the lesion should be coverable through a planned single LITT trajectory and thus have a maximum perpendicular diameter (perpendicular to the laser trajectory) of 3 cm. An intra-operative decision to utilize two trajectories is acceptable and patient may remain on study.","{'in ##c ##al, C ##NS Tu ##mor'}"
1270,344,Must have a primary tumor and/or metastasis amenable for surgery (or tap as indicated).,{''}
1271,345,Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) score greater than or equal to (\>=) 6,"{""S ##jo ##gren ' s S ##yn ##drome""}"
1272,346,Following treatment per A3973 protocol,{''}
1273,347,Arm B (first stage of phase II of TRC102 and pemetrexed) patients with malignant pleural or peritoneal mesothelioma who had progressed while being treated with or had recurred within 6 months of being treated with pemetrexed and cisplatin or carboplatin frontline; intervening treatment is allowed,"{'ma, ##li ##gnant p ##le ##ural or per ##ito ##nea ##l me ##so ##the ##lio ##ma'}"
1274,349,"Advanced histologically confirmed breast cancer that is ER+, PgR+, or both, and HER-2 normal;",{'breast cancer'}
1275,350,Smoking history of ≥10 pack-years,{''}
1276,351,"Existence of extrapancreatic organ damage (1) inflammatory bowel disease, (2) impairment of renal function, (3) repeated infection of mouth, skin, anus or whole body, (4) immune hepatitis, (5) persistent chronic immune iridocyclitis, (6) immune adrenalinitis leading to adrenocortical dysfunction, (7) pituitary inflammation leading to hypophysis, (8) rheumatoid disease, (9) immune vasculitis, (10) systemic lupus erythematosus, (11) other organs besides thyroid function damage. Suffering from one or more of above diseases. Recurrence after receiving regular clinical treatment, including symptomatic treatment of organ protective drugs.","{'extra ##pan ##cre ##atic organ, inflammatory bow ##el disease, imp ##air ##ment of re ##nal function infection of mouth , skin , an, immune he ##pa ##titis, chronic immune i ##rid ##oc ##y ##c ##lit ##is, immune ad ##rena ##lini ##tis, ad ##ren ##oc ##ort ##ical d ##ys ##function, pit ##uit ##ary inflammation, h ##y ##pop ##hy ##sis, r ##he ##uma ##to ##id disease, immune v ##as ##cu ##lit ##is, systemic l ##up ##us er ##yt ##hem ##ato ##sus'}"
1277,352,History or documentation of ticagrelor intake within the prior 3 days,{''}
1278,353,"Patient is receiving adjuvant therapy with an aromatase inhibitor (letrozole, anastrozole or exemestane), with or without a CDK4/6 inhibitor abemaciclib, for no more than 18 months,",{''}
1279,354,a. Active disease despite use of standard therapy (i) and one or more additional therapies (ii).,{''}
1280,355,average basal pain intensity (average 7 days) in the lumbar spine on NRS 0-10 ≥2.5,{''}
1281,356,Subjects can be enrolled as (1) TKI naïve or (2) after ≤ 8 weeks of first-line brigatinib treatment without disease progression.,{''}
1282,357,Patient is eligible for Tofacitinib treatment according to Summary of Product Characteristics (SmPC),{''}
1283,358,"Histologically proven, advanced high-grade osteosarcoma not suitable for local treatments with curative intent",{'o ##ste ##osa ##rc ##oma'}
1284,359,"Non-smoker and in good general health, as determined by medical screening evaluation, performed by PI or delegated sub-investigator no greater than 28 days before the first dose in the form of medical history, clinical laboratory tests and physical examination.",{''}
1285,361,"Confirmed by review of the electronic medical record (EMR) and subsequently recorded in Survivor Health History. In cases where the EMR isn't clear, their Oregon Health \&amp; Science University (OHSU) provider will be contacted for confirmation. For non-OHSU patients, we'll initially collect their cancer health history by a self-report questionnaire and confirm when we receive the survivor's outside medical record (through a signed Release of Information)",{'cancer'}
1286,362,T-DXd (DS-8201a)-naive disease,{''}
1287,363,have access to internet and a smart device with a camera and microphone.,{''}
1288,364,≤ 3 metastases in any non-bone organ system,{''}
1289,366,Subject meets the DSM-5 criteria for a primary diagnosis of schizophrenia.,{'s ##chi ##zophrenia'}
1290,367,Demonstrates comprehension of the protocol procedures and knowledge of the trial by passing a written comprehension examination (passing grade \> 70%).,{''}
1291,370,Patients in ASA II-III group,{''}
1292,371,Willingness to use adequate contraception to avoid pregnancy or impregnation for the duration of study participation; Note,{''}
1293,373,Available for the duration of the study,{''}
1294,374,"age greater than 18 years,",{''}
1295,375,Life expectancy of greater than 3 months,{''}
1296,376,Diagnostic and Statistical Manual of Mental Disorder-5 criteria for Alcohol Urge Questionnaire (moderate or severe defined as meeting 4 or more of the 11 criteria) AND a concurrent Diagnostic and Statistical Manual of Mental Disorder-5 recurrent unipolar major depression with HRSD-25 score of 18 or above.,"{'Al U of Mental Di ##sor ##der, un ##ip ##olar major depression'}"
1297,378,Subject has an arteriovenous fistulae (AVF) fistula that was determined to be mature by standard clinical definition,"{'art ##eri ##ove ##nous fist ##ula ##e, A ##V ##F ) fist ##ula'}"
1298,379,Age between 18-80 years old,{''}
1299,380,peripheral saturation (SpO2) strictly inferior to 90% and/or hypercapnic acidosis (pH strictly inferior to 7.35 and pCO2 strictly superior to 45mmHg) on arterial blood gases;,"{'h, ##yper ##cap ##nic acid ##osis'}"
1300,381,Electrocorticogram (ECOG) score ranges from 0 to 1 points;,{''}
1301,382,Hospitalized for acute exacerbation of COPD.,{''}
1302,384,Patient treated with furosemide at least 40 mg in the last 24 hours.,{''}
1303,385,Confirmed PD-L1 expression status (accepts PD-L1 expression test results confirmed by the investigator).,{''}
1304,386,"participants must be willing to use an electronic food diary and consume study provided foods,",{''}
1305,388,Patient with a current DSM-IV diagnosis of moderate or severe major depressive episode (MDE) without psychotic features (based on clinical assessment and confirmed by the MINI interview and the QIDS).,"{'major de ##pressive episode, MD ##E, ##ych'}"
1306,389,The mother has milk,{''}
1307,391,English speaking or Spanish speaking,{''}
1308,392,not seen outside the healthcare system,{''}
1309,394,Hemoglobin A1C less than 9.0%,{''}
1310,395,Bilateral ethmoid disease confirmed on CT,{''}
1311,396,Wants to quit cigarette smoking within the next 30 days (consistent with text messaging intervention trials),{''}
1312,398,scheduled for unilateral mastectomy without immediate breast reconstruction with or without axillary surgery (sentinel lymph node biopsy or axillary lymph node dissection),{''}
1313,399,Currently receiving methadone or buprenorphine treatment for OUD and considered to be stable on current dose for at least 30 days,{'O ##U ##D'}
1314,400,Can be retained to at least 1ml venous blood sample;,{''}
1315,402,Individuals who are normal healthy or have a diabetes diagnosis with a current HbA1c (glycated glucose)\< 7.0.,{'diabetes'}
1316,403,Participants with histologically confirmed diagnosis of a solid tumor (specifications for the different parts of the study below) will be enrolled onto this study,{'solid tumor'}
1317,404,Subjects without significant medical history and currently not on medications that might complicate the results,{''}
1318,405,In Part B eGFR 30-90 ml/min/1.73m\^2 (with no more than 20% having an eGFR \>75 ml/min/1.73m\^2) using CKD-EPI formula at screening visit and at least one historical value of eGFR \<60 mL/min/1.73 m\^2 within 3 months or have a registered diagnostic of CKD.,"{'C, ##K ##D'}"
1319,406,"Symptomatic intracranial arterial stenosis (intracranial segment of internal carotid artery (Petrous segment and above), middle cerebral artery, intracranial segment of vertebral artery, basilar artery, etc.) within 6 months, the degree of stenosis of the diseased artery is between 70% and 99% (WASID method);","{'in ##tra ##c ##rani ##al art ##erial s ##ten ##osis, s ##ten ##osis artery'}"
1320,408,"Histologically confirmed adenocarcinoma of the left colon or rectum (originate in the splenic flexure, descending colon, sigmoid colon, or rectum) in patients with unresectable (not amenable to radical surgery of metastases at the study inclusion) metastatic (M1) disease.","{'ad ##eno ##car ##cin ##oma of the left co ##lon or re, meta'}"
1321,410,Type of Participant and Disease Characteristics,{''}
1322,411,Age between 13-65 years old.,{''}
1323,412,Subject with a Body Mass Index (BMI)\* between 18.5 and 28.0 kg/㎡;,{''}
1324,413,Be willing to adhere to the study intervention through \[18F\]FDG PET/CT or LDCT imaging,{''}
1325,414,Not a woman of childbearing potential (WOCBP),{''}
1326,415,Ability to communicate with investigative staff,{''}
1327,416,Received post-test genetic counseling from MSK Clinical Genetics Service within the last 3 months,{''}
1328,417,The type and dose of drugs used for fibromyalgia should be stable for at least 2 weeks;,"{'fi, ##bro ##my ##al ##gia'}"
1329,418,Obtained written informed consent.,{''}
1330,419,Patient weighing more than 40 kg,{''}
1331,420,"Female or male, aged from 0 to \<20 years (at time of original diagnosis)",{''}
1332,421,"Has relatives in family that contains pancreatic cancer, and carries a known germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53.",{'pan ##cre ##atic cancer'}
1333,422,Parents of children under 18 years old,{''}
1334,423,"DSM-5 criteria for opioid use disorder, moderate to severe",{'op ##io ##id use disorder'}
1335,425,A female is considered of childbearing potential unless she is,{''}
1336,426,"Subjects must possess 10-100 total non-inflammatory lesions (open comedones and closed comedones), 10-50 total inflammatory lesions, no cysts, and up to 2 nodules (if deemed appropriate by the PI) on the face.","{'non, inflammatory lesions, c ##ts'}"
1337,427,At least one site of disease 1.5 cm or greater is needed to meet the spatial resolution limits of PET imaging.,{''}
1338,429,Patients attending outpatient clinics in a CS-specialist centre,{'CS'}
1339,431,Patients with HER2-positive breast carcinoma\* (confirmed by a local pathologist).,{'breast car ##cin ##oma'}
1340,432,"Oral cavity, larynx, hypopharynx, or p16-negative oropharynx cancer must be stages T1-2N2-3 or T3N1-3 or T4N0-3 (American Joint Committee on Cancer \[AJCC\] version 8);","{'Oral cavity , la ##ryn ##x , h ##y ##pop ##har ##ynx, or ##op ##har ##ynx cancer'}"
1341,434,Disease Status There are no disease status requirements for enrollment.,{''}
1342,435,Patients with protein energy expenditure (defined by serum albumin \< 3.8 g/dl),{''}
1343,436,"Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant.","{'o, ##bs ##truct ##ive or genetic h ##yper ##tro ##phic card ##io ##my ##op ##athy, in, ##fi ##lt ##rative / storage disorder, cardiac am ##yl ##oid ##osis'}"
1344,437,All above participants must have completed the written informed consent,{''}
1345,438,Treatment with Diet and Exercise alone at least 90 days prior to day of screening.,{''}
1346,439,Subject is intolerant of positive airway pressure therapy (defined as \<2 hours of sleep time with use per night for at least 5 nights per week as measured objectively by evaluation of continuous positive airway pressure (CPAP) machine memory chip and interpreted by the study sleep medicine specialist),{''}
1347,440,Patients must have consented to surgery with a board-certified Gyn surgeon,{''}
1348,441,All participants must be able to complete the Sonsken logMAR Test (SLT) either verbally or via use of a matching card.,{''}
1349,442,Endometrial cancer,{'End ##ome ##tri ##al cancer'}
1350,443,Diagnosis of MAS according to treating physician in the medical record.,{'MA ##S'}
1351,445,Eastern Cooperative Oncology Group Performance Status of 0 or 1,{''}
1352,446,Participant who had received appropriate prior empiric antibacterial therapy for a carbapenem-resistant pathogen must meet at least 1 of the following criteria no or no more than 24h; worsening of objective symptoms or signs after at least 48 hours of antibacterial therapy; no change of objective symptoms or signs after at least 72 hours of antibacterial therapy.,{''}
1353,449,Have a signed informed consent by participant or surrogate/representative,{''}
1354,450,"-13-year-old male and female students in randomly selected schools with at least 100 students in target classes (year-5 primary, year-1, 2 and 3 secondary)",{''}
1355,452,"Willing to comply with study instructions, agree to make study appointments, and complete the course of the study",{''}
1356,453,Language Proficiency Proficiency in English equivalent to middle school/high school level.,{''}
1357,456,ASA(American Society of Anesthesiologists) ≤ II 4.18kg/m2\<BMI\<30 kg/m2,{''}
1358,457,The subject initiates oral antibiotic treatment in the ambulatory setting.,{''}
1359,458,Presence of a BRAF V600E mutation confirmed as per standard of care according to international guidelines at any time prior to Screening.,{''}
1360,459,Measurement of blood glucose at least 4 times a day,{''}
1361,461,Patient initiating antifungal prophylaxis with micafungin.,{''}
1362,465,BMI greater than 35 to 50 Kg/m2,{''}
1363,466,Patients who are available for the entire trial period and willing to adhere to the protocol requirements,{''}
1364,468,ECOG performance status ≤ 2,{''}
1365,470,Medically fit and willing to undergo resection of disease,{''}
1366,472,Patients with a diagnosis of ALL who are receiving treatment with PEG-asparaginase or inotuzumab ozogamicin with Tbili \> 3 x ULN,{'AL ##L'}
1367,473,English speaker,{''}
1368,474,Participants with TSC associated with renal AML which is eligible for treatment with everolimus per local reimbursement criteria.,"{'T, re ##nal AM ##L'}"
1369,475,Patients whose body weight before operation \> 2 kg;,{''}
1370,476,Patients must have measurable disease at diagnosis per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1,{'Solid Tu ##mor'}
1371,477,Informed consent of parents,{''}
1372,478,Planned elective body reduction surgery to remove excess skin on the abdomen in ≥ 12 to ≤ 18 weeks,{''}
1373,479,Individuals must be ≥ 70 years of age at the time of signing the informed consent form.,{''}
1374,480,At least 1 measurable lesion per Response Evaluation Criteria in solid tumor (RECIST 1.1).,{'solid tumor'}
1375,482,Participants with histologically documented locally advanced or metastatic solid tumor,{''}
1376,483,EDSS score of 6.5 (constant bilateral assistance required to walk about 20 meters without resting) as assessed by a Neurologist with a specialty in MS,{'MS'}
1377,484,"Failed trial of conservative therapy (including bladder training, fluid modification, diet modification, caffeine restriction, or pelvic floor training) -Failed trial of at least one pharmacologic treatment (anticholinergics, β3- adrenoceptor agonist) either due to inability to take the medication, adverse reaction to medication, or no improvement on medication",{''}
1378,485,With an information leaflet and non-opposition form signed by one or both parent(s) or by the legal representative.,{''}
1379,486,"Being between the ages of 18-22,",{''}
1380,489,Stated willingness to comply with all study procedures and availability for the duration of the study;,{''}
1381,490,Signs of histological activity of the NTI objectified during the centralized rereading and defined by,{'N'}
1382,491,Indirect hyperbilirubinemia with TSB levels between 14-20 mg/dL,"{'##dir, h ##yper ##bil ##ir ##ubi ##ne ##mia'}"
1383,492,both partners should have their own mobile devices with access to the internet,{''}
1384,493,Participant fluency in primary language of country in which study is being conducted.,{''}
1385,495,Runs independently,{''}
1386,498,self-identified history of violent victimization,{''}
1387,499,Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.,{''}
1388,500,"Moderately to severely active UC, defined as a baseline modified Mayo score of 5 to 9, inclusive, using the Mayo endoscopic subscore assigned during the concurrent local and central reading of the video endoscopy.",{'UC'}
1389,503,body mass index range 25.0 to 40 kg/m2,{''}
1390,504,Moderate or higher depression confirmed by DIAMOND interview,{''}
1391,505,In regular follow-up in either of the two study centres,{''}
1392,506,Presence of a dental/skeletal malocclusion,{'dental / skeletal ma ##loc ##c ##lusion'}
1393,507,Ability of normal oral ingestion,{''}
1394,510,Patients receiving curative or adjuvant pelvic radiation including,{''}
1395,511,Aged 19-42 years;,{''}
1396,512,"Community dwelling, assisted living conditions or care home residents.",{''}
1397,513,Manifest Refraction - Spherical Equivalent Refractive Error (SERE) at baseline between -0.75 D and -4.00 D inclusive (at the corneal plane) in each eye,{''}
1398,515,"Must, at the time of randomization, be newly initiated on BUP (i.e., within 7 to 28 days) during the current treatment episode, be taking ≥ the recommended target dose for transmucosal BUP57 (or equivalent for extended-release), and have documentation of receiving BUP, including dose and the start date of the current treatment episode, from their BUP provider;",{''}
1399,516,"Those who have listened to a detailed explanation of the clinical trial, fully understand it, voluntarily decide to participate, and provide written consent to comply with precautions.",{''}
1400,517,not taking medication for FM for at least 4 weeks;,{'FM'}
1401,518,years ≤ age ≤ 65 years.,{''}
1402,519,Stable dosing of medications (if taking) for pain and sleep;,{''}
1403,523,Individuals who have ovarian cancer or breast cancer who are recommended to start olaparib,"{'o ##var ##ian cancer, breast cancer'}"
1404,524,Signature of informed consent by the patient or his legal representative,{''}
1405,525,"Decrease in kidney function GFR (or eGFR) less than 60 mL/min, or investigator's decision",{''}
1406,526,Willing to sleep with a weighted blanket for up to 3 months,{''}
1407,527,ability to commit to study visits.,{''}
1408,528,Relapsed/refractory CLL eligible to receive single-agent VEN or VEN in combination with rituximab at Screening.,{'C ##LL'}
1409,529,Members of the tribal communities that participate in the Strong Heart Study in southwestern Oklahoma,{'Strong Heart'}
1410,530,T-NHL PATIENTS,{'T - NHL'}
1411,531,Subjects with severe visual disturbance (count-fingers or worse vision for severe eyes) at the time of obtaining the consent,"{'visual disturbance, count - fingers or, worse vision eyes'}"
1412,532,Patients eligible to receive temozolomide as standard of care adjuvant therapy,{''}
1413,533,Age greater than or equal to 12 years. (Turnstile I),{''}
1414,535,Has a body mass index (BMI) within 18 to 35 kg/m2 and weighs at least 50 kg,{''}
1415,536,Child's parents or guardians are willing and able to give consent,{''}
1416,537,Phototypes l to lV of the Fitzpatrick scale,{''}
1417,538,Subject must have a clinical diagnosis of Rheumatoid Arthritis (RA) at least 6 months prior to Screening,"{'R, ##he ##uma ##to ##id Art ##hr ##itis, RA'}"
1418,539,Stated willingness to comply with all study procedures and availability for the duration of the study,{''}
1419,540,"Living in the same house with their spouse,",{''}
1420,541,Main place of residence in France,{''}
1421,542,Ability to return for all study visits over 48 months,{''}
1422,545,HbA1c ≥ 7.0% and ≤ 10.5% managed with diet and exercise alone or with a stable dose of metformin or an SGLT2 inhibitor for at least one month prior to screening.,{''}
1423,546,years old ≤ 80 years old;,{''}
1424,547,People of childbearing potential,{''}
1425,548,Moderate to severe active Crohn's disease.,"{""C ##ro ##hn ' s disease""}"
1426,549,ECOG physical status score is 0 or 1;,{''}
1427,550,Histologically confirmed recurrent glioblastoma (grade IV) as per WHO criteria 2021 (IDH- wild type only) where the subjects have an Ommaya reservoir in an intralesional cavity of at least 5 mL volume.,"{'g, ##lio ##blast ##oma'}"
1428,551,Normal hearing,{''}
1429,553,Patients who belongs to surgical or trauma subject.,{'trauma'}
1430,554,Part B and Part C Have received 1 to 3 prior lines of anti-myeloma therapy.,{'my ##ma'}
1431,555,"Those who are not currently using Metformin, can tolerate fasting for 8 hours, have not used antibiotics within 3 months, and have no obvious intestinal diseases.","{'in, ##test ##inal diseases'}"
1432,556,"Patients must have been diagnosed between 1990 and 2006 with a clinically localized (clinical stage T1-T3, N0 or NX, MO or MX) prostate cancer, in the judgment of the treating physician","{'pro, ##state cancer'}"
1433,557,"Subjects 50 to 80 years of age, inclusive, on the day of consent.",{''}
1434,558,ICU LOS ≥ 24h,{''}
1435,559,Disease Status Patients must have measurable disease.,{''}
1436,561,"Is male or female ≥18 to ≤85 years of age, inclusive, at screening.",{''}
1437,562,Willingness to comply with study procedures and availability for duration of study,{''}
1438,564,"Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 60 days after the final study drug administration.",{''}
1439,566,o Patients with International agreement on staging (INSS) stage 4 are eligible with the following,{''}
1440,567,willing to participate the study,{''}
1441,568,the participants were aged between 65 and 95,{''}
1442,569,"ECOG Performance Status of 0, 1 or 2.",{''}
1443,570,Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study,{''}
1444,571,Ability to read and write in English,{''}
1445,1,Presence of fewer than ten intracranial lesions,{'in ##tra ##c ##rani ##al lesions'}
1446,2,Presence of at least 1 non-irradiated tumor lesion detected at conventional imaging (computed tomography / magnetic resonance imaging (CT/MRI)) documented within 4 weeks prior to the 68Ga-NYM096 administration which should be measurable per response evaluation criteria in solid tumors (RECIST) v1.1.,"{'tumor, solid tumors'}"
1447,4,Has no evidence of distant metastases based on PSMA-PET/CT performed ≤28 days prior to enrollment.,{''}
1448,6,Have measureable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).,{'Solid Tu ##mor'}
1449,7,No psychiatric history and not using medication,{''}
1450,8,Scheduled to receive or planning to receive a ≤28-day course of SOC antibiotic therapy for CDI. Participant must have been diagnosed with CDI for 7 or fewer days at time of initial study drug administration. SOC antibiotic therapy is defined as the receipt of oral fidaxomicin or oral metronidazole or oral vancomycin (see Section 8.2.6),"{'CD ##I, CD ##I'}"
1451,10,Patients must be willing and able to provide a written informed consent,{''}
1452,11,"Ability to read, speak, and understand English",{''}
1453,13,Controlled cholesterol of less than 200 mg/dl,{''}
1454,14,"Have no measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Ascites and pleural effusions are not measurable disease, if asymptomatic",{'Solid Tu ##mor e'}
1455,15,Free of any underlying medical conditions,{''}
1456,16,"Patients must be willing to have skin biopsies, blood collection, and total body photography and to comply with clinic visits",{''}
1457,18,Full comprehension ability to comprehend the full nature and purpose of the clinical investigation.,{''}
1458,19,Free of ocular disease or abnormalities (including any corneal scar),"{'o, ##cular disease, abnormal ##ities, corn ##eal scar'}"
1459,20,Written informed consent by subject and/or witness prior to any study-related procedures,{''}
1460,22,"Grade II and Grade III OA according to the Kellgren and Lawrence radiographic classification,",{'O'}
1461,23,"Progressed on, be refractory to, relapsed, or intolerant to standard therapy for their cancer. At least 1 but not more than 3 prior systemic therapies.",{'cancer'}
1462,24,Subjects must have a BCDVA projected to be better than 20/32 after IOL implantation in each eye as determined by the medical judgment of the Principal Investigator.,{''}
1463,26,infection-associated arterial and/or venous thrombosis within 30 days of infection,{'art ##erial and / or ve ##nous th ##rom ##bos ##is'}
1464,27,"Willing to wear one Dexcom CGM transmitter and sensor (sensor must be changed every 10 days), and one infusion set that must be replaced at least every 3 days.",{''}
1465,29,Willing to be treated with non-opioid treatments for pain (in addition to opioid being tapered) for duration of study.,{''}
1466,30,Body weight between 60.0 and 100.0 Kilogram (kg) (both inclusive),{''}
1467,34,FVC ≥45% predicted at Screening.,{''}
1468,35,"The patient has a history of allergy, hypersensitivity, or any serious reaction to the echinocandin class of antifungals.","{'all ##er ##gy, h ##yper ##sen ##si ##ti ##vity'}"
1469,36,Ability to safely ride a stationary exercise bike (SARA sitting sub-score \<3),{''}
1470,37,Fasting blood glucose less than 180 mg,{''}
1471,38,"Proximal DVT involving at least 1 of the following proximal veins the popliteal vein, the femoral vein, the common femoral vein and the external iliac vein",{'D ##V ##T'}
1472,39,Individuals without widespread visceral or musculoskeletal pain were included.,{'v ##is ##cer ##al or m ##us ##cu ##los ##kel ##etal pain'}
1473,43,"Have expressed, in the questionnaire survey, interest in receiving a digital social intervention.",{''}
1474,44,Height ≥ 48 inches,{''}
1475,45,Completeness of clinical documentation.,{''}
1476,46,Minimum of 2 exacerbations in the last 12 months. Or 1 exacerbation in case that patient had been receiving oral glucocorticoid therapy for at least 6 continuous months directly before enrollment (equivalent to a prednisolone or prednisone dose of 7.5 to 40.0 mg per day),{''}
1477,47,Must have a negative serum pregnancy test at screening (V1),{''}
1478,48,MD report of difficulty walking ¼ mile or climbing 10 steps without resting,{''}
1479,49,Age ≥ 18 years,{''}
1480,50,"Full-time and regular desk worker for the last 3 years,",{''}
1481,51,Be affiliated to a health insurance scheme,{''}
1482,52,willing to receive support from the research team on how to access Zoom (as needed),{''}
1483,54,Have internet access to complete the 3 online study visits,{''}
1484,56,schizoaffective disorder,{'s ##chi ##zo ##af ##fect ##ive disorder'}
1485,58,Patients with wildtype BRCA1/2 mutation status or with a deleterious BRCA1/2 mutation in germline or somatic testing if they underwent PARP inhibitor therapy in previous treatment line.,{''}
1486,59,Disease progression during or after first- or second-line hormonal therapy with CDK4/6 inhibitor,{''}
1487,60,ECOG score 0-1;,{''}
1488,63,Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy.,"{'C ##IS, Ta / T ##1 ( non ##in ##vasive p ##ap ##illa ##ry disease, tumor'}"
1489,64,Have at least 8 mental health providers on staff,{'mental'}
1490,65,Have adequate clearance between distal end and ground for necessary knee and foot components,{''}
1491,66,"Female subjects must not donate ova starting at informed consent and throughout the clinical study period, and for 28 days after the final study drug administration.",{''}
1492,68,Exclusion Criteria for Adolescent,{''}
1493,72,Have Body Mass Index (BMI) ≥23.0 kilogram per square meter (kg/m²),{''}
1494,73,Radiological progression in soft-tissue lesions according to PCWG3 modification of RECIST v1.1 criteria,{'soft - tissue lesions'}
1495,74,Patients must be \>= 365 days and =\< 31 years of age (B-ALL patients with DS).,"{'B - AL ##L, DS'}"
1496,75,Score ≥0.5 and ≤15 on CDR plus NACC FTLD sum of boxes.,{'F ##TL ##D'}
1497,76,Presence of more than 10 adenomatous polyps in the colon or rectum.,{'ad ##eno ##mat ##ous p ##oly ##ps in the co ##lon or re ##ct ##um'}
1498,77,Left ventricular ejection fraction (LVEF) \< 35% or equal,{''}
1499,78,Registered with the French health insurance system,{''}
1500,80,Receiving enteral feedings of 120 mL/kg/day or greater,{''}
1501,82,"For children \<1 year of age, ≥2 RTIs (as reported by parents or LAR of subject), including ≥1 episode of wLRIs (including ≥1 triggering hospitalisation or medical visit) within 6 months prior to enrolment.","{'R, w ##LR ##I'}"
1502,85,No prior orthodontic intervention.,{''}
1503,86,) KPS ≥ 60 points;,{''}
1504,87,Written informed consent;,{''}
1505,88,Study participant has Myasthenia Gravis Foundation of America (MGFA) Class II to IVa at Visit 1,{'My ##ast ##hen ##ia G ##ra ##vis'}
1506,92,Has an implanted spinal cord epidural stimulation unit that is eligible for software upgrade as part of a previous study.,{''}
1507,93,Fluent in English or Spanish,{''}
1508,94,Adult able to provide written consent,{''}
1509,96,Lenvatinib 7 days,{''}
1510,97,Willing and able to provide informed consent,{''}
1511,98,"Anatomic or mechanical compromise of critical organ function by tumor (e.g., respiratory distress/failure, abdominal compartment syndrome, urinary obstruction, etc)","{'tumor, respiratory distress failure, abdominal compartment syndrome, u, ##rina ##ry o ##bs ##truction'}"
1512,100,History of AD for ≥ 12 months at screening.,{'AD'}
1513,102,Women of childbearing potential must commit to either abstain continuously from sexual intercourse or to use 2 methods of reliable birth control simultaneously as deemed appropriate by the Investigator. Contraception must begin 4 weeks prior to dosing and must continue for 3 months after the last dose of daratumumab,{''}
1514,104,Two or more vein grafts to native vessels having at least 75% stenosis and comparable runoff.,{''}
1515,105,Participants must have positive PD-L1 expression (Combined Positive Score \[CPS\] ≥ 1),{''}
1516,106,"\< 51 applications difference between each eye, in the superior or inferior hemisphere.",{''}
1517,107,Participant was less than 21 years of age at time of diagnosis.,{''}
1518,109,ECOG Performance Status of ≤ 2.,{''}
1519,111,Criteria for clinical deterioration to be determined and agreed upon by treating physician and Principal Investigator,{''}
1520,114,Total or partial gastrectomy patients,{''}
1521,117,"Participants with a documented history of PD-L1 positive NSCLC. Any number of prior treatment lines are allowed in this study, however at least one of the treatment line(s) must include an anti-PD(L)-1 antibody. Participants with any documented PD-L1 positivity by immunohistochemistry (IHC) without prior treatment with anti-PD(L)-1 antibody may be allowed on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.","{'N, ##SC ##LC'}"
1522,118,"-- Participants 12 to \<18 years of age may enroll with either evaluable (i.e. anatomically visible tumor on cross sectional imaging, but tumors do not need to be \>1 cm) or measurable disease per RECIST v1.1.",{'tumors'}
1523,122,WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 28 days after Investigational Product (IP) administration.,{''}
1524,125,"Born assigned to Male gender, age 18 and above. Female identifying transgender or gender fluid are allowed on study provided they have not undergone testosterone suppressing therapy and were born with a prostate.","{'pro, ##state'}"
1525,126,Proficient in the language of the intervention and assessment tools.,{''}
1526,127,Ability to understand and follow study-related instructions.,{''}
1527,128,Those subjects or/and their legal representatives who voluntarily agreed to participate in this human test and signed a written consent form and a consent form for research on human-derived materials,{''}
1528,130,"Positive for at least one islet cell autoantibody; Glutamate decarboxylase (GAD)65A, mIAA (if obtained within 10 days of the onset of insulin therapy), IA-2A, ICA, or ZnT8A",{''}
1529,131,Having mobile phones to receive text messages.,{''}
1530,132,"willing to ingest a dietary BC supplement or placebo (up to 900 mg/day, two 450 mg capsules) as well as 400 mg calcium and 500 IU vitamin D daily",{''}
1531,136,"Fitzpatrick skin phototype I to IV,",{''}
1532,138,English-speaking,{''}
1533,139,BMI between 18 and 35 kg/m\^2.,{''}
1534,140,Inpatient population,{''}
1535,144,BMI of 30-50 kg/m2 for ambulatory participants (less than or equal to 350 lbs.),{''}
1536,146,"Subject meets the ACR 1991 Revised Criteria for Global Functional Status in RA Class I, II or III at Screening and Baseline",{''}
1537,147,Patients with Child-Pugh class A or B.,{''}
1538,148,Receipt of ADT for mCSPC for at least 6 months and no greater than 12 months at time of enrollment.,"{'m, ##CS ##PC'}"
1539,149,Fasting blood glucose less than 180 mg/dl,{''}
1540,150,Immediate initiation of RRT for management of AKI is planned OR additional RRT sessions are imminently planned for patients who already received RRT during their ICU admission;,{'AK ##I'}
1541,151,Suffer from histologically confirmed locally unresectable advanced or metastatic solid tumors and meet the criteria of corresponding cohort as follows,{'advanced or meta ##static solid tumors'}
1542,152,Score ≥12 scale Postpartum depression questionnaire Edinburgh.,{''}
1543,154,Patients who do not have complications such as pre-eclampsia or gestational diabetes.,"{'pre - e ##c ##lamp ##sia, g ##esta ##tional diabetes'}"
1544,155,"Rating IIIv, IV and V on the Norwood Hamilton Scale; subject is willing to receive a ink dot tattoo;",{''}
1545,157,One male or female with an occupation.,{''}
1546,159,Patients must have measurable disease according Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria,{''}
1547,161,Resident in the area and not planning to leave the region.,{''}
1548,162,Patients must have measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) criteria,{'Solid Tu ##mor'}
1549,164,Has mild to severe ileal and/or colonic CD.,{'il ##eal and / or co ##lon ##ic CD'}
1550,165,"At least 1 month has passed since the stroke,",{''}
1551,167,"obese (body mass index 30-40 kg/m\^2),",{'o'}
1552,168,BMI \> 25kg/m2,{''}
1553,171,are able to complete assessments in English; and,{''}
1554,172,Present with chronic PsO based on a confirmed diagnosis of chronic PsO vulgaris for at least 6 months prior to baseline,"{'chronic P ##s ##O, chronic P ##s ##O v ##ul ##gar ##is'}"
1555,177,"Understanding of the research procedures and methods, potential benefits and risks of the trial, and sign written informed consent.",{''}
1556,179,surgical resection of primary melanoma is allowed,{'me ##lan ##oma'}
1557,181,Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,{''}
1558,182,"Confirmed germline mutation carrier (BRCA2, FAMMM (CDKN2A/p16), PALB2, BRCA1, ATM, HNPCC, Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM) PRSS1, PRSS2, R122H, N291l, SPINK1, CFTR",{'Lynch S ##yn ##drome'}
1559,183,Must have capacity to verbally consent,{''}
1560,184,Diagnosis of radiological progression while on or after first platinum-based systemic therapy administered for advanced or metastatic disease.,{''}
1561,185,At least one resectable lesion (solitary or aggregate lesions) for TIL generation.,{''}
1562,186,No prior systemic therapy for ES-SCLC.,{'E ##S - SC ##LC'}
1563,187,Active uptake when the tumoral lesion shows SSTR expression higher than the one of the background cerebral uptake.,{'tumor'}
1564,188,Subjects have no confirmed prior history of FIX inhibitor formation,{''}
1565,189,Ewing sarcoma,{'Ewing sa ##rc ##oma'}
1566,190,"Patients with M1 stage according to the Tumor, Node and Metastasis Classification of Malignant Tumours (TNM)",{'Mali ##gnant Tu ##mour'}
1567,191,Individuals who have the ability to comply with study procedures including follow-up.,{''}
1568,192,Informed consent;,{''}
1569,195,Be affiliated to a social security scheme,{''}
1570,196,Subject must agree not to participate in any other clinical investigation for a period of 1 year following the procedure,{''}
1571,197,"Patients followed at psychiatry clinics or primary care clinics at an enrolling site (such as, but not limited to, Internal Medicine, Family Medicine, or Pediatrics)",{''}
1572,198,"Use of non-steroidal anti-inflammatory drugs \[NSAIDs\], cyclooxygenase-2 (COX-2) inhibitors, or oral corticosteroids for the treatment of RA must be stable for at least 28 days prior to start of the study",{''}
1573,199,Hemoglobin at least 5.5 and 10.5 gram per deciliter (g/dL) at the most. Hemoglobin concentration must be based on an average of at least 2 Hb concentration measurements (separated by ≥7 days) collected during the Screening Period;,{''}
1574,200,Express consent to participate in the study,{''}
1575,201,Patients with no intra-bony defect.,{'in ##tra - bony defect'}
1576,202,Competent to provide written informed consent,{''}
1577,203,Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2,{''}
1578,204,"Elective/planned surgery types with planned or anticipated to be treated with tramadol, hydrocodone, or codeine pain management at an enrolling site, which may include orthopedic surgeries (e.g. arthroplasty, spine, etc.), open abdominal surgery, or cardiothoracic surgery and others",{'card ##hora ##ci ##c'}
1579,205,"Women of non-childbearing potential were defined as women who were post menopausal or had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least 6 weeks prior to first dosing of study treatment. In the case of oophorectomy alone, only when the reproductive status of the woman was confirmed by follow-up hormone level assessment was she considered not of childbearing potential. Women were considered post-menopausal if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms).","{'am ##eno ##rr ##hea, v, ##as ##tor symptoms'}"
1580,206,Female participant is not pregnant and at least 1 of the following conditions apply,{''}
1581,210,The patient reports knee symptoms in the last month.,{'knee symptoms'}
1582,212,These criteria were selected to target individuals with low and high-frequency cannabis use in order to examine the direct effect of tolerance on study outcome measures.,{''}
1583,213,Serum FSH level on the second day of menstruation was ≤12U/L,{''}
1584,215,Having access to internet,{''}
1585,218,Absence of nuclear jaundice,{''}
1586,220,NOTE At least two Viral Load (VL) measurements within 48 weeks prior to the Step 0 screening visit must be available for review. A single plasma HIV-1 RNA \> 50 copies/mL but \< 200 copies/mL that is followed by an HIV-1 RNA \<50 copies/mL is permitted.,{''}
1587,221,Histologically or cytologically confirmed diagnosis of small cell lung cancer,{'small cell lung cancer'}
1588,222,"Shops at the selected Northgate Gonzalez Market regularly, at least two times per month",{''}
1589,223,postmenopausal for at least 12 months prior to study drug administration;,{''}
1590,225,Patients currently receiving bone loss prevention treatment with bone-sparing agents must be on stable doses for at least 4 weeks prior to randomization,{'bone loss'}
1591,226,Male participant with pregnant partner(s) must agree to use a condom and spermicide for the duration of the pregnancy throughout the study and for 90 days after IP administration.,{''}
1592,229,Eastern Cooperative Oncology Group Performance status ≤ 2.,{''}
1593,231,Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure,{''}
1594,232,Have adequate renal function defined as Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Estimated Glomerular Filtration Rate (eGFR) \>=40 milligrams per minute (mL/min) computed with the calculator on the CKD-EPI website,"{'Ch, ##ronic Kid ##ney Disease'}"
1595,233,Overweight or obese,{'Over o ##bes'}
1596,234,ECOG 0-1.,{''}
1597,237,"Positive response to an AChEI test (eg, edrophonium chloride test), or",{''}
1598,239,No active self-harm or active suicidal intent,{''}
1599,241,Must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the laboratory screening tests are outside the laboratory normal reference ranges and additionally within the limits of toxicity Grade 2 according to the US FDA toxicity scale the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant and appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator,{''}
1600,242,"ability to participate in cognitive assessments,",{''}
1601,246,"Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).",{''}
1602,248,Smart phone access,{''}
1603,249,Lesions must have shown radiological evidence of disease progression in the 12 months prior to enrollment.,{''}
1604,250,"Missing no more than 2 incisors in a single jaw,",{''}
1605,252,\> 18 years of age,{''}
1606,256,"Participants who received a first generation anti-androgen (eg, bicalutamide, flutamide, nilutamide) must have at least a 6-week washout prior to randomization and must show continuing disease (PSA) progression (an increase in PSA) after the washout period",{''}
1607,258,"Low grade follicular lymphoma (grade 1-2 or 3A by WHO-HAEM4R and/or cFL by WHO-HAEM5). Specifically, grade 3B or FLBL will not be allowed. Must not have evidence of transformed lymphoma at the time of study enrollment.","{'f, ##oll ##icular l ##ymph ##oma, transformed l ##ymph ##oma'}"
1608,259,Patients must have had histologic verification of LCH (from either original diagnosis or relapse/progression) at the time of study entry (must be obtained within 28 days prior to enrollment and start of protocol therapy) (repeat if necessary),{'L ##CH'}
1609,261,"Have moderate to severe VVA as determined by self-assessment of the following symptoms (as none, mild, moderate, or severe), with at least 1 symptom reported as moderate or severe vaginal dryness; vaginal and/or vulvar irritation/itching; dysuria; vaginal pain with sexual activity (dyspareunia); vaginal bleeding associated with sexual activity (presence versus absence).","{'V ##VA, v, ##agi ##nal dry ##ness, v, ##agi ##nal and / or v ##ul ##var irritation it ##ching, d, ##ys ##uria, v, ##agi ##nal pain, sexual activity, d, ##ys ##par ##eu ##nia, v, ##agi ##nal bleeding'}"
1610,263,"premature infants without complications (including bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, intraventricular hemorrhage and late-onset septicemia) at the time of admission.","{'br ##on ##cho ##pu ##lm ##ona ##ry d ##ys ##p ##lasia, re, ##tino ##pathy of pre ##mat ##urity, ne ##c ##rot ##izing enter ##oc ##oli ##tis, in ##tra ##vent ##ric ##ular hem ##or ##r ##hage, late - onset, se ##ptic ##emia'}"
1611,264,"Newly diagnosed Minnesota standard risk aGVHD Ann Arbor 3 biomarkers tested by Viracor. For ordering information, see https//www.viracor-eurofins.com/test-menu/403572p-agvhd-symptomatic- onset-algorithm/",{'##G ##V ##HD'}
1612,265,Participants must have histologically or cytologically confirmed Stage I-III breast cancer with the following criteria met,{'Stage I - III breast cancer'}
1613,266,In case of remnant colon documented colonoscopy which does not give rise to any safety concerns.,{'remnant co ##lon'}
1614,267,Received standard (thrice-weekly HD) for at least 3 months,{''}
1615,270,"No history of bleeding diathesis,",{'bleeding'}
1616,271,"Subjects must be treatment-experienced to WD who have received standard treatment (eg, D-penicillamine or zinc acetate) for at least 6 months prior to the screening period.",{'W ##D'}
1617,272,Favorable risk AML is defined as having one of the following,{'AM ##L'}
1618,275,Patient admitted to the unit participating in the study.,{''}
1619,276,"the attending physician deems that an intra-articular corticosteroid injection would be beneficial, rather than opting for other types of intervention such as surgery",{''}
1620,277,Histological or cytological confirmation of metastatic breast cancer is required in case of normal CA 15.3 levels,{'meta ##static breast cancer'}
1621,278,"have stable hemodynamic and physiological parameters (pulse, respiration, blood pressure, oxygen saturation, pain),",{''}
1622,281,Patients must have at least one other lesion that is measurable by RECIST criteria.,{''}
1623,285,"The institutional Heart Team agrees that guideline-directed medical therapy (GDMT) has been initiated for ≥1 month in prevalent and newly diagnosed cases. In patients hospitalized with newly diagnosed iLVSD (with or without acute coronary syndrome (ACS)) requiring revascularization before discharge, GDMT needs to be initiated, when possible in-hospital before randomization, with the expectation that it will be titrated to maximally tolerated doses after revascularization.","{'i ##L ##VS ##D, acute co ##rona ##ry syndrome, AC ##S'}"
1624,288,There are any of the following evidences of fatty liver,{'fatty liver'}
1625,290,CMV-seropositive recipient,{''}
1626,291,Must have received neoadjuvant chemotherapy at the discretion of medical oncology,{''}
1627,293,Subject has active RA as evidenced by both of the following,{''}
1628,295,Subject informed of study participation and not objecting to participation,{''}
1629,296,On NRTI therapy with HBV DNA \< LLOQ for ≥ 6 months.,{''}
1630,298,Platelet count from approximately 7 days prior to starting avatrombopag,{''}
1631,299,first time giving birth,{''}
1632,300,Participated in the Run-in Period for at least 1 month (CSL312-naïve subjects only),{''}
1633,301,Report ≥6 hours of sedentary behavior on a typical day OR report engagement in ≤90 minutes of moderate-to-vigorous physical activity in the past week,{''}
1634,304,≥ 6 tender/painful joints;,{''}
1635,307,"Participants with selected histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have been previously treated.",{'solid tumors'}
1636,308,EXTENSION PART,{''}
1637,309,"Escalation and expansion cohorts wild type (WT) TP53 status defined as no mutation on a Clinical Laboratory Improvement Amendments (CLIA)-certified next-generation sequencing (NGS) assay that has sequenced the full length TP53 gene. Patients can be enrolled based on tissue testing or liquid biopsies. If enrolled based on liquid biopsies, testing should have detected other somatic mutations.",{''}
1638,310,Patients plan to or have received ADCs for the second or more time.,{''}
1639,311,"Good general Health as determined by medical history, physical exam, screening lab tests, urinalysis, and EKG.",{''}
1640,313,A high-grade endometrioid histological type and/or,{''}
1641,315,Patient have measurable and amenable to biopsy under local anesthesia without the need for imaging directed procedure,{''}
1642,316,no history of using rigid gas permeable lenses or orthokeratology (OK) lenses prior to examination,{''}
1643,318,skin and soft tissue infection,{'skin and soft tissue infection'}
1644,321,"In good health, as determined by the medical history and clinical judgment of the investigator Note Healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.",{''}
1645,322,Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements,{''}
1646,323,Confirmed as mCRPC;,{'m ##CR ##PC'}
1647,324,Postmenopausal women,{''}
1648,325,Self-sufficiency (with a score \>60 on the Barthel index),{''}
1649,326,Mayo stage I-IIIA cardiac disease at Screening,{''}
1650,327,Diagnosis of histologically or cytologically confirmed diagnosis of cutaneous melanoma belonging to one of the following AJCC TNM stages,{'cut ##aneous me ##lan ##oma'}
1651,328,Men and women of all ethnicities/races and socio-economic status.,{''}
1652,331,"Subjects who could not tolerate a PI, IMiDs, or a CD38-directed cytolytic antibody are eligible to enroll in the study.",{''}
1653,332,"Histologically confirmed advanced malignant solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.","{'ma, ##li ##gnant solid tumor'}"
1654,333,) measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.,{'Solid Tu ##mor'}
1655,335,Reports at least one DSM-5 traumatic event that occurred 1+ months ago,{''}
1656,337,Memory loss lasted for at least 6 months and tended to worsen gradually;,{''}
1657,338,"abdominal instability,",{'abdominal instability'}
1658,340,"CD10-negative non-GCB DLBCL, not otherwise specified (NOS) (i.e., CD10-/BCL6- or CD10-/BCL6+/MUM1+ DLBCL)",{'DL'}
1659,342,Surgeries are performed by the same chief surgeon.,{''}
1660,343,Patient must be at least 3 months post initial SRS treatment of the target lesion,{''}
1661,344,Must be willing to undergo a surgical tumor biopsy (or tap as indicated) prior to registration.,{'tumor'}
1662,345,"At least one abnormal laboratory marker of pSS-related inflammatory disease activity, and at least low activity in one or more specified European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) domains","{""p ##SS R ##he ##uma ##tism, S, ##jo ##gren ' s S ##yn ##drome""}"
1663,346,Following treatment per Pediatric Oncology Group (POG)-9341/9342 protocol,{''}
1664,347,Prior pemetrexed is allowed except Arm A dose level 4 (cisplatin 75 mg/m\^2),{''}
1665,349,Up to one prior hormone therapy and up to one prior chemotherapy in the advanced setting is allowed;,{''}
1666,350,"For former smokers Participants who report that they are not currently smoking, and smoking cessation must have occurred ≥6 months prior to Screening (Visit 1) with an intention to quit permanently.",{''}
1667,351,"Gene mutation was found according to gene diagnosis gene mutation was found by gene sequencing. Literature searches at home and abroad confirmed that the defect of the gene resulted in autoimmune or immune dysfunction, resulting in multiple organ dysfunction and poor prognosis.","{'auto ##im ##mu ##ne or immune d ##ys ##function, multiple organ d ##ys ##function'}"
1668,352,Patients described below who require urgent reversal of the antiplatelet effects of ticagrelor,{''}
1669,353,"Treatment of BC is being conducted at OIL,",{'BC'}
1670,354,"i. Corticosteroids (CS), Hydroxychloroquine ii. Mycophenolate mofetil (MMF), Methotrexate (MTX), Azathioprine (AZA), Tacrolimus (TAC), Cyclophosphamide (CYC), Rituximab, and/or belimumab b. Active disease due to intolerance of standard therapy (i) and one or more additional therapies (ii).",{''}
1671,356,Candidate for local consolidative therapy to at least one site of residual disease,{''}
1672,357,Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.,{''}
1673,358,"Confirmed disease progression by radiological report to at least one line of standard chemotherapy containing cisplatin and anthracycline, and no more than 2 previous lines.",{''}
1674,359,Normal Electrocardiogram (ECG).,{''}
1675,361,Scheduled to receive radiation therapy for curative intent,{''}
1676,362,"In the dose expansion, patients must have histologically documented locally advanced, unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer that has progressed following at least one prior line of treatment in the metastatic setting and have all of the following",{'gas ##tric or gas ##tro ##es ##op ##hage ##al junction ( GE ##J ) cancer'}
1677,364,Zoladex must commence within 12 weeks prior to randomization or within 12 weeks after randomization.,{''}
1678,366,PANSS total score ≥ 70.,{''}
1679,367,Available for the duration of the trial.,{''}
1680,370,"Patients complying with preoperative fasting instructions (at least 6 hours for solids, at least 2 hours for clear liquids)",{''}
1681,371,"The effects of INO-8000 with or without INO-9012 on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation",{''}
1682,373,"Participants undergoing double mastectomy surgery followed by one of the following (1) Immediate reconstruction with tissue expander placement, (2) Delayed reconstruction with tissue expander or implant placement, (3) Immediate reconstruction with implant placement, (4) Second-stage reconstruction with tissue expander to implant exchange",{''}
1683,374,patient who has signed informed consent and affiliated to social security.,{''}
1684,375,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 2,{''}
1685,376,A history of a depressive episode occurring or persisting during a period of one-month abstinence.,{'de'}
1686,379,Diagnosed Medium-chain acyl-CoA dehydrogenase deficiency (MCADD,"{'Medium - chain a ##cy ##l - Co ##A de ##hy ##dr ##ogen ##ase deficiency, MCA ##D'}"
1687,380,Spontaneous ventilation.,{''}
1688,381,Expected survival is greater than 12 weeks；,{''}
1689,382,Be willing to adhere to trial and follow-up procedures and give informed consent,{''}
1690,384,NT-proBNP levels\>1000 pg/ml at least 1 time since the onset of decompensation.,{''}
1691,385,HER2 expression (accepts HER2 expression test results confirmed by the investigator),{''}
1692,386,only individuals able to provide a US address will be included.,{''}
1693,388,"Patient who has not responded to at least two antidepressant treatments of different classes, administered appropriately in terms of dose and duration, for a moderate to severe major depressive episode.",{''}
1694,389,Gestational age ≤32 weeks,{''}
1695,391,"Seen at primary care clinics (such as, but not limited to, Internal Medicine, Family Medicine or Pediatrics) or patients seen in pain-relevant specialty clinics",{''}
1696,394,Fasting blood glucose less than 180 mg/dl,{''}
1697,395,Mean 3 cardinal symptom (3CS) score,{''}
1698,396,"If concurrently using any other nicotine or tobacco products, wants to quit using them within the next 30 days",{''}
1699,399,Willingness to engage with study protocol,{''}
1700,400,Biological parent or guardian's informed consent.,{''}
1701,402,Partially edentulous patients (18-85 years of age) requiring maxillary sinus augmentation for dental implant placement,{''}
1702,403,"• Dose escalation All solid cancers, except primary central nervous system cancers","{'solid cancer, primary central nervous system cancer'}"
1703,405,≤UACR \<5000 mg/g at screening visit (mean value from 3 morning void samples) and documentation of albuminuria/proteinuria (quantitative or semi-quantitative measurement) in the participant's medical records at least 3 months prior to screening,"{'album, ##in ##uria, protein'}"
1704,406,"Patients with symptoms occurring more than once (symptoms refer to stroke or transient ischemic attacks) after intensive drug therapy of internal medicine (including antiplatelet therapy, antihypertensive therapy, hypoglycemic therapy and lipid-lowering therapy);","{'stroke, trans ##ient is ##che ##mic attacks'}"
1705,408,Patients who had wild-type RAS status confirmed as per standard of care according to international guidelines prior to first-line initiation.,{''}
1706,410,"Chinese participants who are healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.",{''}
1707,411,Diagnosed as idiopathic scoliosis The diagnosis of scoliosis was confirmed by antero-posterior plain Xray with Cobbs angle larger than 10 degrees.,"{'id, ##io ##pathic s ##co ##lio ##sis, s ##co ##lio ##sis'}"
1708,412,subjects with a normal laboratory examination，ECG， X-ray.,{''}
1709,413,Signed written informed consent form,{''}
1710,414,WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 28 days after IP administration.,{''}
1711,415,Competence to give written informed consent,{''}
1712,416,years of age or older,{''}
1713,417,The VAS score of item 10 (sensitivity to cold) in FIQR scale ≧4 points;,{''}
1714,419,"If the patient is being treated with autologous serum, a delay of 8 weeks after the last blood collection",{''}
1715,420,"Participants must have normal organ and bone marrow function (ALT \<5x institutional upper limit of normal, creatinine \<1.5x institutional upper limit of normal for age, WBC \>1000/mm3, platelets \> 20,000/mm3. Patients with values less than WBC 2000/mm3 or platelets 50,000/mm3 will require initiation of treatment with etoposide and cyclophosphamide at a lower starting dose as defined within the protocol.",{''}
1716,421,OR,{''}
1717,422,Access to computer/laptop/mobile device and the Internet,{''}
1718,423,Fentanyl positive on urine drug test,{''}
1719,425,postmenopausal for at least 12 months prior to study drug administration;,{''}
1720,426,Subjects with all Fitzpatrick skin types I-VI.,{'Fi'}
1721,427,Patients must have been off tamoxifen or other estrogen receptor blocking agents for at least 6 weeks and off chemotherapy for 3 weeks for the initial baseline FES.,{''}
1722,431,Patients with breast carcinoma with positive or negative hormone receptor status.,{'breast car ##cin ##oma'}
1723,432,"p16-positive oropharynx cancer patients, stages T4N0-3 or T1-3N2-3 (AJCC version 8);",{'or ##op ##har ##ynx cancer'}
1724,434,Measurable disease is not required. Patients without measurable disease are eligible.,{''}
1725,435,Patients with protein energy expenditure (defined by 24-hour recall less than a dietary protein intake \<0.6 g/kg/d or have a consumption \<25 kcal/kg/d,{''}
1726,436,Other protocol-defined Inclusion/Exclusion criteria apply.,{''}
1727,438,% ≤ HbA1c ≤10.0% at screening.,{''}
1728,439,Subject signs and dates a written informed consent form and indicates understanding of the study procedures and risks,{''}
1729,440,"Patients must have no had adjuvant therapy for the management of endometrial carcinoma. This includes chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance therapy. Chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen. This also pertains to hormonal, vascular, and targeted therapy for the management of endometrial cancer.","{'end ##ome ##tri ##al car ##cin ##oma, end ##ome ##tri ##al cancer'}"
1730,442,Head and neck squamous cell carcinoma (HNSCC),"{'Head and neck sq ##ua ##mous cell car ##cin ##oma, H ##NS ##CC'}"
1731,443,Patients who have received at least 3 consecutive days of GC after diagnosis of MAS and/or are judged by the Investigator to be refractory to GC due to clinical worsening of patient's condition .,{'MA ##S'}
1732,445,Radiographically documented progressive disease on or after the most recent therapy,{''}
1733,446,Capable of giving signed informed consent,{''}
1734,449,"Have a local diagnosis (confirmed or suspected) of influenza, or of a targeted non-influenza viral respiratory infection\*, resulting in (or extending a previous) hospitalization","{'in, ##fluenza, non - in ##fluenza viral respiratory infection'}"
1735,450,-13-year-old males and females who are out-of-school and living in 2 remote villages each from four randomly selected health centers located around the selected schools,{''}
1736,452,Must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate,{''}
1737,453,Registration Completion of registration via the provided RedCap link prior to the Bingo session.,{''}
1738,456,"Informed consent, voluntary participation in the experiment, and signed by the subject informed consent",{''}
1739,457,Acceptable antibiotic therapy,{''}
1740,458,Microsatellite stable (MSS) or Mismatch-Repair proficient (pMMR) disease confirmation assessed by local PCR or immunohistochemistry (IHC).,"{'Mi ##sma ##tch - Rep ##air pro ##ficient, p, ##MM ##R'}"
1741,459,Volunteering to participate in the study,{''}
1742,465,ASA physical status classes I and II.,{''}
1743,466,Ability to take oral medication and willing to adhere to the drug regimen,{''}
1744,468,"Prior to surgery, patients must have adequate organ and marrow function as defined below (within 30 days of registration)",{''}
1745,470,Age ≥ 18 years,{''}
1746,472,Signed informed consent,{''}
1747,473,Baseline pain rating (NRS/VAS) \>=6,{''}
1748,475,Patients diagnosed of type-III BA and underwent KP in Children's Hospital of Fudan University;,"{'type - III BA, K'}"
1749,476,"At least 4 cycles of perioperative chemotherapy (gemcitabine \[Gem\]/nab-paclitaxel or fluorouracil, irinotecan, leucovorin and oxaliplatin \[FOLFIRINOX\]) received with no evidence of progression on restaging scans per RECIST 1.1",{''}
1750,478,"Participant is judged, by the clinical investigator, to be healthy as evidenced by lack of clinically significant abnormal findings on medical history, physical examination, vital signs, and clinical laboratory tests.",{''}
1751,479,Individuals must have a confirmed diagnosis of Heart Failure (HF) according to clinical practice guidelines NYHA functional class I-III (with HFrEF or HFpEF).,"{'Heart F ##ail ##ure, H ##F, H ##F ##r ##EF, H ##F ##p ##EF'}"
1752,480,Patients who have progressed to the standard therapy and have no approved optional therapy available.,{''}
1753,482,Cohort 1 NSCLC,{'N'}
1754,483,Able to ambulate 10 feet independently with or without gait aid use,{''}
1755,484,Willing to complete study questionnaires,{''}
1756,486,"Being a volunteer,",{''}
1757,489,"BMI \>/= 1.2 times the 95th percentile or BMI \>/= 35 Kg/m2, whichever is lower;",{''}
1758,490,An inflammation of more than 10% of the surface of the entire cortical parenchyma (fibrous and non-fibrous) or a ti score \> or = 1 according to the Banff classification,{''}
1759,491,Born via either cesarean or vaginal delivery,{''}
1760,493,Current antiplatelet or anticoagulant therapy.,{''}
1761,498,"have no indication of current suicidal risk,",{''}
1762,499,Expected survival \>=12 weeks.,{''}
1763,500,Has a screening endoscopy with ≥2 endoscopic subscore in the Mayo score component assessment as determined by concurrent local and central reading of the video endoscopy.,{''}
1764,503,average self-reported habitual sleep duration of ≤6 hours,{''}
1765,504,"Proficient English reading, writing, and speaking ability",{''}
1766,506,Permanent dentition with second molars completely erupted in the arch,{''}
1767,507,Able to give informed consent by the patient or the legal representative,{''}
1768,510,Prostate cancer where nodal treatment is required,{'Pro ##state cancer'}
1769,511,Low risk for an NTD-affected pregnancy,{'N ##T ##D'}
1770,512,"Ability to walk 10 m independently, or with support if using a cane or walker.",{''}
1771,513,Best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye.,{''}
1772,515,"Must be willing to be randomized to tirzepatide or placebo and to comply with study procedures, including weekly visits for 6 months;",{''}
1773,517,no special eating habits.,{''}
1774,518,"Received prednisolone within 72 hours since initial symptoms of BP, the prednisolone dose used was 60 mg per day for 5 days and then reduced by 10 mg per day.",{'BP'}
1775,519,Reports symptoms of insomnia;,"{'ins, ##om ##nia'}"
1776,523,Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below,{''}
1777,525,Hypertension systolic/diastolic blood pressure 130/80 mmHg or more or treatment with an antihypertensive drug,"{'H, ##yper ##tens ##ion'}"
1778,526,BMI of at least 18.5 and able to safely lift up to 15lb,{''}
1779,528,Newly-diagnosed CLL eligible to receive VEN in combination with obinatuzumab at Screening.,"{'C, ##LL'}"
1780,529,Only one person per household will be eligible,{''}
1781,530,"For T-NHL patients with tissue available for flow cytometry, the criterion for diagnosis should be analogous to T-ALL; for tissue processed by other means (i.e. paraffin blocks), the methodology and criteria for immunophenotypic analysis to establish the diagnosis of T-NHL defined by the submitting institution will be accepted","{'T - NHL, T - AL ##L, T - NHL'}"
1782,532,"Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 60",{''}
1783,533,Clinical performance status of ECOG 0-2. (Turnstile I),{''}
1784,536,Child is between 33-39 months of age,{''}
1785,537,Facial melasma,"{'F, ##ac ##ial me ##las'}"
1786,538,Subject must be on a stable 15 - 25 mg dose of methotrexate \> 28 days prior to Screening,{''}
1787,539,"Female, aged \>18",{''}
1788,540,"Having a medium socioeconomic level,",{''}
1789,541,Hospitalized in a department of the CH of Melun,{''}
1790,542,Age ≥ 8 years,{''}
1791,545,Body mass index of ≥ 23 kg/m2.,{''}
1792,546,ASA classification I-II;,{''}
1793,547,Must have a negative serum pregnancy test at screening (V1),{''}
1794,548,"Ileal/ileocecal (L1), colonic (L2), or ileocolonic (L3) disease, as classified based on the localisation of active inflammation.","{'Il ##eal / il ##eo ##ce ##cal ( L ##1 ) , co ##lon ##ic ( L ##2 ) , or, il ##eo ##co ##lon ##ic ( L ##3 ) disease'}"
1795,549,Patients with non resectable or metastatic advanced ESCC confirmed by pathological ocytological examination;,{''}
1796,550,"Documented recurrent disease (radiological, based on RANO v.1.0) within 3 months prior to first study drug administration with no suitable standard of care options available.",{''}
1797,551,No speech disorder or reading disability,"{'speech disorder, reading disability'}"
1798,555,Subjects and their families agree to join the trial and agree to undergo fluorine-18 deoxyglucose positron imaging (100 subjects will be paid for by research funds) and phosphonium-99m dopamine transporter scan (20 non-Parkinson's patients will be paid for by research funds) syndrome patients) examination.,{''}
1799,556,The initial diagnostic biopsy sample must be available for review. Patients should have (but are not required to have) tissue blocks available for review.,{''}
1800,557,Body Mass Index (BMI) ≤40 kg/m2.,{''}
1801,559,Stratum 1 Patients with progressive or recurrent ACP who demonstrate cystic and/or solid recurrence or progression at least 6 months post completion of radiation therapy,"{'AC ##P, c ##tic and / or solid'}"
1802,561,"Has a BMI 18.0 to 42.0 kg/m2, inclusive, at screening.",{''}
1803,562,Ability to apply topical medications and willing to adhere to regimen,{''}
1804,564,"Female subject must not donate ova starting at Screening and throughout the study period, and for 60 days after the final study drug administration.",{''}
1805,566,"MYCN amplification, regardless of age or additional biologic features",{''}
1806,569,"Histologically confirmed diagnosis of classical Hodgkin lymphoma that is relapsed or refractory - historical biopsy at last relapse is acceptable. NOTE a repeat biopsy is not required for Phase I if the historical biopsy was performed at the most recent relapse, without remission in between. A fresh biopsy is not required for Phase II.",{'classical Ho ##d ##g ##kin l ##ymph ##oma'}
1807,1,Each lesion measures three centimeters or less,{''}
1808,2,ECOG= 0 or 1,{''}
1809,4,"Is a candidate for radical prostatectomy, and scheduled radical prostatectomy date must be 3 to 14 days after enrollment.",{''}
1810,6,Have a performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) scale.,{''}
1811,7,Not drinking alcohol in the last 24 hours,{''}
1812,8,May be on systemic antibiotics for an infection unrelated to the gastrointestinal tract.,{''}
1813,10,"Patients must not have symptoms or signs of benign or malignant breast disease (eg, nipple discharge, breast lump) warranting a diagnostic rather than a screening mammogram, and/or other imaging studies (eg, sonogram); patients with breast pain are eligible as long as other criteria are met","{'ben ##ign or ma ##li ##gnant breast disease, nipple discharge, breast lump, breast pain'}"
1814,13,Controlled blood pressure of less than 140/90 mmHg,{''}
1815,14,All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of the study,{''}
1816,15,Exclusion Criteria (non-burned individuals),{''}
1817,18,"Patient with diagnosis of mono or bilateral moderate knee osteoarthritis with knee pain intensity \> 40 mm on a 0-100 mm VAS, able to independently ambulate without walking aid.","{'mon ##o or bilateral moderate knee o ##ste ##oar ##th ##rit ##is, knee pain'}"
1818,19,The parent/guardian must be capable of comprehending the nature of the study and consent to the use and release of their child's de-identified health care encounter data to be used for purposes of this study. Assent will be obtained from the child in a manner specified by the IRB.,{''}
1819,20,Adult male and female subjects ≥ 18 years old,{''}
1820,22,Score of 24 and above on the Standardized Mini Mental State Examination,{''}
1821,23,"Fluorodeoxyglucose-avid disease by positron emission tomography and measurable disease of at least 1.5 cm by computed tomography, as assessed by the site radiologist.",{'##lu ##oro ##de ##ox ##y ##g ##lu ##cos ##e - avid disease'}
1822,24,Subjects must have clear intraocular media other than the cataract in both eyes.,{'cat ##ara ##ct'}
1823,26,Vaccine-associated arterial and/or venous thrombosis within 30 days of vaccination,{'art ##erial and / or ve ##nous th ##rom ##bos ##is'}
1824,27,Endocrinology practice criterion is that diabetes is managed using sensor-augmented insulin pump therapy or artificial pancreas therapy for ≥ 3 months),{'diabetes'}
1825,29,Willing to abstain from alcohol use during the study.,{''}
1826,30,"Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator",{''}
1827,34,Subjects on pirfenidone or nintedanib must be on a stable and optimized dose for ≥30 days prior to Baseline. Concomitant use of both pirfenidone and nintedanib is not permitted.,{''}
1828,35,The patient has a confirmed systemic fungal infection with a non-Candida species.,{'systemic fun ##gal infection'}
1829,37,Hematocrit levels within normal limits,{''}
1830,38,adequate visualization of the most proximal end of the thrombus,{''}
1831,43,Experience troublesome asthma (i.e. asthma control test (ACT) score of less than 20).,"{'troubles, as ##th ##ma, as ##ma'}"
1832,44,Ambulatory without assistance,{''}
1833,46,Documented peripheral blood eosinophil count ≥ 300 cells/μL or ≥150 cells/μL blood in case that patient had been receiving oral glucocorticoid therapy for at least 6 continuous months directly before enrollment (equivalent to a prednisolone or prednisone dose of 7.5 to 40.0 mg per day).,{''}
1834,47,Must agree not to try to become pregnant during the study until 5 half-lives after the last dose of any study drug.,{''}
1835,48,Medical monitor approves patient eligibility for participation,{''}
1836,49,"Patients must have had at least one but no more than two prior chemotherapeutic regimens for management of endometrial carcinoma (including neo-adjuvant and/or adjuvant chemotherapy). Initial treatment may include chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance therapy. Chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen. Prior hormonal therapy will not count as a prior regimen. Prior treatment with trastuzumab is allowed.",{'end ##ome ##tri ##al car ##cin ##oma'}
1837,50,Participants who use a computer at a desk for at least 3 hours a day will be included.,{''}
1838,51,Sign informed consent form,{''}
1839,52,"EITHER a) have familiarity using digital technology and/or a video conferencing app such as Zoom, FaceTime, or Facebook Messenger, OR b) have a family member or friend who can facilitate Zoom access (i.e., ""helper"").",{''}
1840,56,delusional disorder,{'del ##usion ##al disorder'}
1841,58,Patients must be willing to provide archival tumor tissue from current relapse or previous surgeries/biopsies for central confirmation of FRα high status by PS2+ scoring,{'tumor'}
1842,60,Patients with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) and other solid tumors confirmed by histopathology and/or cytology;,"{'head and neck sq ##ua ##mous cell car ##cin ##oma, non - na ##so ##pha ##ryn ##ge ##al car ##cin ##oma, solid tumors'}"
1843,63,"Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy, or",{'Ta / T ##1 disease'}
1844,64,Therapists,{''}
1845,65,Medicare Functional Classification Level (K-Level) 4,{''}
1846,66,"Male subjects and female spouse/partners who are of childbearing potential must be using condom and one of the highly effective birth control starting informed consent throughout the clinical study period and for 90 days after final study drug, if vasectomy is not performed for male subjects.",{''}
1847,68,Score over 20 on the Eating Attitudes Test (EAT-26),{''}
1848,73,Progression of bone disease (defined as ≥ 2 new bone lesions according to PCWG3 bone scan criteria),{'bone disease'}
1849,74,Patients must be \>= 365 days and =\< 31 years of age (B-LLy patients with or without DS).,"{'B - LL ##y, DS'}"
1850,75,Stable use of background medications at least 8 weeks prior to LY3884963 dosing.,{''}
1851,76,Normal liver and kidney function.,{''}
1852,77,Willing and capable of undergoing the device implant procedure and participating in all testing associated with this clinical study,{''}
1853,78,Understanding and speaking French,{''}
1854,80,Expected to be hospitalized for at least 28 days after enrollment,{''}
1855,82,Parents or LAR of subject have provided the appropriate written informed consent. Written informed consent must be provided before any study-specific procedures are performed including screening procedures.,{''}
1856,85,The vertical skeletal classification shows a horizontal or neutral growth pattern.,{''}
1857,86,)Expected survival \> 3 months;,{''}
1858,88,Study participant with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of at least 3 (with ≥3 points from non-ocular symptom) AND a quantitative myasthenia gravis (QMG) score of at least 11 at Visit 1 and at Baseline (Visit 2),"{'My ##ast ##hen ##ia G ##ra ##vis, my ##ast ##hen ##ia g ##ra ##vis'}"
1859,92,Unable to stand independently with epidural stimulation turned off.,{''}
1860,93,Receives HIV care at study site clinic,{''}
1861,94,Minors aged 12 to 17 able to provide assent,{''}
1862,96,Abstains from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agrees to remain abstinent. OR,{''}
1863,97,ECOG PS 0-2,{''}
1864,98,Uncorrectable coagulopathy,{'co ##lop ##athy'}
1865,100,History of TCS and/or TCI treatment failure (due to inadequate response or intolerance) or subjects for whom these topical AD treatments are medically inadvisable.,{'AD'}
1866,102,"Man, who is sexually active with a woman of child-bearing potential must agree to use a latex or synthetic condom, even if he had a successful vasectomy, must agree to use an adequate contraception method as deemed appropriate by the Investigator, and must also agree to not donate sperm during the study and for 4 weeks after last dose of lenalidomide and 4 months after last dose of daratumumab",{''}
1867,104,IMA graft indicated for the LAD.,{''}
1868,105,Have at least 1 measurable lesion as defined per RECIST v1.1,{''}
1869,107,Speaks and understands English (polysomnography device speaks to patients only in English).,{''}
1870,109,"Stage IA-IIB (T1a-T3bN0) presumed non-small cell lung cancer, carcinoid tumors, or lung metastasis that have ≥ 1 cm of respiratory associated motion measured on 4DCT at time of simulation for SBRT with or without respiratory motion suppression techniques. Histologic confirmation of malignancy is encouraged but not required. Primary or metastatic tumor ≤ 7 cm.","{'non - small cell lung cancer, car ##cin ##oid tumors, lung meta ##sta'}"
1871,111,All detectable sites of MCC are amenable to comprehensive ablative radiation therapy in opinion of treating radiation oncologist and principal investigator,{'MCC'}
1872,114,Children (ages 12-17) with functional dyspepsia,{'functional d ##ys ##pe ##ps ##ia'}
1873,117,Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.,{''}
1874,118,Participants should have no single tumor deposit exceeding 4.0 cm in the greatest dimension.,{'tumor'}
1875,122,Female participant must agree not to breastfeed starting at screening and throughout the study period and for 28 days after IP administration.,{''}
1876,125,Has a serum testosterone at the Screening visit of \>150 ng/dL,{''}
1877,127,"Be willing and able to participate in all scheduled visits, treatment plan, laboratory tests and other trial procedures according to the study protocol and the standard medical practice.",{''}
1878,128,"A person who can provide reliable information on the condition of the test subject during the human test period, attend all planned visits to the institution, supervise the intake of food for human test, and have the participation of a parent or the same legal representative who can fully understand and speak Korean, and conduct a questionnaire evaluation of the subject.",{''}
1879,130,Stimulated C-peptide of ≥0.2 pmol/mL measured during mixed-meal tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes,{''}
1880,131,Agrees to participate in the study.,{''}
1881,132,willing to avoid other dietary supplements for the duration of the study,{''}
1882,136,presenting dark hair,{''}
1883,138,Parents,{''}
1884,139,Part B1 - May or may not be receiving moderate- or high-intensity statin therapy.,{''}
1885,140,Emergency department population,{''}
1886,144,BMI of 25-50 kg/m2 for wheelchair users (less than or equal to 350 lbs.),{''}
1887,146,Subject's other medication taken for treatment of RA must be stable for at least 28 days prior to start of the study,{''}
1888,147,Patients who meet at least one of 1) to 3) for diagnosis of liver cirrhosis.,{'liver c ##ir ##r ##hos ##is'}
1889,148,"Receipt of ARPI (e.g. abiraterone acetate, enzalutamide, apalutamide, or darolutamide) for at least 4 months at time of enrollment",{''}
1890,149,Hematocrit levels within normal limits,{''}
1891,151,Part I - Mono-therapy dose escalation and expansion phase,{''}
1892,152,Pregnant who has the firm intention of breastfeeding her child for at least the first month.,{''}
1893,154,Breastfeeding (+/- milk pump) or exclusive artificial breastfeeding.,{''}
1894,155,"Subject is willing to maintain the same hairstyle, hair length, and hair color at each visit;",{''}
1895,157,One male or female without an occupation.,{''}
1896,159,"Must have MS/MMR result available at time of registration; MS/MMR status is to be determined per local practice (i.e. immunohistochemistry \[IHC\], polymerase chain reaction \[PCR\], or other methods)",{''}
1897,161,Have a confirmed diagnosis at the time of screening of active hepatitis C infection - defined as detectable HCV RNA using a molecular diagnostic assay with a sensitivity of \>100IU/ml OR detectable HCV Core antigen using an assay with a sensitivity of \>1.5 pg/ml.,{'he ##pa ##titis C infection'}
1898,162,"Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of ASTX660 (tolinapant) in combination with eribulin mesylate in patients \< 18 years of age, children are excluded from this study",{''}
1899,164,Participant has no more than 4 naïve or anastomotic small bowel strictures by MRE or IU in the terminal ileum at Screening. A stricture is defined as,{''}
1900,165,"Modified Rankin Score ≥ 3,",{''}
1901,167,"sedentary, and",{''}
1902,168,Agree not to participate in another clinical trial while enrolled in this trial,{''}
1903,171,"agree to have their female coparents (mother of the youngest child) contacted for participation of their youngest child. If a participant has more than one child in the age range, the youngest will be the target of assessment and treatment.",{''}
1904,172,Have ≥10% Body Surface Area (BSA) of psoriasis at screening (Visit 1) and baseline,"{'ps, ##oria ##sis'}"
1905,179,prior radiotherapy to the primary melanoma is allowed,"{'me, ##lan ##oma'}"
1906,182,Endoscopic evaluation of pancreas scheduled,{''}
1907,184,Patients who received adjuvant or neoadjuvant platinum-based chemotherapy (after surgery and/or radiation therapy) and developed metastatic disease within 6 months of completing therapy are eligible.,{''}
1908,185,"Following tumor resection for TIL generation, the participant will have at least one remaining measurable lesion for response assessment.",{'tumor'}
1909,186,At least one measurable lesion as assessed according to RECIST 1.1 within 4 weeks prior to randomization.,{''}
1910,187,Negative uptake when the tumoral lesion shows no SSTR expression. Patients with active uptake in the majority of the tumoral lesions will be considered to have a positive SSTR-PET and will be therefore eligible for the trial.,"{'tumor, tumor'}"
1911,189,Rhabdomyosarcoma (RMS),"{'R ##hab ##dom ##yo ##sar ##com ##a, R ##MS'}"
1912,190,Patients with an EGFR deletion or mutation known (from tumour biopsy or plasma) to be associated with EGFR TKI sensitivity,{'t'}
1913,192,"Age 0-17 years old, male or female;",{''}
1914,195,Written informed consent obtained,{''}
1915,196,Male and female subjects over 40 years old,{''}
1916,197,Documentation of depression and/or provider report of depression,{''}
1917,198,Male and female subjects must be willing to comply with contraception requirements as well as restrictions regarding egg and sperm donation,{''}
1918,199,"If taking hydroxyurea, the hydroxyurea dose must be stable for at least 90 days before starting study drug. Discontinuation of hydroxyurea requires a 90-day washout prior to informed assent/consent;",{''}
1919,200,Affiliated or beneficiary of a social security scheme,{''}
1920,201,Adults aged 18 years old and above,{''}
1921,202,Ages 18 and older,{''}
1922,203,Haven't received any prior systemic chemotherapy for Stage IV NSCLC (unless received as neoadjuvant or adjuvant therapy for early-stage NSCLC disease and completed therapy at least 6 months prior to enrollment),"{'Stage IV N ##SC ##LC, N ##SC ##LC'}"
1923,204,Exclusion Criteria,{''}
1924,205,"Must have been a non-smoker or a light smoker who smoked no more than 10 cigarettes (or equivalent) per day, at Screening. Smokers must have agreed to smoke no more than 5 cigarettes (or equivalent) per day from check-in until after Study Completion evaluations.",{''}
1925,206,Not a woman of childbearing potential (WOCBP),{''}
1926,210,The patient has a mobile phone with internet access.,{''}
1927,213,Agree and sign the informed consent form,{''}
1928,215,Having an active email address,{''}
1929,218,Absence of endocrine disorders,{'end ##oc ##rine disorders'}
1930,220,"Current CD4+ T cell counts \> 450 cells/mcL, CD4+ T cell % ≥ 15%, and CD4+ T cell count nadir of ≥ 200 cells/mcL.",{''}
1931,221,"Extensive disease (American Joint Committee on Cancer Stage (8th edition) IV SCLC \[T any, N any, M1 a/b\]), or",{'SC'}
1932,223,without a uterus and/or both ovaries; or,{''}
1933,225,"Patients who received a first generation anti-androgen (for example, bicalutamide, flutamide, nilutamide) must have at least a 4-week washout prior to randomization AND must show continuing disease (PSA) progression (an increase in PSA) after washout",{''}
1934,226,"Participant has regular bowel habits (i.e., at least 1 bowel movement per day).",{''}
1935,229,At least one measurable lesion.,{''}
1936,232,Participants must have laboratory parameters in the required range,{''}
1937,233,Insulin resistant based on screening oral glucose tolerance testing.,{''}
1938,234,Patients with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) confirmed by histopathology and/or cytology,"{'head and neck sq ##ua ##mous cell car ##cin ##oma, non - na ##so ##pha ##ryn ##ge ##al car ##cin ##oma'}"
1939,237,"Improvement of signs or symptoms related to MG during treatment with an oral AChEI, as determined by the treating physician",{'MG'}
1940,239,No scheduled transfer or release for at least three months,{''}
1941,242,"fluency in Dutch or French,",{''}
1942,249,"Demonstration of lesional SSTR2 expression using an FDA-approved somatostatin receptor PET imaging agent, i.e.\[68Ga\]DOTATATE, \[64Cu\]DOTATATE, or \[68Ga\]DOTATOC, (SSTR2 positivity defined as uptake \> background liver) obtained and interpreted in accordance with product labeling and appropriate clinical use criteria within 12 months of enrollment.",{''}
1943,250,"No other systemic diseases,",{''}
1944,252,"Scheduled for complex aortic surgery, liver resection or pancreatic resection",{''}
1945,256,"Prostate cancer progression documented by prostate-specific antigen (PSA) according to the Prostate Cancer Clinical Trials Working Group (PCWG2) or radiographic progression of soft tissue according to modified Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST) modified based on PCWG2, or radiographic progression of bone according to PCWG2","{'Pro, ##state cancer, Pro, ##state Cancer, Solid Tu ##mor'}"
1946,258,"Stage II, III, or IV by Ann Arbor staging system.",{''}
1947,259,Tissue confirmation of relapse is recommended but not required,{''}
1948,261,"Women who currently have vaginal intercourse or other sexual activity (masturbation, etc.) at least once a month (with or without a partner), or who had intercourse or other sexual activity at least once a month in the past, but later decreased sexual activity due to excessive pain or vaginal dryness. Participants must be willing to engage in vaginal intercourse or other sexual activity (masturbation, etc.) at least 1 time between Days 49-56 of the clinical study.","{'excessive, pain, v, ##agi ##nal dry ##ness'}"
1949,264,Renal Serum creatinine ≤2.5x upper limit of normal (ULN),{''}
1950,265,"If node-negative or if node status unknown (because it was not assessed), tumor must be \>5 mm of any hormone receptor subtype (document ER/PR status if some ER/PR staining is present, ER and PR negative are defined as being positive in \<10% cells \[per local pathology read\]).",{''}
1951,267,No active substance use (e.g. heavy etoh or opiates),{''}
1952,270,"No history of anticoagulant use that contraindicates block application according to guidelines,",{''}
1953,271,Subjects must restrict food with high copper content for at least 6 months prior to screening and continue this restriction during the entire duration of study participation.,{''}
1954,272,Acute lymphoblastic leukemia (ALL)/lymphoma,"{'A, ##cute l ##ymph ##ob ##lastic le ##uke ##mia, AL ##L, l ##ymph ##oma'}"
1955,276,"can read, understand and respond in French or English.",{''}
1956,277,Primary tumor or metastasis tissue (10 x10 μm blank slides FFPE tumor material) sent to NKI-AVL for BRCA-like testing,{'tumor'}
1957,278,"be not intubated,",{''}
1958,281,Patient's tumor must harbor an activating BRAF mutation (listed in Table 4 or approved by the study Principal Investigator) or a fusion involving the kinase domain of BRAF,{'tumor'}
1959,288,Controlled attenuation parameter (CAP) \> 285 dB/m within 24 months before enrollment;,{''}
1960,290,planned transplant with minimal or no T-cell depletion,{''}
1961,291,Medical oncology consultation to confirm that patient is an appropriate candidate for concurrent chemotherapy and surgical oncology consultation for confirmation of resection status.,{''}
1962,293,≥ 6 tender/painful joints (using 68-joint assessment),{''}
1963,296,Serum ALT and AST ≤ ULN at screening visit.,{''}
1964,298,Platelet count on Procedure Day,{''}
1965,299,can speak/read/write in English,{''}
1966,300,Experienced at least an average of 1 HAE attack per month during the Run-in Period,{'H ##A ##E'}
1967,301,Reside in a community-based setting,{''}
1968,304,≥ 6 swollen joints;,{''}
1969,307,≥ 1 measurable or nonmeasurable lesion as assessed by RECIST v1.1. for Phase 1a Part A; ≥ 1 measurable lesion per RECIST v1.1. for Phase 1a Part B and Phase 1b.,{''}
1970,308,"Participants who received the first trial vaccination at least 5 months earlier and are currently enrolled in the Main Part (ie, not have withdrawn or discontinued early).",{''}
1971,309,"Expansion cohort A only estrogen receptor (ER) positive (\> 1%), human epidermal growth factor 2 (HER2) negative, WT TP53 metastatic or inoperable locally advanced or locally recurrent breast cancer regardless of progresterone receptor (PR) status, HER2 status will be defined according to the ASCO/CAP 2018 recommendationa (Patients can be HER2 0+ or 1+ by immunohistochemistry (IHC), 2+ by IHC and fluorescent in situ hybridization (FISH) non-amplified to be considered HER2 negative). Standard treatment with therapies known to confer a survival benefit does not exist, is no longer effective or tolerated, or the patient declines standard treatment. For the dose expansion cohort only, breast cancer patients with ER+, HER2- status must have received prior endocrine therapy and CDK4/6 inhibitors","{'breast cancer, breast cancer'}"
1972,310,Complete medical history was available.,{''}
1973,311,Weight Stable (±3 lbs) over the preceding 3 months,{''}
1974,313,P53 mutation and/or,{''}
1975,315,Ability to understand and provide signed informed consent,{''}
1976,318,urinary tract infection/pyelonephritis,"{'u, ##rina ##ry tract infection, p ##ye ##lone ##ph ##rit ##is'}"
1977,321,Intention to deliver at a hospital or birthing facility where study procedures can be performed,{''}
1978,322,Patient has medical insurance that covers this standard of care procedure and all other anticipated and unanticipated procedure related care.,{''}
1979,323,Initiated olaparib + abiraterone after site activation,{''}
1980,324,Measurable disease as per Response Evaluation Criterion in Solid Tumors \[RECIST\] or bone-only disease,{'Solid Tu ##mor only'}
1981,325,Fasting plasma glucose ≤ 7.2 mmol/l or glycosylated hemoglobin (HbA1c) ≤ 8% in the last 6 months.,{''}
1982,326,"Relapsed patients must have received at least 1 line of treatment, including Dara and bortezomib. Patients must have received at least two cycles of therapy. However, patients who have received high-dose therapy with melphalan as their only therapy are also eligible.",{''}
1983,327,Tx or T1-4 and,{''}
1984,328,-80 years.,{''}
1985,331,Measurable disease as per IMWG response criteria,{''}
1986,332,At least 1 measurable tumor (It is acceptable to allow patients with no measurable lesion but evaluable tumor lesion in the first 2 dose levels in Phase I and at least 1 measurable tumor lesion must be present in Phase IIa) according to RECIST v1.1,"{'tumor, tumor, tumor'}"
1987,333,) willing and able to provide tumor lesions or excisional biopsy tissue. 7) a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. Demonstrate adequate organ function.,{'tumor'}
1988,335,Current PTSD severity of 33+ on the PCL-5,{'PT ##SD'}
1989,337,Subjects with mild or moderate illness 11 ≤ total score of MMSE ≤ 26;,{''}
1990,338,abdominal wall and/or lower back pain despite physical therapy / structured physical exercise for at least 6 months,{'abdominal wall and / or lower back pain'}
1991,340,"CD10-negative GCB DLBCL, NOS (i.e., CD10-/BCL6+/MUM1- DLBCL)","{'G, ##C ##B, DL'}"
1992,343,Target lesion must be amenable to undergo surgical biopsy and LITT treatment as determined by the treating neurosurgeon.,{''}
1993,344,"Must have at least 1 additional radiologically measurable lesion of the primary cancer type, evaluable per RECIST 1.1, that will remain untouched by surgical harvest procedure for the assessment of tumor size throughout the study.","{'cancer, tumor'}"
1994,345,"It is recommended that participants are up to date on all age-appropriate vaccinations prior to screening as per routine local medical guidelines. For study participants who received locally-approved (and including emergency use-authorized) coronavirus disease 2019 (COVID-19) vaccines recently prior to study entry, applicable local vaccine labelling, guidelines, and standards-of-care for participants receiving immune-targeted therapy will be followed when determining an appropriate interval between vaccination and study enrollment","{'co, ##rona ##virus disease'}"
1995,346,Following treatment per CCG3891,{''}
1996,347,Eastern Cooperative Oncology Group (ECOG) performance status 0 -1 (Karnofsky \>= 70%),{''}
1997,349,"Availability of a representative, formalin-fixed, paraffin-embedded tumor specimen that enabled the diagnosis of breast cancer with viable tumor cells in a tissue block or unstained serial slides accompanied bay an associated pathology report;","{'tumor, breast cancer, tumor'}"
1998,350,"For current smokers (not eligible for Part A) Participants who report that they are currently smoking tobacco (participant smoked at least 5 cigarettes per day on average during the past 7 days) at Screening (Visit 1) and at Baseline, and who are not currently participating in, or planning to initiate, a smoking cessation intervention at Screening (Visit 1) or during the screening period.",{''}
1999,352,"Patients with uncontrolled major or life-threatening bleeding, requiring urgent reversal of the antiplatelet effects of ticagrelor. It is expected that enrolled patients would have characteristics similar to those described below",{''}
2000,353,"Patient has mandatory health insurance through Health Insurance Institute of Slovenia,",{''}
2001,354,c. Steroid-Dependent Disease,"{'St, ##ero ##id - De ##pen ##dent Disease'}"
2002,356,Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2,{''}
2003,358,Measurable disease as per RECIST v1.1 criteria and documented by CT/MRI (Appendix 1 - RECIST Response Criteria). NOTE Lesions to be used as measurable disease for the purpose of response assessment must either,{''}
2004,359,Echocardiogram (ECHO) that is normal or with findings that are considered trivial and clinically insignificant such as 'Clinically insignificant/trivial mitral regurgitation,{'mit ##ral re ##gu ##rg ##itation'}
2005,361,"Confirmed by review of the EMR and subsequently recorded in Survivor Health History. In cases where the EMR isn't clear, their OHSU provider will be contacted for confirmation/ For non-OHSU patients, we'll initially collect their cancer health history by a self-report questionnaire and confirm when we receive the survivor's outside medical record (through a signed Release of Information)",{'cancer'}
2006,362,"CCNE1 amplification, AND",{''}
2007,364,Radiology (CT/MRI chest/abdomen/pelvis) within 42 days of randomization,{''}
2008,367,Willingness to participate in the study and cooperate with the study procedures as evidenced by signing the informed consent document.,{''}
2009,370,Term pregnant women (gestational age ≥ 36 weeks),{''}
2010,371,"For men and women who are not postmenopausal (i.e., \>= 12 months of non-therapy-induced amenorrhea, confirmed by follicle stimulating hormone \[FSH\], if not on hormone replacement) or surgically sterile (vasectomy in males or absence of ovaries and/or uterus in females), agreement to remain abstinent or use highly effective or combined contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and at least through week 12 after last dose","{'am, ##eno ##rr ##hea, absence of o ##ies and / or u ##us'}"
2011,374,Patient available at the proposed slots over 4 weeks,{''}
2012,375,Age ≥18 years,{''}
2013,376,"Participants should express the desire to reduce or stop alcohol consumption, report 28 or more standard drinks (SD) per week for males or 21 for females over four weeks during the 90 days preceding study enrollment.",{''}
2014,380,"Patients presenting a clinical severity score of Grade 1 with signs of struggle, as well as those with Grade 2 and Grade 3. A clinical severity score will be used as follows Grade 1 Minimal polypnoea with respiratory rate (RR) between 20 and 25 ; Grade 2 Moderate polypnoea with respiratory rate (RR) between 25 and 35; Grade 3 Major polypnoea with respiratory rate (RR) between 35 to 50.","{'p ##oly ##p ##no ##ea, p ##oly ##p ##no ##ea, p, ##oly ##p ##no ##ea'}"
2015,381,Confirmed to have at least one measurable lesion according to RECIST 1.1 (solid tumor) or Lugano 2014 (lymphoma) criteria；,"{'solid tumor, l, ##ymph ##oma'}"
2016,384,Presence of tibio-malleolar edema at least grade II/IV at the time of inclusion.,{'t ##ibi ##o - mall ##eo ##lar ed ##ema'}
2017,385,"Cohort 1 and Cohort 2 HER2-positive defined as IHC 3+, or IHC 2+ and ISH or FISH positive. ISH positivity is defined as a HER2 gene copy number to CEP17 copy number ratio ≥2.0; if the ratio is \<2.0 but the HER2 gene copy number \>6, it is also considered ISH positive.",{''}
2018,388,"Patients receiving antidepressant treatment of the SSRI (Selective Serotonin Reuptake Inhibitors) or SNRI (Serotonin Norepinephrine Reuptake Inhibitors) classes may maintain this treatment for the duration of the trial, without modification • Patient with a score \> 10 on the QIDS scale.",{''}
2019,389,Birth weight ≤2000 grams,{''}
2020,391,History of pain for at least the last 3 months,{''}
2021,394,Hematocrit levels within normal limits,{''}
2022,395,Undergone at least 2 trials of medical treatments in the past,{''}
2023,396,Interested in learning skills to quit smoking,{''}
2024,399,Use of birth control (as appropriate),{''}
2025,402,At minimum 5mm of native bone below the maxillary sinus inferior border,{''}
2026,403,The following tumor types will be recruited to the monotherapy expansion cohorts,{'tumor'}
2027,405,"Participant with type 2 diabetes (T2D) as defined by the American Diabetes Association (ADA 2021), with glycated hemoglobin (HbA1c) at screening \<11%.","{'type 2 diabetes, T ##2 ##D, Di'}"
2028,406,The intracranial arterial stenosis lesion to be treated is a single lesion;,{'in ##tra ##c ##rani ##al art ##erial s ##ten ##osis les ##ion'}
2029,408,"\*RAS analysis should include at least KRAS exons 2, 3 and 4 (codons 12, 13, 59, 61, 117 and 146) and NRAS exons 2, 3 and 4 (codons 12, 13, 59, 61 and 117)",{''}
2030,410,Weight,{''}
2031,414,Female participant must agree not to breastfeed starting at screening and throughout the study period and for 28 days after IP administration.,{''}
2032,415,Ability to comply with the entire study procedure,{''}
2033,416,"Self-reported ""very well"" comprehension of written and verbal English language",{''}
2034,417,Sign informed consent.,{''}
2035,419,"If a blood donation has been made, a delay of 8 weeks must be respected after the last donation",{''}
2036,420,"Karnofsky performance status ≥50. For infants and children less than 12 years of age, the Lansky play scale ≥50% will be used",{''}
2037,421,"Is a first- or second-degree blood relative of an individual with a diagnosis of pancreatic ductal adenocarcinoma (PDAC) and this PDAC patient has a germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53.","{'pan ##cre ##atic duct ##al ad ##eno ##car ##cin ##oma, PD ##AC, PD ##AC'}"
2038,423,Able to provide written informed consent in English prior to any study-related procedure,{''}
2039,425,without a uterus and/or both ovaries; or,{''}
2040,426,Subjects who agree to use only the study products for acne treatment. No other medicated cleansers or moisturizers or acne treatments of any kind are allowed.,"{'a, ##c ##ne, a, ##c ##ne'}"
2041,427,Patients must be selected for an endocrine targeted therapy regimen for treatment of their breast cancer by the referring oncologist. Selected treatments may be part of experimental treatment protocols for which the patient would be separately consented.,{'breast cancer'}
2042,431,"Patients prior to initiation of neoadjuvant, adjuvant or palliative chemotherapy\*\* in combination with HER2-targeted therapy (including tyrosine kinase inhibitors \[TKI\]) or an antibody-drug conjugate therapy.",{''}
2043,432,The patient has measurable disease as defined by the presence of at least one measurable lesion per RECIST 1.1;,{''}
2044,434,Patients with metastatic/disseminated or multifocal disease or gliomatosis cerebri are eligible.,"{'meta di ##minated, multi ##fo ##cal disease, g, ##lio ##mat ##osis c ##ere ##bri'}"
2045,435,Patients who can read and write (or primary caregiver),{''}
2046,440,Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,{''}
2047,442,Unresectable biliary adenocarcinoma (gallbladder or biliary tree \[intrahepatic or extrahepatic\] cholangiocarcinoma),"{'bi ##lia ##ry ad ##eno ##car ##cin ##oma ##he ##he, ch, ##ola ##ng ##io ##car ##cin ##oma'}"
2048,443,The onset of the index MAS episode occurred between 01 January 2012 and 30 September 2022.,{'MA ##S'}
2049,445,"Received standard-of-care therapies, (except for Part 1C, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated",{'tumor'}
2050,449,A list of targeted non-influenza respiratory viruses is maintained on the INSIGHT website.,{''}
2051,453,Consent Willingness to provide written consent at the beginning of the Bingo session to participate in the research study.,{''}
2052,457,Broad-spectrum penicillins,{''}
2053,458,Participants with CRC who have one of these criteria,{'CR ##C'}
2054,466,"Female patients are eligible to participate if not pregnant, or not breastfeeding and must refrain from donating or storing eggs. For females of reproductive potential use of highly effective contraception (e.g., method of birth control throughout the study period and for 4 weeks after study completion defined as a method which results in a failure rate of less than 1% per year) such as",{''}
2055,468,"absolute neutrophil count \>1,500/mcL",{''}
2056,470,"ECOG performance status 0, 1, or 2",{''}
2057,475,The type-III BA diagnosis is based on cholangiography or operation;,{'type - III BA'}
2058,476,Age ≥ 18 years,{''}
2059,478,"Participant should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods (laser devices, topical prescriptions, or other known hair growth treatments) in the treatment area during the entire study period.",{''}
2060,479,Individuals must have previously been admitted to hospital due to HF decompensation requiring intravenous diuretics.,{'H ##F de ##com ##pen ##sation'}
2061,480,ECOG performance status of 0/1,{''}
2062,482,Cohort 2 MSS CRC and ovarian cancer,"{'CR ##C, o ##var ##ian cancer'}"
2063,483,At least 22 years of age,{''}
2064,484,Willing to adhere to 12 office visits for PTNS over 3 months if randomized to that arm,{''}
2065,486,Being literate in Turkish.,{''}
2066,489,Tanner stage \>/= 2;,{''}
2067,490,AND/OR the presence of at least one granuloma on the biopsy,{''}
2068,491,Birth weight greater than 2500 grams,{''}
2069,498,"able to identify one ""Safe Support Person"" (SSP) in the community who can be trusted to support recovery and is willing to be contacted about participation",{''}
2070,499,Signed informed consent form.,{''}
2071,500,Has a baseline rectal bleeding subscore of ≥1 and baseline a stool frequency score of ≥1 as determined by the Mayo score component assessment.,"{'re, ##ct ##al bleeding'}"
2072,503,self-identify as Black or African American.,{''}
2073,504,Able to provide consent,{''}
2074,506,"Correct tooth shape, with sufficient height of the clinical crowns",{''}
2075,510,Prostate cancer post prostatectomy,"{'Pro, ##state cancer, pro'}"
2076,512,Ability to understand instructions regarding the use of the technology and execution of the exercise program.,{''}
2077,513,Anisometropia ≤ 1.50D SERE.,{'An ##is ##ome ##tro ##pia'}
2078,515,"Must be able to understand the study, and having understood, provide written informed consent in English;",{''}
2079,518,Signed informed consent and volunteered to participate in this study.,{''}
2080,519,Reports chronic pain,{''}
2081,523,Haemoglobin ≥ 9 g/dL with no blood transfusion in the past 28 days,{''}
2082,525,"Hyperlipidaemia LDL cholesterol 120 mg/dL or more, or treatment with an antihyperlipidemic drug","{'H, ##yper ##lip ##idae ##mia, ##hy ##ide'}"
2083,526,Willing and able to use their personal smartphone for the ecological momentary assessment app to submit ratings using personal data plan,{''}
2084,528,Patients who have been receiving stable doses of VEN for at least 5 days prior to initiation of PIT add-on therapy.,{''}
2085,530,Prior therapy restrictions,{''}
2086,532,Expected survival ≥ 6 months in the opinion of treatment team,{''}
2087,533,"Patients previously treated with immunotherapy, targeted therapy, or no therapy will be eligible. Patients receiving cytotoxic agents will be evaluated by the PI or his designee as to suitable eligibility. (Turnstile I)",{''}
2088,536,Child does not have significant congenital anomaly (blind or deaf) that would affect them from completing study assessments,"{'con ##gen ##ital an ##oma ##ly, blind or deaf'}"
2089,537,"Healthy participants without clinical skin comorbidities (psoriasis, vitiligo, rosacea and dermatoses)","{'skin com, ps ##oria ##sis, v ##iti ##li ##go, r ##osa ##cea, der ##mat ##ose ##s'}"
2090,538,"If subject is on a non-biologic disease modifying anti-rheumatic drug (DMARDs) therapy, the dose must be stable \> 28 days prior to Screening",{''}
2091,539,Diagnosed with Hidradenitis Suppurativa,{'Hi ##dra ##den ##itis'}
2092,540,"The mother and baby are healthy,",{''}
2093,541,Exclusion Criteria,{''}
2094,542,Not planning to enroll in an experimental clinical trial for the treatment of PCDH15 for the duration of this study,{''}
2095,545,Stable self-reported body weight for 3 months prior to randomization (+/- 5% body weight change).,{''}
2096,546,kg/m2 \&amp;lt;BMI \&amp;lt;30 kg/m2;,{''}
2097,547,Must agree not to try to become pregnant during the study until 5 half-lives after the last dose of any study drug.,{''}
2098,548,Capable of giving signed informed consent.,{''}
2099,549,No previous systemic treatment;,{''}
2100,550,Eastern Cooperative Oncology Group Performance status of 0 or 1.,{''}
2101,556,There must be no evidence of metastatic disease,{''}
2102,557,Symptoms (including pain) associated with OA of the index shoulder for ≥3 months prior to Screening Visit (subject self-report is acceptable).,{'O ##A of the index shoulder'}
2103,559,Stratum 2 Patients with measurable ACP who have undergone surgery but have NOT previously undergone irradiation (but may have received prior systemic or intracystic therapy). Progressive disease is allowed but not required.,{'AC ##P'}
2104,561,"Female subjects of childbearing potential must be surgically sterile, or postmenopausal, or agree use an acceptable method of birth control from the time of ICF or 10 days prior to check-in and until 30 days after Day 21. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at check-in.",{''}
2105,564,"Male subject and female spouse/partners who are of childbearing potential must be using 1 form of highly effective birth control starting at Screening and throughout the study period, and for 90 days after the final study drug administration.",{''}
2106,566,"Age \>18 months, regardless of biologic features OR",{''}
2107,569,"Presence of radiographically measurable disease (defined as the presence one or more ≥ 1.5 cm lesions, as measured in the longest dimension by PET/CT) within 4 weeks of study registration.",{''}
2108,1,Life expectancy of greater than three months,{''}
2109,2,Written informed consent.,{''}
2110,4,"Has not received nor plans to receive neoadjuvant (preoperative) radiation therapy, androgen deprivation therapy (ADT), or any other anticancer therapy.",{''}
2111,6,"Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug.",{'cancer'}
2112,7,"Those who have not received body-mind therapy (yoga, reiki, massage, meditation) in the last six months",{''}
2113,8,Ability to take oral medication and willingness to adhere to the study medication regimen.,{''}
2114,10,Patients must not have had a screening mammogram within the last 11 months prior to date of randomization,{''}
2115,14,Have estimated life expectancy of at least 3 months,{''}
2116,15,Any burn-related injuries resulting in at least one night of hospitalization.,{'burn'}
2117,18,Availability of a radiography of the selected knee not older than 6 months.,{''}
2118,19,Parent/Guardian must sign the Release of Medical Records associated with the outcomes of interest identified from claims data.,{''}
2119,20,≥ 2 corneal quadrants covered by pathological corneal neovascularization,{''}
2120,23,Life expectancy \>12 weeks.,{''}
2121,24,"Have discontinued use of contact lenses for at least 2 weeks (for hard or toric lenses) or 3 days (for soft contact lenses) prior to the pre-operative examination, and through the day of surgery and must be willing to refrain from use of contact lenses throughout the clinical investigation.",{''}
2122,26,Recurrent arterial or venous thrombosis despite anticoagulant therapy,{'art ##erial or ve ##nous th ##rom ##bos ##is'}
2123,27,Primary care practice criteria are that diabetes is managed by multiple daily insulin injections (insulin-pump naïve).,{'diabetes'}
2124,29,Willing to partner with his or her pain physician on a subject-centered pain management plan during the study.,{''}
2125,34,"Women of childbearing potential must be non-pregnant (as confirmed by a urine pregnancy test at Screening and Baseline) and non-lactating, and will abstain from intercourse (when it is in line with their preferred and usual lifestyle) or use 2 medically acceptable, highly effective forms of contraception for the duration of the study, and at least 30 days after discontinuing study drug.",{''}
2126,37,Having obtained his/her informed consent,{''}
2127,38,receiving therapeutic dose anticoagulation with low molecular weight heparins (LMWHs) and/or direct oral anticoagulants (DOACs) according to the respective product labels,{''}
2128,43,Sufficiently fluent in English to take part in a consultation and subsequent data collection procedures.,{''}
2129,44,English speaking,{''}
2130,46,Provision of signed written ICF indicating that they understand the purpose of the study and procedures required for participation in the study.,{''}
2131,47,Must agree not to breastfeed from the time of signed ICF until 5 half-lives after the last dose of any study drug.,{''}
2132,49,Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.,{''}
2133,56,major depressive disorder,{'major de ##pressive disorder'}
2134,58,all tumors must exhibit ≥75% of tumor cells with FRα membrane staining and ≥ 2+ intensity by immunohistochemistry (IHC) using the Ventana FOLR1 (FOLR1 2.1) CDx assay.,"{'tumors, tumor'}"
2135,60,Patients must provide a documented tumor tissue specimen of the primary or metastatic tumor within 3 years for PD-L1 testing and other testing;,"{'tumor, tumor'}"
2136,63,T1 high-grade disease at the first evaluation following an induction BCG course (at least 5 or 6 doses),{''}
2137,64,Employed as staff or trainee at a participating program,{''}
2138,65,Socket-Comfort Score 6 or above to ensure adequate socket fit,{''}
2139,66,"Male subjects must not donate sperm starting at informed consent and throughout the clinical study period, and for 90 days after study drug administration.",{''}
2140,68,Any unhealthy weight control behaviors,{''}
2141,73,"Previous treatment with at least 1 novel androgen axis drug (NAAD) (e.g., enzalutamide, apalutamide, darolutamide and/or abiraterone).",{''}
2142,74,"B-ALL patients without DS must have an initial white blood cell count \< 50,000/uL (performed within 7 days prior to enrollment).","{'B - AL ##L, DS'}"
2143,75,Carrier of a pathogenic progranulin gene (GRN) mutation.,{''}
2144,76,Willing to participate in vitamin B1 therapy and commit to regular follow-up appointments.,{''}
2145,77,"Have a life expectancy of more than 180 days, per physician discretion",{''}
2146,85,Overjet ≥ 8mm.,{''}
2147,86,)Substantially normal bone marrow reserve function and normal liver and renal function (laboratory tests need to be fulfilled before receiving QH104 Cell Injection for the first time)White blood cell count (WBC) ≥ 3 x 109/L;Lymphocyte count (LY) ≥ 0.8 x 109/L;Hemoglobin (Hb) ≥ 90g/L;Platelet (PLT) ≥80×109/L;Albumin transaminase (ALT) \& albumin transaminase (AST) \<1.5×ULN;Serum creatinine (Cr) \<1.5 x ULN;Total bilirubin \< 1.5 x ULN;PT \& PTT ≤ 1.25 x ULN.,{''}
2148,88,Study participant is considered for additional treatment such as intravenous immunoglobulin g (IVIg) or plasma exchange (PEX) by the Investigator,{''}
2149,93,Has a moderate depression severity score or higher (Patient Health Questionnaire-9 score \>9; PHQ),{''}
2150,94,Parent/guardian's able to provide consent for minors,{''}
2151,96,Uses contraception unless confirmed to be azoospermic,{''}
2152,97,Age ≥ 21 years,{''}
2153,98,"For a patient to maintain eligibility for AHEP0731 when emergent treatment is given, the following must occur",{''}
2154,100,AD involvement of ≥10% body surface area at screening and baseline.,{'AD'}
2155,104,"Appropriately sized and accessible target coronary arteries, with a minimum diameter of 2 mm and adequate vascular bed (without significant distal stenosis), as assessed by pre-operative cardiac angiography and verified by diameter gauging intraoperatively.",{''}
2156,105,Eastern Cooperative Oncology Group Performance Status of 0 or 1,{''}
2157,107,Remote participant must have Wi-Fi access,{''}
2158,109,"Subjects may be receiving systemic chemotherapy or other systemic agents prior to enrollment, but these agents must be stopped during SBRT treatments.",{''}
2159,111,≥18 years of age,{''}
2160,114,Children (ages 12-17) with chronic nausea,{''}
2161,117,Participants must have a life expectancy of \>4 months in the opinion of the Investigator.,{''}
2162,118,"Participants must have RAI-refractory disease, as defined by",{'RA ##I - re ##fra ##ctor ##y disease'}
2163,122,Female participant must not donate ova starting at first dose of IP and throughout the study period and for 28 days after IP administration.,{''}
2164,125,Has a serum PSA concentration at the Screening visit of \> 0.2 ng/mL,{''}
2165,130,HbA1c ≤ 10 %,{''}
2166,132,willing to avoid intake of foods extremely rich in anthocyanins and fermented dairy products containing viable Bifidobacteria or Lactobacilli,{''}
2167,138,Aged 18 years or older,{''}
2168,139,Part B3,{''}
2169,144,Ambulatory with or without a walking device or use of a manual wheelchair for mobility.,{''}
2170,146,Male and female subjects must be willing to comply with contraception requirements as well as restrictions regarding egg and sperm donation,{''}
2171,147,FIB-4 index value is 3.25 or higher.,{''}
2172,148,Potential trial participants should have recovered from clinically significant adverse events of their most recent therapy/intervention prior to enrollment.,{''}
2173,149,Having obtained his/her informed consent,{''}
2174,151,Mono-therapy dose escalation study The subjects who have no option of or are intolerable to SOC.,{''}
2175,152,Sign the Informed Consent.,{''}
2176,154,No opposition from the mother,{''}
2177,155,Willing to use highly effective contraceptive measures during the study period and 3 months after the last dose.,{''}
2178,157,"Two subjects, depending on the number of medications (more or less medications) that the subject is taking.",{''}
2179,159,"Prior therapy eligible subjects must have had at least one line of platinum-based chemotherapy; this may be adjuvant therapy or first line of cytotoxic therapy for metastatic disease; prior hormonal therapy for metastatic/recurrent disease, prior targeted therapy, and prior radiotherapy are allowed; no maximum number of previous lines of chemotherapies; concomitant chemo-radiation is not considered as previous line of systemic chemotherapy",{''}
2180,161,Treatment experience within the last 24 months of antiviral therapy drugs recommended by the government program and administered in line with national recommendations. The current recommendations are that patients without cirrhosis should receive sofosbuvir 400 mg per day in combination with daclatasvir 60 mg per day for a total of 12 weeks and for patients with cirrhosis therapy should involve sofosbuvir 400 mg per day in combination with daclatasvir 60 mg per day for a total of 24 weeks. Patients who receive additional medication (including ribavirin) can be enrolled in the study but the additional medication should be noted.,"{'c, ##ir ##r ##hos ##is, c, ##ir ##r ##hos ##is'}"
2181,162,Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%),{''}
2182,164,localized luminal narrowing (luminal ≤ 50% relative to normal adjacent bowel); AND,{''}
2183,165,"Ability to communicate,",{''}
2184,167,willing to participate in all aspects of the proposed intervention.,{''}
2185,168,Agree not the change their diet or exercise while enrolled in this trial,{''}
2186,172,Have both an sPGA score of ≥3 and PASI score ≥12 at screening and baseline,{''}
2187,179,Has provided a baseline tumor biopsy,{'tumor'}
2188,184,"Patients with metastatic disease more than 6 months after adjuvant or neoadjuvant platinum-based chemotherapy, who also subsequently progressed during or after a platinum- based regimen given to treat the advanced or metastatic disease, are eligible.",{'meta'}
2189,185,Preplanned surgical procedure(s) will take place at least 14 days (for major operative procedures) prior to the tumor resection.,{'tumor'}
2190,186,Major organs are functioning well.,{''}
2191,187,"For the rest of the patients, the evaluation of SSTR expression will be classified according to a qualitative 4-point scale SSTR expression V (visual score)",{''}
2192,189,Non-rhabdomyosarcoma soft tissue sarcomas (STS) including microphthalmia transcription factor associated STS (alveolar soft part sarcoma \[ASPS\] and clear cell sarcoma \[CCS\]),"{'Non - r ##hab ##dom ##yo ##sar ##com ##a soft tissue sa ##rc ##oma, STS, micro ##ph ##thal ##mia, STS, al ##ve ##olar soft part sa ##rc ##oma, AS ##PS, clear cell sa ##rc ##oma, CC ##S'}"
2193,190,Existence of measurable or evaluable disease (as per RECIST 1.1 criteria).,{''}
2194,192,Taking bile acid chelator (colenemide) has no obvious effect or intolerance.,{''}
2195,196,MRI positive for full acute ACL injury,{''}
2196,197,Evidence of depressive symptoms for at least 3 months based on patient interview or documentation in electronic health records,{'de'}
2197,198,"Female subject must not be breastfeeding at Screening or during the study period, and for 60 days after the final study drug administration",{''}
2198,199,Women capable of becoming pregnant must agree to use 2 forms of contraception.,{''}
2199,200,Exclusion Criteria,{''}
2200,202,"If being treated with psychoactive medication, no change in drugs or dose for the past 2 months",{''}
2201,203,Availability of adequate tumor material (block or slides),{'tumor'}
2202,204,Trial-wide,{''}
2203,205,Must have been able to communicate well with the investigator and to understand and comply with the requirements of the study.,{''}
2204,206,WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 28 days after final IP administration.,{''}
2205,215,Fluent in English or French,{''}
2206,218,Absence of maternal use of illicit drugs prenatally,{''}
2207,220,"If on an NNRTI-based regimen, willing to switch to an integrase inhibitor-based regimen for at least 4 weeks prior to discontinuing ART.",{''}
2208,221,T3-4 disease due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan.,{'T ##3 - 4 disease'}
2209,223,Has been surgically sterile for at least 6 months prior to study drug administration.,{''}
2210,225,"At least 4 weeks must have elapsed from the use of 5-alpha reductase inhibitors, estrogens, and any other anti-cancer therapy prior to randomization",{'cancer'}
2211,226,Participant agrees not to participate in another interventional study while participating in the present study.,{''}
2212,229,\>2 weeks since prior radiation therapy or systemic therapy at the time of leukapheresis.,{''}
2213,233,BMI 25 to 40 kg/m2 inclusive,{''}
2214,234,"Cohort_A, B, and Cohort_C Stage I patients who had failed or were intolerant to 1 or more lines of systemic therapy for recurrent or metastatic HNSCC (non-nasopharyngeal carcinoma);","{'H ##NS ##CC, non - na ##so ##pha ##ryn ##ge ##al car ##cin ##oma'}"
2215,237,Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at the Screening Visit.,{'My ##ast ##hen ##ia G ##ra ##vis'}
2216,239,Are able and willing participate.,{''}
2217,242,"ability to undergo an EEG during the first 24 hours after onset of stroke symptoms,",{'stroke'}
2218,249,ECOG Performance Status 0-2.,{''}
2219,250,"The child's family has a certain level of reading and comprehension ability, can effectively understand the questionnaire content, and is willing to sign the informed consent form.",{''}
2220,256,"Participants who cross-over from Prednisone alone to open-label apalutamide plus AAP should still be in the double-blind phase of the study, should be receiving AAP alone and should have ECOG 0-1-2.",{''}
2221,258,Meet the definition of high tumor burden follicular lymphoma as defined by Groupe d'Etude des Lymphomes Follicularies (GELF) Criteria or be defined as high risk by the follicular lymphoma international prognostic index (FLIPI) 1 or FLIPI 2.,"{'tumor, f, ##oll ##icular l ##ymph ##oma, f, ##oll ##icular l ##ymph ##oma'}"
2222,259,Pathology report must be submitted for central confirmation of diagnosis within 7 days of enrollment.,{''}
2223,261,"Participants, upon pelvic examination with speculum examination, must have a normal-appearing vulva other than atrophic changes, normal-appearing cervix other than atrophic changes (i.e., cervical stenosis and/or flushness with the vaginal wall) and normal-appearing vagina (without erosions, ulcerations, scarring, or evidence of dermatoses) other than atrophic changes (loss of ruggae, mucosal pallor, mucosal dryness, mucosal petechiae).","{'at, at, c ##er ##vic ##al s ##ten ##osis, flush ##ness with the v ##agi ##nal wall, erosion, ul ##cer, scar ##ring, der ##mat ##ose, at, m p ##r, m dry ##ness, m, pet ##ech ##iae'}"
2224,264,Cardiac Left ventricular ejection fraction (LVEF) ≥ 35%,{''}
2225,265,"If node-positive (N1-N3), T1mi, T1a, T1b, T1c, T2, or T3 tumors are eligible (see below for further details on defining node-negative disease) Definition of node-negative disease (when node status known) If the patient has had a negative sentinel node biopsy and/or a negative axillary dissection, then the patient is determined to be node-negative. Axillary nodes with single cells or tumor clusters ≤ 0.2 mm by either H\&E or IHC will be considered node-negative. Any axillary lymph node with tumor clusters between 0.02 and 0.2cm is considered a micrometastasis. Patients with a micrometastasis are eligible even if their tumor is \</= 5mm. An axillary dissection is not required to be performed in patients with a positive sentinel node and management of the axilla will be left up to the treating provider. In cases where the specific pathologic size of lymph node involvement is subject to interpretation, the principal investigator will make the final determination as to eligibility. In these special situations, the investigator must document this approval in the patient medical record.","{'T , T ##2 or T ##3, tumors'}"
2226,267,Speak English or Spanish as a primary language,{''}
2227,270,"No history of neuropathic diseases such as Diabetes Mellitus,","{'ne ##uro ##pathic diseases, Di, ##abe ##tes Mel ##lit ##us'}"
2228,271,"Subjects must be willing to refrain from donating blood, organs, tissues or cells during study participation.",{''}
2229,272,"Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features.","{'My, ##elo ##dy ##sp ##lasia, MD ##S, IP, An ##emia, pan ##cy ##top ##enia'}"
2230,277,Pretreatment histological biopsy of a metastatic lesion for the translational research questions (tumor tissue from bone metastases cannot be used).,{'tumor'}
2231,278,be willing to participate in the study.,{''}
2232,281,Mechanistically validated activating non-V600 BRAF mutants,{''}
2233,288,Liver ultrasonography showed fatty liver within 24 months before enrollment;,{'fatty liver'}
2234,290,"Acute Lymphoblastic Leukemia (ALL) in first or second remission; Acute Myeloid Leukemia (AML) in first or second remission; Chronic Myelogenous Leukemia (CML) in first chronic or accelerated phase, or in second chronic phase; Hodgkin's and non-Hodgkin's lymphoma; myelodysplastic syndrome","{""A, ##cute L ##ymph ##ob ##lastic Le ##uke ##mia, AL ##L, A, ##cute My ##elo ##id Le ##uke ##mia, AM ##L, Ch, ##ronic My ##elo ##gen ##ous Le ##uke ##mia, C ##ML, Ho, ##d ##g ##kin ' s and non - Ho ##d ##g ##kin ' s l ##ymph ##oma, my, ##elo ##dy ##sp ##lastic syndrome""}"
2235,291,"Note Patients who have received previous chemotherapy for pancreatic cancer are allowed to participate in this study, unless they experienced a previous allergic reaction to the drugs used in this study.","{'pan ##cre ##atic cancer, all'}"
2236,293,≥ 6 swollen joints (using 66-joint assessment),{''}
2237,301,"Are mobile within their home, with or without an assistive device and without physical assistance",{''}
2238,304,CRP of ≥ 0.5 mg/dL or ESR of ≥ 28 mm/h.C-Reactive Protein (CRP) of ≥ 0.8 mg/dL or Erythrocyte Sedimentation Rate (ESR) of ≥ 28 mm/hr,{''}
2239,307,Adequate organ function.,{''}
2240,309,"Expansion cohort B only advanced or metastatic solid tumors with MDM2 or MDM4 amplifications and WT TP53 metastatic for which standard treatment with therapies known to confer a survival benefit does not exist, is no longer effective or tolerated, or the patient declines standard treatment.",{'solid tumors'}
2241,311,ages from 18-50,{''}
2242,313,a non-endometrioid histological type regardless of P53 status.,{''}
2243,315,"Females must be surgically or biologically sterile or postmenopausal (amenorrhoeic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment. Women of childbearing potential must agree to use an adequate method of contraception during the study and until the last radiation treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study and until the last radiation treatment","{'am, ##eno ##rr ##hoe'}"
2244,318,pneumonia,{''}
2245,321,Eligible to receive either product per recommended guidelines at the recommended gestational age and during the recommended seasonal time period. (Maternal RSVpreF from 32 0/7 to 36 6/7 weeks GA from September 1 to January),{''}
2246,324,Eastern Cooperative Oncology Group \[ECOG\] 0-1,{''}
2247,325,Must be able to swallow capsules,{''}
2248,326,"Measurable hematologic disease a dFLC \>20 mg/L with an abnormal κ/λ ratio (with Freelite® test kits, The Binding Site) or presence of a monoclonal spike ≥0.5 g/dL.",{'hem ##ato ##log ##ic disease'}
2249,327,"N1b, or N1c, or N2b, or N2c, or N3b, or N3c and",{''}
2250,328,Signed Informed consent.,{''}
2251,331,Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2,{''}
2252,332,Life expectancy ≥ 12 weeks.,{''}
2253,333,) a negative pregnancy test in a fertile female patient.,{''}
2254,335,"Current hazardous alcohol use (2+ heavy episodic drinking occasions \[4+ drinks on one occasion for women, 5+ drinks on one occasion for men\] in past month, 1+ negative consequences related to alcohol use)",{''}
2255,337,Total score of Clinical Dementia Rating Scale (CDR),{'De ##ment ##ia'}
2256,340,CD10-negative HGBCL with MYC and BCL6 (without BCL2) translocations (HGBCL-DH-BCL6),{''}
2257,343,Frozen pathology diagnosis must be attainable.,{''}
2258,344,Must have a life expectancy estimate of at least 4 months.,{''}
2259,346,Following treatment on New Approaches to Neuroblastoma Therapy (NANT) 2001-02,"{'N, ##eur ##ob ##last ##oma'}"
2260,347,Life expectancy of greater than 3 months,{''}
2261,349,Measurable disease. Patients with non-measurable bone or skin disease as their only manifestation of advanced breast cancer are also eligible;,"{'bone or skin disease, advanced breast cancer'}"
2262,350,"Participant-reported history of signs and symptoms of chronic bronchitis (chronic productive cough for at least 3 months in the year before screening in a participant in whom other causes of chronic cough \[eg, inadequately treated gastroesophageal reflux or chronic rhinosinusitis; or clinical diagnosis of bronchiectasis\] have been excluded).","{'chronic br ##on ##chi ##tis productive cough, chronic cough, gas ##tro ##es ##op ##hage ##al re ##f ##lux, chronic r ##hino ##sin ##us ##itis, br, ##on ##chi ##ec ##tas ##is'}"
2263,352,"Potentially life-threatening bleeding with signs or symptoms of hemodynamic compromise, e.g., systolic blood pressure \< 90 mm Hg and signs or symptoms of low cardiac output not otherwise explained","{'bleeding, hem, ##ody compromise, low cardiac output'}"
2264,353,"Patient understands Slovenian language, and",{''}
2265,354,Subjects must meet organ function criteria,{''}
2266,356,Males or females aged at least 18 years.,{''}
2267,358,"not reside in a field that has been subjected to prior radiotherapy, or",{''}
2268,359,"Women must agree not to become pregnant during the trial. If they are sexually active, they must use an effective method of birth control, e.g. insertable, injectable, transdermal, or combination oral contraceptive approved by Health Canada combined with a barrier contraceptive and have negative results on a serum or urine pregnancy test done before administration of study medication.",{''}
2269,361,Co-residing with an intimate partner or spouse who is willing to participate,{''}
2270,362,"HER2 expression by IHC (1+, 2+, or 3+) or HER2 amplification by ISH or NGS (on any CLIA platform), AND",{''}
2271,364,Bone scan within 42 days of randomization,{''}
2272,367,"Persons of childbearing potential must have used effective birth control methods for at least one month prior to vaccination, and agree to continue with 'per label/fully effective use' for the chosen method for the duration of the study (30 days prior to first vaccination until 12 months after first vaccination), from amongst these",{''}
2273,370,-120kg weight,{''}
2274,371,"Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception",{''}
2275,375,Have measurable disease,{''}
2276,376,Increased inflammation (\[serum C-reactive protein\] ≥3.0 mg/L.,{''}
2277,381,Late stage malignant tumor subjects who have failed standard treatment or lack effective treatment；,"{'Late, ma ##li ##gnant tumor'}"
2278,384,"Inferior vena cava (IVC) diameter on ultrasonography ≤21 mm at the time of the ""screening"" visit.",{''}
2279,385,"Cohort 3 HER2 low expression, defined as IHC 1+ or IHC 2+ but ISH or FISH negative.",{''}
2280,388,Patient available for a 4-month follow-up.,{''}
2281,389,Babies who will be examined for ROP for the first time,{'R'}
2282,391,"Currently treated or being considered for treatment with tramadol, hydrocodone, or codeine to improve pain management",{''}
2283,394,Having obtained his/her informed consent,{''}
2284,395,Has been informed of the nature of the study and provided written informed consent,{''}
2285,396,Willing to be randomly assigned to either intervention,{''}
2286,399,Exclusion criteria,{''}
2287,403,Non-small cell lung cancer (NSCLC),"{'Non - small cell lung cancer, N ##SC ##LC'}"
2288,405,"Participant treated with the clinically maximum tolerated dose, as per investigator judgment, of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), but not both, for more than 1 month at screening visit.",{''}
2289,406,"Patients with at least 1 risk factor for intracranial atherosclerotic plaque, including previous or existing hypertension, hyperlipidemia, diabetes, smoking;","{'in ##tra ##c ##rani ##al at ##her ##os ##cle ##rot ##ic plaque, h ##yper ##tens ##ion, h ##yper ##lip ##ide ##mia, diabetes'}"
2290,408,At least one unidimensionally measurable lesion per RECIST criteria (version 1.1).,{''}
2291,410,Body weight within 50.0-100.0 kg and BMI within the range 19.0-28.0 kg/m2 (inclusive) at screening.,{''}
2292,414,Female participant must not donate ova starting at dose of IP and throughout the study period and for 28 days after IP administration.,{''}
2293,415,All sexes and genders will be eligible for the study,{''}
2294,416,Has at least one ARR who meets criteria for study enrollment (see below),{''}
2295,419,For controls,{''}
2296,420,Written informed consent of patients and / or parents,{''}
2297,421,OR,{''}
2298,425,Has been surgically sterile for at least 6 months prior to study drug administration.,{''}
2299,426,"Subjects agree not to introduce any new colored cosmetics or skin care products while participating in the study (lipsticks, eye shadows, facial foundations, blush, powder, cleansers, moisturizers).",{''}
2300,427,Patients must be willing to undergo serial imaging procedures.,{''}
2301,431,ECOG performance Status ≤ 1.,{''}
2302,432,Please note A histological or pathological specimen from cervical lymph nodes with well-defined primary site documented clinically or radiologically is acceptable,{''}
2303,434,Patients with a primary spinal tumor are eligible.,{'spinal tumor'}
2304,435,Domicile within the metropolitan area,{''}
2305,440,Patients with stage I-IVA are eligible,{''}
2306,442,Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).,"{'Aden ##oc ##ar ##cin ##oma, sq ##ua ##mous cell car ##cin ##oma of the es ##op ##ha ##gus Si ##ew ##ert type 1 ad ##eno ##car ##cin ##oma of the gas ##tro ##es ##op ##hage ##al junction, GE ##J'}"
2307,445,"Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant",{'meta'}
2308,457,Cephalosporins,{''}
2309,458,Locally advanced colorectal cancer with initially unresectable but potentially resectable disease according to the local Multidisciplinary Tumour Board (MTB).,"{'color ##ec ##tal cancer, Tu'}"
2310,466,"Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)",{''}
2311,468,"platelets \>100,000/mcL",{''}
2312,470,"ANC ≥ 1.5 cells/mm3, PLT≥100,000/mm3, PT/aPTT within normal limits at time of surgery",{''}
2313,475,"Patients whose histological features of liver biopsies are reported. HE staining and Masson staining are required, and edema, inflammation, fibrosis, and hyperplasia of intrahepatic bile duct should be reported;","{'ed, inflammation, fi ##bro ##sis, h ##yper ##p ##lasia of in ##tra ##he ##pa ##tic bi ##le duct'}"
2314,476,Performance status Eastern Cooperative Oncology Group (ECOG) 0-1,{''}
2315,478,Females of childbearing potential must be using an approved method of birth control for the past month and during the entire study period. Participants who can become pregnant will undergo a pregnancy test prior to treatment.,{''}
2316,479,Individuals must have been stabilised for at least 24-48h of their HF decompensation before randomisation.,{'H ##F de ##com ##pen ##sation'}
2317,480,Age greater than 18 years (inclusive).,{''}
2318,482,Prior 10 therapy exposure (Cohort 1 only).,{''}
2319,483,No changes to spasticity medications or dalfampridine over the last 3 months,{'spa ##stic ##ity'}
2320,484,No contraindication to undergoing PTNS or TENS therapy,{''}
2321,486,Exclusion criteria,{''}
2322,489,"Male or female, aged 12-17 at time of consenting;",{''}
2323,500,"Participants with inadequate response/non-response, loss of response, or are intolerant of standard biologic therapy for their UC AND/OR Inadequate or non-responders, have shown loss of response, or are intolerant to at least 1 of the following treatments oral corticosteroids (≤20 mg/day), 5-aminosalicylic acid (ASA) compounds, immunomodulators, small molecules.",{'UC'}
2324,504,Provide informed consent,{''}
2325,506,Good compliance during treatment,{''}
2326,510,Bladder cancer,{'B ##lad ##der cancer'}
2327,513,Astigmatism ≤ 0.75 D,{''}
2328,515,"Must not be breastfeeding; if of child bearing potential, must test negative on the study-administered pregnancy test(s), and if of childbearing potential and engaging /planning to engage in sexual intercourse must agree to effective contraception for the duration of the trial through 30 days after the trial; effective contraception is defined as using a) birth control injection, an intrauterine device, or implant; or b) two birth control methods - for example birth control pills with a barrier method (e.g., condoms, etc.). o If ever of childbearing potential, a participant is considered to not be of childbearing potential for the study if they are 1) infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, tubal implants, or tubal ligation), congenital anomaly such as Mullerian agenesis; are 2) post-menopausal defined as ≥ 55 years old not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea; 3) ≥ 55 years old with a diagnosis of menopause prior to starting hormone replacement therapy; or 4) ≥ 40 years old with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, AND a follicle-stimulating hormone ≥ 40 mIU/mL; participants in this category must test negative on the study-administered pregnancy test(s).","{'##fer, con, ##gen ##ital an ##oma ##ly, Muller ##ian age ##nes ##is, am ##eno ##rr ##hea, men ##op ##aus ##e'}"
2329,523,Absolute neutrophil count (ANC) ≥ 1.5 x 109/L,{''}
2330,525,"Rejection antibody mediated rejection by Banff classification borderline changes or more severe, or investigator's decision",{''}
2331,528,Age ≥ 18 years.,{''}
2332,530,Patients shall have had no prior cytotoxic chemotherapy with the exception of steroids and/or IT cytarabine,{''}
2333,532,"Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations",{''}
2334,533,Patients must be HLA-A2 for cohort A. (Turnstile II-Chemotherapy/Cell Infusion-,{''}
2335,536,Child does not have other medical conditions that would preclude the child from completing study assessments.,{''}
2336,538,Subject must be willing and able to comply with the study requirements,{''}
2337,539,Hidradenitis Suppurativa affecting the axilla,{'Hi ##dra ##den ##itis Su ##pp ##ura ##ti ##va'}
2338,540,"Not having sensory losses such as vision or hearing,",{'sensory losses as vision or hearing'}
2339,541,Does not speak French or dementia,{'dem'}
2340,542,"Must meet one of the Genetic Screening Criteria, defined below",{''}
2341,546,"Informed consent, voluntary participation in the trial, and informed consent signed by the subjects themselves.",{''}
2342,547,Must agree not to breastfeed from the time of signed ICF until 5 half-lives after the last dose of any study drug.,{''}
2343,548,A history of at least one of,{''}
2344,549,Expected survival time ≥ 3 months;,{''}
2345,550,Adequate organ function,{''}
2346,556,"While data collection will include review of the reports of any imaging studies of the prostate, bones, or soft tissues, these studies are not essential",{''}
2347,557,Shoulder pain due to OA for \>15 days over the last month (as reported by the subject).,"{'Should ##er pain, O ##A'}"
2348,559,"Performance Level Karnofsky ≥ 50% for patients \> 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age (See Appendix I). Note Neurologic deficits in patients with CNS tumors must have been stable for at least 7 days prior to study enrollment. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.","{'C ##NS tumors, para ##lysis'}"
2349,561,"Male subjects with female partners of childbearing potential must be vasectomized, be willing to use an acceptable method of birth control, or to practice abstinence during the study from check-in until 90 days following Day 21.",{''}
2350,564,"Male subject must not donate sperm starting at Screening and throughout the study period, and for 90 days after the final study drug administration.",{''}
2351,566,"Age 1-18 months, with any of the 3 following unfavorable biologic OR features MYCN amplification, unfavorable pathology, and/or DNA index = 1",{''}
2352,569,"Prior therapy with check-point inhibitors (nivolumab, pembrolizumab, others) and subsequent progressive disease, stable disease or mixed response",{''}
2353,1,Adequate organ and marrow function,{''}
2354,2,For Phase B 68Ga-NYM096 should meet the imaging inclusion criteria,{''}
2355,4,Has a life expectancy \>5 years.,{''}
2356,7,Mothers who volunteer to participate in the research will be included.,{''}
2357,8,Stated willingness and ability to comply with all study procedures and availability for the duration of the study and investigator believes individual will complete the study.,{''}
2358,10,Patients must not have previous personal history of breast cancer including ductal carcinoma in situ,"{'breast cancer, duct ##al car ##cin ##oma in sit ##u'}"
2359,14,Be willing and able to provide written informed consent/assent for the trial,{''}
2360,15,"Heart disease or any other chronic medical condition requiring regular medical therapy including cancer, diabetes, and hypertension.","{'Heart disease, chronic medical condition, cancer, diabetes, h ##yper ##tens ##ion'}"
2361,18,Patient is either not of childbearing potential or must agree not to start a pregnancy from the signature of the informed consent up to the final visit,{''}
2362,19,Interested in wearing contact lenses for approximately 10 hours per day and 6 days per week.,{''}
2363,20,Absence of other clinical contraindications to any part or product of the treatment plan,{''}
2364,23,Adequate organ function as determined by,{''}
2365,24,"Contact lens wearers must demonstrate a stable refraction (within ±0.50 D for both sphere and cylinder) in both eyes, as determined by distance manifest refraction on two consecutive examination dates at least one week apart after discontinuation of contact lens wear.",{''}
2366,27,TH group criterion is that participant must have hardware and internet access capable of 2-way video and audio communication,{''}
2367,29,"In generally good health, in the opinion of the Investigator, other than the underlying chronic pain syndrome",{'chronic pain syndrome'}
2368,34,Males with a partner of childbearing potential must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.,{''}
2369,38,Measured body weight within 50 to 130 kg,{''}
2370,43,"Competent to consent for themselves, as determined by a qualified primary care healthcare professional.",{''}
2371,44,Normotensive (\<95th percentile for age; okay if managed with antihypertensive medication),{''}
2372,46,"Patients must be able and willing to read and comprehend written instructions and comprehend and complete the questionnaires required by the protocol (SGRQ, ACQ-5, PGIC and PGIS).",{''}
2373,47,"If partner is not sterilized, must agree to use highly effective contraceptive measuresfrom screening (V1) until 5 half lives after last dose of any study drug",{''}
2374,49,LVEF ≥ 50% on baseline screening ECHO.,{''}
2375,56,bipolar disorder,{'bi ##pol ##ar disorder'}
2376,58,Patients must have measurable disease or evaluable disease in combination with GCIG CA-125 criteria.,{''}
2377,60,At least one measurable lesion meeting the RECIST v1.1 definition was required;,{''}
2378,63,Participant must be ineligible for or refusing a radical cystectomy,{''}
2379,64,Employed at the program for at least the next 12 months,{''}
2380,65,PLUS-M T-score of 55 or above,{''}
2381,68,Severe anxiety or depression,{''}
2382,73,Prior orchiectomy and/or ongoing androgen deprivation therapy and a castrate level of serum testosterone (\<50 ng/dL or \<1.7 nmol/L).,{'or'}
2383,74,B-ALL patients with DS are eligible regardless of the presenting white blood cell count (WBC) (performed within 7 days prior to enrollment).,"{'B - AL ##L, DS'}"
2384,75,Negative screening test for Mycobacterium tuberculosis (MTB) or documented negative MTB test within 1year prior to screening.,"{'My tuberculosis, M ##T, M'}"
2385,76,Exclusion Criteria,{''}
2386,77,"Age 40 or above, ensuring of legal age to give informed consent specific to state and national law",{''}
2387,86,)No obvious hereditary diseases;,{'hereditary diseases'}
2388,93,"Agrees to discuss depression, treatment preferences, and mobile health",{''}
2389,94,Negative pregnancy test for women aged between 13 and 49,{''}
2390,96,"Female participants are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) OR use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after the last dose of pembrolizumab or pembrolizumab/quavonlimab, or 30 days after the last dose of lenvatinib, whichever occurs last",{'W'}
2391,97,English speaking,{''}
2392,98,"The patient must have a clinical diagnosis of hepatoblastoma, including an elevated alpha fetoprotein, and must meet all AHEP0731 eligibility criteria at the time of emergent treatment","{'he, ##pa ##to ##blast ##oma'}"
2393,100,An EASI score of ≥16 at screening and at baseline.,{''}
2394,104,-,{''}
2395,105,Adequate hematologic and organ function as indicated by specific laboratory values within 7 days of first dose of study drug,{''}
2396,109,"Females of childbearing potential (FCBP) must have a negative serum pregnancy test within 14 days prior to day 1 of treatment. NOTE Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause).","{'child, FC'}"
2397,111,Performance status ≤2 on the Eastern Cooperative Oncology Group Performance Scale,{''}
2398,117,Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female subjects will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. Female subjects \< 50 years old who meet the criteria for post-menopausal status without previous surgical sterilization should be considered for further investigation with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels to confirm serological post-menopausal status.,"{'child ##be, W, ##OC ##P, W, ##OC ##B ##P, am, ##eno ##rr ##he ##ic'}"
2399,118,The malignant tissue does not concentrate RAI on a whole body scan following radioiodine administration,{''}
2400,122,Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 28 days after IP administration.,{''}
2401,125,Able to swallow pills and take medication orally (no documented inability to eat solids and swallow pills) and be willing to adhere to the tice daily regimen of medication (if assigned to the experimental arm).,{''}
2402,130,Body weight ≥ 35kg at screening,{''}
2403,132,"willing to have 3 blood draws, 2 stool collections, and 2 bone scans",{''}
2404,138,Parent (or legal caregiver) of a child with cancer of any age who meets the above criteria for cohorts 1-3 OR of a child who died from cancer 6-24 months from enrollment (cohort 4).,"{'cancer, cancer'}"
2405,139,May or may not be receiving moderate- or high-intensity statin therapy.,{''}
2406,146,"Female subject must not be breastfeeding at Screening or during the study period, and for 60 days after the final study drug administration",{''}
2407,147,Liver hardness value by FibroScan is 11.8 kPa or more.,{''}
2408,148,Serum testosterone \<1.7 nmol/L or 50 ng/dL.,{''}
2409,151,Mono-therapy dose expansion study The subjects with positive CDLN18.2 expression in tumor tissue (defined as CLDN18.2 membranous staining ≥1+ in ≥10% of tumor cells by immunohistochemistry (IHC) in the central laboratory) confirmed by the central laboratory at enrollment. The dose expansion study may include the following 3 cohorts,"{'tumor, tumor'}"
2410,154,Ability to master the French language required.,{''}
2411,157,Participation available Period subjects who have received tacrolimus twice daily (b.i.d) for a minimum of 6 months to a maximum of 12 months after surgery and who are within 1 month of switching to Advagraf (once daily (q.d) regimen of modified release tacrolimus).,{''}
2412,159,Availability of archival tissue for correlative analysis,{''}
2413,161,The subject's medical records must include sufficient detail of prior treatment to confirm eligibility.,{''}
2414,162,"Leukocytes ≥ 3,000/mcL",{''}
2415,164,wall thickening (≥ 125% relative to adjacent bowel); AND,{''}
2416,165,Agreeing to participate in the study.,{''}
2417,172,For PsA Participants,{'P ##s ##A'}
2418,179,Male participants who receive gebasaxturev are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 120 days after the last dose of gebasaxturev,{''}
2419,184,Patients should not receive any systemic therapy after platinum failure before enrollment into the study. Maintenance therapy after platinum based therapy and prior to progression is allowed.,{'platinum failure'}
2420,185,"All prior anticancer treatment-related AEs should be recovered, exceptions are peripheral neuropathy, alopecia, vitiligo, or medically controlled endocrine dysfunction.","{'peripheral ne ##uro ##pathy, al ##ope ##cia, v ##iti ##li ##go, end ##oc ##rine d ##ys ##function'}"
2421,186,Every effort should be made to provide tumor tissues for the determination of PD-L1 expression.,{'tumor'}
2422,187,Score = 0 Below or equal to blood pool,{''}
2423,189,Osteosarcoma,{'O ##ste ##osa ##rc ##oma'}
2424,190,"Possibility of obtaining sufficient tissue sample, via a biopsy or surgical resection of the primary tumour or metastatic tumour tissue","{'t, meta t ##umour'}"
2425,196,Arthrometric evaluation (KT1000) with a side-to-side difference greater than 3 mm,{''}
2426,197,"Recent initiation of SSRI therapy, recent revised SSRI therapy, or anticipated need for revised or new SSRI therapy per health care provider",{''}
2427,198,Subject agrees not to participate in another interventional study while on treatment,{''}
2428,200,Need for combined PKE + EK surgery,{''}
2429,202,Willingness to be audio-taped,{''}
2430,204,Life expectancy less than 12 months,{''}
2431,205,"Participants with mild, moderate, and severe HI (Groups 1, 2 and 3)",{'H ##I'}
2432,206,Female participant must agree not to breastfeed starting at screening and throughout the study period and for 28 days after final IP administration.,{''}
2433,218,Non - sedated neonates,{''}
2434,220,"For participants who can become pregnant (i.e., participants who have not been post-menopausal for at least 24 consecutive months, who have had menses within the preceding 24 months, or who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy), negative pregnancy test at screening (Step 0) and within 48 hours prior to day 0 (Step 1 entry).",{''}
2435,221,"No prior systemic therapy for small-cell lung cancer, with the following exceptions",{'small - cell lung cancer'}
2436,223,Reliable methods of contraception are,{''}
2437,225,At least 4 weeks must have elapsed from major surgery or radiation therapy prior to randomization,{''}
2438,229,Total bilirubin ≤ 1.5 mg/dL (except in patients with Gilbert's syndrome).,"{""Gilbert ' s syndrome""}"
2439,233,Stable weight for at least 3 months (± 5 lbs.),{''}
2440,234,"Cohort_C Stage II patients who had not received any previous systemic antitumor therapy (other than induction chemotherapy, neoadjuvant, or adjuvant therapy) for recurrent or metastatic HNSCC (non-nasopharyngeal); Treatment failure was defined as disease progression during or after systemic antitumor therapy.","{'meta, H ##NS ##CC'}"
2441,237,MG-ADL total score must be ≥ 5 (with at least 50% of the score attributed to non-ocular elements) at the Screening Visit and at randomization (Day 1).,{''}
2442,242,ability to undergo MRI of the brain.,{''}
2443,249,Subjects with HIV positivity are allowed if CD4 Count \> 500 cells/μL.,{''}
2444,258,--GELF Criteria (Must meet ≥ 1 of the following),{''}
2445,259,Formalin-fixed paraffin-embedded (FFPE) blocks or unstained slides (initial diagnosis and/or subsequent biopsies) will be required for retrospective central confirmation of diagnosis and molecular studies,{''}
2446,261,Have an intact uterus and no prior history of endometrial ablation.,{''}
2447,264,Voluntary written consent (adult or parent/guardian with minor assent for 12 through 17-year-olds).,{''}
2448,265,ER/PR determination assays performed by IHC methods according to the local institution standard protocol.,{''}
2449,267,Participants must be able to provide informed consent,{''}
2450,270,No known allergy to local anesthetics.,{''}
2451,271,Negative pregnancy test in women of childbearing potential (WOCBP).,{''}
2452,272,Age 60 years of age or younger at the time of consent,{''}
2453,277,No previous cytotoxic therapy for metastatic disease,{''}
2454,281,P367L/S,{''}
2455,288,Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) examination within 24 months before enrollment showed liver fat fraction ≥ 5%; and any of the following evidence of liver fibrosis,{'liver fi ##bro ##sis'}
2456,291,"Planned to receive CRT, consisting of PBT or IMRT (45 Gy/15 fractions) with concurrent chemotherapy with 5FU or Capecitabine.",{''}
2457,293,"Subject has CRP \> 0.50 mg/dL. The re-test of CRP will be allowed, if the subject's CRP value at the time of screening test is more than 0.30 mg/dL and also his/her most recent CRP value which was carried out up to 90 days before the date of screening test was more than 0.5 mg/dL.",{''}
2458,301,Are able to identify an eligible caregiver who will engage in assessments and intervention.,{''}
2459,304,"Subject meets the ACR 1991 Revised Criteria for the Classification of Global Functional Status in RA, Class I, II or, III at screening",{''}
2460,309,"Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. In the dose escalation stage, patients without measurable disease by RECIST 1.1, but evaluable disease are also eligible.",{'Solid Tu ##mor'}
2461,311,Male/Female,{''}
2462,313,Patient affiliated to a social security scheme,{''}
2463,318,viral infection not otherwise specified,{''}
2464,324,Adequate organ and marrow function,{''}
2465,326,"Adequate bone marrow function, without transfusion or growth factors within 5 days prior to the first drug intake (C1D1), defined as",{''}
2466,327,M0,{''}
2467,328,"Physically fit enough to undergo exercise as screened using the Physical Activity Readiness Questionnaire (PAR-Q) and the cardiovascular section of the Health History \&amp; Demographics Questionnaire. An affirmative response (i.e., \&#34;yes\&#34;) to any single item regarding an individual's health status is grounds for the necessary medical clearance before enrollment.",{''}
2468,331,Inclusion criteria specific to AMG 701-P±d include,{''}
2469,332,"Adequate organ function, as indicated by the following laboratory values •Hematology (no growth factor and blood transfusion are allowed within 14 days before start of first dose study treatment) Hemoglobin ≥90g/L Absolute neutrophil count ≥1.5×109/L Platelet count ≥100×109/L",{''}
2470,335,Owns a functioning cellular phone,{''}
2471,337,Mild dementia CDR = 1.0; Moderate dementia CDR = 2.0;,{''}
2472,340,"CD10-negative HGBCL, NOS (without MYC and BCL2 translocations)",{''}
2473,343,Patient must be symptomatically stable for a minimum of 3 days prior to the procedure date on a on a max total daily steroid dose equivalent to 4mg of Dexamethasone.,{''}
2474,344,Must have Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 to 1.,{''}
2475,346,Enrollment on or following treatment per ANBL02P1,{''}
2476,347,"Absolute neutrophil count \>= 1,500/uL",{''}
2477,349,Eastern Cooperative Oncology Group (ECOG) status of 0 or 1;,{''}
2478,350,"Documented or self-reported history of exacerbation having had ≥1 moderate or severe exacerbation within the 5 years prior to Screening (Visit 1), with at least 1 exacerbation treated with systemic corticosteroids",{''}
2479,352,"Bleeding in a critical organ or closed space, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular bleed with compartment syndrome",{'compartment syndrome'}
2480,353,Patient agrees to participate in the study and provides written informed consent.,{''}
2481,354,Creatinine clearance more than or equal to 30 ml/min calculated by the Cockcroft - Gault formula,{''}
2482,356,"Adequate organ function laboratory values, defined as",{''}
2483,358,have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrolment.,{''}
2484,359,Intention to reside in the geographical area for next 10 months and not intending to travel overseas for at least 30 days following the last study vaccine administration.,{''}
2485,361,Confirmed by self-report on the Demographic Questionnaire,{''}
2486,362,T-DXd (DS-8201a)-naive disease,{''}
2487,364,All tumours (Primary prostate and metastases) must be amenable to local ablative therapy (radiation and/or surgery).,"{'t, ##umour pro ##state'}"
2488,367,"pharmacologic/hormonal contraceptives, including oral, parenteral, subcutaneous, and transcutaneous delivery;",{''}
2489,370,cm height or taller,{''}
2490,371,"Examples of contraceptive methods with an expected failure rate of \< 1% per year include male sterilization and hormonal implants; alternatively, proper use of combined oral or injected hormonal contraceptives and certain intrauterine devices or two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of \< 1% per year (barrier methods must always be supplemented with the use of a spermicide)",{''}
2491,375,Patients acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator).,{'tumor'}
2492,376,Agree to taper and discontinue antidepressant medications during the 12-week trial.,{''}
2493,381,Women of childbearing age should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study; Men should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study period.,{''}
2494,385,No prior systemic anti-tumor therapy. 7.With at least one measurable lesion (RECIST 1.1 criteria) in the subject . 8.Expected survival ≥ 3 months. 9.ECOG 0/1. 10.Adequate organ function is determined by the following criteria,{'tumor'}
2495,388,Patient able to speak and understand French easily.,{''}
2496,391,Exclusion Criteria,{''}
2497,395,Agrees to comply with all study requirements,{''}
2498,396,Resides in United States (US) and will continue to reside in the US for the next 12 months,{''}
2499,399,Psychiatric or medical conditions that are judged by the investigators to interfere with participation or that are contraindicated for use with SUVO,{'##sy ##chia or medical conditions'}
2500,403,Gastric/Gastroesophageal Junction (GEJ) adenocarcinoma,{'Gas ##tric / Gas ##tro ##es ##op ##hage ##al Junction ( GE ##J ) ad ##eno ##car ##cin ##oma'}
2501,406,"Preoperative mRS ≤ 2, and NIHSS≤8;",{''}
2502,408,ECOG performance status \< 2.,{''}
2503,414,Male participant with female partner(s) of childbearing potential (including breastfeeding partner\[s\]) must agree to use contraception throughout the study period and for 28 days after IP administration.,{''}
2504,415,Exclusion Criteria,{''}
2505,416,"First in the family to test positive for PV at MSK in any of the following cancer susceptibility genes, or an ARR of an MSK proband who converted to the proband role","{'cancer, MS ##K'}"
2506,419,Non-aniridia (no clinical signs),{'an ##iri'}
2507,421,Is a first- or second-degree blood relative of an individual with a germline mutation in one of these genes and where the mutation carrier is also a first-degree relative to a PDAC case.,{'PD ##AC'}
2508,425,Reliable methods of contraception are,{''}
2509,426,"Subjects agree to arrive at all visits with a clean face, having washed his/her face and removed all facial and eye makeup products within 2 hours to 4 hours prior to the visit and is not to use/apply any topical facial product(s) until the visit is completed.",{''}
2510,427,Patients must agree to allow access to clinical records regarding response to treatment and long term follow up.,{''}
2511,431,Sufficient command of the German language as assessed by the investigator.,{''}
2512,432,Clinical stage noted above should be based upon following diagnostic workup,{''}
2513,434,"Patients with secondary, radiation related HGG are eligible.",{''}
2514,440,Adequate hematologic defined by the following laboratory results obtained within 11 days prior to first study treatment,{''}
2515,442,Triple-negative breast cancer (TNBC),"{'Triple - negative breast cancer, T ##NBC'}"
2516,457,Quinolones,{''}
2517,458,"Oligometastatic colorectal cancer (possible metastasis sites liver, lung, lymph nodes and peritoneum) with","{'O, ##li ##met color ##ec ##tal cancer'}"
2518,466,"Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)",{''}
2519,468,total bilirubin ≤ 1.5 mg/dL,{''}
2520,470,"Life expectancy, in the clinician's judgment, greater than 1 year.",{''}
2521,475,Patients who are not allergic to postoperative medications;,{''}
2522,476,"Absolute neutrophil count ≥ 1,500/mcL",{''}
2523,479,Individuals must have a confirmed diagnosis of Chronic Kidney Disease defined as a renal impairment of eGFR less than 60ml/min/1.73 m2.,"{'Ch ##ronic Kid ##ney Disease, re, ##nal imp ##air ##ment'}"
2524,480,"Adequate bone marrow, renal and hepatic function",{''}
2525,482,"Anti-PD-1/PD-L1 na""i""ve (Cohort 2 only).",{''}
2526,486,"Those with a high metabolic aerobic threshold according to the International Physical Activity Questionnaire (3000 METs and above),",{''}
2527,489,"For females of reproductive potential when sexually active, agreement to use highly effective contraception (oral contraceptive pill, intra-uterine device (IUD), or implant) during study participation;",{''}
2528,510,Rectal cancer,{'Re ##ct ##al cancer'}
2529,513,Free of ocular disease or abnormalities (including any corneal scar),"{'o, ##cular disease, abnormal ##ities, corn ##eal scar'}"
2530,523,Platelet count ≥ 100 x 109/L,{''}
2531,525,Other adverse events and patients who cannot continue cyclosporine treatment based on investigator's decision,{''}
2532,528,Patients who are already on statins for dyslipidemias are eligible if their previous statin is stopped at least 72 hour prior to starting VEN-based therapy; administration of other statins is prohibited during the study.,{'d ##ys ##lip ##ide ##mia'}
2533,530,"IT chemotherapy with cytarabine is allowed prior to registration for patient convenience; this is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture; (Note the CNS status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment); systemic chemotherapy must begin within 72 hours of this IT therapy",{''}
2534,532,Participants who do not have devices that will permit telehealth visits will be provided such tablet devices to facilitate appointments for the duration of the study,{''}
2535,539,Exuding lesion that requires wound dressings,{''}
2536,540,"Not having a diagnosed psychiatric history,",{''}
2537,541,Patient's refusal to participate in the study,{''}
2538,542,"Screening Group A At least 2 disease-causing variants in the PCDH15 gene which are homozygous or heterozygous in trans, based on a report from a clinically certified lab (or a report from a research lab that has been pre- approved by the Genetics Committee)",{''}
2539,547,"If partner is not sterilized, must agree to use highly effective contraceptive measuresfrom screening (V1) until 5 half lives after last dose of any study drug",{''}
2540,548,"Intolerance or inadequate response to conventional treatment (oral corticosteroid, azathioprine, 6-mercaptopurine, or methotrexate), biologics, or other approved advanced therapy (eg, JAK inhibitors) OR",{''}
2541,549,Patients must have at least one measurable metastatic lesion according to RECIST version 1.1;,{''}
2542,550,"Women of childbearing potential must use two forms of reliable contraception before starting 123I-ATT001 treatment, during therapy and for 6 months after receiving the last dose of 123I-ATT001. All male subjects must agree to not donate sperm during the study and for 6 months after the last dose of study drug.",{''}
2543,556,Each patient should have had an adequate medical evaluation to document the status of disease for the first five years after diagnosis. Follow-up should include an annual PSA and digital rectal examination. Records will be reviewed to seek all information about medical evaluation after the time of diagnosis.,{''}
2544,557,"Grade 2 or 3 OA in the index glenohumeral joint based on the Samilson-Prieto classification system as confirmed by X-ray (axillary view and true anterior-posterior view) taken at, or within 6 months of, the Screening Visit and read by the central reader.",{'O'}
2545,559,Prior Therapy Patients must have recovered or stabilized from the acute toxic effects of prior treatments,{''}
2546,561,Male subjects must refrain from sperm donation from check-in until 90 days following Day 21.,{''}
2547,564,"Subject agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form until completion of the last study visit.",{''}
2548,566,o Patients with INSS stage 3 are eligible with the following,{'IN ##SS'}
2549,569,"Failed at least 2 prior therapies including cytotoxic chemotherapy including ABVD or similar, autologous transplantation, brentuximab vedotin, allogenic transplantation without active graft versus host disease Note Patients who are eligible and willing to undergo autologous transplant should not be enrolled on this trial",{'g versus host disease'}
2550,1,Ability to understand and willingness to sign a written informed consent document,{''}
2551,4,Additional key eligibility criteria immediately postoperative for inclusion in the randomized population include,{''}
2552,8,Access to a mobile smartphone.,{''}
2553,10,"Patients must not have breast enhancements (e.g., implants or injections)",{''}
2554,14,Be \>= 18 years of age on day of signing informed consent,{''}
2555,15,Abnormalities detected on routine screening,"{'A, ##b'}"
2556,19,"Possesses, or obtains prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.",{''}
2557,20,A cooperative attitude to follow up the study procedures,{''}
2558,23,Absolute neutrophil count ≥ 1.0×10\^9/L (1000/mm3) (without receiving granulocyte-colony stimulating factor),{''}
2559,24,Subjects must require an IOL power from +18.0 diopter (D) to +26.0 D in both eyes.,{''}
2560,27,Exclusion Criteria,{''}
2561,29,Women of childbearing potential must have a negative pregnancy test at Screening.,{''}
2562,34,"In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.",{''}
2563,38,Signed informed consent,{''}
2564,44,SpO2 \>92%,{''}
2565,47,Participants must fulfill mutation status and EYO criteria,{''}
2566,49,"Resolution of adverse effects of recent surgery, radiotherapy, or chemotherapy to Grade ≤ 1 prior to first study treatment (with the exception of alopecia or clinically insignificant laboratory values).",{'al ##ope ##cia'}
2567,56,generalized anxiety disorder,{'generalized anxiety disorder'}
2568,58,Patients had one or more prior lines of chemotherapy. The last line of chemotherapy should have included platinum and has resulted in a partial or complete response.,{''}
2569,60,"No blood transfusion and no use of cell growth factors and/or platelet-raising drugs within 14 days before screening, and the organ function level must meet the requirements;",{''}
2570,63,All visible papillary Ta/T1 tumors must be completely resected within 60 days prior to enrollment.,"{'p, Ta / T ##1 tumors'}"
2571,64,Providing psychotherapy services to children,{''}
2572,65,Six months or more experience on a prosthesis,{''}
2573,68,Participation in another Pediatric Weight Management Clinic study,{''}
2574,73,Prior taxane treatment,{''}
2575,74,"Patient has newly diagnosed B-cell ALL, with or without Down syndrome \> 25% blasts on a bone marrow (BM) aspirate;","{'B - cell AL ##L, Down syndrome'}"
2576,75,Age- and gender-appropriate cancer screenings are up-to-date and completed.,{'cancer'}
2577,76,"Use of medications for more than one week in the past three months, or inability to avoid continuous use during the study period, that may affect colorectal polyps, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), ω-3 polyunsaturated fatty acids, rapamycin, and curcumin.",{'color ##ec ##tal p ##oly ##ps'}
2578,86,)Normal cardiac function with cardiac ejection index \>55%;,{''}
2579,93,Owns a mobile phone that can send/receive short-message service (SMS) text messages,{''}
2580,94,Agreement to adhere to study visits and procedures,{''}
2581,96,Has adequate organ function,{''}
2582,98,Patient must be enrolled on AHEP0731 prior to initiating protocol therapy; a patient will be ineligible if any chemotherapy is administered prior to AHEP0731 enrollment,{''}
2583,100,An Investigator's Global Assessment (IGA) score of ≥3 at screening and at baseline.,{''}
2584,105,Willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of study drug(s),{''}
2585,109,"The effects of radiation on the developing human fetus are not well described. For this reason, women of child-bearing potential and non-sterilized men who are sexually active with a woman of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. FCBP must be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of \<1% per year when used consistently and correctly) from the time of informed consent until 5 days after last dose of SBRT. Contraceptive methods with low user dependency are preferable but not required.",{''}
2586,111,Able to provide valid written informed consent,{''}
2587,117,"WOCBP must agree to use a highly effective method of contraception during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 6 months after the last dose of 177Lu-RAD204tr, whichever occurs later. Acceptable methods of contraception are described the Protocol.",{''}
2588,118,"The tumor tissue has lost the ability to concentrate RAI on a whole body scan following radioiodine administration after previous evidence of uptake at any earlier timepoint,",{'tumor'}
2589,122,Male participant must not donate sperm during the treatment period and for 28 days after IP administration.,{''}
2590,125,For patients of reproductive potential use of condoms or other methods (including abstinence) to ensure effective contraception with partner during radiotherapy and through 4 months after the last dose of the study drug or radiotherapy,{''}
2591,130,Willing to comply with intensive diabetes management and wear a Continuous Glucose Monitoring Device (CGM),{''}
2592,132,willing to take urine pregnancy test if they are perimenopausal.,{''}
2593,138,English-speaking,{''}
2594,139,Diagnosed with T2D with hemoglobin A1c (HbA1c) \< 8% level.,{'T ##2 ##D'}
2595,146,Subject agrees not to participate in another interventional study while on treatment,{''}
2596,147,Abdominal CT scan shows changes in liver shape and/or portal hypertension symptoms.,{'portal h ##yper ##tens ##ion'}
2597,148,"PSA ≥ 0.2 ng/ml (0.2 ug/L) within 14 days of enrollment. If there is any rise in PSA since starting ADT and achieving castrate-level testosterone, PSA must be repeated and must not fulfill ineligibility criteria 4.2.1.",{''}
2598,151,"Cohort A Subjects with G/GEJ adenocarcinoma who have no option of or are intolerable to SOC; Cohort B Subjects with ductal adenocarcinoma of pancreas who have no option of or are intolerable to SOC; Cohort E Subjects with other locally advanced or metastatic solid tumors excluding G/GEJ adenocarcinoma (limited to biliary tract neoplasms, lung adenocarcinoma or colorectal cancer) who have no option of or are intolerable to SOC; Part II - Dose escalation and expansion phase for combination medication","{'G / GE ##J ad ##eno ##car ##cin ##oma, duct ##al ad ##eno ##car ##cin ##oma of pan ##cre ##as solid tumors, G / GE ##J ad ##eno ##car ##cin ##oma, bi ##lia ##ry tract neo ##p ##las ##ms, lung ad ##eno ##car ##cin ##oma, color ##ec ##tal cancer'}"
2599,154,Freezer at home.,{''}
2600,157,Subjects who understood the purpose and risks of the questionnaire development and who were well-acquainted with the contents and submitted the written consent to participate in the interview for the questionnaire development.,{''}
2601,159,"Age \>=18 years. Because no dosing or adverse event data are currently available on the use of cabozantinib and nivolumab in patients \< 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials",{''}
2602,161,Have a stored sample of serum or plasma that is known to contain detectable HCV RNA and which can be made available to the study team or be willing to provide such a sample,{'HC'}
2603,162,"Absolute neutrophil count ≥ 1,500/mcL",{''}
2604,164,length \< 20 cm,{''}
2605,172,"Have a diagnosis of active PsA for at least 6 months (based on a detailed medical history provided by the patient, and a physical exam by the Study Investigator, and/or other evidence such as that provided by joint x-rays, that establishes a history consistent with a diagnosis of active PsA of at least 6 months' duration) and currently meet the Classification for PsA (CASPAR) criteria.",{'P ##s ##A'}
2606,179,Male participants who receive ATRA are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 7 days after the last dose of ATRA,{''}
2607,184,ECOG Score of 0-2,{''}
2608,185,"Agreement to abide by the protocol indicated contraception use, including refraining from donating sperm or eggs (ova, oocytes), as appropriate for the age and sexual activity of pediatric, adolescent, and young adult participants and as required by local regulations.",{''}
2609,186,An ECOG PS score of 0 or 1.,{''}
2610,187,Score = 1 Above blood pool and lower than liver,{''}
2611,189,Wilms tumor,{'W ##il ##ms tumor'}
2612,190,WHO performance status 0-1,{''}
2613,196,Symptomatic subjects with no previous knee injury,{''}
2614,197,Exclusion Criteria,{''}
2615,200,Primary endothelial decompensation,{'Primary end ##oth ##eli ##al de ##com ##pen ##sation'}
2616,204,Are too cognitively impaired to provide informed consent and/or complete study protocol,{''}
2617,205,"Must have weighed at least 50 kg to participate in the study and must have had a body mass index (BMI) within the range of 18.0 to 35.0 kg/m2, inclusive, at Screening.",{''}
2618,206,Female participant must not donate ova starting at first dose of IP and throughout the study period and for 28 days after final IP administration.,{''}
2619,218,Positive bilateral transient evoked otoacoustic emissions,{''}
2620,220,"Participants who can become pregnant must agree to use two methods of contraception, one of which must be from the highly effective methods for contraception listed below. Barrier methods of contraception are permitted for the second method of contraception. Contraception must be used from 10 days prior to the first of the investigational products (IP), while receiving the IPs, for 12 months after the last IP dose and until ART is reinitiated and viral suppression is achieved.",{''}
2621,221,--Up to one cycle of platinum doublet chemotherapy with or without durvalumab is allowed up to 4 weeks prior to registration on this study. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab and monalizumab may be included only after consultation with the sponsor-investigator. Patients should not have received trilaciclib.,{''}
2622,223,Hormonal methods or intrauterine device in use \> 90 days prior to study drug administration;,{''}
2623,225,Eastern Cooperative Oncology Group Performance Status 0 or 1,{''}
2624,229,Aspartate aminotransferase/alanine transferase ≤ 2.5 X institutional upper limit of normal.,{''}
2625,233,Sedentary status (self-report \< 30 minutes/week regular exercise).,{''}
2626,234,Intolerance refers to the refusal of patients to continue the original regimen due to grade 3-4 adverse reactions after receiving standard treatment.,{''}
2627,237,"Participants receiving treatment with protocol-specified immunosuppressive therapies, corticosteroids, or acetylcholinesterase inhibitors must have been receiving treatment and on a stable dose prior to the date of the Screening Visit, with no changes to the regimen expected during screening, the PEP, and/or the ETP.",{''}
2628,249,Concurrent SSA use while on protocol therapy is allowed provided that the subject 1) has a functional tumor and 2) has previously demonstrated radiographic disease progression while on SSA therapy.,{'tumor'}
2629,258,Any nodal or extranodal mass ≥ 7 cm in diameter,{''}
2630,259,Patients with mixed histiocytic disorders (e.g. LCH with juvenile xanthogranuloma) may be included,"{'his ##ti ##oc ##ytic disorders, L ##CH, juvenile x ##ant ##hog ##ran ##ulo ##ma'}"
2631,261,Vaginal cellular cytology with ≤ 5% superficial cells.,{''}
2632,265,Standard chemotherapy/trastuzumab declined by patient OR patient is deemed by physician for any reason to not be a candidate for standard therapy (i.e. patient and/or provider choose not to pursue standard trastuzumab-based chemotherapy regimen because of concerns related to toxicity or provider/patient preference).,{''}
2633,272,Karnofsky performance status ≥ 70% or Lansky play score 50% for ≤16 years of age.,{''}
2634,277,Disease-free interval of at least 12 months after completion of adjuvant paclitaxel or platinum compound therapy,{''}
2635,281,G464V/E,{''}
2636,288,<!-- -->,{''}
2637,291,Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 or Karnofsky Performance Status 70-100 (Appendix III).,{''}
2638,293,"Subject meets the ACR 1991 Revised Criteria for the Classification of Global Functional Status in RA Class I, II, or III.",{''}
2639,309,"Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (see Section 12, Appendix A).",{''}
2640,311,BMI from 23-28 kg/m2 -,{''}
2641,313,Information and signature of informed consent prior to any specific study procedure,{''}
2642,318,influenza,{''}
2643,324,Patient must agree to provide tumor tissue,{'tumor'}
2644,326,"Absolute neutrophils ≥1,000/mm3,",{''}
2645,327,Patients are eligible for this trial either at presentation for primary melanoma with concurrent regional nodal metastasis; or at the time of clinical detected nodal recurrence; and may belong to any of the following groups,{'##lan ##oma'}
2646,328,Normal or corrected-to-normal vision based on the minimal 20/20 standard in order to complete the cognitive tasks (below 20/20 vision).,{''}
2647,331,"Subjects must have received ≥ 2 lines of prior therapy that must include a proteasome inhibitor (PI), lenalidomide, and where approved and available a CD38-directed antibody. These therapies may be in the same line or separate lines of treatment.",{''}
2648,332,Hepatic Serum total bilirubin ≤1.5 × upper limit of normal (ULN); or direct bilirubin ≤ULN for patients with total bilirubin levels \>1.5 × ULN,{''}
2649,335,Is willing to receive weekly study text messages for 4 consecutive weeks,{''}
2650,337,The total score of HIS ≤ 4;,{''}
2651,340,CD10-negative T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) OR,"{'T, ##H ##RL ##BC ##L'}"
2652,343,≥18 years of age,{''}
2653,344,Must have no major impairment of liver function Alanine aminotransferase (ALT) ≤ 2.5 × the upper limit of the normal range (ULN); bilirubin ≤ 1.5 × ULN. Exceptions,{'imp ##air ##ment of liver function'}
2654,346,Enrollment on or following treatment per ANBL07P1,{''}
2655,347,"Platelets \>= 100,000/uL",{''}
2656,350,"Moderate exacerbations are defined as an acute worsening of respiratory symptoms that requires either systemic corticosteroids (intramuscular \[IM\], intravenous \[IV\], or oral) and/or antibiotics.",{'respiratory symptoms'}
2657,352,"Visible, uncontrolled bleeding associated with a corrected hemoglobin level \< 8.0 g/dL, a fall in hemoglobin level of ≥ 2.0 g/dL (1.24 mmol/L) from a known baseline, or requirement for transfusion of 2 or more units of packed red blood cells (PRBC)",{''}
2658,354,Subjects must have adequate cardiac function as defined as left ventricular ejection fraction ≥ 40% on the most recent echocardiogram.,{''}
2659,356,Absolute neutrophil count (ANC) ≥ 1.5 x 109/L or at least 1500/mm3 or at least 1.5 x 109/L,{''}
2660,358,Provision of a newly obtained tumour biopsy (either from the primary tumour or from metastases) during screening and on-treatment from all patients \>16 years of age. Notes,{'t'}
2661,359,Agree not to participate in any other clinical trial during the trial.,{''}
2662,361,INTERVENTION (SURVIVORS AND PARTNERS) INCLUSION,{''}
2663,362,"Received prior trastuzumab-based treatment, if eligible for such treatment",{''}
2664,364,Age ≥ 18,{''}
2665,367,condoms or diaphragm with spermicide;,{''}
2666,370,Written informed consent,{''}
2667,371,"Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately",{''}
2668,375,Ability to take oral medication,{''}
2669,376,Able to provide informed consent and comply with study procedures.,{''}
2670,385,"Hematological (no transfusions or growth factor support allowed within 7 days before the first dose)Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L (1,500/mm³); Platelet count ≥ 100 × 10\^9/L (100,000/mm³);Hemoglobin ≥ 90 g/L or ≥ 5.6 mmol/L.",{''}
2671,391,Trial-wide,{''}
2672,395,"If currently on a waiting list for sinonasal surgery, willing to be removed from the waiting list or have preplanned surgery date cancelled for the duration of the study. \[Note this does not preclude a participant from receiving or being recommended for sinonasal surgery as rescue treatment during the study\].","{'sin, sin'}"
2673,396,Has at least daily access to their own smartphone,{''}
2674,399,Pregnant or breastfeeding,{''}
2675,403,The following tumor types will be recruited to the BAY 2965501 and pembrolizumab combination expansion cohorts,{'tumor'}
2676,406,Patients whose life expectancy is greater than 12 months as assessed by the investigator.,{''}
2677,408,Adequate bone marrow function neutrophils ≥1.5 x109 / L; platelets ≥100 x109 /L; haemoglobin ≥ 9 g/dL.,{''}
2678,414,Male participant must not donate sperm during the study period and for 28 days after IP administration.,{''}
2679,415,Planned deceased donor liver transplantation,{''}
2680,416,APC I1307K GREM1 RAD51D ATM MLH1 SMAD4 BARD1 MSH2 BMPR1A MSH6 BRCA1 PALB2 BRCA2 PMS2 BRIP1 POLD1 CDKN2A (P16) POLE CHEK2 PTEN EPCAM RAD51C,{''}
2681,419,Weighing more than 40 kg,{''}
2682,421,OR,{''}
2683,425,Hormonal methods or intrauterine device in use \> 90 days prior to study drug administration;,{''}
2684,426,"No known medical conditions that, in the investigator's opinion, may interfere with study participation.",{''}
2685,427,Ability to understand and the willingness to sign a written informed consent document.,{''}
2686,431,"Presence of a personal smartphone with iOS or Android system. The operating system must be updated to the latest, second or third most recent major version and the medidux™ app must be installed prior to the start of the first treatment cycle.",{''}
2687,432,History/physical examination within 30 days prior to registration;,{''}
2688,434,"Prior Therapy for HGG Surgery, radiation, and/or dexamethasone are permissible. Temozolomide concurrent with radiation is permissible, but not recommended. No other prior anticancer therapy for HGG will be allowed.",{'H'}
2689,440,Absolute neutrophil count (ANC) ≥1.5 k/mcl,{''}
2690,442,Hepatocellular carcinoma (HCC),"{'He, ##pa ##to ##cellular car ##cin ##oma, HC ##C'}"
2691,457,Tetracyclines,{''}
2692,458,"i. Initially resectable disease according to the local MTB or ii. Initially unresectable but potentially resectable disease according to the local MTB c. Stage II-IV colorectal cancer treated with previous neoadjuvant and/or adjuvant chemotherapy, for R0, if the shorter time from the resection or from the end of the adjuvant treatment to the relapse of colorectal cancer (possible metastasis sites liver, lung, lymph nodes and peritoneum) is longer than 6 months. This relapse (locoregional and/or systemic) should be initially resectable or initially unresectable but potentially resectable disease according to the local MTB 8. ECOG performance status of 0 or 1. 9. Measurable or evaluable disease as assessed by investigator, according to RECIST v1.1.","{'color ##ec ##tal cancer, color ##ec ##tal cancer'}"
2693,466,Intrauterine device (IUD),{''}
2694,468,creatinine ≤ 1.5 mg/dL,{''}
2695,475,Patients who haven't accepted other antibiotic or probiotic therapy.,{''}
2696,476,"Platelets ≥ 100,000/mcl",{''}
2697,479,Individuals receiving background standard of care for HF and treated according to international guidelines. Specific treatment should include RAASi and/or MRA treatment and at least should have been stable for ≥ 4 weeks at maximum tolerated doses.,{'H ##F'}
2698,480,Able and willing to give valid written consent for available archival tumor samples (mandatory) and tumor biopsies before and during protocol (immune)therapy (optional in escalation phase and mandatory in expansion phase).,"{'tumor, tumor'}"
2699,482,One lesion suitable for repeat biopsy without significant risk to the patient.,{''}
2700,486,"Students who answered ""Yes"" to any of the 7 questions in the General Health Questions section of the Exercise Readiness for All Questionnaire,",{''}
2701,489,For males of reproductive potential use of condoms or other methods to ensure effective contraception with partner.,{''}
2702,510,Anal cancer,{''}
2703,513,Currently have good general health.,{''}
2704,523,Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN),{''}
2705,528,ECOG performance status ≤ 2 at baseline.,{''}
2706,530,"Patients diagnosed as having T-NHL or T-ALL with respiratory distress or hyperleukocytosis may require steroids prior to the initiation of additional systemic therapy; they are eligible for AALL0434 and will be stratified, based on the initial complete blood count (CBC); steroid pretreatment may alter the risk group assessment; if the T-ALL patient's clinical status precludes a lumbar puncture within 48 hours of the initiation of steroid therapy, T-ALL patients CANNOT be classified as low risk and will be Intermediate or high risk based on the results of the day 29 marrow as above; patients with T-NHL who receive steroid pre-treatment will be classified as high risk; the dose and duration of previous steroid therapy should be carefully documented","{'T - NHL, T - AL ##L, respiratory distress, h ##yper ##le ##uk ##oc ##yt ##osis, T - AL ##L, T - AL ##L, T - NHL'}"
2707,532,Participants who do not have financial resources to travel for in-person visits will be provided assistance for cost of travel,{''}
2708,540,"Being able to read and write Turkish,",{''}
2709,542,"Screening Group B Only 1 disease-causing variant in the PCDH15 gene, based on a report from a clinically certified lab (or a report from a research lab which has been pre-approved by the Genetics Committee)",{''}
2710,547,Participants must fulfill mutation status and EYO criteria,{''}
2711,548,Corticosteroid dependency (defined as inability to taper below budesonide 6 mg/day or prednisolone 10 mg/day without recurrent active disease) for the treatment of Crohn's disease.,"{""Co depend, C ##ro ##hn ' s disease""}"
2712,549,Normal organ function,{''}
2713,550,"Be able to understand and comply with the requirements of the study, as judged by the Investigator.",{''}
2714,557,Average daily mean pain score ≥4.0 and ≤9.0 in index shoulder (0-10 numeric rating scale \[NRS\]) using the average daily ratings for at least 4 out of the 7 days prior to Baseline/Day 1.,{''}
2715,559,"Biologic (anti-neoplastic agent) At least 7 days must have elapsed after the last (systemic or intracystic) dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair",{''}
2716,561,Additional,{''}
2717,566,"MYCN amplification, regardless of age or additional biologic features OR",{''}
2718,569,Prior cancer treatment must be completed at least 14 days prior to registration and the patient must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤Grade 1 or baseline. Radiation therapy must be completed at least 7 days prior to registration.,"{'cancer, al ##ope ##cia'}"
2719,4,Stage \>pT3a (tumor has extended outside of the prostate on one side).,{'tumor'}
2720,8,For females of reproductive potential use of highly effective contraception for at least 4 weeks prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of study drug administration.,{''}
2721,10,ANNUAL SCREENING REGIMEN ELIGIBILITY CHECK,{''}
2722,14,Have a performance status of 0 or 1 on the on the Eastern Cooperative Oncology Group (ECOG) performance scale,{''}
2723,15,Individuals who participate in a structured aerobic exercise training program at moderate to high intensities.,{''}
2724,20,In case of bilateral disease only one eye will be included,{'bilateral disease'}
2725,23,Platelet count ≥ 50×10\^9/L (without transfusion),{''}
2726,24,"Subjects must be willing and able to comply with all treatment and follow-up Clinical Investigation visits and procedures, and to undergo second eye surgery on the same day as the first eye surgery. Illiterate subjects must be able to identify letters as required for the assessments.",{''}
2727,27,Unable to provide informed consent (e.g. impaired cognition or judgment),{''}
2728,29,"Non-pregnant, non-lactating women who are postmenopausal, naturally or surgically sterile, or who agree to use acceptable contraceptive methods throughout the course of the study.",{''}
2729,44,Not pregnant,{''}
2730,47,"Participant is a carrier of a mutation in an APP, PSEN1, or PSEN2 gene that is associated with DIAD or does not know their mutation status and there is a mutation in their family pedigree that puts them at a direct risk of inheriting the known mutation;",{'D ##IA ##D'}
2731,49,"Patients must have measurable disease. Measurable disease is defined by RECIST (version 1.1). Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each non-nodal lesion must be 10 mm when measured by CT, MRI or caliper measurement by clinical exam; or 20 mm when measured by chest x-ray. Lymph nodes must be ≥ 15 mm in short axis when measured by CT or MRI.",{''}
2732,56,PTSD,{'PT'}
2733,58,"Major surgery (not including placement of vascular access device, tumor punch/scrape biopsies or secondary wound closure) must be completed four weeks prior to Day 1.",{'tumor'}
2734,60,The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;,{''}
2735,63,"Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2.",{''}
2736,64,Has an eligible child on current caseload (see below),{''}
2737,65,Body weight between 50kg and 116kg (110lbs - 256lbs),{''}
2738,68,Developmental delay,{'Development delay'}
2739,73,"Dose Escalation Participants must either have had prior treatment with at least 1 but no more than 2 taxane regimens, or been deemed ineligible for or refused taxane therapy on consultation with their physician",{''}
2740,74,"OR if a BM aspirate is not obtained or is not diagnostic of B-ALL, the diagnosis can be established by a pathologic diagnosis of B-ALL on a BM biopsy;","{'B - AL ##L, B - AL ##L'}"
2741,75,"Patient and/or patient's legally authorized representative has the ability to understand the purpose and risks of the study, and provide written informed consent and authorization to use protected health information.",{''}
2742,76,"Use of medications for more than one week in the past three months, or inability to avoid continuous use during the study period, that may affect vitamin B1 absorption, metabolism, or excretion, including aminoglycoside antibiotics, thiazide diuretics, oral contraceptives, antiepileptic drugs, and antituberculosis drugs.",{'##tub ##er ##cu ##los ##is'}
2743,86,)No bleeding and coagulation disorders;,"{'bleeding, co ##agu ##lation disorders'}"
2744,93,Agrees to participate in the intervention that lasts three months,{''}
2745,94,For pediatric active cohort,{''}
2746,96,Female participants agree to abstain from breastfeeding during the study intervention period and for at least the time needed to eliminate study intervention after the last dose of study intervention. The length of time required for each study intervention is,{''}
2747,98,"If the patient receives AHEP0731 chemotherapy PRIOR to undergoing a diagnostic biopsy, pathologic review of material obtained in the future during either biopsy or surgical resection must either confirm the diagnosis of hepatoblastoma or not reveal another pathological diagnosis to be included in the analysis of the study aims","{'he, ##pa ##to ##blast ##oma'}"
2748,100,Emollient twice daily (or more) for at least 14 days prior to baseline.,{''}
2749,109,"As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study",{''}
2750,111,Normal organ and marrow function,{''}
2751,117,"Male subjects who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 6 months after the last dose of 177Lu-RAD204tr, whichever occurs later. All male subjects must agree to not donate sperm during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 4 months after the last dose of Lu-RAD204tr, whichever occurs later. Acceptable methods of contraception are described in the Protocol.",{''}
2752,118,RAI is taken up in some but not all tumor deposits on a whole body scan following radioiodine administration and/or,{'tumor'}
2753,122,Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 28 days after IP administration.,{''}
2754,125,Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration,{''}
2755,130,Participants who are Cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) seronegative at screening must be CMV and/or EBV Polymerase chain reaction (PCR) negative within 30 days of randomization and may not have had signs or symptoms of a CMV and/or EBV-compatible illness lasting longer than 7 days within 30 days of the baseline visit (V0).,"{'Cy ##tom ##eg ##alo ##virus, C, E ##ps ##tein - Barr virus E ##B, C E, C ##M ##V and / or E ##B ##V - compatible'}"
2756,138,Oncologists,{''}
2757,139,Parts B1 and B3,{''}
2758,147,Patients who meet any of 1) to 3) for anti-HCV therapy.,{''}
2759,148,Candidate for docetaxel chemotherapy,{''}
2760,151,Dose escalation study of combination medication (dose escalation part),{''}
2761,154,Affiliation to a social security scheme.,{''}
2762,157,Selection criteria for validation stage subjects,{''}
2763,159,Eastern Cooperative Oncology Group (ECOG) performance status 0-2,{''}
2764,161,"Have undergone, or be willing to undergo, an approved screening test for determining liver cirrhosis either by",{'liver c ##ir ##r ##hos ##is'}
2765,162,"Platelets ≥ 100,000/mcL",{''}
2766,164,"If participants are using a treatment for CD, they should be on a stable dose for at least 3 months prior to study commencement. Acceptable treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and anti-inflammatory biologics.",{'CD'}
2767,172,"Have active PsA defined as the presence of at least 3/68 tender and at least 3/66 swollen joints, as determined by the Tender and Swollen Joint Count Assessment Form at screening and baseline.","{'P ##s ##A, Ten, ##der and S ##wo ##llen Joint'}"
2768,179,"Female participants are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) OR use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after the last dose of pembrolizumab, vibostolimab, gebasaxturev, or MK-4830, favezelimab + pembrolizumab, or 30 days after the last dose of ATRA, whichever occurs last",{'W'}
2769,184,Assigned by the physician to receive either docetaxel or immune checkpoint inhibitor per standard of care regimen,{''}
2770,185,Signed informed consent and assent when applicable.,{''}
2771,186,An expected survival ≥ 12 weeks.,{''}
2772,187,Score = 2 Equal to or above liver and lower than spleen,{''}
2773,189,Rare tumors,{''}
2774,190,Life expectancy ≥12 weeks,{''}
2775,196,"Subjects without concomitant pathologies (fracture, infections, immunodepression, HIV, HCV) that could influence the outcome of the study or prevent the subject from following the post-operative follow-up program as per protocol","{'fracture, infections, im ##mu ##no ##de ##press ##ion, HIV, HC'}"
2776,197,Trial-wide,{''}
2777,200,At least one contraindication to endothelial transplantation,{''}
2778,204,Are institutionalized or too ill to participate (i.e. mental or nursing home facility or incarcerated),{''}
2779,205,Seated vital signs must have been within the following ranges at Screening and Baseline,{''}
2780,206,Male participant with female partner(s) of childbearing potential (including breastfeeding partner\[s\]) must agree to use contraception throughout the treatment period and for 28 days after final IP administration.,{''}
2781,218,Stable clinical condition,{''}
2782,220,"Participants who can impregnate a partner and who are engaging in sexual activity that could lead to pregnancy must agree to use condoms from 10 days prior to the first dose of the investigational products (IP), while receiving the IPs, and for 12 months after the last IP dose to avoid impregnating a partner who can get pregnant.",{''}
2783,221,Measurable disease according to RECIST v1.1,{''}
2784,223,Barrier methods plus spermicide in use at least 14 days prior to study drug administration; or,{''}
2785,225,Resolution of all acute toxic effects of prior therapy or surgical procedure to Grade \<= 1 or baseline prior to randomization,{''}
2786,229,Serum creatinine \< 1.5 mg/dL.,{''}
2787,233,"Lean, physically active",{''}
2788,234,Note Recurrence or disease progression within 6 months after the last chemotherapy of multimodal therapy was considered as the first line of treatment.,{''}
2789,249,"Long-acting somatostatin analogues are allowed but should be withheld within 30 days prior to \[68Ga\]DOTATATE PET/CT (or another SSTR2-PET), if clinically possible. Short acting somatostatin analogues should be withheld for 24 hours.",{''}
2790,258,Involvement of ≥ 3 nodal sites ≥ 3 cm,{''}
2791,259,"Patients must have measurable disease, documented by radiographic imaging (LCH- specific response criteria (must be obtained within 28 days prior to enrollment and start of protocol therapy) (repeat if necessary).",{''}
2792,261,Vaginal pH \> 5 at Screening Visit.,{''}
2793,265,"For patients with bilateral or multifocal/multicentric breast cancers, one of the following criteria must be met to enroll (1) each cancer individually meets criteria for enrollment (only ONE tumor has to undergo central confirmation for HER2), (2) at least one tumor meets eligibility (per tumor size/nodes/subtype outlined above) and the other foci in the ipsilateral or contralateral breast are also HER2-positive but are too small for enrollment (e.g., a patient is eligible if a cancer is T2N0 and HER2-positive in one breast, but the contralateral breast has a T1a HER2+ cancer that isn't eligible on its own, (3) there is at least one qualifying tumor of \>5mm but there are other small foci of disease that are too small to test for ER/PR/HER2 and are felt to be a part of the same tumor or similar tumor, OR (4) at least one tumor meets eligibility and the other foci in the ipsilateral or contralateral breast are HER2-negative and do not meet criteria for adjuvant chemotherapy per provider discretion (e.g. if a patient has a HER2-positive tumor meeting eligibility but also has a second, HER2-negative, small, node-negative, ER+, low grade cancer present, she is still eligible for enrollment). However, in the specific case that a second breast cancer is stage III and HER2-negative, that patient is excluded (because the second cancer is high-risk and likely will require non-HER2-directed therapy).","{'bilateral or multi ##fo ##cal / multi ##centric breast cancer, low grade cancer, breast cancer'}"
2794,272,Adequate organ function,{''}
2795,277,Disease-free interval of at least 6 months after completion of adjuvant docetaxel,{''}
2796,281,G469A/V/R,{''}
2797,288,Liver stiffness measurement (LSM) ≥ 7.5kPa by vibration-controlled transient elastography (VCTE) within 24 months before enrollment;,{''}
2798,291,"Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study, IRB 15-000136",{''}
2799,293,Subject has inadequate response or intolerance for MTX.,{''}
2800,309,Demonstrate adequate organ function as defined by the parameters listed below,{''}
2801,318,Exclusion Criteria,{''}
2802,326,"Platelets ≥75,000/mm3,",{''}
2803,327,Primary cutaneous melanoma with clinically apparent regional lymph node metastases.,{''}
2804,328,"Able to speak, read, and write English.",{''}
2805,331,Subjects must have responded to at least 1 prior line with at least a PR.,{''}
2806,332,Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (ALT and AST ≤ 5 × ULN for subjects with liver metastases),{'liver'}
2807,335,"Is willing to provide contact information including phone number (for text messages and reminders), email (reminders), and mailing address (payment)",{''}
2808,337,The total score of Hamilton Depression Scale (HAMD 17 item version) is ≤ 10;,{''}
2809,340,CD10-positive or negative HGBCL with MYC and BCL2 rearrangements (with or without BCL6 rearrangement) (HGBCL-DH-BCL2),{''}
2810,343,KPS ≥70,{''}
2811,344,Liver metastases ALT ≤ 5 × ULN; bilirubin ≤ 3 × ULN;,{''}
2812,346,Tandem transplant patients are eligible,{'Tan transplant'}
2813,347,Hemoglobin \>= 10.0 g/dl,{''}
2814,350,Severe exacerbations are defined as AECOPD that require hospitalization or observation for \>24 hours in emergency department/urgent care facility.,"{'A, ##EC ##OP ##D'}"
2815,352,Patients requiring urgent surgery or invasive procedure when it is not medically advisable either to proceed urgently with impaired hemostasis or to delay the urgent procedure for 3 or more days due to the high risk of bleeding. These patients may typically be in any of the following clinical situations,{''}
2816,354,Adequate pulmonary function with pulse oximetry ≥92% on room air,{''}
2817,356,"Platelet count at least 75,000/mm3 or at least 75 x 109/L",{''}
2818,358,The identified lesion to be biopsied should not have been previously irradiated and should not be the only lesion being used as a measurable-disease target lesion for objective response assessment. Patients must have tumour lesions that can be accessible for biopsy with acceptable clinical risk in the judgement of the Investigator.,{'t'}
2819,359,Agree not to donate blood for the duration of the trial.,{''}
2820,361,years of age and older,{''}
2821,362,"For the dose escalation and dose expansion, patients can have evaluable or measurable disease",{''}
2822,364,ECOG performance 0-2,{''}
2823,367,intrauterine device;,{''}
2824,371,"Should a female partner of a male study participant become pregnant while the male participant is on study, the male participant should inform his study physician immediately",{''}
2825,375,Patients must have adequate organ and marrow function defined by study-specified laboratory tests,{''}
2826,376,Able to read English and understand study instruments.,{''}
2827,385,"LiverSerum albumin ≥ 28 g/L (no albumin infusions allowed within 14 days before the first dose);Total bilirubin (TBil) ≤ 1.5 × ULN; for subjects with liver metastases or evidence/suspicion of Gilbert's disease, TBil ≤ 3 × ULN; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; for subjects with liver metastases, AST and ALT ≤ 5 × ULN.","{""Gilbert ' s disease""}"
2828,391,Life expectancy less than 12 months,{''}
2829,396,Has text messaging on their smartphone and knows how to download a smartphone application,{''}
2830,399,"Current use of benzodiazepines, tranquilizers, or other schedule IV sleep medications",{''}
2831,403,NSCLC participants with tumors that are TPS score ≥50% PDL-1 high (based on local historical testing) and are eligible for standard of care anti-PD(L)-1 monotherapy in the first line incurable treatment setting.,"{'N ##SC ##LC, tumors'}"
2832,406,"Patients or their guardians can understand the trial purpose, voluntarily participate in and sign the informed consent form, and can accept follow-up visits.",{''}
2833,408,"Hepatic, renal and metabolic function as follows",{''}
2834,414,Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 28 days after IP administration.,{''}
2835,415,Uncontrolled / unresolved local or systemic infection,{''}
2836,416,Principal Investigator discretion will be used to determine whether specific variants within the above genes meet a clinical actionability threshold to warrant familial genetic testing.,{''}
2837,419,Matched to a case for sex and age +/-5 years,{''}
2838,421,Is a blood relative to a PDAC patient in a family that contains three blood relatives (all maternal side or all paternal side) with PDAC.,"{'PD ##AC, PD ##AC'}"
2839,425,Barrier methods plus spermicide in use at least 14 days prior to study drug administration; or,{''}
2840,426,"Women of childbearing potential must be willing to use a form of birth control during the study. For the purpose of this study, the following are considered acceptable methods of birth control oral contraceptives, Norplant, Depo-Provera, double barrier methods (e.g., condom and spermicide) and abstinence.",{''}
2841,431,"\* HER2-positive in the context of the study defined as ""eligible for an approved HER2-targeted therapy,"" i.e., in addition to immunohistochemistry (IHC) scores of 3+ and 2+ with positive results of in-situ hybridization (ISH+), also according to new standard HER2 low (IHC 1+ and 2+ with simultaneous negative result of in-situ-hybridization (ISH-))",{''}
2842,432,"Examination by radiation oncologist or medical oncologist or otolaryngology (ENT) or head \& neck surgeon 30 days prior to registration, including fiber optic exam with laryngopharyngoscopy;",{'head \\ & neck'}
2843,434,"Timing from surgery to start of RT For patients who have started RT, radiation must have started within 31 days of definitive surgery or biopsy (if patient had two surgeries, radiation must have started within 31 days from second surgery).",{''}
2844,440,Platelet count ≥ 100k/mcl,{''}
2845,442,"Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra",{'U ##roth ##eli ##al car ##cin ##oma of the re ##nal p ##el ##vis'}
2846,457,"Sequential administration of two antibiotics from the allowed groups is permitted, if the total duration of the antibiotic treatment does not exceed 10 days.",{''}
2847,458,Adequate bone marrow function characterized by the following at screening,{''}
2848,466,Intrauterine hormone-releasing system (IUS),{''}
2849,468,AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal,{''}
2850,476,Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) if no biliary stenting has been done or 2.0 x ULN if patient is status post (s/p) biliary stenting or two down trending values,{''}
2851,479,Patients on RAASi blocker treatment with less than or equal to 75% of the maximum recommended dose.,{''}
2852,480,Prior immunotherapy is also allowed.,{''}
2853,482,Measurable disease per the Response Evaluation Criteria in Solid Tumors. Measurable disease should not be the lesion needed for repeat biopsy.,{'Solid Tu ##mor'}
2854,486,"Those with a history of neurological disease or epilepsy,","{'ne, ##uro ##logical disease, e, ##pile ##psy'}"
2855,510,Adjuvant radiotherapy for gynaecological cancers,"{'g, ##yna ##ec ##ological cancer'}"
2856,513,Agree to accept the lens as assigned by the randomization.,{''}
2857,523,Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5x ULN,{''}
2858,528,Creatinine clearance 30 mL/min or higher; patients assigned to the highest dose level of PIT add-on therapy must have creatinine clearance 60 mL/min or higher.,{''}
2859,530,"For the management of airway compromise, patients who have received emergent chest irradiation up to 600 cGy will be eligible for this study",{'air ##way compromise'}
2860,532,Ability to complete patient experience surveys by the participant with or without assistance from their caregiver,{''}
2861,540,"Being open to communication and cooperation,",{''}
2862,542,"Screening Group C At least 2 disease-causing variants in the PCDH15 gene which are unknown phase, based on a report from a clinically certified lab (or a report from a research lab which has been pre-approved by the Genetics Committee)",{''}
2863,547,"Participant is a carrier of a mutation in an APP, PSEN1, or PSEN2 gene that is associated with DIAD or does not know their mutation status and there is a mutation in their family pedigree that puts them at a direct risk of inheriting the known mutation;",{'D ##IA ##D'}
2864,549,Hematology Absolute neutrophil count (ANC) ≥ 1.5 × 109/L (1500/mm3); Platelet count ≥ 100 × 109/L (100000/mm3); Hemoglobin ≥ 90g/L;,{''}
2865,557,Average Shoulder Pain and Disability Index (SPADI) pain score ≥5.0 and ≤9.0 in index shoulder prior to Baseline/Day 1.,{'Should ##er Pain and Di ##sa ##bility'}
2866,559,"Immunotherapy At least 42 days after the completion of any type of systemic immunotherapy, e.g. tumor vaccines.",{'tumor'}
2867,566,"Age \> 18 months with unfavorable pathology, regardless of MYCN status",{''}
2868,569,Absolute Neutrophil Count ≥ 1000/μL,{''}
2869,4,"Gleason score of 8, 9, or 10 (high/very high) on prostatectomy specimen.",{''}
2870,8,For males of reproductive potential agreement to use condoms or other methods to ensure effective contraception with partner during study participation and for an additional 4 weeks after the end of study drug administration.,{''}
2871,10,To be eligible for inclusion in the annual screening regimen one of the following three conditions must be met in addition to the eligibility criteria above,{''}
2872,14,"Absolute neutrophil count (ANC) \>= 1,500/mcL (performed within 14 days of treatment initiation)",{''}
2873,15,"Current smokers, as well as individuals who regularly smoked within the past 3 years.",{''}
2874,20,Steroid responders with adequate control regiment or local/systemic therapy can be included,{''}
2875,23,"Hemoglobin ≥ 9.0 g/dL, without packed red blood cell transfusion within the last 1 week of starting study drug",{''}
2876,27,"Unable to safely comply with study procedures and reporting requirements (e.g. impairment of vision or dexterity that prevents safe operation of the bionic pancreas, impaired memory)","{'imp ##air ##ment of vision or de ##x ##ter ##ity, impaired memory'}"
2877,29,Other criteria will be discussed in detail with potential subjects by Site Investigator,{''}
2878,44,ALL survivor specific must have completed therapy ≥ 3 months prior to study entry,{'AL ##L'}
2879,47,"Participant is -25 to -11 EYO based on their mutation type or family pedigree Note If the at-risk parent is deemed a non-carrier through confirmed genetic testing at any time during the study, the participant will be withdrawn.",{''}
2880,49,No active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection).,{''}
2881,56,fluent and literate in English,{''}
2882,58,"Patients must have adequate hematological, liver, cardiac and kidney function",{''}
2883,60,"For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, a serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.",{''}
2884,64,Autistic Child/Caregiver Participants (enrolled in a dyad with a participating therapist),{'Au ##tist ##ic'}
2885,68,Significant co-morbidity that might cause weight fluctuations in weight,{''}
2886,73,"Dose Expansion Group A Participants must have had prior treatment with at least 1 but no more than 2 taxane regimens, in the castration-resistant setting",{'cast'}
2887,74,"OR a complete blood count (CBC) documenting the presence of at least 1,000/uL circulating leukemic cells;",{'le'}
2888,75,"Patient has a reliable study partner/informant (e.g. family member, friend) willing and able to participate in the study as a source of information on the patient's health status and cognitive and functional abilities.",{''}
2889,76,Attenuated familial adenomatous polyposis (AFAP).,"{'At, ##ten, ##uated f ##ami ##lial ad ##eno ##mat ##ous p ##oly ##po ##sis, A, ##FA ##P'}"
2890,86,")Women of childbearing age (15-49 years old) must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception during the clinical trial and for 3 months after the last cell infusion;",{''}
2891,93,Agrees to have medical and clinical data abstracted one year after baseline,{''}
2892,94,Children in the age of highest burden at the time of enrollment (under 5 years of age in Mozambique or 5-15 in Kenya),{''}
2893,96,MK-1308A 120 days,{''}
2894,98,Patients will be staged for risk classification and treatment at diagnosis using Children's Oncology Group (COG) staging guidelines,{''}
2895,109,Exclusion Criteria,{''}
2896,111,"Hematologic Neutrophil count ≥1500/mm\^3, platelet count ≥100,000/mm\^3, hemoglobin ≥9 g/dL",{''}
2897,117,Subjects with previously treated brain metastases are eligible to participate if they are clinically and radiologically stable (no evidence of progression by imaging; same imaging modality \[magnetic resonance imaging (MRI) or computed tomography (CT) scan\] must be used for each assessment) for at least 28 days prior to the first dose of 177Lu-RAD204; and any neurologic symptoms returned to baseline. Note Subjects with a history of leptomeningeal disease may not participate even if stable clinically.,{'le ##pt ##ome ##ning ##eal disease'}
2898,118,There is progressive disease per RECIST v1.1 despite RAI uptake on a whole body scan following radioiodine administration and/or,{''}
2899,122,Participant agrees not to participate in another interventional study while participating in the present study.,{''}
2900,125,"Clinical favorable intermediate risk prostate cancer Gleason score must be Gleason 3+4 with a PSA \< 20 ng/mL, or Gleason 6 (3+3) and PSA \> 10 ng/mL and \< 20 ng mL.",{'pro ##state cancer'}
2901,130,"Participants who are CMV and/or EBV seropositive at screening must be CMV PCR negative and/or EBV PCR \<2,000 IU/mL and must have no signs or symptoms of acute infection at the time of the baseline visit (V0).",{''}
2902,138,Pediatric oncologists who treat patients at SJCRH or who refer patients for treatment to SJCRH,{''}
2903,139,- Participants on medications should be on stable medication for ≥ 3 months before Screening with no planned medication or dose change during study participation.,{''}
2904,147,Patients who have not reached the sustained virological response (SVR) \* with the direct acting antivirals (DAA) therapy. \* SVR shall be as SVR12 (persistent virus negative at 12 weeks after the end of administration).,{''}
2905,148,ECOG Performance Status (PS) 0 to 2.,{''}
2906,151,Cohort C/G Subjects with HER2 negative or unknown G/GEJ adenocarcinoma who have not received prior systemic chemotherapy. The subjects who have completed neoadjuvant or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study can be enrolled.,{'G / GE ##J ad ##eno ##car ##cin ##oma'}
2907,157,Males and females aged 19 to 65 years old.,{''}
2908,159,"Absolute neutrophil count \>= 1,500/mcL",{''}
2909,161,APRI score - calculated from serum AST concentration in IU/L and platelet count /L (a result of ≥2 demonstrates presence of cirrhosis),"{'c, ##ir ##r ##hos ##is'}"
2910,162,Hemoglobin ≥ 9 g/dL,{''}
2911,164,Ability to participate fully in all aspects of this clinical trial. Full comprehension of consent language and written informed consent must be obtained from the participant and documented.,{''}
2912,172,Presence of active PsO or a documented history of psoriasis.,"{'P ##s ##O, ps ##oria ##sis'}"
2913,179,Has adequate organ function,{''}
2914,184,Able to operate the NovoTTF-200T device independently or with the help of a caregiver,{''}
2915,185,Written authorization for use and disclosure of protected health information.,{''}
2916,186,Subjects with prior denosumab use that can and agree to switch to bisphosphonate therapy for bone metastases starting prior to randomization and throughout treatment.,{'bone meta'}
2917,187,Score = 3 Equal to or above spleen Patients with scores ≥ 2 in the majority of the tumoral lesions will be considered to have a positive SSTR-PET and will be therefore eligible for the trial. Patients with a higher score are presumed to have a better response to the treatment.,{'tumor'}
2918,189,Medullary thyroid carcinoma (MTC),"{'Me ##du ##llar ##y thy ##roid car ##cin ##oma, M ##TC'}"
2919,190,Capacity to swallow,{''}
2920,196,I and II degree chondral lesions,{'ch ##ond ##ral lesions'}
2921,197,Life expectancy less than 12 months,{''}
2922,200,Presence of a stromal corneal cleft,{''}
2923,204,Have a history of allogeneic stem cell transplant or liver transplant,{''}
2924,205,"body temperature, 35.0 to 37.5°C, inclusive",{''}
2925,206,Male participant must not donate sperm during the treatment period and for 28 days after final IP administration.,{''}
2926,218,Absence of brain injury,{''}
2927,220,Willingness to use barrier protection (male or female) during sexual activity during analytical treatment interruption (ATI) and until viral re-suppression for those who re-start ART.,{''}
2928,221,Subjects with treated brain metastasis and those with untreated asymptomatic brain metastasis are eligible if they are clinically stable per investigator discretion and not requiring systemic steroids for ≥ 7 days. Prophylactic cranial radiation (PCI) is allowed per investigator's discretion.,{'brain meta'}
2929,223,Vasectomized partner (vasectomy must be performed 3 months prior to first study drug administration or in the alternative a zero sperm count will suffice).,{''}
2930,225,Adequate organ function according to protocol-defined criteria,{''}
2931,229,"Cardiac ejection fraction of \>50%, and no evidence of pericardial effusion, as determined by an echocardiogram.",{'per ##ica ##al e ##ff ##usion'}
2932,233,physically active subjects defined as 3-5 aerobic exercise sessions/week,{''}
2933,234,"Consent to provide archival tumor tissue specimens (10-12 unstained sections (anti-slip) surgical specimens (thickness 4-5μm)) or fresh tissue samples from primary or metastatic lesions within 3 years. If participants cannot provide tumor tissue samples, they can be enrolled if they meet other inclusion and exclusion criteria after the evaluation of the investigator.","{'tumor, tumor'}"
2934,249,Progressive Disease on approved therapies other than radionuclide therapy.,{'Progressive Disease'}
2935,258,Systemic or B symptoms,{''}
2936,259,Patients must have progressive or refractory disease or experience relapse after at least one previous systemic treatment strategy,{''}
2937,261,Endometrial thickness ≤ 4 mm on transvaginal ultrasound.,{''}
2938,265,All tumor removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy).,{''}
2939,277,Measurable disease according to RECIST v1.1,{''}
2940,281,L485W,{''}
2941,288,The elasticity value of magnetic resonance elastography (MRE) examination within 24 months before enrollment is ≥2.93kPa;,{''}
2942,291,Patients do not need to agree to Biobank blood draw.,{''}
2943,293,"For inadequate responder to MTX, subject has had regular use of MTX for at least 90 days prior to screening at a dose that, in accordance with local clinical practice, is considered acceptable to adequately assess clinical response. The dose of MTX must have been a stable, unchanging oral dose of 7.5 to 20 mg/week (or the equivalent injectable dose) for at least the 28 days prior to screening. Subject is able to continue stable dose of MTX from at least 28 days prior to screening until the end of the administration period of study drug.",{''}
2944,309,Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or ≥ 45 mL/min/1.73m2 by CKD-EPI equation for subjects with creatinine levels \> 1.5 x institutional ULN.,{''}
2945,318,Ineligible children include those,{''}
2946,326,Hemoglobin ≥8.5 g/dL.,{''}
2947,327,Clinically detected recurrent melanoma at the proximal regional lymph node(s) basin.,"{'me, ##lan ##oma'}"
2948,328,Ambulatory without pain or the assistance of walking devices.,{''}
2949,331,Subjects that have previously received pomalidomide must not have been removed from therapy due to toxicity attributable to pomalidomide and must be at least 6 months from their last dose of pomalidomide.,{''}
2950,332,RenalSerum creatinine ≤1.5 × ULN,{''}
2951,337,"If the subject is currently receiving an approved AD treatment, such as acetylcholinesterase inhibitors (AChEI) and/or memantine, they must have been using a stable dose for at least 4 weeks prior to baseline and maintain a stable dose throughout the study;",{'AD'}
2952,340,NOTE The site principal investigator must review and verify the pathology report findings to ensure the patient is eligible and is assigned to the respective cohort at the time of registration,{''}
2953,343,Patient is able and willing to complete study requirements,{''}
2954,344,Documented diagnosis of Gilbert syndrome total bilirubin ≤ 3 × ULN.,{'Gilbert syndrome'}
2955,346,Following treatment on or per ANBL0532,{''}
2956,347,Prothrombin time or international normalized ratio (INR) =\< 1.5 x upper limit of normal (ULN),{''}
2957,350,"Participants treated with SoC controller therapy for ≥3 months before Screening (Visit 1) and at a stable dose and regimen of controller therapy for at least 1 month before the screening visit AND during the screening period, including either triple therapy with LAMA + LABA + ICS or double therapy with ICS + LABA or LABA + LAMA or ICS + LAMA, or monotherapy with LABA or LAMA.",{'So'}
2958,352,"Requires urgent surgery or invasive procedure known to be associated with a risk of significant bleeding (such as cardiac surgery, neurosurgery, or major orthopedic surgery)","{'cardiac surgery, ne ##su or ##th ##oped ##ic surgery'}"
2959,354,Total Bilirubin ≤ 1.5x the institutional upper limit of normal (except in patients with Gilbert's syndrome),"{""Gilbert ' s syndrome""}"
2960,356,Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline,{''}
2961,358,"In case a patient has had a tumour biopsy in the previous 6 months and a paraffin block is available, a new biopsy does not need to be done at Screening (if they have received no treatment after biopsy).",{'t'}
2962,359,"Agree to restrain from intensive physical exercise i.e. exercise that varies significantly from an everyday exercise routine, 3 days before and after (± 3 days) administration of each dose, including each interim visit for blood sample collection.",{''}
2963,361,"For survivors confirmed by review of the date of birth as documented in the Electronic Medical Record (EMR) and subsequently recorded in Survivor Health History. For non-OHSU patients, we'll collect their age by self-report on the Survivor Health History",{'OH ##SU'}
2964,362,Potential trial participants should have recovered from clinically significant adverse events (AEs) of their most recent therapy/intervention prior to enrollment,{''}
2965,364,Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and economics questionnaires in either English or French,{''}
2966,367,absolute abstinence from heterosexual intercourse as a matter of normal preferred lifestyle;,{''}
2967,371,Willingness to avoid excessive use of alcohol during the study; note excessive use is defined as drinking \>= 8 alcoholic drinks per week on average,{''}
2968,375,Must use acceptable form of birth control while on study,{''}
2969,376,Entry criteria for depression and alcohol use disorder (moderate or severe) will be established using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID) for categorical diagnosis.,"{'depression, alcohol use disorder Mental Di ##sor ##ders'}"
2970,385,"RenalSerum creatinine ≤ 1.5 × ULN or calculated creatinine clearance (CrCl) ≥ 50 mL/min (calculated using the Cockcroft-Gault formula);Urinalysis urine protein \< 2+; if urine protein ≥ 2+, then 24-hour urine protein ≤ 1 g.",{''}
2971,391,Are too cognitively impaired to provide informed consent and/or complete study protocol,{''}
2972,396,"Willing and able to read in English, and",{''}
2973,399,Moderate or severe substance use disorder other than opioid or stimulant use disorder,"{'substance use disorder, op ##io ##id or s ##ti ##mu ##lant use disorder'}"
2974,403,NSCLC,{'N ##SC ##LC'}
2975,408,"Total bilirubin count ≤1.5 x upper limit of normal (ULN), serum glutamic pyruvic transaminase/alanine aminotransferase (SGPT/ALT) and serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST) ≤ 2.5 x ULN (5 x ULN for subjects with liver involvement of their cancer or 10 x ULN for subjects with bone involvement).","{'liver involvement of their cancer, bone involvement'}"
2976,414,Participant agrees not to participate in another interventional study while participating in the present study.,{''}
2977,415,Body mass index \> 40,{''}
2978,416,EfFORT Trial At-Risk Relatives (ARRs),{''}
2979,419,No known diabetes,{''}
2980,421,Age,{''}
2981,425,Vasectomized partner (vasectomy must be performed 3 months prior to first study drug administration or in the alternative a zero sperm count will suffice).,{''}
2982,426,Subjects are dependable and able to follow directions and willing to comply with the schedule of visits.,{''}
2983,431,"\*\* Patients receiving chemotherapy in combination with HER2-targeted therapy as part of a (neo)adjuvant sequence therapy (e.g. as second part after previous EC therapy) may be included. Accordingly, the PRO2 study will not start until patients begin combination of chemotherapy and HER2-targeted therapy.",{''}
2984,432,"Diagnostic quality computed tomography (CT) or magnetic resonance imaging (MRI) of neck, with contrast, within 30 days prior to registration. Fludeoxyglucose F-18 (18F-FDG) whole body positron emission tomography (PET)-CT scan within 42 days of registration is strongly recommended but does not replace the CT or MRI study. Note If CT component of the PET/CT is of diagnostic quality then PET/CT can be used for eligibility, however the PET/CT scan must be done within 30 days prior to registration",{''}
2985,434,Tumor Sample Availability OR results from previous molecular profiling/targeted sequencing,"{'Tu, ##mor'}"
2986,440,Hemoglobin ≥ 9.0 g/dL,{''}
2987,442,Ovarian cancer,{'O ##var ##ian cancer'}
2988,457,Planned duration of the antibiotic treatment of 5 to 10 days.,{''}
2989,458,ANC ≥1.5 × 109/L,{''}
2990,466,Bilateral tubal occlusion,{''}
2991,468,"Patients must be \> 2 weeks from prior chemotherapy or radiation therapy, except for bevacizumab treatment which requires \>6 weeks",{''}
2992,476,Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamic-pyruvic transaminase \[SPGT\]) ≤ 2.5 X ULN,{''}
2993,479,Hyperkalemic patients (sK+ 5.1-5.9 mmol/L at screening / study enrolment) or Normokalemic patients at risk of developing HK defining as having a history of hyperkalaemia (sK+ \>5.0 mEq/L) within the prior 24 months and sK+ ≥4.5 mEq/L ≤ 5.1 mEq/L at inclusion,"{'H, ##yper ##em, Nor, ##mo ##kal ##em, HK, h, ##yper ##kal ##ae ##mia'}"
2994,482,Eastern Cooperative Oncology Group (ECOG) performance status of O or 1.,{''}
2995,486,Those with problems that prevent participation in exercise such as hypertension or other cardiovascular diseases.,"{'h ##yper ##tens ##ion, card ##iovascular diseases'}"
2996,510,Pelvic Lymph nodes only,{''}
2997,513,Be capable of comprehending the nature of the study and be willing and able to adhere to the instructions set forth in this protocol.,{''}
2998,523,Patients must have creatinine clearance estimated of ≥51 mL/min,{''}
2999,528,Liver Function tests within the following ranges,{''}
3000,530,"Patients with a prior seizure disorder requiring anti-convulsant therapy are not eligible to receive nelarabine; in addition, patients with pre-existing grade 2 (or greater) peripheral neurotoxicity, as determined prior to Induction treatment by the treating physician or a neurologist, are not eligible to receive nelarabine; these restrictions in eligibility are designed to prevent excessive nelarabine-induced central and peripheral neurotoxicity in at-risk patients; for the purposes of this study, this includes any patient that has received anticonvulsant therapy to prevent/treat seizures in the prior two years","{'seizure disorder peripheral ne ##uro ##to ##xi ##city, central and peripheral ne ##uro ##to ##xi ##city, seizure'}"
3001,540,Being a volunteer to participate in the research.,{''}
3002,542,"Note pertaining to all Screening Groups if a participant has a variant(s) of unknown significance, he/she would still qualify if there is at least 1 disease-causing variant(s) on the PCDH15 gene. The Genetics Committee will review unique cases where segregation analysis is not feasible to determine eligibility.",{''}
3003,547,"Participant is -25 to -11 EYO based on their mutation type or family pedigree Note If the at-risk parent is deemed a non-carrier through confirmed genetic testing at any time during the study, the participant will be withdrawn.",{''}
3004,549,"KidneyThe calculated value of creatinine clearance rate (CrCl) is ≥ 50 mL/min;Normal urine routine, urine protein\<2+or 24-hour (h) urine protein quantification\<1.0 g;",{''}
3005,557,Willingness to abstain from use of protocol-specified restricted medications and therapies during the study.,{''}
3006,559,Monoclonal antibodies At least 21 days after the last dose of a monoclonal antibody.,{''}
3007,566,o Patients with INSS stage 2a or 2b are eligible with the following,{'IN ##SS'}
3008,569,"Platelets ≥ 75,000/μL (or ≥50,000/mm3 if known BM involvement)",{'B ##M'}
3009,4,Subjects with pT3b or pT4 tumors with a Gleason sum 7 (4+3) are eligible.,{'p ##3 ##b or p ##T ##4 tumors'}
3010,10,Patients are pre-menopausal; OR,{''}
3011,14,"Platelets \>= 100,000/mcL (performed within 14 days of treatment initiation)",{''}
3012,15,Body mass index of greater than 30 kg/m\^2.,{''}
3013,23,"Prothrombin time international normalized ratio and partial thromboplastin time ≤1.5 × upper limit of normal (ULN), unless participant is receiving anticoagulant therapy and prothrombin time or activated partial thromboplastin time is within therapeutic range of intended use of anticoagulants",{''}
3014,27,"Unable to speak and read English, as iLet BP support materials and device menus are currently available in English only.",{''}
3015,44,Controls,{''}
3016,47,Cognitive status of participant is normal (CDR-SB 0).,{''}
3017,49,All patients must consent to mandatory pre-treatment and post-treatment core needle biopsies.,{''}
3018,56,no impairment in hearing or vision,{'imp ##air ##ment in hearing or vision'}
3019,58,Hemoglobin ≥ 10.0 g/dL.,{''}
3020,64,Child age 7-12 years,{''}
3021,68,Current participation in a weight loss research study,{'weight loss'}
3022,73,Dose Expansion Group B Participants must not have received any taxane regimens since becoming castration-resistant,{'cast'}
3023,74,"OR patient has newly diagnosed B-cell LLy Murphy stages I or II, with or without Down syndrome.","{'B - cell LL ##y, Down syndrome'}"
3024,75,Patient is not dependent on a walker or wheelchair.,{''}
3025,76,Allergy to vitamin B1.,{'All ##er ##gy to vitamin B ##1'}
3026,86,) Sign the informed consent form.,{''}
3027,93,Able and willing to consent to participate,{''}
3028,94,Residents of the study area,{''}
3029,96,MK-3475 120 days,{''}
3030,98,"At the time of study enrollment, the patient's treatment regimen must be identified; if the patient's primary tumor was resected prior to the day of enrollment and a blood specimen for the determination of serum alpha fetoprotein was not obtained prior to that surgery, the patient will be considered to have alpha fetoprotein of greater than 100 ng/mL for the purpose of treatment assignment; if tumor samples obtained prior to the date of enrollment were not sufficient to determine whether small cell undifferentiated (SCU) histology was present, treatment assignment will be made assuming SCU is not present in the tumor",{'tumor'}
3031,109,Subjects meeting any of the criteria below may not participate in the study,{''}
3032,111,"Hepatic Total bilirubin ≤ 1.5 times the upper limit of normal, unless Gilbert's syndrome; aspartate transaminase and alanine transaminase ≤ 2.5 times the upper limit of normal (in the absence of hepatobiliary metastases); ≤ 3.0 times the upper limit of normal (in the presence of hepatobiliary metastases)","{""Gilbert ' s syndrome""}"
3033,117,"For Phase I Participants must have positive lesion(s) by 177Lu-RAD204im SPECT/CT as described in Image Review Manual. Estimated total radiation dose to healthy organs derived from phase 0 dosimetry must not exceed dose constraints according to the American Association of Physicists in Medicine Quantitative Analysis of Normal Tissue Effect in the Clinic (QUANTEC) and International Commission on Radiological Protection (ICRP), in discussion with study Sponsor.",{''}
3034,118,"For patients 12 to \<18 years of age, there is persistent anatomically visible tumor on cross sectional imaging following prior therapeutic radioiodine administration",{'tumor'}
3035,122,Participant has normal renal function as defined by estimated glomerular filtration rate (eGFR) using Modification of Diet in Renal Disease formula ≥ 90 mL/min per 1.73 m\^2 or participant has varying degrees of chronic kidney disease as defined by the National Kidney Foundation and by eGFR,{'chronic kidney disease'}
3036,125,Decipher GC score of 0.6 or higher or higher indicating high genomic risk for most recent biopsy,{''}
3037,130,Be up to date on recommended vaccinations based on age of participants\*,{''}
3038,139,Parts A2 and B2,{''}
3039,147,Patients who have difficulty in performing DAA therapy.,{''}
3040,148,Adequate organ and marrow function measured within 14 days prior to enrollment.,{''}
3041,151,Cohort D The subjects with G/GEJ adenocarcinoma who have received at least prior first-line systemic chemotherapy; Cohort F The subjects with biliary neoplasm who have not received prior systematic chemotherapy. The subjects who have completed neoadjuvant or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study can be enrolled.,"{'G / GE ##J ad ##eno ##car ##cin ##oma, bi ##lia ##ry neo ##p ##las ##m'}"
3042,157,Participation Available Period the first survey is conducted on the subjects who have received tacrolimus twice daily (b.i.d) for a minimum of 6 months to a maximum of 12 months during the period. The second survey is conducted within one month after switching to Advagraf (once daily (q.d) regimen of modified release tacrolimus).,{''}
3043,159,Platelets \>= 100 x 10\^9/L,{''}
3044,161,Liver transient elastography assessment (a 'Fibroscan'). A result of ≥12.5 kPa will demonstrate cirrhosis.,"{'c, ##ir ##r ##hos ##is'}"
3045,162,Total bilirubin ≤ 1.8 mg/dL,{''}
3046,179,Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia),{'al ##ope ##cia'}
3047,184,Signed informed consent for the study protocol,{''}
3048,185,Ability to adhere to the study visit schedule and other protocol requirements.,{''}
3049,186,Participant must keep contraception.,{''}
3050,187,"It is admissible to have non-measurable disease only (e.g., HR-NB with bone-only or bone marrow-only active disease).",{'H ##R - N ##B'}
3051,189,Renal cell carcinoma (RCC),"{'Ren ##al cell car ##cin ##oma, RC ##C'}"
3052,190,Patients able to complete study and within geographical proximity allowing for adequate follow up,{''}
3053,197,Are too cognitively impaired to provide informed consent and/or complete study protocol,{''}
3054,200,Inflammatory or degenerative corneal pathology other than endothelial,"{'In, ##f, ##lam or de ##gene ##rative corn ##eal path, end ##oth ##al'}"
3055,204,People with prior clinical pharmacogenetic test results for genes relevant for the study in which they will enroll (CYP2D6 for the pain studies and CYP2D6 or CYP2C19 for depression) or already enrolled in an ADOPT PGx trial,"{'pain, depression'}"
3056,205,"systolic blood pressure (BP), 90 to 160 mmHg, inclusive",{''}
3057,206,Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 28 days after final IP administration.,{''}
3058,221,Demonstrate adequate organ function. All screening labs to be obtained within 28 days prior to registration.,{''}
3059,223,Exception Female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.,{''}
3060,225,Administration of growth factors or blood transfusions will not be allowed within 4 weeks of the hematology labs required to confirm eligibility,{''}
3061,229,Adequate pulmonary function as defined as pulse oximetry ≥ 92% on room air.,{''}
3062,233,matched to age and gender,{''}
3063,234,Must have at least one measurable lesion according to RECIST v1.1 definition; Lesions that had been previously treated with radiation could be included in a measurable lesion only if there was definite disease progression after radiation therapy.,{''}
3064,249,Must have clinically demonstrated adequate catecholamine blockade if catecholamine-secreting pheochromocytoma/paraganglioma tumors are present.,"{'cat ##ola ##mine - secret ##ing, p ##he ##och ##rom ##oc ##yt ##oma, para ##gan ##gli ##oma tumors'}"
3065,258,Presence of serous effusion,{'se ##rous e ##ff ##usion'}
3066,259,"Pathogenic somatic mutation detected in genes encoding tyrosine kinase receptors (CSFR1, ERBB3 or ALK), RAS or RAF (may be from original or subsequent biopsy or peripheral blood/bone marrow aspirate). Clinical mutation reports may include quantitative polymerase chain reaction (PCR) (e.g. BRAFV600E) and/or Sanger or next generation sequencing. Immunohistochemistry (e.g. VE1 antibody for BRAFV600E) alone is not sufficient",{''}
3067,261,Current on all recommended screening and management requirements for cervical cancer.,{'c ##er ##vic ##al cancer'}
3068,265,"NOTE Management of axillary lymph nodes is up to the treating provider; however, all surgical margins should be clear of invasive cancer or DCIS (i.e., no tumor on ink). The local pathologist must document negative margins of resection in the pathology report. If all other margins are clear, a positive posterior (deep) margin is permitted, provided the surgeon documents that the excision was performed down to the pectoral fascia and all tumor has been removed. Likewise, if all other margins are clear, a positive anterior (superficial; abutting skin) margin is permitted provided the surgeon documents that all tumor has been removed.","{'invasive cancer, DC ##IS'}"
3069,277,WHO performance status of 0 or 1,{''}
3070,281,N486_A489delinsK,{''}
3071,288,"If there is no liver biopsy and no liver elastography equipment is available in the research center, FIB-4\>1.3 (under 65 years old) or\>2 (over 65 years old) within 3 months before enrollment.",{''}
3072,291,Patients at Mayo Clinic Arizona are not required to consent to the Registry.,{''}
3073,293,"For subject who is intolerant of MTX, subject has had regular use of the following DMARDs, and when the following DMARDs are concomitantly administered to subject, the drugs must be administered for at least 90 days prior to screening, and must be stable from at least 28 days prior to screening until the end of the administration period of study drug.",{''}
3074,309,"Total bilirubin ≤ 1.5 x ULN, or direct bilirubin ≤ ULN for subjects with total bilirubin levels \> 1.5 x ULN, or unless due to Gilbert's Syndrome.","{""Gilbert ' s S ##yn ##drome""}"
3075,318,"with planned admissions (i.e., chemotherapy)",{''}
3076,326,"Adequate organ function, defined as",{''}
3077,327,Clinically detected primary cutaneous melanoma involving multiple regional nodal groups.,{'cut ##aneous me ##lan ##oma'}
3078,328,Reliable means of transportation (if participating in Boston).,{''}
3079,331,Subjects must not have known intolerance to doses of dexamethasone up to 40 mg weekly (20 mg weekly if \> 75 years).,{''}
3080,332,"Coagulation Prothrombin time/international normalized ratio ≤1.5 × ULN or activated partial thromboplastin time ≤ 1.5 × ULN (for subjects on anticoagulants, prothrombin time or activated partial thromboplastin time must be within the normal range foranticoagulants).",{''}
3081,337,There was no obvious positive sign in nervous system examination;,{''}
3082,340,Patient must have relapsed and/or refractory disease after at least 1 prior anthracycline and anti-CD20 antibody-containing regimen,{''}
3083,343,Patients with adequate hematologic parameters (all tests to be performed within \<4 weeks of biopsy),{''}
3084,344,Must have no major impairment of renal function Estimated glomerular filtration rate (eGFR) \> 30 mL/min as calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI).,"{'imp ##air ##ment of re ##nal function, Ch, ##ronic Kid ##ney Disease, C'}"
3085,346,Following treatment per POG 9640,{''}
3086,347,Total bilirubin \< 1.5 x ULN,{''}
3087,350,"Participants who have received appropriate vaccination according to local recommendations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), administered a minimum of 1 week prior to Screening (Visit 1).","{'severe acute respiratory syndrome, co ##rona 2, SA ##RS'}"
3088,352,"Requires urgent surgery or invasive procedure that may have an adverse procedural outcome if hemostasis is impaired (such as neurological, spinal, ophthalmological, urological, or orthopedic surgery)",{''}
3089,354,ALT (SGPT) and AST (SGOT) \< 3x the institutional upper limit of normal,{''}
3090,356,Serum creatinine ≤ 1.5 × ULN or ≥ 60 mL/minute for subjects with creatinine levels \> 1.5 × the institutional ULN,{''}
3091,358,Documented progression on or following the last line of therapy.,{''}
3092,359,Up to date on seasonal influenza vaccine and recommended COVID-19 vaccines and booster doses at the time of study enrolment.,{''}
3093,361,For partners confirmed by self-report on the Health History Questionnaire,{''}
3094,362,"Age ≥ 18 years. Because no dosing or AE data are currently available on the use of T-DXd (DS-8201a) in combination with azenosertib (ZN-c3) in patients \< 18 years of age, children are excluded from this study",{''}
3095,364,Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate,{''}
3096,367,"or must be surgically sterile or have documented menopause, having had no menses at all for at least one full year.",{''}
3097,371,Willingness to provide blood samples for research tests specified in the protocol,{''}
3098,375,Ability to understand and willingness to sign a written informed consent document,{''}
3099,376,Have a score of ≥18 on the Hamilton Depression Rating Scale for Depression (HAM-D).,{''}
3100,385,CoagulationInternational normalized ratio (INR) ≤ 1.5 × ULNActivated partial thromboplastin time (aPTT) ≤ 1.5 × ULN;Prothrombin time (PT) ≤ 1.5 × ULN.,{''}
3101,391,Are institutionalized or too ill to participate (i.e. mental or nursing home facility or incarcerated),{''}
3102,396,Not using other smoking cessation interventions (This eligibility requirement helps ensure results are due to the treatments we recommend rather than those that participants are doing on their own.),{''}
3103,399,SUVO consumption in the last 30 days,{''}
3104,403,Gastric/GEJ adenocarcinoma,{'Gas ##tric / GE ##J ad ##eno ##car ##cin ##oma'}
3105,408,"Renal function, calculated as creatinine clearance or 24-hour creatinine clearance ≥ 50 mL/min.",{''}
3106,414,Additional Criteria for Participants with Hepatic Impairment,{'He ##pa ##tic I ##mp ##air ##ment'}
3107,415,Planned pancreaticoduodenectomy or sleeve gastrectomy,{'pan ##cre ##atic ##od ##uo ##den ##ec gas ##tre ##ct'}
3108,416,"Biological first-, second-, or third- degree relative of enrolled MSK proband",{'MS ##K'}
3109,419,"If a blood donation has been made, a delay of 8 weeks must be respected after the latter",{''}
3110,421,"or older, OR",{''}
3111,425,Exception Female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.,{''}
3112,426,Subjects in generally good physical and mental health.,{''}
3113,432,"Diagnostic quality, cross sectional imaging of the thorax within 42 days prior to registration; 18-F-FDG-PET/CT or conventional CT are acceptable",{''}
3114,434,"If a patient screens through OPTION #1, tumor sample in addition to normal comparator tissue (peripheral blood or saliva) must be submitted for comprehensive molecular screening at the time of screening enrollment.",{'tumor'}
3115,440,Adequate hepatic function defined by the following laboratory results obtained within 11 days prior to first study treatment,{''}
3116,442,Gastric cancer,{'Gas ##tric cancer'}
3117,457,Body mass index (BMI) of 18.0 to 29.9 kg/m2,{''}
3118,458,Platelets ≥100 × 109/L,{''}
3119,466,Vasectomized partner (performed at least 2 months before screening) (if the partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success),{''}
3120,468,Ability to understand and the willingness to sign a written informed consent document (either directly or via a legally authorized representative),{''}
3121,476,Creatinine (Cr) ≤ 1.5 mg/dL or Cr clearance ≥ 30 mL/min (as estimated by Cockcroft Gault),{''}
3122,482,Adequate organ and marrow function as defined below within 28 days of study treatment initiation,{''}
3123,510,Ability to understand and the willingness to sign an informed consent,{''}
3124,513,"Ability to comply with study procedures, including high and low (sub-study only) contrast high and low (sub-study only) lighting visual acuity, axial length, and cycloplegic auto-refraction measurements taken for both eyes.",{''}
3125,523,Eastern Cooperative Oncology Group (ECOG) performance status 0-1).,{''}
3126,528,Aspartate aminotransferase (AST) ≤ 3.0 × ULN,{''}
3127,542,Ocular,{''}
3128,547,Cognitive status of participant is normal (CDR-SB 0).,{''}
3129,549,"LiverTotal serum bilirubin (TBiL) ≤ 1.5 × ULN;AST and ALT ≤ 2.5 × ULN; For subjects with liver metastasis, AST and ALT can be ≤ 5 × ULN;Serum albumin (ALB) ≥ 30g/L;",{'liver'}
3130,557,"Sexually active males or females of childbearing potential must agree to use a highly effective method of contraception throughout the duration of the study. Females of childbearing potential are defined as females who are not surgically sterile or postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause) as documented in medical history. Highly effective methods of contraception include abstinence; oral, injected, or implanted hormonal methods of contraception; intrauterine device or intrauterine system; condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; or monogamous intercourse with a partner who is surgically sterile (post-vasectomy, -hysterectomy, or -tubal ligation).",{'h'}
3131,559,Radiation therapy Patients must have had their last (conventional or hypofractionated) fraction of a) Focal irradiation \> 6 months prior to enrollment and b) No prior craniospinal irradiation is permitted.,{''}
3132,566,"MYCN amplification, regardless of age or additional biologic features",{''}
3133,569,Calculated creatinine clearance ≥ 40 cc/min using the Cockcroft-Gault formula,{''}
3134,4,Pelvic lymph node dissection (PLND) is required with either pN0 or pN1 nodal staging permitted.,{''}
3135,10,Post-menopausal aged 45-69 with any of the following three risks factors,{''}
3136,14,Hemoglobin (Hgb) \>= 9 g/dL or \>= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 14 days of treatment initiation),{''}
3137,15,Pregnant individuals,{''}
3138,23,Calculated creatinine clearance (CrCl) according to Cockcroft-Gault formula and based on ideal body weight or 24-hour urine CrCl ≥ 50 mL/minute,{''}
3139,27,Plan to change usual diabetes regimen in the next 3 months including before and during participation in the study,{''}
3140,44,-25 years old,{''}
3141,47,"Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning. Participants must be fluent in languages for which cognitive and clinical measures have been translated and validated for use in the DIAN-TU. Fluency is generally defined as daily or frequent functional use of a language generally from birth or a young age. In cultures where multiple languages are spoken or for participants who are multilingual, determination as to whether a participant's level of fluency in languages for which clinical and cognitive measures are available meets qualification for the study should be made by the site PI.",{''}
3142,49,"Patients must have adequate hematological, liver, cardiac and kidney function within 14 days prior to first treatment",{''}
3143,58,Absolute neutrophil count (ANC) ≥ 1.5 x 109/L,{''}
3144,64,Receiving services from an enrolled therapist,{''}
3145,73,"Dose Expansion Group C Participants must either have had prior treatment with at least 1 but no more than 2 taxane regimens, or been deemed ineligible for or refused taxane therapy on consultation with their physician",{''}
3146,74,"Note For B-LLy patients with tissue available for flow cytometry, the criterion for diagnosis should be analogous to B-ALL. For tissue processed by other means (i.e., paraffin blocks), the methodology and criteria for immunophenotypic analysis to establish the diagnosis of B-LLy defined by the submitting institution will be accepted (diagnostic biopsy for B-LLy must be performed within 14 days prior to enrollment).","{'B - LL ##y, B - AL ##L, B - LL ##y, B - LL ##y'}"
3147,75,Patient is living in the community (i.e. not in nursing home); some levels of assisted living may be permitted at the discretion of the investigator.,{''}
3148,76,"Contraindications to vitamin B1, such as liver or kidney dysfunction, or severe neuropsychiatric disorders.","{'liver or kidney d ##ys ##function, ne, ##uro ##psy ##chia ##tric disorders'}"
3149,94,Parent/guardian's able to provide consent for minors,{''}
3150,96,Lenvatinib 30 days,{''}
3151,98,"For patients with stage I or II disease, specimens for rapid central review have been submitted and the rapid central review diagnosis and staging must be available to be provided on the AHEP0731 eligibility case report form (CRF)",{''}
3152,109,Prior radiation to the chest that would overlap with the current radiation fields and determined by the treating physician to impede the treatment of the study malignancy.,"{'ma, ##li'}"
3153,111,Renal Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula.,{''}
3154,118,Participants may have received no more than a total cumulative RAI dose for treatment (not including RAI given for diagnostic purposes only) of 500 mCi (18.5 GBq).,{''}
3155,122,to \< 90 mL/min per 1.73 m\^2 for participants with mild renal impairment,"{'re, ##nal imp ##air'}"
3156,125,Documented prostate volume (by MRI or ultrasound) \<= 80 cc,{''}
3157,130,Participants are required to receive killed influenza vaccination at least 2 weeks prior to the baseline visit (V0) when vaccine for the current or upcoming flu season is available.,{'flu'}
3158,139,"- Participants are to be Japanese, defined as having both parents and 4 grandparents who are Japanese.",{''}
3159,147,Patients who have passed 24 weeks or more after achieving SVR\* with DAA therapy or IFN therapy.,{''}
3160,148,Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrollment in the trial to document their willingness to participate.,{''}
3161,151,Cohort H The subjects with G/GEJ adenocarcinoma who have received at least prior second-line systemic chemotherapy;,{'G / GE ##J ad ##eno ##car ##cin ##oma'}
3162,157,Subjects who understood the purpose and risks of the questionnaire development and who were well-acquainted with the contents and submitted the written consent to participate in the interview for the questionnaire development.,{''}
3163,159,"Total bilirubin =\< 1.5 ULN (upper limit of normal), unless due to Gilbert's syndrome","{""Gilbert ' s syndrome""}"
3164,161,liver biopsy within 1 year of screening,{''}
3165,162,Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3 x institutional upper limit of normal (ULN) or ≤ 5 x institutional ULN if known liver metastases,{''}
3166,185,Acceptable hematologic parameters.,{''}
3167,187,Performance status ≥ 50% according to Lansky scale (\&amp;lt;16 years old) or Karnofsky scale (for ≥16 years old).,{''}
3168,189,Hepatocellular carcinoma (HCC),"{'He, ##pa ##to ##cellular car ##cin ##oma, HC ##C'}"
3169,190,Resolution of all acute toxic effects of previous anticancer therapy,{''}
3170,197,Are institutionalized or too ill to participate (i.e. mental or nursing home facility or incarcerated),{''}
3171,200,Progressive corneal infection,{''}
3172,204,Acute Pain Trial,{''}
3173,205,"diastolic BP, 50 to 100 mmHg, inclusive",{''}
3174,206,Participant agrees not to participate in another interventional study while participating in the present study.,{''}
3175,221,Absolute Neutrophil Count (ANC) \> 1500mm\^3,{''}
3176,223,ii. Facial acne IGA score of 3 or 4.,"{'F, ##ac ##ial a ##c ##ne'}"
3177,229,Subjects (or legal guardians) must have the ability to understand and the willingness to sign a written informed consent document.,{''}
3178,233,generally healthy with normal fasting glucose levels (glucose ≤100 mg/dL).,{''}
3179,234,"No blood transfusions and no use of cell growth factors and/or platelet-raising drugs during the 14 days prior to the screening period must be allowed, and the organ function level must meet the following criteria",{''}
3180,249,Able to sign informed consent and comply with all study requirements.,{''}
3181,258,Splenic enlargement,"{'S, ##ple ##nic en ##lar ##gement'}"
3182,259,"Participant must be able to take an enteral dose and formulation of medication. Study medication is only available as an oral suspension or tablet, which may be taken by mouth or other enteral route such as nasogastric, jejunostomy, or gastric tube",{''}
3183,261,Normal mammogram report within 2 years of screening.,{''}
3184,265,"-≤90 days from the patient's most recent breast surgery for this breast cancer. Note In cases where registration will occur \>90 days from surgery but within an acceptable time frame, patient may be eligible for enrollment with approval from the PI, Rachel Freedman MD, MPH.",{'breast cancer'}
3185,277,"Adequate bone marrow function neutrophils ≥ 1.5 x 10E9 cells/l, platelets ≥100 x 10E9 cells/l, Hb ≥ 6.2 mmol/l.",{''}
3186,281,N486_P490del,{''}
3187,291,"Willing to sign consent for blood collection onto the Pancreas SPORE, IRB 354-06.",{''}
3188,293,Hydroxychloroquine,{''}
3189,309,Alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤ 5 x ULN if hepatic abnormalities are related to underlying liver metastases or liver/biliary primary.,"{'he, ##pa ##tic abnormal ##ities'}"
3190,318,"admitted to non-pediatric hospital medicine services (i.e., intensive care)",{''}
3191,326,"Serum creatinine clearance (CKD-EPI formula) ≥20 mL/min,",{''}
3192,327,Clinical detected nodal melanoma (if single site) arising from an unknown primary.,{'nod ##al me ##lan ##oma'}
3193,328,No diagnosis of a neurological disease.,{'ne ##uro ##logical disease'}
3194,337,"Coronal scanning of head MRI in screening stage the MTA grade of medial temporal lobe atrophy visual assessment scale is grade 1-2. If the subject can provide the head MRI film that meets the requirements within 3 month before screening, it can be used as the basis for enrollment without repeated shooting; If the researcher cannot judge whether the subject's condition has changed, the coronal MRI scan of the head before enrollment can be added;",{'medial temporal lobe at ##rop ##hy'}
3195,340,Patient must not have confirmed or suspected primary mediastinal large B-cell lymphoma (PMBL),"{'media ##st ##inal large B - cell l ##ymph ##oma, PM ##BL'}"
3196,343,ANC ≥ 1.5 X 109/L,{''}
3197,344,Must have no major impairment of bone marrow function (without hematological support within 7 days prior to assessment) Hemoglobin ≥ 9.0 g/dL; complete blood count (CBC) ≥ 2.5 × 109/L; neutrophils ≥ 1.5 × 109/L; platelets ≥ 75 × 109/L.,{''}
3198,346,Following treatment per COG ANBL00P1,{''}
3199,347,Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional ULN or =\< 5 x ULN if metastatic disease involves liver,{''}
3200,350,Body mass index (BMI) ≥18 kg/m2,{''}
3201,352,"At risk of experiencing life-threatening events, such as, shock, myocardial infarction, or stroke, if significant intraoperative or postoperative bleeding occurs (such as in elderly patients or patients with underlying cardiac or pulmonary disease who have limited cardiopulmonary reserve)","{'shock, my ##oc ##ard ##ial in ##far ##ction, stroke, cardiac or pulmonary disease ##pu'}"
3202,356,Serum total bilirubin less than or equal to ≤ 1.5 × ULN or direct bilirubin ≤ ULN for subjects with total bilirubin levels \> 1.5 × ULN,{''}
3203,358,ECOG performance status 0-2 (Appendix 2 - Performance Status Criteria).,{''}
3204,361,\&lt; 2 structured strength training sessions for less than 30 minutes per week in the last month,{''}
3205,362,"Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 (Karnofsky ≥ 70%). Both T-DXd (DS-8201a) and azenosertib (ZN-c3) have fatigue as an adverse effect. Due to the overlapping adverse effect, the performance status cannot be less restrictive",{''}
3206,364,"Patients must be medically suitable for study treatments as assessed by the appropriate specialties medical, radiation, and surgical",{''}
3207,367,All persons of childbearing potential must provide samples for urine and serum pregnancy testing prior to enrollment and prior to vaccination. Pregnancy risk assessment and pregnancy prevention counseling will occur at each point of contact.,{''}
3208,371,Ability to understand and willingness to sign a written informed consent document,{''}
3209,385,Cardiac functionNew York Heart Association (NYHA) class \< III;Left ventricular ejection fraction (LVEF) ≥ 50%.,{''}
3210,391,Have a history of allogeneic stem cell transplant or liver transplant,{''}
3211,399,Use of medications that are contraindicated with the study,{''}
3212,414,"Participant has mild (Child-Pugh classification Class A, score 5 or 6) or moderate (Child-Pugh classification Class B, score 7 to 9) hepatic impairment at screening","{'he, ##pa ##tic imp ##air ##ment'}"
3213,415,Anticipation of 3 biliary anastomoses (we will include those anticipated to have 1 or 2 biliary anastomoses as detailed below),{''}
3214,416,years of age or older,{''}
3215,421,Or within 10 years of the age of diagnosis of the youngest PDAC blood relative.,{'PD ##AC'}
3216,425,ii. Facial acne IGA score of 3 or 4.,"{'F, ##ac ##ial a ##c ##ne'}"
3217,426,"Able to read, write, speak, and understand English",{''}
3218,432,Age \>= 18 years,{''}
3219,434,"If a patient screens through OPTIONS #2 or #3, results from previously performed molecular profiling must be submitted following enrollment. It is highly recommended that results be uploaded within 7 days of enrollment (if results are available at time of enrollment) or within 7 days of results becoming available (if pending at time of enrollment) to allow adequate time for central review.",{''}
3220,440,Total bilirubin≤1.5x the upper limit of normal (ULN),{''}
3221,442,Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.,{''}
3222,457,"In the opinion of the Investigator, the subject can adhere to the visit schedule, to be compliant with the trial treatment regimen and to complete the study.",{''}
3223,458,Hemoglobin ≥9.0 g/dL (with or without blood transfusions). 11. Adequate hepatic and renal function characterized by the following at screening,{''}
3224,466,A male patient must agree to use contraception during the whole study period and for at least 1 week after the last dose of study treatment and refrain from donating sperms during this period,{''}
3225,476,"Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately",{''}
3226,482,Hemoglobin \>9.0 g/dl (red blood cell/plasma transfusion is not allowed within 2 weeks prior to screening assessment erythropoiesis-stimulating agents/colony- stimulating factors are not allowed within 1 week prior to screening assessment),{''}
3227,513,Able to maintain the visit schedule.,{''}
3228,523,Patients must have a life expectancy ≥ 16 weeks.,{''}
3229,528,Alanine aminotransferase (ALT) ≤ 3.0 × ULN,{''}
3230,547,"Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning. Participants must be fluent in languages for which cognitive and clinical measures have been translated and validated for use in the DIAN-TU. Fluency is generally defined as daily or frequent functional use of a language generally from birth or a young age. In cultures where multiple languages are spoken or for participants who are multilingual, determination as to whether a participant's level of fluency in languages for which clinical and cognitive measures are available meets qualification for the study should be made by the site PI.",{''}
3231,549,"Normal coagulation function, international standardized ratio (INR) ≤ 1.5 x ULN, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN;",{''}
3232,559,Corticosteroids Patients receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to enrollment,{''}
3233,566,o Patients with INSS stage 4s are eligible with the following,{'IN ##SS 4'}
3234,569,Bilirubin ≤ 1.5 x upper limit of normal (ULN),{''}
3235,4,Subjects must have negative surgical margins or microscopic-only positive surgical margins.,{''}
3236,10,"Dense breasts (BIRADS density categories c-heterogeneously dense or d-extremely dense), or",{''}
3237,14,Creatinine =\< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance \>= 30 mL/min for subject with creatinine levels \> 1.5 x institutional ULN (performed within 14 days of treatment initiation),{''}
3238,23,Total bilirubin ≤ 1.5 × ULN or direct bilirubin ≤ ULN for participants with total bilirubin levels \> 1.5 × ULN. For participants with Gilbert's disease ≤ 3.0 mg/dL or discussion with the Medical Monitor,"{""Gilbert ' s disease""}"
3239,27,"This would include changing from MDI to pump or from pump to MDI, and starting a CGM if not previously used",{''}
3240,44,Height ≥ 48 inches,{''}
3241,47,Participant has adequate visual and auditory abilities to perform all aspects of the cognitive and clinical assessments.,{''}
3242,49,Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L (\> 1500 per mm\^3),{''}
3243,58,Platelet count ≥ 100 x 109/L.,{''}
3244,64,Documented or suspected\* autism diagnosis,{'autism'}
3245,73,Prior treatment with 177Lu-PSMA more than 6 weeks before the start of study treatment is required for participants in Dose Expansion Group C.,{''}
3246,74,All patients and/or their parents or legal guardians must sign a written informed consent.,{''}
3247,75,Pneumococcal pneumonia and shingles vaccines are required within 10 years of Screening (allowed to be performed during Screening but must be given at least 4 weeks prior to initiation of immunosuppressant regimen).,"{'P, ##ne ##um ##oc ##oc ##cal pneumonia, s ##hing ##les'}"
3248,76,"History of total colectomy, with no remaining bowel segments.",{''}
3249,94,Minors aged 12 to 15 in Kenya able to provide assent,{''}
3250,98,"Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores 0, 1, or 2; use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age",{''}
3251,109,Active ongoing pulmonary infection or pneumonitis that is requiring active treatment with antibiotics or steroids. Prior pneumonitis from drug or other therapies that has been treated within 15 days of first day of treatment.,"{'pulmonary infection, p, ##ne ##um ##oni ##tis, p, ##ne ##um ##oni ##tis'}"
3252,118,"Participants must have asymptomatic or minimally symptomatic disease, as judged by the treating investigator. For example, patients with bone metastasis associated with mild pain not requiring narcotics for pain control, or patients with lung metastasis associated with mild cough that does not limit the participant's activities, may be considered minimally symptomatic. If confirmation of this criterion is needed, discussion with the protocol chairperson is required prior to enrollment.","{'bone meta ##sta ##sis, pain, lung meta ##sta ##sis, cough'}"
3253,122,to \< 60 mL/min per 1.73 m\^2 for participants with moderate renal impairment,"{'re, ##nal imp ##air'}"
3254,130,Enrollment must be delayed at least 4 weeks from administration of a killed vaccine other than influenza and COVID-19 and 6 weeks from a live vaccination. Live vaccinations and non-live vaccinations (other than influzena and COVID-19) should not be given while on study drug and be postponed at least 3 months after the last dose of study drug.,{''}
3255,139,Part A3,{''}
3256,147,Patients with Performance Status 0-2.,{''}
3257,148,"Participants must be accessible for treatment and follow-up. Investigators must assure themselves the participants enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.",{''}
3258,151,Dose expansion study of combination medication (dose expansion part),{''}
3259,159,Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x institutional upper limit of normal,{''}
3260,161,Females of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 prior to enrolment.,{''}
3261,162,Alkaline phosphatase ≤ 3 x institutional ULN or ≤ 5 x institutional ULN if known liver and/or skeletal metastases,{'liver and / or skeletal meta'}
3262,185,Adequate organ function.,{''}
3263,187,Life expectancy of at least 3 months.,{''}
3264,189,Hepatoblastoma,"{'He, ##pa ##to ##blast ##oma'}"
3265,190,"Female patients must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential",{''}
3266,197,Have a history of allogeneic stem cell transplant or liver transplant,{''}
3267,200,"Degenerative retinal pathology not allowing visual recovery postoperatively (for the purposes of this study, we accept patients who have had retinal detachment and whose loss of vision is clearly attributable to endothelial decompensation)","{'De ##gene ##rative re ##tina ##l path ##ology, re, ##tina ##l detachment, loss of vision, end ##oth ##eli ##al de ##com ##pen ##sation'}"
3268,204,Undergoing a laparoscopic surgery,{''}
3269,205,"pulse rate, 50 to 110 bpm, inclusive",{''}
3270,221,Hemoglobin ≥ 9 g/dL,{''}
3271,223,"iii. Able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian.",{''}
3272,229,For women of childbearing potential agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of \< 1% per year during the treatment period and for at least 90 days after the BAFF CAR-T cell infusion.,{''}
3273,234,Blood routine hemoglobin (HGB) ≥ 90g/L; Absolute neutrophil count (NEUT) ≥ 1.5×10 9 /L; Platelet count (PLT) ≥ 100×10 9 /L;,{''}
3274,249,Life expectancy \> 3 months.,{''}
3275,258,"Risk of compression syndrome (epidural, ureteral, etc)",{'compression syndrome'}
3276,259,Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 50% for patients =\< 16 years of age,{''}
3277,261,Normal manual breast examination by investigator at baseline.,{''}
3278,265,ECOG Performance Status (PS) 0-2. See Appendix F.,{''}
3279,277,"Normal liver function bilirubin \< 1.5 x upper limit of the normal range (ULN); alkaline phosphatase \< 2.5 x ULN (\< 5 x ULN in case of liver metastases, and \< 7 x ULN in case of bone metastases); transaminases (ASAT/ALAT) \< 2.5 x ULN (and \< 5 x ULN in case of liver metastases).","{'liver, bone, liver'}"
3280,281,E586K,{''}
3281,291,Able to complete standard of care clinical questionnaire(s) by themselves or with assistance.,{''}
3282,293,Salazosulfapyridine,{''}
3283,309,Absolute neutrophil count (ANC) ≥1500/mm3(without G-CSF in the 2 weeks prior to treatment start),{''}
3284,318,transferred from other hospitals,{''}
3285,326,"Serum SGPT/ALT \<5.0 x Upper Limit of Normal (ULN),",{''}
3286,327,In-transit and/or satellite metastases with regional lymph node involved permitted if considered potentially surgically resectable at baseline.,{''}
3287,328,No intracerebral brain bleeds.,"{'in, ##tra ##cer ##eb ##ral brain bleed'}"
3288,337,"The subjects should have stable and reliable caregivers, who will take care of them at least 3 days a week and at least 4 hours a day. The caregivers will accompany the subjects to participate in the whole process of the study. Caregivers must accompany the subjects to the study visit and assist the investigator in completing the Neuropsychiatric Inventory (NPI), Alzheimer's Disease Collaborative Study-Ability of Daily Living Scale (ADCS-ADL), and Clinician Interview Based Impression of Severity (CIBIC -plus), and other scale scores;","{""Alzheimer ' s Disease""}"
3289,340,Patient must not be pregnant due to the potential harm to an unborn fetus with the treatment regimens being used.,{''}
3290,343,Platelet count ≥ 100 x 109/L,{''}
3291,344,"Must have no major impairment of coagulation status International normalized ratio (INR) ≤ 1.5 × ULN (without anticoagulation therapy), prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤ ULN.",{'imp ##ment of co ##lation'}
3292,346,Following treatment per CHP 594/Dana-Farber Cancer Institute (DFCI) 34-DAT,{''}
3293,347,Serum creatinine =\< 1.5 x ULN or a calculated creatinine clearance \>= 60 ml/min/1.73 m\^2 (Cockcroft-Gault method) for patients receiving combination of cisplatin and pemetrexed and \>= 45 ml/min/1.73 m\^2 for patients receiving pemetrexed; 24 hour urine for creatinine clearance is acceptable if the calculated creatinine clearance is insufficient,{''}
3294,350,"A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies",{''}
3295,356,Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN except for subjects with liver mets for whom ALT and AST should be ≤ 5× ULN,{'liver met'}
3296,358,Life expectancy of ≥ 12 weeks as estimated by the treating physician.,{''}
3297,361,Confirmed by self-report on Health History Questionnaire,{''}
3298,362,Absolute neutrophil count ≥ 1.5 × 10\^9/L (within 7 days of study treatment initiation),{''}
3299,364,Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen,"{'ma, ##li ##gna ##ncy'}"
3300,367,Willingness to refrain from blood donation during participation in the study and for at least 1 year after receiving the second dose of vaccine.,{''}
3301,371,REGISTRATION INCLUSION CRITERIA,{''}
3302,385,"For premenopausal women, a negative serum pregnancy test must be confirmed within 7 days before the first dose, and they must agree to use effective contraception during the study drug administration period and for 120 days after the last dose.",{''}
3303,391,People with prior clinical pharmacogenetic test results for genes relevant for the study in which they will enroll (CYP2D6 for the pain studies and CYP2D6 or CYP2C19 for depression) or already enrolled in an ADOPT PGx trial,"{'pain, depression'}"
3304,399,Past 30-day suicidal behavior,{'su'}
3305,415,Pregnancy or breastfeeding,{''}
3306,416,Resides within the United States,{''}
3307,421,Individual with a valid United States mailing address. -,{''}
3308,425,"iii. Able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian.",{''}
3309,426,"Individual (and/or his/her legally acceptable representative, as applicable) has signed the Consent for Photograph Release and ICD (and/or Assent Document, as applicable) including Health Insurance Portability and Accountability Act (HIPAA) disclosure.",{''}
3310,432,Patients must have a contraindication to cisplatin as defined in the following bullet points. Sites must complete the online tool at comogram.org prior to registration to determine if the patient is eligible. The scores must be recorded on a case report form (CRF). (Refer to data submission table on the NRG-HN008 protocol page on the NRG website);,{''}
3311,434,"Informed Consent All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.",{''}
3312,440,AST and ALT ≤ 3.0x ULN,{''}
3313,442,Adequately controlled blood pressure (BP) with or without antihypertensive medications.,{''}
3314,457,The patient has a smartphone and can use it.,{''}
3315,458,<!-- -->,{''}
3316,476,"A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria Has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)",{'h'}
3317,482,Absolute neutrophil count 1500/ml (growth factors are not allowed within 2 weeks prior to screening assessment),{''}
3318,513,Willingness to participate in the trial for 4 years.,{''}
3319,523,At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT and is suitable for repeated assessment.,{''}
3320,528,Bilirubin ≤ 1.5 × ULN (unless elevated bilirubin due to leukemic involvement in the liver or Gilbert's disease),"{""le ##uke ##mic involvement in the liver, Gilbert ' s disease""}"
3321,547,Participant has adequate visual and auditory abilities to perform all aspects of the cognitive and clinical assessments.,{''}
3322,549,"Women of childbearing age must undergo a pregnancy test (serum or urine) with a negative result within 14 days before enrollment, and voluntarily use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of the study drug; For males, surgical sterilization or agreement to use appropriate methods of contraception during observation and within 8 weeks after the last administration of study medication should be considered;",{''}
3323,559,Myelosuppressive systemic therapy At least 21 days must have elapsed after the last systemic myelosuppressive therapy.,{''}
3324,566,"MYCN amplification, regardless of additional biologic features Patients must have undergone chemotherapy and surgery for high-risk neuroblastoma prior to enrollment on trial.",{'ne ##uro ##blast ##oma'}
3325,569,Aspartate aminotransferase (AST) ≤ 2.5 × ULN,{''}
3326,4,Final eligibility criteria at 2 months postoperative for randomization include,{''}
3327,10,"Family history of breast cancer (first degree relative with breast cancer), or, positive genetic testing for any deleterious genes that indicate an increased risk for breast cancer, or","{'breast cancer, breast cancer, breast cancer'}"
3328,14,Total bilirubin =\< 1.5 X ULN OR direct bilirubin =\< ULN for subjects with total bilirubin levels \> 1.5 X ULN (performed within 14 days of treatment initiation),{''}
3329,23,Aspartate aminotransferase and alanine transaminase ≤ 2.5 × ULN (≤ 5 × ULN for participants with liver metastases),{''}
3330,27,"This would not include changes to any insulin doses, including basal rates/long acting insulin doses, carbohydrate to insulin ratios and correction factors",{''}
3331,44,Ambulatory without assistance,{''}
3332,47,"Participant is receiving stable doses of medication(s) for the treatment of non-excluded medical condition(s) for at least 30 days prior to baseline visit (V2) except for medications taken for episodic conditions (e.g., migraine abortive therapy, antibiotics, and other medications for upper respiratory and gastrointestinal ailments).","{'e, ##pis ##od ##ic conditions, mi ##gra ##ine, upper respiratory and gas ##tro ##int ##est ##inal a ##il ##ments'}"
3333,49,"Platelet ≥ 100 X 109/L (\>100,000 per mm\^3)",{''}
3334,58,Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).,{''}
3335,64,"In the event of suspected autism diagnosis, the presence of elevated autism symptoms on the Social Responsiveness Scale-2nd Edition or the Autism Diagnostic Observation Scale-2nd Edition","{'autism, autism, Au'}"
3336,73,Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.,{''}
3337,74,"All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.",{''}
3338,76,Pregnant or breastfeeding individuals.,{''}
3339,94,For cross sectionals,{''}
3340,98,Patients may have had surgical resection of some or all sites of hepatoblastoma prior to enrollment,"{'he, ##pa ##to ##blast ##oma'}"
3341,118,"Prior external beam radiotherapy is allowed. For participants with disease limited to a prior radiotherapy field, this must be considered measurable per RECIST v1.1.",{''}
3342,122,"\< 30 mL/min per 1.73 m\^2 and not on hemodialysis, with approximately 50 percent of participants to have eGFR ≤ 20 mL/min per 1.73 m\^2 for participants with severe renal impairment",{'re ##nal imp ##air'}
3343,130,"If participant is female with reproductive potential, she must have a negative pregnancy test at screening and be willing to avoid pregnancy using a highly-effective contraceptive method for the duration of the study",{''}
3344,139,"- Participants are to be Chinese, defined as having both parents and 4 grandparents who are Chinese.",{''}
3345,147,Male patients aged 20 to under 75 at the time of obtaining written consent.,{''}
3346,148,"In accordance with CCTG policy, protocol treatment is to begin within 5 working days of participant enrollment.",{''}
3347,151,The subjects with positive CDLN18.2 expression in tumor tissue confirmed by the central laboratory will be enrolled as follows,{'tumor'}
3348,159,Creatinine =\< 1.5 ULN OR creatinine clearance \>= 50 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal,{''}
3349,161,Lactating females must agree to discontinue nursing before starting study drug.,{''}
3350,162,Lipase ≤ 1.5 x ULN,{''}
3351,185,Modified Ross criteria class 1 and an LVFS \> 25% or an LVEF ≥ 50%.,{''}
3352,187,Availability of ability to swallow tablets,{''}
3353,189,Adrenal coertex carcinoma,{'Ad ##rena ##l co ##ert ##ex car ##cin ##oma'}
3354,190,Male patients must be willing to use barrier contraception,{''}
3355,197,People with prior clinical pharmacogenetic test results for genes relevant for the study in which they will enroll (CYP2D6 for the pain studies and CYP2D6 or CYP2C19 for depression) or already enrolled in an ADOPT PGx trial,"{'pain, depression'}"
3356,200,"End-stage glaucoma not allowing visual recovery post-operatively (for this study, we accept patients who have had filtering surgery for glaucoma, which is stabilized at the time of surgery. Decline in vision must be clearly attributable to endothelial decompensation)","{'End - stage g ##lau ##com ##a, g ##lau ##com ##a, end ##oth ##eli ##al de ##com ##pen ##sation'}"
3357,204,"Receiving chronic opioid therapy, defined as use of opioids on most days for \>3 months",{''}
3358,205,Had impaired hepatic function as defined by the Child-Pugh classification for severity of liver disease and had a Child-Pugh score in line with one of the following HI groups at Screening,{'liver disease'}
3359,221,"Platelet Count (PLT) ≥ 100,000 per mm3",{''}
3360,229,"For men agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.",{''}
3361,234,"Renal function creatinine (Cr) ≤1.5 ULN, or creatinine clearance (Ccr) ≥50 mL/min (according to Cockcroft and Gault formula).",{''}
3362,258,Leukemic phase of disease,{'Le ##uke ##mic'}
3363,259,"Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age",{''}
3364,261,"Baseline hematology, clinical chemistry, urinalysis, prothrombin time/partial thromboplastin time (PT/PTT) and viral serologies for human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B surface antigen (HBsAg) all within normal limits OR accepted by the investigator and medical monitor as not clinically significant.","{'human im ##mu ##no ##de ##ficiency virus, HIV, he ##pa ##titis C virus, HC ##V, he ##pa ##titis B'}"
3365,265,Baseline ejection fraction ≥50% by MUGA scan or echocardiogram performed ≤60 days prior to registration.,{''}
3366,277,Normal renal function,{''}
3367,281,L597Q/V/S,{''}
3368,293,Gold,{''}
3369,309,"Platelet count ≥ 100,000/mm3",{''}
3370,326,"Serum total bilirubin \<2.0 mg/dL or direct bilirubin ≤30% of the total, unless the patient has Gilbert's syndrome, where direct bilirubin should then be \<2.0 mg/dL,","{""Gilbert ' s syndrome""}"
3371,327,NOTE Patients whose sole site of disease is regional lymph node involvement of the parotid LN basin are not eligible for this neoadjuvant study.,{''}
3372,328,"Access to a mobile device, laptop or desktop computer with internet access and Bluetooth.",{''}
3373,337,"Agree to participate and sign the informed consent form by the legal guardian. Due to the subject's limited cognitive ability and other reasons, the subject's signature is allowed to be left blank, and the reason is explained. In addition, the legal guardian shall sign the reason statement, and the legal guardian shall sign the informed consent.",{''}
3374,340,All patients of childbearing potential must have a serum or urine study with a sensitivity of at least 25 mIU/mL within 14 days prior to registration to rule out pregnancy and again within 24 hours prior to starting cycle 1 day 1 of treatment.,{''}
3375,343,Blood chemistry laboratory value for serum creatinine \< 1.5 x ULN (test to be performed within \<4 weeks of biopsy),{''}
3376,344,May be male or female.,{''}
3377,346,"No more than 12 months from the date of starting the first induction chemotherapy after diagnosis to the date of ASCT except for the rare occasions as noted below; for tandem ASCT patients, this will be the date of the FIRST stem cell infusion; exception for those who are initially diagnosed as non-high risk neuroblastoma, but later converted (and/or relapsed) to high risk neuroblastoma, the 12 months restriction should start from the date of induction therapy for high risk neuroblastoma (not from the initial induction therapy for non-high risk disease), to the date of ASCT","{'AS ##CT, ne ##uro ##blast ##oma, ne ##uro ##blast ##oma, ne ##uro ##blast ##oma'}"
3378,347,For patients enrolled in Arm B (first stage of phase II of TRC102 and pemetrexed) measurable disease is required according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural mesothelioma; pleural effusion and ascites are not considered measurable disease,"{'Solid Tu ##mor, solid tumors, ma, ##li ##gnant p ##le ##ural me ##so ##the ##lio ##ma, p, ##le ##ural e ##ff, as'}"
3379,350,Not a women of child-bearing potential (WOCBP) or,{''}
3380,356,International Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants,{''}
3381,358,"Resolution of all acute, reversible toxic effects of prior therapy or surgical procedure to Grade ≤1 (except alopecia and peripheral neuropathy to Grade ≤2).","{'al ##ope ##cia, peripheral ne ##uro ##pathy'}"
3382,361,Home internet sufficient for videoconferencing,{''}
3383,362,No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment,{''}
3384,364,"Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up",{''}
3385,367,Willingness to refrain from receiving vaccines or other investigational products during the first 90 days of the study after enrollment.,{''}
3386,371,"Serum or plasma HCV RNA level \>= 10,000 IU/mL",{''}
3387,385,Compliance with the trial schedule and follow-up procedures,{''}
3388,391,Chronic Pain,{'Ch Pain'}
3389,399,Use of continuous positive airway pressure (CPAP) device for sleep apnea,{'sleep a ##p ##nea'}
3390,415,Non-liver cancers (we will include certain patients with primary liver cancer as detailed below),"{'Non - liver cancer, liver cancer'}"
3391,416,Self-reported medical insurance which can be in or out of network with MSK,{''}
3392,426,"Subject must avoid sun exposure, or use sunscreen if sun exposure is unavoidable.",{''}
3393,432,"Age \>= 70 with moderate to severe comorbidity, defined as having one or more of the following conditions within 30 days prior to registration;",{''}
3394,434,Enrollment timeline Patients are eligible to enroll on the TarGeT-SCR anytime between diagnosis and the following specific timepoints post completion of RT,{''}
3395,440,Albumin ≥ 3.5 g/dL,{''}
3396,442,Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).,"{'Human im ##mu ##no ##de ##ficiency virus, HIV, HIV'}"
3397,458,Serum total bilirubin ≤1.5 x ULN. Note 1 Total bilirubin \>1.5 x ULN is allowed if direct (conjugated) ≤1.5 x ULN and indirect (unconjugated) bilirubin is ≤4.25 x ULN.,{''}
3398,476,Ability to understand and the willingness to sign a written informed consent,{''}
3399,482,"Platelets 75,000/ml",{''}
3400,513,Interested in wearing contact lenses for approximately 10 hours per day and 6 days per week.,{''}
3401,528,Ability to understand and willingness to sign the informed consent.,{''}
3402,547,"If participant is receiving stable doses of medication(s) for the treatment of non-excluded medical condition(s) for at least 30 days prior to baseline visit (V2) except for medications taken for episodic conditions (e.g., migraine abortive therapy, antibiotics, and other medications for upper respiratory and gastrointestinal ailments).","{'e, ##pis ##od ##ic conditions, mi ##gra ##ine, upper respiratory and gas ##tro ##int ##est ##inal a ##il ##ments'}"
3403,549,"Comply with the scheduled visits, treatment plans, laboratory tests, and other requirements of the study;",{''}
3404,559,Surgery At least 6 weeks must have elapsed since surgery.,{''}
3405,566,Age at time of enrollment of ≥1 month and ≤18 years,{''}
3406,569,Alanine aminotransferase (ALT) ≤ 2.5 × ULN,{''}
3407,4,FK-PC101 has been produced for the subject and meets all release specifications.,{''}
3408,10,Currently on hormone therapy; OR,{''}
3409,14,Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine transferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X ULN OR =\< 5 X ULN for subjects with liver metastases (performed within 14 days of treatment initiation),{'liver'}
3410,23,Serum albumin \> 2.5 g/dL,{''}
3411,27,"Current use of non-FDA approved closed-loop or hybrid closed-loop insulin delivery system (e.g. ""Loop"" or ""Open APS"")",{''}
3412,44,English speaking,{''}
3413,47,"The participant has a study partner who in the PI's judgment can provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide information at the study visits that require study partner input for scale completion, and who signs the necessary ICF, if applicable.",{''}
3414,49,Hemoglobin ≥ 8.0 g/dL,{''}
3415,58,"Aspartate aminotransferase/Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and Alanine aminotransferase/Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤ 2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x ULN.",{''}
3416,64,Non-Autistic Child/Caregiver Participants (enrolled in a dyad with a participating therapist),{'Au'}
3417,73,"Adequate bone marrow, hepatic, and renal function, as assessed by the following laboratory requirements within 30 days before start of study treatment, as indicated below. Note that blood transfusions (red blood cells or platelets) and administration of G-CSF or GM-CSF are prohibited within 21 days prior to screening for the below bone marrow-related parameters.",{''}
3418,76,Presence of advanced colorectal cancer or metastatic cancer in other locations.,"{'advanced color ##ec ##tal cancer, meta ##static cancer'}"
3419,94,Residents of the area for at least 3 months prior to enrolment,{''}
3420,98,"Organ function requirements are not required for enrolled patients who are stage I, PFH and will not be receiving chemotherapy",{'P ##H'}
3421,118,"Participants may have had no more than one prior systemic therapy for RAI-refractory thyroid cancer, including lenvatinib, sorafenib, or other MKIs. This also includes chemotherapy and/or targeted therapy administered within a clinical trial, but does not include I-131 NaI or levothyroxine. Prior RET-specific kinase inhibitor therapy, such as selpercatinib and pralsetinib, is not allowed.",{'RA ##I - re ##fra ##ctor ##y thy ##roid cancer'}
3422,122,Participant has adequate venous access.,{''}
3423,130,Males of reproductive age must use a highly-effective contraceptive method during the treatment phase and for 3 months following last dose of study drug,{''}
3424,147,Patients who provided voluntary written consent to participate in this clinical trial.,{''}
3425,148,"If the participant and the participant's partner are of childbearing potential, they must agree to use medically accepted methods of contraception",{''}
3426,151,Cohort C/G Subjects with HER2 negative or unknown G/GEJ adenocarcinoma who have not received prior systemic chemotherapy. The subjects who have completed neoadjuvant or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study can be enrolled.,{'G / GE ##J ad ##eno ##car ##cin ##oma'}
3427,159,Serum albumin \>= 28 g/L,{''}
3428,161,Subjects must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.,{''}
3429,162,Creatinine ≤ 1.5 x institutional ULN OR glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m\^2,{''}
3430,185,Adequate pulmonary function.,{''}
3431,187,"Adequate organ function within 28 days prior to enrolment, as defined by",{''}
3432,189,"Pediatric solid tumors (including central nervous system \[CNS\] tumors) with known molecular alterations in the targets of XL184 (i.e., MET amplification, overexpression, activating mutation, MET translocation, MET exon skipping mutations, activating RET mutations, RET rearrangement, overexpression or activation of AXL); documentation of the alteration from a Clinical Laboratory Improvement Act (CLIA) certified laboratory will be required",{'central nervous system \\ [ C ##NS \\ ] tumors'}
3433,197,Depression Trial,{''}
3434,200,Personal history of corneal transplantation on the eye to be operated on,{''}
3435,205,"Group 1; mild (Class A); Child-Pugh score 5-6, inclusive",{''}
3436,221,Calculated creatinine clearance ≥ 40 mL/min,{''}
3437,234,"Liver function total bilirubin (TBIL≤1.5 ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were all ≤2.5 ULN, and AST and ALT were both ≤5.0 ULN when liver metastasis was present;",{'liver'}
3438,258,"Cytopenia deemed due to disease involvement (hemoglobin \< 10, granulocyte count \< 1.5×10\^9/L, or platelet count \< 100×10\^9/L)",{'Cy ##top ##enia'}
3439,259,Myelosuppressive chemotherapy Patients must not have received within 14 days of entry onto this study,{''}
3440,261,Normal 12-lead electrocardiogram (ECG).,{''}
3441,265,The following laboratory values obtained ≤14 days prior to registration,{''}
3442,277,\> calculated (Cockcroft-Gault) or measured creatinine clearance \> 50 mL/min,{''}
3443,281,T599TT/TS,{''}
3444,293,D-penicillamine,{''}
3445,309,Hemoglobin ≥ 9 g/dL (without blood transfusion in the 2 weeks prior to treatment start),{''}
3446,326,Serum albumin ≥\<2.5 gr/dl (medication to correct serum albumin levels is permitted).,{''}
3447,327,NOTE Patients with only in-transit and/or satellite metastases without regional lymph node involvement are not eligible for this neoadjuvant study.,{''}
3448,340,"A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)","{'am, ##eno ##rr ##hea, cancer'}"
3449,343,Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal),{'h ##ec'}
3450,344,A male participant with a female partner of childbearing potential must agree to remain sexually abstinent or use condoms during the treatment period with MVX-ONCO-2 and for 60 days after the last treatment; and the patient must also refrain from donating sperm during this period.,{''}
3451,346,"At pre-ASCT evaluation patients must meet the International Neuroblastoma Response Criteria (INRC) for CR, VGPR, or PR for primary site, soft tissue metastases and bone metastases; patients who meet those criteria must also meet the protocol specified criteria for bone marrow response as outlined below","{'N, ##eur ##ob ##last ##oma'}"
3452,347,Patients must be able to swallow whole capsules; nasogastric or gastrointestinal (G)-tube administration is not allowed,{''}
3453,350,A WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 20 weeks after the last dose of study intervention.,{''}
3454,356,Activated PTT (aPTT) ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulant,{''}
3455,358,Adequate organ function.,{''}
3456,361,Confirmed by staff review of Internet Connectivity Screening Guide with the participants and outcome recorded in a CRF,{''}
3457,362,No administration of granulocyte colony-stimulating factor is allowed within 1 week prior to screening assessment,{''}
3458,364,"In accordance with CCTG policy, ablative therapy to metastases is to begin within 6 weeks after patient randomization",{''}
3459,371,"Screening HCV genotype, demonstrating genotype 1",{'HC'}
3460,391,Plan to move out of the area within 6 months of enrollment,{''}
3461,415,Treatment with any investigational drug / device within 60 days prior to study entry,{''}
3462,416,"Self-reported ""very well"" comprehension of written and verbal English language",{''}
3463,426,Subject must avoid professional or facial spa procedures during the study.,{''}
3464,432,Modified Charlson Comorbidity Index \>= 1,{''}
3465,434,Patients screening through OPTION #1 are eligible to enroll anytime between diagnosis and 10 days post RT.,{''}
3466,440,Adequate renal function defined by the following laboratory results obtained within 11 days prior to first study treatment,{''}
3467,442,Male participants must agree to follow contraceptive guidance.,{''}
3468,458,"Note 2 Participants with hyperbilirubinemia due to non-hepatic cause (e.g., hemolysis, hematoma) may be enrolled following discussion and agreement with the medical monitor.","{'h ##yper ##bil ##ir ##ubi ##ne ##mia, hem ##oly ##sis, hem ##ato ##ma'}"
3469,482,Total bilirubin $1.5 x institutional upper limit of normal (ULN). Documented Gilbert syndrome is allowed if total bilirubin is $3 x ULN.,{'Gilbert syndrome'}
3470,513,"Possesses, or obtains prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.",{''}
3471,528,"For the duration of the study treatment period and for at least 90 days following the last dose of study drug female of childbearing potential (FCBP) who are sexually active must agree to employ effective contraceptive methods. Effective contraceptive methods include use of hormonal contraception or an intrauterine device (IUD) by the female partner, or use of condoms by the male partner. An FCBP is a sexually mature woman who 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).","{'FC, FC ##B'}"
3472,547,"The participant has a study partner who in the PI's judgment can provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide information at the study visits that require study partner input for scale completion, and who signs the necessary ICF, if applicable.",{''}
3473,559,Organ Function Requirements,{''}
3474,566,Female patients of childbearing potential must have a negative pregnancy test within 14 days of radiation start.,{''}
3475,569,"Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration. NOTE Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months",{''}
3476,4,An undetectable PSA (\<0.04 ng/mL) on the most recent test performed prior to randomization (Day -4 to -7).,{''}
3477,10,Post-menopausal ages 70-74 with either of the following two risk factors,{''}
3478,14,International normalized ratio (INR) or prothrombin time (PT) =\< 1.5 X ULN unless patient is receiving anticoagulant therapy (as long as PT or partial thromboplastin time \[PTT\] is within therapeutic range of intended use of anticoagulants) (performed within 14 days of treatment initiation),{''}
3479,23,Serum calcium \< 12 mg/dL or corrected serum calcium \< ULN,{''}
3480,27,Unwilling to switch to lispro or aspart for the duration of the study's iLet arm (e.g. from Fiasp or Lyumjev),{''}
3481,44,No history of arrhythmia or known cardiac dysfunction at baseline,"{'a, ##rr ##hy ##th ##mia, cardiac d ##ys ##function'}"
3482,47,"The participant agrees not to donate blood or blood products for transfusion from the time of Screening (V1) for a study drug arm, for the duration of the study, and for 5 half lives after the final dose of study drug.",{''}
3483,49,"Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN). (Unless Gilbert's Syndrome, for which Bilirubin ≤ 3 x institutional upper limit of normal (ULN), without concurrent clinically significant liver disease) AST (SGOT)/ALT (SGPT) ≤ 3 x institutional upper limit of normal (ULN) unless liver metastases are present, in which case it must be ≤ 5x ULN.","{""Gilbert ' s S ##yn ##drome, liver disease""}"
3484,58,Serum creatinine ≤ 1.5 x institutional ULN and glomerular filtration rate of at least 40 ml/minute according to Cockroft-Gault formula.,{''}
3485,64,Child age 7-12 years,{''}
3486,73,Hemoglobin ≥9.0 g/dL,{''}
3487,76,"Previous radiotherapy, chemotherapy, or tumor immunotherapy.",{'tumor'}
3488,94,Parent/guardian's consent for minors,{''}
3489,98,Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 OR serum creatinine based on age/gender as follows,{''}
3490,118,"At least 28 days must have passed since any prior radiation or major surgery. At least 28 days must have passed since any prior systemic therapy for thyroid cancer, excluding thyroid hormone replacement.",{'thy ##roid cancer'}
3491,130,"For COVID-19 vaccination, all participants will be strongly encouraged to be up-to-date with COVID-19 vaccine (s) as indicated by country-specific guidelines at least 2 weeks prior to the baseline visit (V0).",{''}
3492,148,HIV-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.,{'HIV'}
3493,151,Cohort D The subjects with G/GEJ adenocarcinoma who have received at least prior first-line systemic chemotherapy; Cohort F The subjects with biliary neoplasm who have not received prior systematic chemotherapy. The subjects who have completed neoadjuvant or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study can be enrolled.,"{'G / GE ##J ad ##eno ##car ##cin ##oma, bi ##lia ##ry neo ##p ##las ##m'}"
3494,159,Lipase =\< 2 ULN,{''}
3495,162,International normalized ratio (INR) ≤ 1.5 x ULN,{''}
3496,185,Participant and/or the legal guardian who provided consent is willing for the participant to receive optimal supportive care.,{''}
3497,187,Hb ≥10 g/dl (packed red blood transfusion is acceptable up to 24 hours prior starting treatment);,{''}
3498,189,Note Documentation of any known tumor molecular alterations and RET mutation status for patients with MTC (germline) must be uploaded via the RAVE system,"{'tumor, M ##TC'}"
3499,197,Plan to move out of the area within 6 months of enrollment,{''}
3500,200,Medical contraindication to general or local anesthesia,{''}
3501,205,"Group 2; moderate (Class B); Child-Pugh score 7-9, inclusive",{''}
3502,221,"Bilirubin ≤ 1.5 × upper limit of normal (ULN); subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), may be allowed with sponsor-investigator approval.","{""Gilbert ' s syndrome, h ##yper ##bil ##ir ##ubi ##ne ##mia, hem ##sis, he, ##pa ##tic path""}"
3503,234,coagulation function international normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5ULN;,{''}
3504,258,"In addition to meeting GELF criteria, must have at least one FDG-avid site on PET that measures 1.5 cm in at least one dimension of a nodal site or 1cm in at least one dimension for extranodal sites.",{'GE'}
3505,259,Investigational agent or any other anticancer therapy not defined above Patients must not have received any investigational agent or any other anticancer therapy (including MAPK pathway inhibitor) for at least 14 days prior to planned start of tovorafenib (DAY101),{''}
3506,261,"Able to read, understand, and provide written informed consent and applicable data protection authorization after the nature of the study has been fully explained, and must be willing to comply with all study requirements.",{''}
3507,265,Absolute neutrophil count (ANC) ≥1500/mm3,{''}
3508,277,"INR \< 1.5 and APTT normal, unless patient is on stable anti-coagulant treatment for at least two weeks with a low molecular weight heparin or coumarin, then an INR within the target range (usually between 2 and 3) is allowed.",{''}
3509,281,T599I/K,{''}
3510,293,Lobenzarit,{''}
3511,309,"All patients (males and females) of childbearing potential must agree to use medically effective contraception during the study and for 6 months after the last dose of study drugs. A negative urine or serum pregnancy test in women of childbearing potential is required within 72 hours prior to first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",{''}
3512,327,NOTE Determination of potential resectability must be made at baseline to be eligible for this neoadjuvant study.,{''}
3513,340,"Patients of childbearing potential must not expect to conceive children by abstaining from sexual intercourse or by using accepted and effective methods of contraception throughout the entire duration of protocol treatment, including during dose interruptions, and for 6 months after the last dose of protocol treatment. Male patients must not father children by abstaining from sexual intercourse or by using a condom during sexual contact with pregnant partners or partners of childbearing potential throughout the entire duration of protocol treatment, including dose interruptions, and for 6 months after the last dose of protocol treatment even if they have had a successful vasectomy",{''}
3514,343,All patients of reproductive potential must agree to use an effective method of contraception during the study,{''}
3515,344,"A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies",{''}
3516,346,=\< 10% tumor (of total nucleated cellular content) seen on any specimen from a bilateral bone marrow aspirate/biopsy,{'tumor'}
3517,347,"The effects of TRC102 on the developing human fetus are unknown; for this reason and because TRC102 as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after completion of the study drugs; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of TRC102, pemetrexed and cisplatin administration; non-childbearing potential is defined as (by other than medical reasons) \>= 45 years of age and has not had menses for \>= 2 years, amenorrheic for \< 2 years without hysterectomy and oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pretrial (screening) evaluation, or post hysterectomy, oophorectomy or tubal ligation; documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by ultrasound; tubal ligation must be confirmed with medical records of the actual procedure otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit though 4 months after the last dose of study drugs","{'non, am, ##eno ##rr ##he ##ic'}"
3518,356,Female patients of childbearing potential must have a negative pregnancy test documented at time of screening.,{''}
3519,358,"If not postmenopausal or surgically sterile, female patients and female sexual partners of male patients must be willing to use at least one highly effective method of birth control (hormonal contraception, IUD, abstinence, condom) for at least a menstrual cycle before and for 3 months after last study drug administration.",{''}
3520,361,Signed informed consent,{''}
3521,362,Hemoglobin \> 9.0 g/dL (within 7 days of study treatment initiation),{''}
3522,364,Men of childbearing potential must have agreed to use a highly effective contraceptive method to prevent pregnancy while on study,{''}
3523,371,"Alpha feto protein (AFP) levels within normal institutional limits or judged to be not clinically significant by the investigator; Exception If deemed clinically significant, then liver imaging must be available within previous 6 months (e.g., ultrasound, computed tomography \[CT\] scan, magnetic resonance imaging \[MRI\]) showing no evidence of hepatocellular carcinoma","{'he, ##pa ##to ##cellular car ##cin ##oma'}"
3524,391,Undergoing treatment for an active cancer diagnosis,{'cancer'}
3525,415,Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of AMSCs,{''}
3526,416,STRIVE Trial VUS Patients,{''}
3527,432,Adult Comorbidity Evaluation (ACE)-27 Index \>= 1,{''}
3528,434,Patients screening through OPTIONS #2 or #3 are eligible to enroll anytime between diagnosis and 21 days post RT.,{''}
3529,440,° Serum creatinine≤1.5x ULN OR creatinine clearance ≥50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation,{''}
3530,442,"Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.","{'W, W'}"
3531,458,"ALT and AST ≤2.5 × ULN, or ≤5 × ULN in the presence of liver metastases.",{''}
3532,482,Aspartate transaminase/ALT $2.5 x institutional ULN. Transaminases up to 5 x ULN in the presence of liver metastases.,{''}
3533,528,"For the duration of the study treatment period and for at least 90 days following the last dose of study drug, male patients must agree to use effective contraceptive methods during sexual contact with a female of childbearing potential (FCBP) and must agree to refrain from semen or sperm donation during the same timeframe.",{'child'}
3534,547,"The participant agrees not to donate blood or blood products for transfusion from the time of Screening (V1) for a study drug arm, for the duration of the study, and for 5 half lives after the final dose of study drug.",{''}
3535,559,Adequate Bone Marrow Function Defined as,{''}
3536,566,Female patients who are lactating must agree to stop breast-feeding.,{''}
3537,569,Males who are sexually active with partners of child-bearing potential must be willing to abstain from heterosexual activity or adhere to contraception from the time of written consent until 7 months after treatment discontinuation.,{''}
3538,4,"No prior, current, or planned future postoperative or adjuvant XRT, hormonal therapy such as ADT, or any other anticancer therapy (future therapy should not be administered until evidence exists of prostate cancer disease recurrence \[such as PSA recurrence\]).","{'pro, ##state cancer, PS'}"
3539,10,"Dense breasts (BIRADS density categories c-heterogeneously dense or d-extremely dense), or",{''}
3540,14,Activated partial thromboplastin time (aPTT) or PTT =\< 1.5 X ULN unless patient is receiving anticoagulant therapy (as long as PT or PTT is within therapeutic range of intended use of anticoagulants) (performed within 14 days of treatment initiation),{''}
3541,23,"Female participants of childbearing potential who are sexually active with a non-sterilized male partner must agree to use at least 1 highly effective method of contraception from the time of screening and must agree to continue using such precautions for 120 days after the last dose of study drug for participants who receive soquelitinib, or 6 months after the last dose for participants who receive either belinostat or pralatrexate.",{''}
3542,27,Known hemoglobinopathy (sickle cell trait is not an exclusion),"{'hem ##og ##lo ##bino ##pathy, sick ##le cell trait'}"
3543,44,Normotensive (\<95th percentile for age; okay if managed with antihypertensive medication),{''}
3544,47,"In the opinion of the PI, the participant will be compliant and have a high probability of completing the study.",{''}
3545,49,Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN).,{''}
3546,58,Patient is female and ≥18 years of age at the time of the first screening visit.,{''}
3547,64,Receiving services from an enrolled provider,{''}
3548,73,Absolute neutrophil count (ANC) ≥1500/mm\^3,{''}
3549,76,History of alcohol or other substance abuse.,{'alcohol'}
3550,94,Ability to provide assent for minors aged 12 to 17,{''}
3551,98,month to \< 6 months 0.4 mg/dL,{''}
3552,118,Participants must be ≥18 years of age. Patients as young as 12 years of age will be allowed if permitted by local regulatory authorities and institutional review boards.,{''}
3553,148,Participant access to all protocol therapies must be confirmed prior to enrollment,{''}
3554,151,Cohort H The subjects with G/GEJ adenocarcinoma who have received at least prior second-line systemic chemotherapy;,{'G / GE ##J ad ##eno ##car ##cin ##oma'}
3555,159,Urine protein/ creatinine ratio (UPCR) =\< 1,{''}
3556,162,Partial thromboplastin time (PTT) ≤ 1.5 x ULN,{''}
3557,185,A legal guardian or primary caregiver must be available to help the study-site personnel ensure follow-up and accompany the participant to the study site on each assessment day according to the SoA.,{''}
3558,187,White blood cell (WBC) count ≥ 2500/µL (equivalent to 2.5 x 109/L),{''}
3559,189,Patients must have radiographically measurable disease; measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm),{''}
3560,197,"Have active psychosis or diagnosed psychotic disorders (schizophrenia, schizoaffective disorder, delusional disorder, psychotic depression, substance induced psychosis, schizophreniform disorder)","{'ps ##ych ##osis, ps, ##ych ##otic disorders, s ##chi ##zophrenia, s ##chi ##zo ##af ##fect ##ive disorder, del ##usion ##al disorder, ps, ##ych ##otic depression, substance induced ps ##ych ##osis, s, ##chi ##zo ##ph ##ren ##iform disorder'}"
3561,200,Patient under legal protection,{''}
3562,205,"Group 3; severe (Class C); Child-Pugh score 10-15, inclusive",{''}
3563,221,"Apsartate aminotransferase (AST) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤5x ULN",{'liver'}
3564,234,no severe cardiac dysfunction with left ventricular ejection fraction ≥50%;,{'cardiac d ##ys ##function'}
3565,258,"Received no prior therapy except local radiation therapy (field did not exceed 2 adjacent nodal regions), single agent rituximab (limited to 4 doses), or steroids for symptom control in the 28 days preceding trial enrollment.",{''}
3566,259,Radiation therapy (RT) Patient must not have received RT within 2 weeks after the last dose fraction of RT,{''}
3567,261,Willing and able to correctly and independently complete all study procedures.,{''}
3568,265,"Platelet count ≥100,000/mm3",{''}
3569,277,Written informed consent,{''}
3570,281,V600_K601delinsE,{''}
3571,293,Actarit,{''}
3572,309,"Have no concomitant medical condition (including, but not limited to, ongoing or active infection or any psychiatric disorder), that in the judgment of the investigator will interfere with the patient's ability to participate in the study or render such participation medically inappropriate.","{'infection, psychiatric disorder'}"
3573,327,NOTE Patients with mucosal and/or uveal melanoma are not permitted to enroll. Patients with melanomas of unknown primary may be enrolled at the discretion of the treating investigator in discussion with Principal Investigator.,"{'m ##uc ##osa ##l and / or u ##ve ##al me ##lan ##oma, me, ##lan ##oma'}"
3574,340,Male patients must agree to not donate semen or sperm during the entire duration of protocol treatment or for at least 28 days after the last dose of lenalidomide even if they have had a successful vasectomy,{''}
3575,343,Patients must be accessible for follow-up,{''}
3576,344,i. Not a woman of childbearing potential (WOCBP). OR ii. A WOCBP who has had a negative pregnancy test within 7 days before the first study treatment and agrees to follow contraceptive guidance during the treatment period and for at least 60 days after the last dose of study treatment.,"{'W, W, ##OC ##B'}"
3577,346,"Patient who have no tumor seen on the prior bone marrow, and then have =\< 10% tumor on any of the bilateral marrow aspirate/biopsy specimens done at pre-ASCT and/or pre-enrollment evaluation will also be eligible (note that per INRC this would have been defined as ""overall"" response of progressive disease \[PD\])",{'tumor'}
3578,347,Ability to understand and the willingness to sign a written informed consent document,{''}
3579,356,Female patients who,{''}
3580,361,Confirmed by completion of e-Consent in REDCap,{''}
3581,362,No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment,{''}
3582,364,"Patient must consent to provision of, and Investigator must confirm location of and commit to obtain a representative formalin fixed paraffin block of tumour tissue in order that the specific correlative studies described in the protocol may be conducted. Where tissue exists but local centre regulations prohibit submission of blocks of tumour tissue, the approval of the CCTG must be sought prior to randomization of the first patient to allow cores (two 2 mm cores of tumour from the block) and slides (20 x 5 micron thick unstained slides) of representative tumour tissue to be substituted","{'t, t, t'}"
3583,371,Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1,{''}
3584,391,"Currently taking daily opioids other than tramadol, codeine or hydrocodone",{''}
3585,415,Patients who are employees or relatives of the investigator,{''}
3586,416,Current MSK patient,{'MS'}
3587,432,Omega score \< 0.80,{''}
3588,434,"However, it is important to note the following",{''}
3589,440,HbA1c ≤ 7.9 %,{''}
3590,442,Adequate organ function.,{''}
3591,458,"Adequate renal function defined by an estimated creatinine clearance ≥50 mL/min according to the Cockcroft Gault formula or by 24-hour urine collection for creatinine clearance, or according to local institutional standard method.",{''}
3592,482,Serum creatinine $1.5 x ULN OR measured or calculated creatinine clearance (CrCI; glomerular filtration rate can also be used in place of creatinine or CrCI) 30 ml/min for patients with creatinine levels \>1.5 x institutional ULN (CrCI should be calculated per institutional standard),{''}
3593,547,"In the opinion of the PI, the participant will be compliant and have a high probability of completing the study.",{''}
3594,559,Peripheral absolute neutrophil count (ANC) ≥1000/mm3,{''}
3595,566,Sexually active patients of childbearing potential must agree to use effective contraception.,{''}
3596,569,Patient must provide voluntary written informed consent prior to the performance of any research related tests or procedures.,{''}
3597,4,Adequate organ function based on CBC and chemistry studies within 2 weeks of Day 1 (Day -14 to -7). Specific laboratory requirements include,{''}
3598,10,Currently on hormone therapy,{''}
3599,23,Non-sterilized males who are sexually active with a female partner of childbearing potential must use a condom plus spermicide from Day 1 through 120 days after the last dose of study drug.,{''}
3600,27,"Current participation in another diabetes-related clinical trial, has a medical condition, or use of a medication that, in the judgment of the investigator, could compromise the results of this study or the safety of the participant",{'diabetes'}
3601,44,SpO2 \>95%,{''}
3602,47,"The participant is able and willing to complete all study-related testing, evaluations, and procedures.",{''}
3603,49,"For patients of childbearing potential, agreement to use two effective forms of contraception (e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive hormone implants) and to continue its use for the duration of the study and for 12 weeks after the last ZW25 dose.",{''}
3604,58,Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.,{''}
3605,64,No history of documented or suspected autism diagnosis,{'autism'}
3606,73,"Platelet count ≥100,000/mm\^3",{''}
3607,94,Written consent from adults,{''}
3608,98,months to \< 1 year 0.5 mg/dL,{''}
3609,118,-- All patients of 12 to \< 18 years of age will be asked to provide assent and the legally designated representative will be asked to provide written consent.,{''}
3610,151,ECOG performance status of 0-1;,{''}
3611,159,Prothrombin time (PT)/ international normalized ratio (INR) and partial thromboplastin time (PTT) test =\< 1.3 ULN,{''}
3612,162,"Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial provided they are on a stable regimen of anti-retroviral therapy (ART) with no medications otherwise prohibited by this protocol (e.g., drug-drug interactions)","{'Human im ##mu ##no ##de ##ficiency virus, HIV - infected'}"
3613,187,Absolute Neutrophil Count (ANC) ≥ 1000/µl;,{''}
3614,189,Note The following do NOT qualify as measurable disease,{''}
3615,197,"Have dementia or other neurocognitive disorders due to any cause, such as Alzheimer's disease, vascular/subcortical, lewy body disease, frontotemporal lobar degeneration","{""dem ##ent ##ia, ne ##uro ##co ##gni ##tive disorders, Alzheimer ' s disease, vascular / sub ##cor ##tical , le ##wy body disease, front ##ote ##mpo ##ral lo ##bar de ##gene ##ration""}"
3616,200,Pregnant or breast-feeding women,{''}
3617,205,Stable Child-Pugh status and no worsening of more than 1 point in Child-Pugh score within 28 days prior to first dosing of study treatment.,{''}
3618,221,"Alanine aminotransferase (ALT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤5x ULN",{''}
3619,234,proteinuria ≤2+ or ≤1000mg/24h.,{'protein'}
3620,258,"Must have prior EZH2 testing already performed or have tissue available to perform retrospective EZH2 testing. If prior EZH2 results are not available, tissue must be submitted. Tissue block is preferred but unstained slides are also acceptable. Patients who have insufficient or suboptimal tissue must be willing to have a biopsy performed prior to starting study drugs. See Correlative Lab Manual for details.",{''}
3621,259,Patients must have fully recovered from any prior surgery,{''}
3622,265,Hemoglobin \>9.0 g/dL,{''}
3623,281,K601E/N/T,{''}
3624,293,Bucillamine,{''}
3625,309,"No medical history of another cancer (except basal or squamous cell skin cancer or in situ cervical cancer, or carcinomas in situ or other malignancies with a ≥95% 5-year survival) within 2 years of the start of study treatment.","{'cancer, basal or sq ##ua ##mous cell skin cancer, in sit ##u c ##er ##vic ##al cancer, car, ##cin ##oma ##s in sit ##u, ma, ##li ##gna ##ncies'}"
3626,327,Presence of injectable and measurable disease based on RECIST 1.1.,{''}
3627,340,Patient must agree to abstain from breastfeeding during the entire duration of protocol treatment and for at least 6 months after the last dose of protocol treatment,{''}
3628,344,"Has the ability to understand the concept of a clinical study and be willing and have the ability to comply with scheduled visits (including geographical proximity), treatment plans, laboratory tests, and other study procedures.",{''}
3629,346,"Prior to enrollment on ANBL0032, a determination of mandatory disease staging must be performed (tumor imaging studies including computed tomography \[CT\] or magnetic resonance imaging \[MRI\], MIBG scan, and vanillylmandelic acid \[VMA\]/homovanillic acid \[HVA\]; bone marrow aspirates are required but biopsy may be omitted if negative prior to ASCT); this disease assessment is required for eligibility and should be done preferably within 2 weeks, but must be done within a maximum of 4 weeks before enrollment",{''}
3630,356,"Are postmenopausal for at least 1 year before the screening visit, OR",{''}
3631,361,Willing to be randomized into either study arm and adhere to study protocol,{''}
3632,362,No administration of granulocyte colony-stimulating factor is allowed within 1 week prior to screening assessment,{''}
3633,364,Patient must consent to provision of samples of whole blood (for cfDNA) in order that the specific correlative studies described in the protocol may be conducted.,{''}
3634,371,"Screening laboratory values (serum chemistry, hematology, prothrombin time \[PT\](international normalized ratio \[INR\])/activated partial thromboplastin time \[APTT\], and creatine phosphokinase \[CPK\]) obtained up to 45 days prior to administration of first vaccine injection on day 0 within institutional normal range or judged to be not clinically significant by principal investigator (PI) and medical monitor",{''}
3635,416,Received post-test genetic counseling from MSK Clinical Genetics Service within the last 3 months,{''}
3636,432,G-8 score =\< 14,{''}
3637,434,"For treatment protocols that include targeted therapy administered concurrently with RT, patients must start treatment within 10 calendar days of starting RT.",{''}
3638,440,BMI ≥ 23 kg/m2,{''}
3639,458,"Able to swallow, retain, and absorb oral medications.",{''}
3640,482,For participants not receiving therapeutic anticoagulation international normalized ratio or activated partial thromboplastin time 51.5 x ULN. For patients receiving therapeutic anticoagulation stable anticoagulant regimen.,{''}
3641,547,"The participant is able and willing to complete all study-related testing, evaluations, and procedures.",{''}
3642,559,"Platelet count ≥100,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)",{''}
3643,4,Absolute neutrophil count (ANC) \>1000/µL,{''}
3644,10,"Postmenopausal women are defined as those with their last menstrual period more than 12 months prior to study entry; for the purpose of defining menopausal status for women who have had surgical cessation of their periods, women who no longer have menses due to hysterectomy and oophorectomy will be considered postmenopausal; women who no longer have menses due to hysterectomy without oophorectomy will be considered premenopausal until age 52 and postmenopausal thereafter",{''}
3645,27,"History of diabetes due to cystic fibrosis, pancreatitis, or other pancreatic disease, including pancreatic tumor or insulinoma, or history of complete pancreatectomy","{'diabetes, c, ##ys ##tic fi ##bro ##sis, pan ##cre ##ati ##tis, pan ##cre ##atic disease, pan ##cre ##atic tumor, insulin ##oma pan ##cre ##ate ##ct ##omy'}"
3646,44,Not pregnant,{''}
3647,49,Agree to practice total abstinence when this is in line with the preferred and usual lifestyle of the subject.,{''}
3648,58,"Patients must be willing and able to sign the informed consent form, and to adhere to the study visit schedule and other protocol requirements.",{''}
3649,73,"Total bilirubin ≤1.5 x the Upper limit of normal (ULN), except if confirmed history of Gilbert's syndrome (note that participants with Gilbert's syndrome should be carefully evaluated for other liver-related disorders that may impact their suitability for this study).","{""Gilbert ' s syndrome, Gilbert ' s syndrome, liver - related disorders""}"
3650,94,For livestock treatment,{''}
3651,98,to \< 2 years 0.6 mg/dL,{''}
3652,118,Participants ≥ 16 years of age must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. Participants 12 to \<16 years of age must have a Lansky Performance Score of ≥ 60.,{''}
3653,151,Life expectancy ≥ 3 months;,{''}
3654,159,Patient must have disease amenable to biopsy and must agree to have one baseline biopsy,{''}
3655,162,"For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated",{'chronic he ##pa ##titis B virus ( H ##B ##V ) infection'}
3656,187,"Platelets ≥ 50.000/µl, without transfusion in the prior ≥10 days;",{''}
3657,189,"Malignant fluid collections (e.g., ascites, pleural effusions)","{'as, p e'}"
3658,197,"Have cognitive developmental delay and/or cognitive disability, including autism spectrum disorders (Note ADHD is not an exclusion criteria)","{'cognitive developmental delay, cognitive disability, autism spectrum disorders, AD ##HD'}"
3659,205,"Participants with other stable medical disorders such as controlled diabetes, hyperlipidemia, hypothyroidism, etc., may have been eligible as long as they were considered appropriate for enrollment as determined by the investigator by past medical history, physical examination, ECG, and clinical laboratory tests at Screening.","{'medical disorders, controlled diabetes, h ##yper ##lip ##ide ##mia, h ##y ##pot ##hy ##roid ##ism'}"
3660,221,Females of childbearing potential must have a negative serum pregnancy test at screening.,{''}
3661,234,"Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0 (except for asymptomatic laboratory abnormalities such as ALP elevation, hyperuricemia, and hyperglycemia, as judged by the investigator, and toxicity without safety risk, such as alopecia, grade 2 peripheral neurotoxicity, or decreased hemoglobin ≥90g/L, as judged by the investigator).","{'laboratory abnormal ##ities, AL elevation, h, ##yper ##uri ##ce ##mia, h, ##yper ##gly ##ce ##mia, al ##ope ##cia, peripheral ne ##uro ##to ##xi ##city'}"
3662,258,Demonstrate adequate organ function as defined below; all screening labs to be obtained within 28 days prior to registration.,{''}
3663,259,"Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, targeted inhibitor, and/or radiotherapy with toxicities reduced to grade 1 or less (Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0)",{''}
3664,265,"Total bilirubin ≤1.5 x upper limit of normal (ULN). If patient has known Gilbert's syndrome, the suggested threshold for treatment is a total bilirubin ≤2.0 x ULN, but will be left to the treating providers discretion.","{""Gilbert ' s syndrome""}"
3665,281,K601_S602delinsNT,{''}
3666,293,Iguratimod,{''}
3667,309,"No investigational drug or other anticancer treatments (including chemotherapy or radiation, except palliative radiation) within 21 days or at least 5 half-lives, whichever is shorter, of the start of the study treatment. No palliative radiation within 2 weeks prior to the start of the study treatment. Supportive treatments such as LHRH agonists can be continued for patients with castration-resistant prostate cancer or pre-menopausal breast cancer while on treatment.","{'cast ##ration - resistant pro ##state cancer, pre - men ##op ##aus ##al breast cancer'}"
3668,327,"Willing to undergo tumor biopsy (core, punch, incisional or excisional). Patients must undergo biopsy (core, punch) or open biopsy (incisional, excisional) within 4 weeks of registration on the study and at W4-5.",{'tumor'}
3669,340,Patient must agree to abstain from donating blood during the entire duration of protocol treatment and for at least 28 days after the last dose of lenalidomide,{''}
3670,344,"Is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this Protocol.",{''}
3671,346,"For those with residual disease before radiotherapy, re-evaluation of irradiated residual tumors is preferably performed at the earliest 5 days after completing radiotherapy; patients with residual disease are eligible; biopsy is not required; patients who have biopsy proven residual disease after ASCT will be enrolled on Stratum 07",{''}
3672,356,"Are surgically sterile, OR",{''}
3673,361,Confirmed verbally with the participant and response documented in the Participant Tracking database,{''}
3674,362,Platelets ≥ 100 × 10\^9/L (within 7 days of study treatment initiation),{''}
3675,371,"-lead electrocardiogram (ECG) showing normal heart rhythm; note if there are abnormalities, then the abnormalities must be deemed of no clinical significance",{''}
3676,416,years of age or older,{''}
3677,432,Cancer and Aging Research Group (CARG) Toxicity Score \>= 30%,{'Cancer A ##ging'}
3678,434,"For treatment protocols that only include maintenance/adjuvant therapy (no systemic therapy given concurrently with radiation), patients must start treatment by 35 days post RT",{''}
3679,440,Patients must agree to consent to the companion genomic profiling study MSK IRB# 12-245,{''}
3680,482,Life expectancy 3 months.,{''}
3681,559,Hemoglobin \>8 g/dL (may be transfused),{''}
3682,4,"Platelet count \>100,000/µL.",{''}
3683,10,All other postmenopausal women are eligible for inclusion in the biennial screening regimen,{''}
3684,27,"Have a history of intermittently required glucocorticoid treatment (e.g., but not limited to, for the treatment of asthma, inflammatory bowel disease).","{'as, ##th ##ma, inflammatory bow ##el disease'}"
3685,49,"A woman is considered to be of childbearing potential unless 1 of the following applies She is considered to be permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, tubal ligation, and bilateral oophorectomy.",{''}
3686,58,"Women of childbearing potential (a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently ster-ile. Permanent sterilization methods include hysterectomy, bi-lateral salpingectomy and bilateral oophorectomy) must have a negative serum pregnancy test within 3 days from day 1 of cycle 1 and agree to use a highly effective method of contraception while on study treatment and for at least 6 months after end of treatment. Such methods include","{'child, W sa ##l ##ping'}"
3687,73,Alanine transaminase (ALT) and Aspartate transaminase (AST) ˂2.5 x ULN (≤5 x ULN for participants with liver involvement),{'liver involvement'}
3688,94,Owner/guardian able to provide consent,{''}
3689,98,to \< 6 years 0.8 mg/dL,{''}
3690,118,Participants must have a life expectancy greater than 12 months.,{''}
3691,151,The results of laboratory examinations at screening must meet all the following criteria,{''}
3692,159,"The effects of cabozantinib and nivolumab on the developing human fetus are unknown; women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test at screening; WOCBP must agree to use adequate contraception (barrier method of birth control or abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 7 months after the last dose of investigational drug; women must not be breastfeeding; women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over age 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately","{'women, W, W, W, women, W, men ##aus ##e, am, ##eno ##rr ##hea'}"
3693,162,"Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load","{'he, ##pa ##titis C virus (, HC ##V ) infection, HC ##V infection, HC'}"
3694,187,Serum plasma creatinine ≤ 1.5 x upper limit of normal (ULN) OR estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2 (assessed by 2009-Schwartz formula).,{''}
3695,189,Bone marrow infiltration,{''}
3696,197,Has a seizure disorder,{'seizure disorder'}
3697,205,Healthy control participants (Group 4),{''}
3698,221,Females of childbearing potential and male subjects must be willing to abstain from heterosexual intercourse or to use an effective method(s) of contraception.,{''}
3699,234,"For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, the serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the whole treatment cycle and for 6 months after the end of treatment.",{''}
3700,258,Hematological,{''}
3701,259,Steroids =\< 0.5 mg/kg/day of prednisone equivalent (maximum 20 mg/day) averaged during the month prior to study enrollment is permissible,{''}
3702,265,"AST and ALT ≤2.5 x ULN, alkaline phosphatase ≤2.5 x ULN",{''}
3703,281,BRAF kinase duplication,{''}
3704,309,No major surgery within 1 month of treatment and fully recovered.,{''}
3705,327,Performance status of 0 or 1 on the ECOG Performance Scale.,{''}
3706,340,Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible,{''}
3707,344,Patient or legal representative has signed an ICF prior to any study-specific procedures or treatment.,{''}
3708,346,Patients must not have progressive disease at the time of study enrollment except for protocol specified bone marrow response and except for elevations of catecholamines as the only sign of disease in a patient who had normal catecholamines at pre-ASCT evaluation,{''}
3709,356,"If they are of childbearing potential, agree to use a highly effective method of contraception from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse",{''}
3710,361,IMPLEMENTATION INCLUSION,{''}
3711,362,No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment,{''}
3712,416,"Self-reported ""very well"" comprehension of written and verbal English language",{''}
3713,432,Cumulative Illness Rating Scale for Geriatrics (CIRS-G) Score \>= 4 OR,{'Il ##ln'}
3714,434,#SCREENING OPTIONS,{''}
3715,440,Patients must agree to consent for their tumor samples to be used for generation of cellular research tools such as organoids,{'tumor'}
3716,482,Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result at screening.,{'W'}
3717,559,Adequate Renal Function Defined as,{''}
3718,4,Hemoglobin \>8.0 gm/dL.,{''}
3719,10,"For those women who cannot be assigned to annual or biennial screening at the time of study entry and randomization because they are postmenopausal, have no family history or known deleterious breast cancer mutation, are not on hormone therapy AND have not had a prior mammogram, breast density will be determined by the radiologist?s recording of it at the time of interpretation of the first study screening examination, either DM or TM; for those who are randomized to TM, radiologists will assign BI-RADS density through review of the DM or synthetic DM portion of the TM examination; such women cannot be part of the planned stratification by screening frequency and are expected to represent far less than 1% of the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) population","{'breast cancer, D, T, T, D ##M D ##M, T ##M'}"
3720,27,"A1c \>11.0% (most recent value up to 1 year prior acceptable; if none available or \>1 year prior, participant will be instructed to obtain A1c through their usual care provider and to make copy of result available to study team)",{''}
3721,49,"She is postmenopausal, defined as no menses for 12 months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level consistently in the postmenopausal range (30 mIU/mL or higher) may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to confirm a postmenopausal state.","{'am, ##eno ##rr ##hea'}"
3722,58,Combined (estrogen and progestogen containing) hor-monal contraception associated with inhibition of ovulation,{''}
3723,73,"Participants on a stable dose of anticoagulation therapy are allowed to participate if they have no sign of bleeding or clotting, and prothrombin time international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT) test results are acceptable at the Investigator's discretion",{''}
3724,94,Animal expected to spend at least one week every study month inside the cluster border,{''}
3725,98,to \< 10 years 1 mg/dL,{''}
3726,118,Participants must have the ability to swallow medications and have no gastrointestinal abnormality that may alter medication absorption.,{'gas ##tro ##int ##est ##inal abnormal ##ity'}
3727,151,Absolute neutrophil count (ANC) ≥ 1.5×109/L;,{''}
3728,159,Ability to understand and the willingness to sign a written informed consent document,{''}
3729,162,"Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after central nervous system (CNS)-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period",{''}
3730,187,Total bilirubin ≤ 1.5 x the institutional ULN. For patients with known Gilbert's Syndrome ≤ 3.0 ULN is permitted.,"{""Gilbert ' s S ##yn ##drome""}"
3731,189,"Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography \[PET\] scans)",{''}
3732,197,Have bipolar disorder,{'bi ##pol ##ar disorder'}
3733,205,"Each healthy participant must have matched the age (±10 years), body weight (±20%), and gender of at least one participant of Group 1 (Part 1), 2 (Part 1), or 3 (Part 2).",{''}
3734,221,Life expectancy of ≥ 12 weeks.,{''}
3735,258,Platelets ≥ 50 K/dL,{''}
3736,259,Strong inducers or inhibitors of CYP2C8 are prohibited for 14 days before the first dose of tovorafenib (DAY101) and from planned administration for the duration of study participation,{''}
3737,265,"INR \<1.5 x ULN for institution unless patient is on planned therapy with anticoagulants (i.e., warfarin) with higher target planned. In those cases, INR up to 3.5 is acceptable.",{''}
3738,281,Fusions involving BRAF kinase domain,{''}
3739,309,Willing and able to provide informed consent.,{''}
3740,327,Demonstrate adequate organ function as defined below performed on screening labs obtained within 4 weeks of registration.,{''}
3741,340,"Absolute neutrophil count (ANC) ≥ 1,000/mcL without requirement for granulocyte colony stimulating factor (G-CSF) support (obtained ≤ 7 days prior to registration)",{''}
3742,346,"Patients must be enrolled before treatment begins; the date protocol therapy is projected to start must be no later than ten (10) calendar days after the date of study enrollment; patients should be enrolled preferably between day 56 and day 85 after peripheral blood stem cell (PBSC) infusion (day from 2nd stem cell infusion for tandem transplant); patients must be enrolled no later than day 200 after PBSC infusion; enrollment must occur after completion of radiotherapy, and after completion of tumor assessment post-ASCT and radiotherapy; informed consent should be obtained within 3 weeks pre-ASCT up to the time of registration",{''}
3743,356,"Male patients, even if surgically sterilized (i.e., status post-vasectomy), who",{''}
3744,361,"Be one of these key stakeholders patient, spouse/partner, healthcare providers, or administrator",{''}
3745,362,No administration of granulocyte colony-stimulating factor is allowed within 1 week prior to screening assessment,{''}
3746,416,Has a VUS identified in any of the following cancer predisposition genes,{'cancer'}
3747,432,"Age \< 70 with severe comorbidity, defined as having two or more of the following conditions within 30 days prior to registration;",{''}
3748,434,OPTION1 Molecular screening through CONNECT TarGeT Clinical Testing Laboratories,{''}
3749,440,Willingness to travel to the CTSC at WCMC weekly,{''}
3750,482,"WOCBP must agree to use adequate contraception for the duration of study participation and for 10 months after completion of study treatment. A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a post- menopausal state ( 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Mi..illerian agenesis). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.","{'am, ##eno ##rr ##hea, men, ##fer'}"
3751,559,Creatinine clearance or radioisotope GFR \> 70ml/min/1.73 m2 or,{''}
3752,4,Estimated glomerular filtration rate (eGFR) \>60 mL/minute based on Cockcroft-Gault formula.,{''}
3753,10,"Breast density will be determined by prior mammography reports, when available; all other risk factors used to determine patient eligibility for annual or biennial screening will be determined by subject self-report",{''}
3754,27,History of diabetic ketoacidosis (DKA) within the past month,"{'di, ##abe ##tic k ##eto ##ac ##ido ##sis, D ##KA'}"
3755,49,Female patients of childbearing potential must have a negative serum pregnancy test result less than 3 day prior to administration of the first dose of study treatment.,{''}
3756,58,oral,{''}
3757,73,"Estimated glomerular filtration rate (eGFR) \>60 mL/min/1.73 m\^2, according to the Modified Diet in Renal Disease (MDRD) abbreviated formula and serum creatinine ≤1.5 x ULN",{''}
3758,94,Exclusion Criteria,{''}
3759,98,to \< 13 years 1.2 mg/dL,{''}
3760,118,Participants must have adequate organ and marrow function as defined below. Bloodwork must be collected within 7 days prior to Cycle 1 Day 1,{''}
3761,151,Absolute white blood cell (WBC) count ≥2.5×109/L;,{''}
3762,159,CROSS-OVER ELIGIBILITY CRITERIA,{''}
3763,162,Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy,{'le ##pt ##ome ##ning ##eal disease'}
3764,187,Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 3.0 ULN OR ≤ 5.0 ULN for patients with liver metastases.,{'liver'}
3765,189,Elevated tumor markers in plasma or cerebrospinal fluid (CSF),{'tumor'}
3766,205,"Must have weighed at least 50 kg to participate in the study and must have had a BMI within the range of 18.0 to 30.0 kg/m2, inclusive, at Screening.",{''}
3767,221,"Patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the HCV viral load must be undetectable through PCR to be eligible for this trial. Testing is not required for screening unless mandated by local authorities. Local guidelines for testing should be followed.","{'chronic he ##pa ##titis B virus ( H ##B ##V ) infection, he ##pa ##titis C virus (, HC ##V ) infection, HC ##V infection, HC'}"
3768,258,Absolute Neutrophil Count (ANC) ≥ 1000 K/mm3,{''}
3769,259,Medications that are breast cancer resistant protein (BCRP) substrates that have a narrow therapeutic index are prohibited for 14 days before the first dose of tovorafenib (DAY101) and for the duration of study participation,{'breast cancer'}
3770,265,"PTT \<1.5 x ULN for institution unless patient is on planned therapy with heparin or heparin-like products Note In the case of longstanding ethnic neutropenia, patient may be eligible for enrollment with approval from the PI, Rachel Freedman MD, MPH.",{'long ethnic ne ##ut ##rop ##enia'}
3771,281,Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2,{''}
3772,327,"Absolute neutrophil count (ANC) ≥1,500 /mcL",{''}
3773,340,Hemoglobin ≥ 8 g/dL (obtained ≤ 7 days prior to registration),{''}
3774,346,Patients must not have received prior anti-disialoganglioside (GD2) antibody therapy,{''}
3775,356,"Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or",{''}
3776,361,Verbal informed consent following receipt of an Information Sheet,{''}
3777,362,Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN). Documented Gilbert syndrome is allowed if total bilirubin is ≤ 3 × institutional ULN (within 7 days of study treatment initiation),{'Gilbert syndrome'}
3778,416,APC CDK4 MAX MUTYH RAD51B SMAD4 ATM CDKN2A (P16) MBD4 NF1 RAD51C STK11 AXIN2 CHEK2 MEN1 NF2 RAD51D TERT BAP1 CTNNA1 MET NTHL1 RET TMEM127 BARD1 DICER1 MITF PALB2 RNF43 TP53 BLM EPCAM MITF PMS2 RPS20 TSC1 BMPR1A EPCAM MLH1 POLD1 SDHA TSC2 BRCA1 FH MLH3 POLE SDHAF2 VHL BRCA2 FLCN MSH2 POT1 SDHB BRIP1 GREM1 MSH3 PTCH1 SDHC CDH1 HOXB13 MSH6 PTEN SDHD,{''}
3779,432,Modified Charlson Comorbidity Index \>= 1,{''}
3780,434,OPTION2 Molecular screening through a national comprehensive tumor profiling program,{'tumor'}
3781,440,"Patient and/or Legally Authorized Representative must have the ability to read, write, speak and understand English. Note If patient does not have the capability to read or write in English, the patient""s preferred language should be English and the LAR will be responsible for completing all study forms on the patient's behalf.",{''}
3782,482,"Male participants of childbearing potential must agree to use adequate contraception for the duration of study participation and for 7 months after completion of study treatment. In addition, male participants must be willing to refrain from sperm donation during this time.",{''}
3783,559,"A serum creatinine based on (Schwartz et al. J. Peds, 106522, 1985) age/gender as follows",{''}
3784,4,Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both \<2 × upper limit of normal (ULN).,{''}
3785,27,"Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to RF interference",{''}
3786,49,"Patients or their legally authorized representative (LAR) must be willing and able to sign the informed consent form, and to adhere to the study visit schedule and other protocol requirements.",{''}
3787,58,intravaginal,{''}
3788,73,"Participants must have at least one PSMA-positive (prostate-specific membrane antigen) distant metastatic lesion on the screening PSMA PET/CT scan using the study-designated PSMA PET tracers, as determined by the site Investigator. For eligibility purposes, a PSMA-positive lesion must have activity greater than the liver by visual assessment of the screening PSMA PET/CT. A PSMA-positive metastatic lesion should not correspond to a normal tissue structure or benign lesion.",{'meta les'}
3789,94,For human treatment/safety cohort,{''}
3790,98,to \< 16 years 1.5 mg/dL (male) or 1.4 mg/dL (female),{''}
3791,118,"leukocytes ≥3,000/mcL",{''}
3792,151,Platelets ≥ 100×109/L;,{''}
3793,159,"Patient must provide a tumor biopsy at the time of progression on Arm B; if a patient does not have a tumor lesion amenable to biopsy or it has been unsafe for a biopsy to be performed, cross-over will not be allowed","{'tumor, tumor'}"
3794,162,Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial,"{'ma, ##li ##gna ##ncy'}"
3795,187,Albumin \&amp;gt;3.0 g/dL (3.0 g/dL is equivalent to 30 g/L),{''}
3796,189,Previously radiated lesions that have not demonstrated clear progression post radiation,{''}
3797,205,"Must have been in good health as determined by medical history, physical examination, ECG, and clinical laboratory tests at Screening.",{''}
3798,258,Hemoglobin (Hgb) ≥ 8 g/dL,{''}
3799,259,"Peripheral absolute neutrophil count (ANC) \>= 750/uL unless secondary to bone marrow involvement, in such cases bone marrow involvement must be documented (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment)",{''}
3800,265,Life expectancy \>5 years per provider's assessment,{''}
3801,281,"Adequate bone marrow, organ function and laboratory parameters",{''}
3802,327,Hemoglobin ≥9 g/dL or ≥5.6 mmol/L,{''}
3803,340,"Platelets ≥ 75,000/mcL without requirement for platelet transfusion support (obtained ≤ 7 days prior to registration)",{''}
3804,346,Patients must have a Lansky or Karnofsky performance scale score of \>= 50% and patients must have a life expectancy of \>= 2 months,{''}
3805,356,Agree to completely abstain from heterosexual intercourse,{''}
3806,362,No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment,{''}
3807,416,STRIVE Trial PCP Providers,{''}
3808,432,ACE-27 Index \>= 1,{''}
3809,434,OPTION3 Clinically validated targeted sequencing or focused profiling,{''}
3810,482,Willing to undergo mandatory biopsies and blood collections as required by the study.,{''}
3811,559,to \< 2 years maximum serum creatinine 0.6 mg/dL for males and females. 2 to \< 6 years maximum serum creatinine 0.8 mg/dL for males and females. 6 to \< 10 years maximum serum creatinine 1.0 mg/dL for males and females. 10 to \< 13 years maximum serum creatinine 1.2 mg/dL for males and females. 13 to \< 16 years maximum serum creatinine 1.5 mg/dL for males and 1.4 mg/dL for females.,{''}
3812,4,Albumin \>3.0 gm/dL.,{''}
3813,27,Established history of allergy or severe reaction to adhesive or tape that must be used in the study,{'all'}
3814,58,transdermal,{''}
3815,94,Known hypersensitivity to ivermectin or albendazole,{'h ##yper ##sen ##si ##ti ##vity to'}
3816,98,\>= 16 years 1.7 mg/dL (male) or 1.4 mg/dL (female),{''}
3817,118,"absolute neutrophil count (ANC) ≥1,500/mcL",{''}
3818,151,Haemoglobin ≥ 9 g/dL;,{''}
3819,162,"Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. Patients with history of known congestive heart failure (left ventricular ejection fraction \[LVEF\] \< 50%) must have documented LVEF ≥ 50% within 12 months of study enrollment","{'cardiac disease, con ##ges ##tive heart failure'}"
3820,187,A negative serum or urine pregnancy test in women with onset of menses or \&gt;12 years of age.,{''}
3821,189,Leptomeningeal lesions that do not meet the measurement parameters noted above,{'Le ##pt ##ome ##ning ##eal lesions'}
3822,205,Seated vital signs must have been within the following ranges at Screening and Baseline,{''}
3823,258,Renal,{''}
3824,259,"Platelet count \>= 75,000/uL (unsupported/without transfusion within the past 7 days) (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment)",{''}
3825,265,Willing to employ adequate and appropriate birth control if applicable,{''}
3826,281,Absolute neutrophil count (ANC) ≥ 1.5 x 109/L,{''}
3827,327,"Platelets ≥100,000 / mcL",{''}
3828,340,Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (or ≤ 3.0 x institutional ULN for patients with documented Gilberts syndrome) (obtained ≤ 7 days prior to registration),{'Gilbert ##s syndrome'}
3829,346,Total absolute phagocyte count (APC = %neutrophils + %monocytes) X white blood cell (WBC) is at least 1000/uL,{''}
3830,356,"Have normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 milliseconds (msec) in males or ≤470 msec in females.",{''}
3831,362,No administration of granulocyte colony-stimulating factor is allowed within 1 week prior to screening assessment,{''}
3832,416,Designated healthcare provider for an enrolled VUS patient,{'V ##US'}
3833,432,Omega score \< 0.80,{''}
3834,559,≥ 16 years maximum serum creatinine 1.7 mg/dL for males and 1.4 mg/dL for females.,{''}
3835,4,"Capable of giving signed informed consent, which includes compliance with the requirements and restrictions of the study.",{''}
3836,27,"Currently treated with GLP-1 analogue, thiazolidinedione (TZD), sulfonylurea, pramlintide, or SGLT-2 inhibitor medication (use more than 3 months prior to enrollment is acceptable)",{''}
3837,58,Progestogen-only hormonal contraception associated with inhibition of ovulation,{''}
3838,94,"Risk of Loa as assessed by travel history to Angola, Cameroon, Chad, Central African Republic, Congo, DR Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria or Sudan",{'Lo ##a'}
3839,98,Total bilirubin \< 1.5 x upper limit of normal (ULN) for age,{''}
3840,118,"platelets ≥100,000/mcL",{''}
3841,151,International normalized ratio (INR) ≤ 1.5 times upper limit of normal (ULN) / or activated partial thromboplastin time (APTT) ≤ 1.5 times ULN (for the test without anticoagulant);,{''}
3842,162,Patients with history of known type I or type II diabetes must have a fasting glucose level of \< 120 mg/dL on at least 2 separate occasions or glycosylated hemoglobin (HbA1c) \< 8.5% at screening within 14 days prior to registration,{'type I or type II diabetes'}
3843,187,"Patients of reproductive potential must agree to use highly effective contraceptive methods for the entire study duration and up to 7 months, in case of females, and 4 months in case of males, after the last dose of Lutathera, or up to 6 months, in case of females, and 3 months in case of males, after the last dose of olaparib, whichever takes places later.",{''}
3844,189,"Patients must have a Lansky or Karnofsky performance status score of \>= 50, corresponding to Eastern Cooperative Oncology Group (ECOG) categories 0, 1 or 2; use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score",{'para ##lysis'}
3845,205,"body temperature, 35.0 to 37.5°C, inclusive",{''}
3846,258,Calculated creatinine clearance ≥ 40 mL/min using the Cockcroft-Gault formula,{''}
3847,259,"Patients with marrow disease must have platelet count of \>= 75,000/uL (transfusion support allowed) and must not be refractory to platelet transfusions. Bone marrow involvement must be documented",{'ma ##rrow disease'}
3848,265,"NOTE This study is for patients aged 60 and older, and most female patients will have entered menopause by this time; however patients should not become pregnant while on this study because T-DM1 can affect an unborn baby. Pre-menopausal women need to use birth control while on this study and women should not breastfeed a baby while on this study. Any man treated on this study will also need to use contraception if his partner is a premenopausal female. Patients should check with their health care provider about what kind of birth control methods to use and how long to use them.",{'T - D ##M'}
3849,281,Hemoglobin (Hgb) ≥ 8 g/dL with or without transfusions,{''}
3850,327,Serum creatinine or Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 X upper limit of normal (ULN) OR ≥60 mL/min for subject with creatinine levels \> 1.5 X institutional ULN.,{''}
3851,340,Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3.0 x institutional ULN (obtained ≤ 7 days prior to registration),{''}
3852,346,Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 or a serum creatinine based on age/gender as follows,{''}
3853,356,Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol.,{''}
3854,362,"Aspartate aminotransferase (AST \[serum glutamic-oxaloacetic transaminase (SGOT)\])/alanine aminotransferase (ALT \[serum glutamate pyruvate transaminase (SGPT)\]) ≤ 3 × institutional ULN. In the presence of liver metastases, AST or ALT up to 5 × institutional ULN is permitted (within 7 days of study treatment initiation)",{''}
3855,416,Resides within the United States,{''}
3856,432,G-8 score =\< 14,{''}
3857,559,Adequate Liver Function Defined as,{''}
3858,27,"a. If using metformin, participants i. Must be on a stable dose for 1 month prior to enrollment ii. Metformin can be continued while the iLet is used",{''}
3859,58,oral,{''}
3860,94,Pregnant women,{''}
3861,98,Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) \< 10 x ULN for age,{''}
3862,118,hemoglobin ≥9 g/dL,{''}
3863,151,INR ≤ 2.5 times ULN / or APTT ≤ 2.5 times ULN (for the test with anticoagulant);,{''}
3864,162,Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that their medication dose and INR/PTT is stable,{''}
3865,187,"Have the ability to comprehend and willingness to provide written informed consent (ICF) for the study before patient registration or any trial-related screening procedures. If the patient is \&amp;lt;18 years old, the written informed consent must be signed by the parent(s) or legal guardian(s) according to national regulations. In the case of patients between 12 and 17 years, they must sign an assent form, and if the patient turns 18 during their participation in the study, they must sign an informed consent form.",{''}
3866,189,"Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study",{''}
3867,205,"systolic BP, 89 to 139 mmHg, inclusive",{''}
3868,258,or Serum creatinine \< 2 mg/dL,{''}
3869,259,Hemoglobin \>= 8 g/dL (unsupported/without transfusion within the past 7 days). Patients with marrow disease must have hemoglobin \>= 8 g/dL (transfusion support allowed). Bone marrow involvement must be documented,"{'ma, ##rrow disease'}"
3870,265,"Negative urine or serum pregnancy test done ≤7 days prior to registration, for women of childbearing potential only",{''}
3871,281,Platelets (PLT) ≥ 75 x 109/L without transfusions,{''}
3872,327,Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels \> 1.5 ULN.,{''}
3873,340,Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 30 mL/min/1.73 m\^2 (estimated by Cockcroft-Gault method or measured) (obtained ≤ 7 days prior to registration),{''}
3874,346,No greater than 0.4 mg/dL (1 month to \< 6 months),{''}
3875,362,No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment,{''}
3876,432,CARG Toxicity Score \>= 30%,{''}
3877,559,Total bilirubin within normal institutional limits,{''}
3878,27,"Pregnant (positive urine HCG), breast feeding, plan to become pregnant in the next 6 months, or premenopausal participants who are sexually active without use of contraception",{''}
3879,58,injectable,{''}
3880,94,Lactating women in the first week postpartum,{''}
3881,98,Absolute neutrophil count (ANC) \> 750/uL,{''}
3882,118,total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) OR \<3.0 x institutional ULN for participants with Gilbert syndrome,{'Gilbert syndrome'}
3883,151,Total bilirubin \<= 1.5 x ULN (except participants with Gilbert Syndrome who must have a total bilirubin level of \< 3.0 mg/dL).;,{'Gilbert S ##yn ##drome'}
3884,162,"Prophylactic antiemetics may be administered according to standard practice. The routine use of standard antiemetics, including 5-HT3 blockers, such as granisetron, ondansetron, or an equivalent agent, is allowed as needed, as long as corrected QT (QTc) interval on baseline electrocardiogram (ECG) \< 480 msec",{''}
3885,187,Adequate recovery from major surgery prior to receiving study treatment.,{''}
3886,189,Patients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea),{'solid tumors'}
3887,205,"diastolic BP, 50 to 89 mmHg, inclusive",{''}
3888,258,Hepatic,{''}
3889,259,"Hematopoietic growth factors At least 14 days after the last dose of a long-acting growth factor (e.g., Neulasta \[registered trademark\]) or 7 days for short-acting growth factor",{''}
3890,265,"NOTE In the rare case that a woman enrolling on study is of childbearing potential, a pregnancy test is required prior to enrollment on study.",{''}
3891,281,AST and/or ALT ≤ 2.5 × upper limit of normal (ULN); patient with liver metastases ≤ 5 ×ULN,{'liver'}
3892,327,AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN.,{''}
3893,340,Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial,"{'Human im ##mu ##no ##de ##ficiency virus, HIV -'}"
3894,346,No greater than 0.5 mg/dL (6 months to \< 1 year),{''}
3895,362,No administration of granulocyte colony-stimulating factor is allowed within 1 week prior to screening assessment,{''}
3896,432,CIRS-G Score \>= 4 OR,{''}
3897,559,AST (SGOT) ≤ 2.5 × institutional upper limit of normal,{''}
3898,27,"Renal failure on dialysis or chronic renal disease with a GFR or eGFR \<30mL/min (values within the last two years will be accepted; if none available or \>2 years prior, participant will be instructed to obtain GFR or eGFR through their usual care provider and to make copy of result available to study team)","{'Ren ##al failure, chronic re ##nal disease'}"
3899,58,implantable,{''}
3900,94,Children \< 15 kg,{''}
3901,98,"Platelet count \> 75,000/uL",{''}
3902,118,AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN OR ≤5 × institutional ULN if the liver has tumor involvement,{'tumor'}
3903,151,AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for subjects with hepatic cancer or liver metastases); ALT/AST ≤ 3xULN regardless of liver metastasis for cohort G and H only;,"{'he, ##pa ##tic cancer, liver'}"
3904,162,Patients must be willing to have biopsies for this study in order to be enrolled in the dose expansion,{''}
3905,187,"Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial",{''}
3906,189,At least 7 days must have elapsed since the completion of therapy with a growth factor. At least 14 days must have elapsed after receiving pegfilgrastim,{''}
3907,205,"pulse rate, 45 to 90 bpm, inclusive",{''}
3908,258,Bilirubin ≤ 1.5 × upper limit of normal (ULN),{''}
3909,259,"A serum creatinine based on age/gender as follows (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment)",{''}
3910,265,Able to provide informed written consent.,{''}
3911,281,Total bilirubin ≤ 1.5 × ULN and \< 2 mg/dL (Note Patients who have a total bilirubin level \> 1.5 x ULN will be allowed if their indirect bilirubin level is ≤ 1.5 x ULN),{''}
3912,327,International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.,{''}
3913,340,"For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated",{'chronic he ##pa ##titis B virus ( H ##B ##V ) infection'}
3914,346,No greater than 0.6 mg/dL (1 to \< 2 years),{''}
3915,362,Measured of calculated creatinine clearance (CrCl) ≥ 60 mL/min (CrCl should be calculated per institutional standard; glomerular filtration rate can also be used in place of CrCl) ≥ 60 mL/min for patients with creatinine levels \> 1.5 x institutional ULN (within 7 days of study treatment initiation),{''}
3916,432,"Age \>= 18 with an absolute or relative contraindication to cisplatin, defined as one or more of the following criterion within 30 days prior to registration",{''}
3917,559,ALT (SGPT) ≤ 2.5 × institutional upper limit of normal,{''}
3918,27,"Any condition that, in the opinion of the site principal investigator, could interfere with the safe or effective completion of the study.",{''}
3919,58,Intrauterine device (IUD),{''}
3920,94,Currently participating in another clinical trial,{''}
3921,98,Shortening fraction \>= 27% by echocardiogram,{''}
3922,118,creatinine ≤ institutional ULN OR creatinine clearance ≥30 mL/min,{''}
3923,151,Albumin ≥ 30g/L;,{''}
3924,162,"The effects of ASTX660 (tolinapant) on the developing human fetus are unknown. For this reason and because dual IAP antagonist agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential must agree to practice 1 highly effective contraceptive measure of birth control (with a failure rate of \< 1% per year; preferably with low user dependency) during the study and for 6 months after the last dose of study treatment and must agree not to become pregnant for 6 months after completing treatment. Men with female partners of childbearing potential must agree to use a condom and advise their partners to practice 1 highly effective contraceptive measure of birth control (user dependent or with low user dependency) during the study and for at least 3 months after completing treatment, and must agree not to father a child while receiving study treatment and for at least 3 months after completing treatment",{''}
3925,189,Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count \[ANC\] counts) \>= 7 days after the last dose of agent,{''}
3926,258,Aspartate aminotransferase (AST) ≤ 3 × ULN,{''}
3927,259,Age 6 months to \< 1 year; Maximum Serum Creatinine (mg/dL)= 0.5 mg/dl (male and female),{''}
3928,265,Willing to return to consenting institution for follow-up at 6 months,{''}
3929,281,"Serum Creatinine ≤ 1.5 x ULN, or calculated creatinine clearance (determined as per Cockcroft-Gault) ≥ 50 mL/min at screening",{''}
3930,327,Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.,{''}
3931,340,"Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load","{'he, ##pa ##titis C virus (, HC ##V ) infection, HC ##V infection, HC'}"
3932,346,No greater than 0.8 mg/dL (2 to \< 6 years),{''}
3933,362,No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment,{''}
3934,432,Pre-existing peripheral neuropathy grade \>= 1;,{'peripheral ne ##uro ##pathy'}
3935,559,Adequate Neurologic Function Defined as,{''}
3936,27,"a. Conditions to be considered by the investigator may include, but are not limited to, the following i. Alcohol or drug abuse ii. Use of prescription drugs that may dull the sensorium, reduce sensitivity to symptoms of hypoglycemia, or hinder decision making during the period of participation in the study iii. Coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise (e.g. exercise of intensity up to 6 METS) despite medical management, or within the last 12 months before screening, a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting iv. Known history of prolonged QTc interval, malignant arrhythmia, or congenital heart disease v. Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV vi. History of TIA or stroke in the last 12 months vii. Untreated or inadequately treated mental illness viii. History of eating disorder within the last 2 years, such as anorexia, bulimia, or diabulimia or omission of insulin to manipulate weight ix. History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment","{'h ##y ##po ##gly ##ce ##mia, Co, ##rona ##ry artery disease, unstable an ##gin ##a, an, ##gin ##a, my ##oc ##ard ##ial in ##far ##ction ##ry o ##lusion, ma, ##li ##gnant a ##rr ##hy ##th ##mia, con ##gen ##ital heart disease, Con, ##ges ##tive heart failure, T ##IA, stroke, mental illness, eating disorder, an ##ore ##xia, b ##uli ##mia, di ##ab ##uli ##mia, h, ##y ##po ##gly ##ce ##mia'}"
3937,58,Intrauterine hormone-releasing system ( IUS),{''}
3938,94,Unwilling to provide informed consent or assent,{''}
3939,98,Ejection fraction \>= 47% by radionuclide angiogram (multi gated acquisition scan \[MUGA\]); Note the echocardiogram (or MUGA) may be done within 28 days prior to enrollment,{''}
3940,118,"Participants must have serum potassium, calcium and magnesium levels within institutional range of normal (may be receiving supplements). Bloodwork must be collected within 7 days prior to Cycle 1 Day 1.",{''}
3941,151,"Serum creatinine ≤ 1.5 times ULN, or creatinine clearance rate ≥ 60 ml/min (creatinine clearance rate will be calculated using Cock-croft-Gault Equation);",{''}
3942,162,Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants,{''}
3943,189,"Antibodies \>= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =\< 1",{''}
3944,258,Alanine aminotransferase (ALT) ≤ 3 × ULN,{''}
3945,259,Age 1 to \< 2 years; Maximum Serum Creatinine (mg/dL) = 0.6 mg/dl (male and female),{''}
3946,265,Willing to provide blood samples for mandatory correlative research purposes.,{''}
3947,281,Adequate cardiac function,{''}
3948,327,"Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",{''}
3949,340,Patient must not have active central nervous system (CNS) lymphoma requiring treatment,{'central nervous system ( C ##NS ) l ##ymph ##oma'}
3950,346,No greater than 1.0 mg/dL (6 to \< 10 years),{''}
3951,362,No administration of granulocyte colony-stimulating factor is allowed within 1 week prior to screening assessment,{''}
3952,432,Creatinine clearance (CrCl) must be \> 30 and \< 60 mL/min,{''}
3953,559,Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment.,{'ne ##logical deficit'}
3954,27,"Employed by, or having immediate family members employed by Beta Bionics, or being directly involved in conducting the clinical trial, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial",{''}
3955,58,Bilateral tubal occlusion,{''}
3956,94,Unwilling to adhere to study visits and/or procedures,{''}
3957,98,Serum triglyceride level =\< 300 mg/dL (=\< 3.42 mmol/L),{''}
3958,118,Known human immunodeficiency virus (HIV)-infected participants on effective anti- retroviral therapy with an undetectable viral load within 6 months are eligible for this trial.,"{'human im ##mu ##no ##de ##ficiency virus, HIV'}"
3959,151,Male and female of childbearing age should agree to take effective contraception measures (refer to Appendix 3. Contraception) from signing the ICF till at least 120 days post the last dose of TST001 and other study drugs except nivolumab; female of childbearing age should agree to take effective contraception measures (refer to Appendix 3. Contraception) from signing the ICF till at least 5 months post the last dose of nivolumab; Serum β-HCG test for women of childbearing age within 72 hours prior to the initial dosing must be negative;,{''}
3960,189,"\>= 2 weeks must have elapsed since local palliative radiation therapy (XRT) (small port); \>= 6 weeks must have elapsed since treatment with therapeutic doses of M-Iodobenzylguanidine (MIBG); \>= 3 months must have elapsed if prior craniospinal XRT was received, if \>= 50% of the pelvis was irradiated, or if total-body irradiation (TBI) was received; \>= 6 weeks must have elapsed if other substantial bone marrow irradiation was given",{''}
3961,258,Coagulation ---International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤ 2 × ULN,{''}
3962,259,Age 2 to \< 6 years; Maximum Serum Creatinine (mg/dL) = 0.8 mg/dl (male and female),{''}
3963,265,Ability to understand and the willingness to sign a written informed consent document,{''}
3964,281,left ventricular ejection fraction (LVEF) ≥ 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram,{''}
3965,327,"Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 26 weeks after the last dose of study medication (Section 5.7.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year.",{''}
3966,340,Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression,{''}
3967,346,No greater than 1.2 mg/dL (10 to \< 13 years),{''}
3968,362,International normalized ratio/prothrombin time and activated partial thromboplastin time ≤ 1.5 × institutional ULN (within 7 days of study treatment initiation),{''}
3969,432,"For this calculation, use the Cockcroft-Gault formula",{''}
3970,559,Patients with current seizure disorders may be enrolled if seizures are well-controlled on antiepileptic therapies.,{'seizure disorders'}
3971,27,Unable to avoid hydroxyurea for duration of study (interferes with accuracy of Dexcom G6 CGM),{''}
3972,58,Vasectomized partner,{''}
3973,94,"Severely ill either self-reported or in the eyes of the investigator, e.g. defined as need for clinical care, or active or progressive disease interfering with activities of daily living. If in doubt, these criteria can be confirmed after a call with either the site PI/MD/safety officer against a pre-defined list.",{''}
3974,98,Serum cholesterol level =\< 300 mg/dL (7.75 mmol/L),{''}
3975,118,"For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.",{'chronic he ##pa ##titis B virus ( H ##B ##V ) infection'}
3976,151,(For dose expansion phase only) At least one measurable lesion conforming to per RECIST v1.1;,{''}
3977,189,"Subjects should not have any clinically relevant ongoing complications from prior radiation therapy (i.e., radiation esophagitis or other inflammation of the viscera)","{'radiation es ##op ##ha ##git ##is, inflammation of the v ##is ##cer ##a'}"
3978,258,Females of childbearing potential with a male partner able to father a child must have a negative serum or urine pregnancy test within 7 days prior to registration. See the protocol for definition of childbearing potential.,{''}
3979,259,Age 6 to \< 10 years; Maximum Serum Creatinine (mg/dL) = 1.0 mg/dl (male and female),{''}
3980,281,QTc interval ≤ 480 ms (preferably the mean from triplicate ECGs),{''}
3981,327,Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 26 weeks after the last dose of study therapy.,{''}
3982,340,Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial,"{'ma, ##li ##gna ##ncy'}"
3983,346,No greater than 1.4 mg/dL (\>= 13 years \[female\]),{''}
3984,362,No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment,{''}
3985,432,"History of hearing loss, defined as either",{'hearing loss'}
3986,559,"Informed Consent All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.",{''}
3987,58,Sexual abstinence,{''}
3988,94,Currently under treatment with inhibitors of CYP3A or P-gp or other drugs that can interfere with the study,{''}
3989,98,"Random or fasting blood glucose within the upper normal limits for age; if the initial blood glucose is a random sample that is outside of the normal limits, then a follow-up fasting blood glucose can be obtained and must be within the upper normal limits for age",{''}
3990,118,"Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.","{'he, ##pa ##titis C virus (, HC ##V ) infection, HC ##V infection, HC'}"
3991,189,No evidence of active graft versus (vs.) host disease and \>= 2 months must have elapsed since transplant,{''}
3992,258,"Females of childbearing potential must be willing to abstain from vaginal intercourse or use an effective method(s) of contraception from the time of informed consent, during the study and for 6 months after the last dose of study drug(s). Males able to father a child must be willing to abstain from vaginal intercourse or to use an effective method(s) of contraception from initiation of treatment, during the study and for 3 months after the last dose of study drug(s). See the protocol.",{''}
3993,259,Age 10 to \< 13 years; Maximum Serum Creatinine (mg/dL) = 1.2 mg/dl (male and female),{''}
3994,281,Able to take oral medications,{''}
3995,327,Note Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.,{''}
3996,340,Patient must not have taken or require warfarin or other strong CYP3A inhibitors or inducers within 7 days prior to registration.,{''}
3997,346,No greater than 1.5 mg/dL (13 to \< 16 years \[male\]),{''}
3998,362,No administration of granulocyte colony-stimulating factor is allowed within 1 week prior to screening assessment,{''}
3999,432,Existing need of a hearing aid OR,{''}
4000,94,For incidence cohort,{''}
4001,98,"Normal pulmonary function tests (including diffusing capacity of the lungs for carbon monoxide \[DLCO\]) if there is clinical indication for determination (e.g. dyspnea at rest, known requirement for supplemental oxygen); Note for patients who do not have respiratory symptoms or requirement for supplemental oxygen, pulmonary function tests (PFTs) are NOT required","{'d, ##ys ##p, respiratory'}"
4002,118,Participants with treated brain metastases are eligible if the patient is asymptomatic AND follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.,{'brain meta'}
4003,189,"Not previously received XL184 or another MET/HGF inhibitor (tivantinib or crizotinib); there are no limits on number of prior therapeutic regimens; patients who have been treated with prior VEGF pathway, or RET inhibitors (except XL184) may be eligible",{''}
4004,258,"As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.",{''}
4005,259,to \< 16 years; Maximum Serum Creatinine (mg/dL) = 1.5 mg/dl (male) and 1.4 mg/dl (female),{''}
4006,281,Patient is deemed by the Investigator to have the initiative and means to be compliant with the protocol (treatment and follow-up),{''}
4007,340,"NOTE Antiplatelet agents, other anticoagulants aside from warfarin, as well as mild or moderate CYP3A inhibitors or inducers are permitted on study but should be used with caution",{''}
4008,346,No greater than 1.7 mg/dL (\>= 16 years \[male\]),{''}
4009,362,Patients must have left ventricular ejection fraction (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before enrollment,{''}
4010,432,\>= 25 decibel shift over 2 contiguous frequencies on a pretreatment hearing test as clinically indicated,{''}
4011,94,Non-residents,{''}
4012,98,Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and if seizures are well controlled,"{'seizure disorder, seizure'}"
4013,118,"Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. For example, participants with nonmelanoma skin cancer, carcinoma in situ of the cervix or malignancy diagnosed ≥2 years previously and not currently receiving anticancer treatment are eligible. Patients receiving adjuvant hormone therapy for breast or prostate cancer with no evidence of disease are eligible.","{'ma, ##li ##gna ##ncy, non ##mel ##ano ##ma skin cancer, car, ##cin ##oma in sit ##u of the c ##er ##vi ##x, ma, ##li ##gna ##ncy, breast or pro ##state cancer'}"
4014,189,Peripheral absolute neutrophil count (ANC) \>= 1000/uL for patients with solid tumors without bone marrow involvement,{'solid tumors'}
4015,259,Age \>= 16 years; Maximum Serum Creatinine (mg/dL) = 1.7 mg/dl (male) and 1.4 mg/dl (female),{''}
4016,281,"Female patients are either postmenopausal for at least 1 year, are surgically sterile for at least 6 weeks, or must agree to take appropriate precautions to avoid pregnancy from screening through 30 days after the last dose of study drug/treatmentif of childbearing potential (Note Permitted contraception methods listed in Section 9.3 should be communicated to the patients and their understanding confirmed. For females of childbearing potential, the pregnancy test result must be negative at screening.)",{''}
4017,340,Patient must not have an uncontrolled intercurrent illness that would interfere with the safety or efficacy assessment of this protocol,{'inter illness'}
4018,346,Total bilirubin =\< 1.5 x normal,{''}
4019,362,Human immunodeficiency virus-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial,{'Human im ##mu ##no ##de ##ficiency virus'}
4020,432,Zubrod Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 30 days prior to registration,{''}
4021,94,Currently enrolled in other clinical trial,{''}
4022,98,Prothrombin time (PT) \< 1.2 x ULN,{''}
4023,118,"Participants with known history or current symptoms of cardiac disease or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.",{'cardiac disease'}
4024,189,"Platelet count \>= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) for patients with solid tumors without bone marrow involvement",{'solid tumors'}
4025,259,OR- a 24 hour urine creatinine clearance \>= 50 mL/min/1.73 m\^2,{''}
4026,281,Males must agree to take appropriate precautions to avoid fathering a child from screening through 90 days following the end of therapy. (Note Permitted contraception methods listed in Section 9.3 should be communicated to the patients and their understanding confirmed.),{''}
4027,340,Patient must not have evidence of an active infection at the time of registration,{''}
4028,346,Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 5 x normal,{''}
4029,362,"For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated",{'chronic he ##pa ##titis B virus ( H ##B ##V ) infection'}
4030,432,Whole blood cell (WBC) \>= 2000 cells/mm\^3 (within 30 days prior to registration),{''}
4031,94,For cross sectionals,{''}
4032,98,All patients and/or their parents or legal guardians must sign a written informed consent,{''}
4033,118,"Selpercatinib may impair fertility in men and women. The effects of selpercatinib on the developing human fetus are unknown. For this reason and because selpercatinib as well as other therapeutic agents used in this trial may be teratogenic, women of child-bearing potential (WOCBP) and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 6 months after the last dose of study drug. Unless not allowed by local regulations, WOCBP who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same-sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same-sex relationship without sexual relations with males. Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods), declaration of abstinence just for the duration of the trial, and withdrawal are not acceptable methods of contraception. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men with partners who are WOCBP must agree to use a highly effective contraceptive method during treatment with the study drugs and for 6 months following the last dose of study drug.","{'women, W, W, W'}"
4034,189,Hemoglobin \>= 8.0 g/dL (may receive red blood cell \[RBC\] transfusions) for patients with solid tumors without bone marrow involvement,{'solid tumors'}
4035,259,OR- a glomerular filtration rate (GFR) \>= 50 mL/min/1.73 m\^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard),{''}
4036,340,Patient must not have the following current or prior anti-cancer treatment,{''}
4037,346,"Veno-occlusive disease, if present, should be stable or improving",{'V ##eno - o ##cc ##lus ##ive disease'}
4038,362,"Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load","{'he, ##pa ##titis C virus (, HC ##V ) infection, HC ##V infection, HC'}"
4039,432,"Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3 (within 30 days prior to registration)",{''}
4040,94,• Non-residents,{''}
4041,98,"All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met",{''}
4042,118,"WOCBP must have a negative pregnancy test (serum or urine) within 7 days prior to initiating study treatment, and not be breast-feeding within two months prior to study entry, during treatment, and for ≥1 week after the last dose of study therapy.","{'W, ##OC'}"
4043,189,Peripheral absolute neutrophil count (ANC) \>= 750/uL for patients with solid tumors and known bone marrow metastatic disease,{'solid tumors'}
4044,259,"Note Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility",{''}
4045,340,"Any chemotherapy, targeted therapy, or anti-cancer antibodies received within 2 weeks prior to registration",{''}
4046,346,"Shortening fraction of \>= 27% by echocardiogram, or if shortening fraction abnormal, ejection fraction of \>= 55% by gated radionuclide study or echocardiogram; note the echocardiogram or gated radionuclide study must be performed within 4 weeks prior to enrollment",{''}
4047,362,Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression,{''}
4048,432,"Platelets \>= 100,000 cells/mm\^3 (within 30 days prior to registration)",{''}
4049,94,For livestock treatment (Mozambique),{''}
4050,118,Ability to understand and the willingness to sign a written informed consent document.,{''}
4051,189,"Platelet count \>= 50,000/uL for patients with solid tumors and known bone marrow metastatic disease",{'solid tumors'}
4052,259,"Bilirubin (sum of conjugated + unconjugated) =\< 1.5 x upper limit of normal (ULN) for age (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment)",{''}
4053,340,NOTE Short courses of corticosteroids or palliative external beam radiation therapy (XRT) prior to registration are permitted,{''}
4054,346,"Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) \> 60% predicted by pulmonary function test; for children who are unable to do pulmonary function tests (PFTs), no evidence of dyspnea at rest and no exercise intolerance should be documented; note the pulmonary function test must be performed within 4 weeks prior to enrollment","{'d, ##ys ##p ##nea, exercise into ##ler ##ance'}"
4055,362,Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS-specific treatment is not required and is unlikely to be required during the first cycle of study treatment,{'le ##pt ##ome ##ning ##eal disease'}
4056,432,Hemoglobin \>= 9.0 g/dL (within 30 days prior to registration); Note The use of transfusion is acceptable,{''}
4057,94,Received ivermectin less than four weeks ago,{''}
4058,189,Hemoglobin \>= 8.0 g/dL for patients with solid tumors and known bone marrow metastatic disease,{'solid tumors'}
4059,259,"Alanine aminotransferase (ALT) =\< 3 x ULN for age (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment)",{''}
4060,340,"More than 3 prior lines of cytotoxic chemotherapy, excluding targeted therapy, anti-cancer antibodies, antibody-drug conjugates, and bi-specific antibodies",{''}
4061,346,Patients with seizure disorder may be enrolled if on anticonvulsants and well-controlled; central nervous system (CNS) toxicity \< grade 2,"{'seizure disorder, central nervous system ( C ##NS ) toxicity'}"
4062,362,Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial,"{'ma, ##li ##gna ##ncy'}"
4063,432,Creatinine clearance (CrCl) \> 30 mL/min (within 30 days prior to registration),{''}
4064,94,Intention to milk or slaughter the animal for human consumption during the withdrawal period (28 days after dosing),{''}
4065,189,Transfusions are permitted to meet both the platelet and hemoglobin criteria for patients with known bone marrow metastatic disease; patients must not be known to be refractory to red blood cell or platelet transfusions,{''}
4066,259,"Serum albumin \>= 2 g/dl must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment)",{''}
4067,340,"NOTE Cytoreductive chemotherapy followed by autologous stem cell transplant (ASCT) counts as 1 line of cytotoxic therapy. Similarly, cytoreductive chemotherapy (either pre-T-cell collection or as bridging therapy) followed by pre-conditioning therapy/chimeric antigen receptor T-cell (CAR-T) counts as 1 line of therapy, as long as no disease progression occurs between interventions. For both therapies, if progressive disease is documented between 2 distinct regimens, then they should be counted as 2 lines of cytotoxic chemotherapy",{''}
4068,346,Written informed consent in accordance with institutional and Food and Drug Administration (FDA) guidelines must be obtained from parent or legal guardian,{''}
4069,362,Life expectancy ≥ 3 months,{''}
4070,432,Total bilirubin =\< 1.5 x upper limit of normal (ULN) (except patients with Gilbert syndrome who can have total bilirubin \< 3.0 mg/dL) (within 30 days prior to registration),{'Gilbert syndrome'}
4071,94,Calves under 8 weeks and piglets under 6 weeks of age,{''}
4072,189,Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 or a serum creatinine based on age/gender as follows,{''}
4073,259,"For patients with liver disease caused by their histiocytic disorder (as evaluated on radiographic imaging or biopsy) patients may be enrolled with abnormal bilirubin, aspartate aminotransferase (AST), ALT and albumin with documentation of histiocytic liver disease","{'liver disease, his ##ti ##oc ##ytic disorder, his ##ti ##oc ##ytic liver disease'}"
4074,340,Radio- or toxin-immunoconjugates within 10 weeks prior to registration,{''}
4075,346,Females of childbearing potential must have a negative pregnancy test; patients of childbearing potential must agree to use an effective birth control method; female patients who are lactating must agree to stop breast-feeding,{''}
4076,362,Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result within 3 days of study treatment initiation,{'W'}
4077,432,Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x ULN (within 30 days prior to registration),{''}
4078,189,to \< 6 years of age,{''}
4079,259,"Fractional shortening (FS) of \>= 25% or ejection fraction of \>= 50%, as determined by echocardiography or multigated acquisition scan (MUGA) within 28 days prior to study enrollment. Depending on institutional standard, either FS or left ventricular ejection fraction (LVEF) is adequate for enrollment if only one value is measured; if both values are measured, then both values must meet criteria above (must be obtained within 28 days prior to enrollment and start of protocol therapy) (repeat if necessary)",{''}
4080,340,"Previous treatment with more than one of the following study agents venetoclax, ibrutinib, or lenalidomide",{''}
4081,362,"Agents composed of HER2 antibody conjugated to a topoisomerase 1 inhibitor and azenosertib (ZN-c3) are known to be teratogenic; thus, WOCBP must agree to use highly effective contraception from time of screening and throughout the study treatment period and for at least 7 months after final study treatment administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Female patients must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period and for at least 7 months after the final study treatment administration",{''}
4082,432,"For women of child bearing potential (e.g. uterus present and menstruating), a negative serum pregnancy test within 14 days prior to registration. Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL","{'Women, child ##be potential, W ##OC ##P, men, Men, am ##eno ##rr ##hea'}"
4083,189,Male and female 0.8 (maximum serum creatinine \[mg/dL\]),{''}
4084,259,"No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% if there is clinical indication for determination; unless it is due to underlying pulmonary LCH","{'d ##ys ##p ##nea into, pulmonary L ##CH'}"
4085,340,"Prior autologous stem cell transplant (ASCT), chimeric antigen receptor T-cell (CAR-T) therapy, or allogeneic stem cell (or other organ) transplant within 3 months prior to registration",{''}
4086,362,"Women of non-childbearing potential defined as premenopausal females with documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone \> 40 mIU/mL and estradiol \< 40 pg/mL \[\< 147 pmol/L\] is confirmatory) are eligible. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for WOCBP if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their postmenopausal status, they can resume use of HRT during the study without use of a contraception method","{'am ##eno ##rr ##hea, W ##OC ##B ##P'}"
4087,432,The patient must provide study-specific informed consent prior to study entry,{''}
4088,189,to \< 10 years of age,{''}
4089,259,Central Nervous System Function Defined As,{''}
4090,340,Any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to registration,"{'g, ##raft - versus - host disease'}"
4091,362,Male patients involved with WOCBP must agree to use a highly effective form of contraception or avoid intercourse from time of screening and throughout the study treatment period and for at least 4 months after the last dose of study treatment. Male patients must not freeze or donate sperm starting at screening and throughout the study period and at least 4 months after the final study treatment administration. Preservation of sperm should be considered prior to enrollment in this study,{'W ##OC ##B ##P'}
4092,432,Known human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and CD4 T cell count \>= 200 are eligible for this trial. Testing is not required for entry into protocol,"{'human im ##mu ##no ##de ##ficiency virus, HIV'}"
4093,189,Male and female 1 (maximum serum creatinine \[mg/dL\]),{''}
4094,259,Patients with seizure disorder may be enrolled if well controlled,{'seizure disorder'}
4095,340,"NOTE In addition, patient must have recovered (i.e., ≤ grade 1 or baseline) from all adverse events due to previously administered anti-cancer treatment, surgery, or procedure",{''}
4096,362,Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants,{''}
4097,432,Patients with a history of hepatitis B or C infection are eligible if they have an undetectable viral load,{'he ##pa ##titis B or C infection'}
4098,189,to \< 13 years of age,{''}
4099,259,Central nervous system (CNS) toxicity =\< Grade 2,{'Central nervous system C ##NS toxicity'}
4100,340,"NOTE Exceptions to this include events not considered to place the patient at unacceptable risk of participation in the opinion of the treating investigator (i.e., alopecia)",{'al ##ope ##cia'}
4101,362,Willing to undergo biopsy as required by the study (dose expansion only),{''}
4102,432,Willing to use highly effective contraceptives for males and females of childbearing potential during therapy and for 12 weeks after the last dose of M3814 (peposertib); this inclusion is necessary because the treatment in this study may be significantly teratogenic,{''}
4103,189,Male and female 1.2 (maximum serum creatinine \[mg/dL\]),{''}
4104,259,Human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial unless antiretroviral therapy interacts with the metabolism of tovorafenib (DAY101) and cannot safely be changed to antivirals that do not interact with study medication,"{'Human im ##mu ##no ##de ##ficiency virus, HIV infected'}"
4105,340,"Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better",{'cardiac disease'}
4106,432,Patients must be able to swallow whole tablets,{''}
4107,189,to \< 16 years of age,{''}
4108,340,Patient must have adequate formalin fixed paraffin embedded (FFPE) tumor tissue specimen from the initial diagnostic biopsy or on-study repeat tumor tissue biopsy for molecular analysis,"{'tumor, tumor'}"
4109,189,Male 1.5 (maximum serum creatinine \[mg/dL\]),{''}
4110,340,"NOTE Excisional tumor biopsy is preferred. Core needle biopsies will be considered adequate if there is enough tissue for the mandatory molecular analysis. Submission of an entire FFPE tumor block is preferred, but if unavailable 10 x 10um FFPE scrolls may be submitted as an alternative. If adequate archived FFPE tumor tissue is unavailable, the patient must be willing to undergo research biopsy for molecular analysis",{''}
4111,189,Female 1.4 (maximum serum creatinine \[mg/dL\]),{''}
4112,340,Patient must have measurable disease,{''}
4113,189,\>= 16 years of age,{''}
4114,340,Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2,{''}
4115,189,Male 1.7 (maximum serum creatinine \[mg/dL\]),{''}
4116,189,Female 1.4 (maximum serum creatinine \[mg/dL\]),{''}
4117,189,"Urine protein =\< 30 mg/dl in urinalysis or =\< 1+ on dipstick, unless quantitative protein is \< 1000 mg in a 24 hour (h) urine sample",{''}
4118,189,Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age,{''}
4119,189,"Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 135 U/L (3 x ULN) (for the purpose of this study, the ULN for SGPT is 45 U/L)",{''}
4120,189,Serum albumin \>= 2.8 g/dL,{''}
4121,189,"No history of congenital prolonged corrected QT (QTc) syndrome, New York Heart Association (NYHA) class III or IV congestive heart failure (CHF)","{'con, ##ges ##tive heart failure, CH ##F'}"
4122,189,"No clinically significant cardiac arrhythmias, stroke or myocardial infarction within 6 months prior to enrollment","{'cardiac a ##rr ##hy ##th ##mia, stroke, my ##oc ##ard ##ial in ##far ##ction'}"
4123,189,"QTc =\< 480 msec; Note Patients with grade 1 prolonged QTc (450- 480 msec) at the time of study enrollment should have correctable causes of prolonged QTc addressed if possible (i.e., electrolytes, medications)",{''}
4124,189,Patients with a known seizure disorder who are receiving non-enzyme inducing anticonvulsants and have well-controlled seizures may be enrolled,"{'seizure disorder, seizure'}"
4125,189,CNS toxicity =\< grade 2 with the exception of decreased tendon reflex (DTR); any grade of DTR is eligible,"{'decreased tend ##on reflex, D, D'}"
4126,189,"A blood pressure (BP) =\< the 95th percentile for age, height, and gender for pediatric patients \< 18 years old and =\< 140/90 mmHg for patients \>= 18 years old; patients should not be receiving medication for treatment of hypertension (except patients with Wilms tumor and RCC who may be eligible if on stable doses of no more than one anti-hypertensive medication with a baseline BP =\< ULN for pediatric patients and =\< 140/90 for adult patients); please note that 3 serial blood pressures should be obtained and averaged to determine baseline BP","{'h, ##yper ##tens ##ion, W ##il ##ms tumor, RC ##C h'}"
4127,189,International normalized ratio (INR) =\< 1.5,{''}
4128,189,Serum amylase =\< 1.5 x ULN,{''}
4129,189,Serum lipase =\< 1.5 x ULN,{''}
